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FRENCH SUMMARY 
 
La leucémie lymphoblastique aigüe (LLA) est une maladie génétique complexe. 
Malgré que cette maladie hématologique soit le cancer pédiatrique le plus 
fréquent, ses causes demeurent inconnues. Des études antérieures ont 
démontrées que le risque à la LLA chez l‘enfant pourrait être influencé par des 
gènes agissant dans le métabolisme des xénobiotiques, dans le maintient de 
l‘intégrité génomique et dans la réponse au stress oxydatif, ainsi que par des 
facteurs environnementaux. Au cours de mes études doctorales, j‘ai tenté de 
disséquer davantage les bases génétiques de la LLA de l‘enfant en postulant 
que la susceptibilité à cette maladie serait modulée, au moins en partie, par des 
variants génétiques agissant dans deux voies biologiques fondamentales : le 
point de contrôle G1/S du cycle cellulaire et la réparation des cassures double-
brin de l‘ADN. En utilisant une approche unique reposant sur l‘analyse d‘une 
cohorte cas-contrôles jumelée à une cohorte de trios enfants-parents, j‘ai 
effectué une étude d‘association de type gènes/voies biologiques candidats. 
Ainsi, j‘ai évaluer le rôle de variants provenant de la séquence promotrice de 12 
gènes du cycle cellulaire et de 7 gènes de la voie de réparation de l‘ADN, dans 
la susceptibilité à la LLA. De tels polymorphismes dans la région promotrice 
(pSNPs) pourraient perturber la liaison de facteurs de transcription et mener à 
des différences dans les niveaux d‘expression des gènes pouvant influencer le 
risque à la maladie.  
 
En combinant différentes méthodes analytiques, j‘ai évalué le rôle de différents 
mécanismes génétiques dans le développement de la LLA chez l‘enfant. J‘ai 
tout d‘abord étudié les associations avec gènes/variants indépendants, et des 
essaies fonctionnels ont été effectués afin d‘évaluer l‘impact des pSNPs sur la 
liaison de facteurs de transcription et l‘activité promotrice allèle-spécifique. Ces 
analyses ont mené à quatre publications. Il est peu probable que ces gènes de 
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susceptibilité agissent seuls; j‘ai donc utilisé une approche intégrative afin 
d‘explorer la possibilité que plusieurs variants d‘une même voie biologique ou 
de voies connexes puissent moduler le risque de la maladie; ces travaux ont été 
soumis pour publication. En outre, le développement précoce de la LLA, voir 
même in utero, suggère que les parents, et plus particulièrement la mère, 
pourraient jouer un rôle important dans le développement de cette maladie chez 
l‘enfant. Dans une étude par simulations, j‘ai évalué la performance des 
méthodes d‘analyse existantes de détecter des effets fœto-maternels sous un 
design hybride trios/cas-contrôles. J‘ai également investigué l‘impact des effets 
génétiques agissant via la mère sur la susceptibilité à la LLA. Cette étude, 
récemment publiée, fût la première à démontrer que le risque de la leucémie 
chez l‘enfant peut être modulé par le génotype de sa mère.  
 
En conclusions, mes études doctorales ont permis d‘identifier des nouveaux 
gènes de susceptibilité pour la LLA pédiatrique et de mettre en évidence le rôle 
du cycle cellulaire et de la voie de la réparation de l‘ADN dans la 
leucémogenèse. À terme, ces travaux permettront de mieux comprendre les 
bases génétiques de la LLA, et conduiront au développement d‘outils cliniques 
qui amélioreront la détection, le diagnostique et le traitement de la leucémie 
chez l‘enfant.   
  
Mots clés : leucémie lymphoblastique aigüe de l‘enfant, épidémiologie 
génétique, susceptibilité génétique, polymorphisme régulateur, expression 
génique, cycle cellulaire, réparation de l‘ADN, voie biologique, interaction gène-
gène, association génétique fœto-maternelle 
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ENGLISH SUMMARY 
 
Childhood acute lymphoblastic leukemia (ALL) is a complex and heterogeneous 
genetic disease. Although it is the most common pediatric cancer, its etiology 
remains poorly understood. Previous studies provided evidence that childhood 
ALL might originate through the collective contribution of different genes 
controlling the efficiency of carcinogen metabolism, the capacity of maintaining 
DNA integrity and the response to oxidative stress, as well as environmental 
factors. In my doctoral research project I attempted to further dissect the genetic 
intricacies underlying childhood ALL. I postulated that a child‘s susceptibility to 
ALL may be influenced, in part, by functional sequence variation in genes 
encoding components of two core biologic pathways: G1/S cell cycle control and 
DNA double-strand break repair. Using a unique two-tiered study design 
consisting of both unrelated ALL cases and healthy controls, as well as case-
parent trios, I performed a pathway-based candidate-gene association study to 
investigate the role of sequence variants in the promoter regions of 12 
candidate cell cycle genes and 7 DNA repair genes, in modulating ALL risk 
among children. Polymorphisms in promoter regions (pSNPs) could perturb 
transcription factor binding and lead to differences in gene expression levels 
that in turn could modify the risk of disease.  
 
To better depict the complex genetic architecture of childhood ALL, I used 
multiple analytical approaches. First, individual genes/variants were tested for 
association with disease, while functional in vitro validation was performed to 
evaluate the impact of the pSNPs on differential transcription factor binding and 
allele-specific promoter activity. These analyses led to four published articles. 
Given that these genes are not likely to act alone to confer disease risk I used 
an integrative approach to explore the possibility that combinations of 
functionally relevant pSNPs among several components of the same or of 
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interconnected pathways, could contribute to modified childhood ALL risk either 
through pathway-specific or epistatic effects; this work was recently submitted 
for publication. Finally, childhood ALL is thought to arise in utero suggesting that 
the parents, and in particular the mother, may play an important role in shaping 
disease susceptibility in their offspring. Using simulations, I investigated the 
performance of existing methods to test for maternal genotype associations 
using a case-parent trio/case-control hybrid design, and then assessed the 
impact of maternally-mediated genetic effects on ALL susceptibility among 
children. This published work was the first to show that the mother‘s genotype 
can indeed influence the risk of leukemia in children, further corroborating the 
importance of considering parentally-mediated effects in the study of early-onset 
diseases.  
 
In conclusion, my doctoral work lead to the identification of novel genetic 
susceptibility loci for childhood ALL and provided evidence for the implication of 
the cell cycle control and DNA repair pathways in leukemogenesis. Better 
elucidation of the genetic mechanisms underlying the pathogenesis of ALL in 
children could be of great diagnostic value and provide data to help guide risk-
directed therapy and improve disease management and outcome. Ultimately, 
this study brings us one step closer to unraveling the genetic architecture of 
childhood ALL and provides a stepping-stone towards disease prevention. 
 
Key words: childhood acute lymphoblastic leukemia, genetic epidemiology, 
genetic susceptibility, promoter SNP, gene expression, cell cycle, DNA repair, 
pathway, gene-gene interaction, maternally-mediated genotype effect 
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PREFACE 
CHILDHOOD ACUTE LYMPHOBLASTIC 
LEUKEMIA IN THE AGE OF GENOMICS 
xxi 
 
 
 
“Cancer research driven by the allure of miracle cures is impoverished if 
it does not pay equal attention to possible causal mechanisms and 
prospects for prevention.”  
––– M. Greaves, 1999. 
 
 
Over the past decade, a key focus of cancer research has been geared toward 
dissecting variation in cancer predisposition through the identification of 
inherited genetic changes that influence cancer risk, with the ultimate goal of 
decreasing mortality by reducing risk and improving diagnosis and treatment. 
Following the sequencing of the human genome, we moved rapidly into the age 
of genomics leading us from linkage analysis that were successful for identifying 
high-risk gene mutations involved in familial cancers to ever-growing association 
studies that now allow us to identify low to moderate risk alleles involved in 
sporadic cancers. From genotyping a handful of variants in a few candidate 
genes, to genotyping millions of variants genome-wide, to sequencing entire 
genomes, rapid technological advances have allowed us to peer ever so deeper 
into the genomes of cancer cells and into the genomes of individuals genetically 
predisposed to cancer, shedding light on the complex underpinnings of this 
multifaceted disease.  
 
Childhood acute lymphoblastic leukemia (ALL) is one of the great success 
stories of modern medicine; thirty years ago a child that was diagnosed with 
ALL had little chances of survival, today through the application of intensive 
multiagent chemotherapeutic regimens, the cure rate for childhood ALL exceeds 
an impressive 80% in the developed world. This achievement stems mainly from 
advances in our knowledge of the pathobiology of the disease. Several clinical 
and biological features that correlate with outcome are now used to assign risk-
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based treatment regimes to ALL sufferers. However a significant proportion of 
patients still fail therapy for unknown reasons and the long-term effects of the 
intense chemotherapeutic cocktails that are administered to patients can in 
certain instances be as debilitating as the disease itself. And on the downside of 
this success story is the shadowed fact that, in developed countries, ALL is still 
the leading cause of death by disease among children. More striking still is the 
fact that despite success in treating the disease, very little is known of the 
etiology of childhood ALL; and to better treat the disease is to better understand 
it. 
 
ALL results from a series of mutational events within an immature blood cell that 
halt cell maturation and eventually lead to malignant proliferation and disruption 
of normal blood production. Over 200 genetic alterations have been identified so 
far in ALL tumors, with a handful of recurrent chromosomal rearrangements and 
mutations characterizing most of the cases. While there is well-established 
evidence that these mutational events play an important role in driving the 
leukemic process, the events leading up to leukemogenesis are not known. 
Initiation of the disease occurs during fetal life or in early infancy and, as with 
most other cancers, is likely caused by a combination of environmental and 
genetic factors. The assertion that ALL has a genetic basis has long been 
pursued through association studies based on candidate genes. These studies 
were recently complemented by genome-wide studies that vindicated the role of 
common inherited genetic variation in childhood ALL susceptibility.  
 
There is no doubt that the genomics era will have a profound impact on the 
diagnosis and therapy of childhood ALL. But with progress comes new 
challenges; already the issue of missing heritability is daunting researchers 
interested in dissected the genetic architecture of complex diseases. In the 
research presented here I explore the effects of genetic variation on childhood 
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ALL susceptibility by addressing the following questions. Can we deviate from 
traditional analytical approaches to further illuminate the genetic basis of 
childhood ALL? Can deregulation of core cellular functions such as cell division 
and maintenance of genomic integrity influence a child‘s susceptibility to ALL? 
How important are the mother‘s genes in shaping her offspring‘s susceptibility to 
disease? And in light of the growing popularity of agnostic genome-wide 
searches, can candidate gene approaches still help explain some of the 
interindividual variability in complex disease susceptibility? Using a unique 
design that involves collecting DNA from childhood ALL cases as well as their 
parents and unrelated control individuals, I investigate the role of genes involved 
in two cancer-related pathways, the cell cycle control and DNA repair 
mechanisms, in childhood ALL. This pathway-based candidate gene association 
study provides a unique opportunity to investigate some of the genetic subtleties 
involved in this pediatric disorder. It is my hope that this research will provide 
greater insight into the etiologic intricacies of childhood ALL and help pave the 
way toward new opportunities for prevention. Unraveling the genetic 
architecture of childhood ALL will bring us one step closer to that ultimate goal 
of decreasing mortality by reducing risk and improving diagnosis and treatment. 
 
 
 
 
 
 
 
 
 
CHAPTER ONE 
INTRODUCTION 
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CHILDHOOD CANCER 
 
Cancer is thought of as a disease of ageing, one in which the DNA of a 
normal cell accumulates sufficient mutations that it acquires a selective 
advantage and becomes capable of uncontrolled, unlimited proliferation. 
Yet cancer is also the leading cause of death by disease among 
children (1). It is estimated that each year, approximately 150 children 
out of every million children younger than 20 years of age will be 
diagnosed with cancer (2). And while incidence rates have been 
increasing steadily since the mid-1970‘s, the etiology of many childhood 
cancers remains elusive. 
 
Cancer in children differs markedly from its adult counterpart with regard to 
cancer type, site of occurrence, as well as clinical behavior. Beyond the shorter 
latency period observed in pediatric cancers, they are often more aggressive 
and more invasive. The majority of tumors diagnosed in children stem from 
immature ―embryonic-like‖ cell types, whereas adult cancers are mainly 
carcinomas that arise in epithelial tissue (3). Consequently, a more appropriate 
classification system was developed for childhood cancers based on cell 
morphology and tissue of origin rather than on the primary anatomical site of 
appearance as in adult cancers (4). The most common pediatric neoplasms are 
leukemias (cancer of the blood) representing 25% of all cancer cases among 
children younger than 20 years of age, followed by brain and central nervous 
system cancers (17%) and lymphomas (cancer of the lymphatic system) (16%) 
(5). The relative contribution of leukemia to the total childhood cancer burden 
rises as high as 46% among children aged 2-3 years, making this disease the 
leading cause of cancer-related deaths in children.  
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LEUKEMIA 
 
Hematopoiesis is the highly regulated and hierarchical process during which 
blood cells are formed. Self-renewing progenitors in the bone marrow, the 
hematopoietic stem cells (HSCs), give rise to multipotent progenitors that in turn 
produce lineage-committed progenitors that give rise to the mature blood cells 
of either the myeloid or lymphoid lineages (Figure 1). In leukemia, normal 
hematopoiesis is disrupted. Development of normal hematopoietic cells is 
arrested in an early stage of differentiation in the bone marrow, and malignant 
proliferation of the immature lymphoid or myeloid cells depletes the pool of 
functionally mature blood cells and eventually invades the blood, lymph nodes, 
central nervous system and other vital organs (6). Leukemia is a clonal disease 
arising from the neoplastic transformation of a single cell and in many respects 
the initial leukemia cell resembles a stem cell with unlimited proliferation 
potential and self renewal capabilities and the ability to give rise to a new, albeit 
abnormal, hematopoietic tissue (7). 
 
Leukemia is a heterogeneous group of neoplasms classified on the basis of cell 
type of origin. Leukemias can arise during any step of the hematopoietic 
process and are either acute, aggressive diseases affecting mostly immature, 
undifferentiated cells, or chronic, less rapidly progressing diseases affecting 
more mature and differentiated hematopoietic cells. The three major 
classifications of childhood leukemia are acute lymphoblastic leukemia (ALL), 
accounting for 75% to 80% of childhood leukemia cases; acute myelogenous 
leukemia (AML), accounting for 20% to 25% of cases; and chronic myelogenous 
leukemia (CML), accounting for ~3% of cases (6) (Table 1).  
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Figure 1. Hematopoietic differentiation 
As HSCs divide, they can either self-renew, commit to differentiation or die by 
apoptosis in order to maintain a steady-state level of HSCs in the bone marrow 
and constantly provide progenitors for the various haematological lineages. The 
HSC population is made up of long-term HSCs (LT-HSCs) capable of lifetime 
self-renewal and short-term HSCs (ST-HSCs) that only briefly self-renew and 
give rise to multipotent progenitor cells (MPPs) which differentiate into the 
mutually exclusive myeloid and lymphoid lineages. The common myeloid 
progenitors (CMPs) give rise to the myelomonocytic progenitors (GMPs) which 
produce macrophages and granulocytes, and to the megakaryocytic/erythroid 
progenitors (MEPs) which produce megakaryocytes, platelets and erythrocytes. 
The common lymphoid progenitors (CLPs)  give rise to B and T lymphocytes 
and natural killer (NK) cells. Both CMPs and CLPs can give rise to dendritic 
cells. Cell surface markers can be used to discriminate between all stem and 
progenitor hematopoietic cell populations. (7) 
Figure adapted from Larsson & Karlsson, 2005 (8). 
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Table 1. Childhood leukemia – a heterogeneous group of disorders 
categorized by cell type and level of differentiation 
Diagnostic Group Specific Diagnosis 
Rate per 
million
a % of Cases 
Lymphoid leukemia   29.2 100.0 
  Lymphoid leukemia, NOS   0.2 
  Acute lymphoblastic   99.2 
  Subacute lymphoid   0.0 
  Chronic lymphocytic   0.1 
  Aleukemic lymphoid   0.2 
  Prolymphocytic leukemia   0.1 
  Burkitt's cell leukemia   0.5 
  Lymphosarcoma   0.0 
Acute  non-lymphocytic   7.6 100.0 
  Erythroleukemia   0.4 
  Acute erythremia   0.2 
  Acute myeloid leukemia   68.7 
  Aleukemic myeloid   0.0 
  Acute promyelocytic   7.1 
  Acute myelomonocytic   9.3 
  Acute monocytic   9.1 
  Aleukemic monocytic   0.0 
  Acute megakaryoblastic   5.1 
Chronic myeloid leukemia   1.3 100.0 
  
Chronic myeloid 
leukemia   98.6 
  Chronic myelomonocytic   1.4 
Other specified leukemias   0.2 100.0 
  Plasma   0.0 
  Chronic erythremia   0.0 
  Myeloid leukemia, NOS   33.3 
  Subacute myeloid   0.0 
  Basophilic leukemia   0.0 
  Eosinophilic leukemia   0.0 
  Monocytic leukemia, NOS   8.3 
  Subacute monocytic   0.0 
  Chronic monocytic   0.0 
  Mast cell leukemia   0.0 
  Myeloid sarcoma   58.3 
  Acute panmyelosis   0.0 
  Acute myelofibrosis   0.0 
  Hairy cell leukemia   0.0 
Unspecified leukemias   1.2 100.0 
  Leukemia, NOS   20.5 
  Acute leukemia, NOS   79.5 
  Subacute leukemia, NOS   0.0 
  Chronic leukemia, NOS   0.0 
  Aleukemia leukemia, NOS   0.0 
 
Diagnostic groups and subcategories are based on the International 
Classification of Childhood Cancer (ICCC) definitions. Incidence rates adjusted 
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to the 1970 US standard population. In bold are the three major leukemia 
subtypes diagnosed in children. NOS, not otherwise specified. 
a Age-adjusted incidence rates and percent distribution for specific diagnostic 
subcategories of leukemia based on data from the Surveillance Epidemiology 
and End Results, 1975-95 for patients age <20. 
Table adapted from Smith et al., 1999 (5). 
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THE NATURAL HISTORY OF CHILDHOOD ACUTE 
LYMPHOBLASTIC LEUKEMIA 
 
Acute lymphoblastic leukemia (ALL) is the most frequent pediatric cancer and is 
itself a diverse group of diseases distinct both biologically and clinically. ALL can 
arise in either the B or T lineage of lymphocyte cells (Figure 1). Classification of 
B- and T-cell ALL is done based on cell morphology, using cytological features 
distinguished by the French-American-British (FAB) classification system (9) – 
including cell size, nuclear chromatin, nuclear shape, nucleoli, amount of 
cytoplasm, basophilia of cytoplasm, and cytoplasmic vacuolation – and using 
immunophenotyping of lineage- and maturation-specific cell surface antigens via 
flow cytometry (10). B-lineage ALL can be further subdivided into pro-B cell ALL 
(also known as early pre-B and pre-pre-B ALL) and pre-B ALL (also known as 
cALL for common ALL or simply as B-cell ALL) (11). Pro-B ALL is one of the 
most immature ALL subtypes and occurs mainly in infants aged birth to 1 year; it 
is rare and accounts for only ~5% of childhood ALL cases (12). B-cell ALL is the 
most common subtype, accounting for 80%, while T-cell ALL represents 
approximately 15% of all newly diagnosed pediatric ALL cases (13).  
 
Incidence, Survival and Trends 
It is estimated that approximately 1,100 children are diagnosed with ALL each 
year in Canada (14). While ALL occurs in children worldwide, its incidence 
varies between nations with Costa Rica, Finland and Canada experiencing the 
highest rates, China and India the lowest (15). As for most childhood cancers, 
ALL is slightly more prevalent in boys compared to girls with a 1.2:1 male to 
female ratio, except for pro-B ALL which exhibits a slight predominance in 
females (12). Incidence peaks between 2-5 years of age and tends to be higher 
in socioeconomically developed populations compared to developing countries 
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that tend to have lower rates with no obvious age-specific incidence peak (16). 
A two- to three-fold higher incidence rate is observed in white children 
compared to black children and rates among Hispanics are highest of all, 
suggesting differences in disease frequency associated with race and/or 
socioeconomic status (17). 
 
Childhood ALL is one of the great cancer success stories of the 20th century. 
While less than 20% of diagnosed childhood ALL patients survived their disease 
40 years ago, modern treatment protocols have managed to completely reverse 
survival rates. Among patients receiving contemporary chemotherapy treatment, 
the five-year survival rate is now 80% (18). However, 20% of the cases remain 
resilient to current treatment protocols and ultimately succumb to their disease. 
These numbers also conceal that, of the patients that become five-year 
survivors of childhood ALL, a substantial number develop long-term treatment-
related complications including death (19, 20). Therefore, while the marked 
improvement in the overall cure rate for ALL is undoubtedly very impressive, 
treatment is far from being optimal. And importantly, despite decreasing 
mortality rates, the incidence of ALL among children younger than 20 years of 
age has been increasing with improved socio-economic conditions (5). 
 
Pathobiology of Childhood Acute Lymphoblastic Leukemia 
Success in treatment is due in large part to our increased understanding of the 
pathobiology of ALL. Leukemia is a disease of the genome characterized by 
gross genomic and chromosomal alterations which ultimately provide the 
leukemic cell with a selective and proliferative advantage. 
 
 
9 
 
 
Molecular Genetic Alterations 
Although the primary causes of childhood ALL remain unknown, the 
mechanisms through which the disease arises can be postulated based on 
specific genetic alterations found in ALL. Over 200 somatic genetic alterations 
have been identified in ALL but for the most part they are characterized by gross 
chromosomal changes such as changes in DNA ploidy, chromosomal 
translocations and deletions. The acquired genetic lesions lead to precise stage-
specific developmental arrest and allow unlimited self-renewal and clonal 
expansion of the B or T progenitor cell. Table 2 summarizes the main molecular 
alterations observed in ALL. The most frequent are hyperdiploidy (>50 
chromosomes) and the t(12;21)/ETV6-AML1 gene fusion; together they 
constitute 50% of all childhood ALL and almost 80% of ALL occurring between 
the ages of 2-5 years (21-23).  
 
 
Table 2. Main chromosomal changes in childhood acute lymphoblastic 
leukemia 
Cell type 
Chromosome 
abnormality 
Molecular lesion Frequency (%) Functional product 
Pro-B  
(in infants) 
11q23 
translocations 
MLL-AF4, 
MLL-ENL 
and other fusions 
85 (of infant 
ALL) 
Modified transcription factor 
B-cell Hyperdiploidy Increased gene 
dosage 
35 (of B-cell 
ALL) 
Unknown 
  t(12;21) ETV6-AML1 
fusion 
20 (of B-cell 
ALL) 
Chimeric transcription 
factor 
  t(1;19) E2A-PBX1 fusion 5 (of B-cell ALL) Chimeric transcription 
factor 
  t(9;22) BCR-ABL fusion 5 (of B-cell ALL) Activated kinase 
T-cell  1q deletion; 
t(1;14) 
SIL-SCL fusion 25 (of T-cell 
ALL) 
Dysregulated transcription 
factor 
 
Table adapted from Greaves & Wiemels, 2003 (24). 
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Hyperdiploid ALL is characterized by the nonrandom gain of chromosomes X, 4, 
6, 10, 14, 17, 18, and 21. Though hyperdiploidy is suspected to incur a selective 
advantage to leukemic cells through gene dosage effects, the precise 
mechanism through which it occurs and its impact on leukemogenesis are 
unknown (23). 
 
Chromosomal translocations are initiated by DNA double-strand breaks that 
occur simultaneously in a single cell. Through the process of repair, fusion gene 
products are formed resulting in functionally viable chimeric proteins with altered 
or dysregulated function (24). Several recurrent translocations are found in 
childhood ALL patients (Figure 2). The most prevalent is the t(12;21) 
translocation which creates a fusion gene that involves the transcriptional 
repressor ETV6 and the hematopoietic-specific transcription factor AML1. The 
resulting ETV6-AML1 chimera leads to impaired hematopoietic differentiation, 
however the precise mechanisms by which it causes leukemia remain elusive.  
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Figure 2. Chromosomal translocations in childhood ALL 
The t(12;21) translocation which gives rise to the TEL/AML1 (also known as the  
ETV6/AML1) fusion gene is the most prevalent among pre-B ALL cases. Note 
however that while chromosomal translocations are frequent in leukemia, 
roughly 30% of childhood ALL cases harbor no apparent alterations. 
Figure adapted from Pui et al., 2004 (25).  
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Prenatal Origin  
There is well-established evidence for prenatal initiation of the leukemogenesis 
process in children (26-28). The early age of onset in childhood ALL (peak 
incidence in patients aged 2 to 5 years) is highly suggestive of a latency period 
that begins before the birth of the child. Moreover, molecular studies have 
shown that several of the common chromosomal translocations, mainly 
t(4;11)MLL/AF4 in infant ALL and t(12;21)ETV6/AML1 in childhood B-cell ALL, 
occur in utero. First, retrospective DNA screening of archived neonatal blood 
spots revealed the presence of the fusion genes in patients that developed ALL 
later on between the ages of 5 months to 2 years (26, 29). And concordance of 
ALL in identical, monozygotic twins – ranging from 50% in twin pairs diagnosed 
before the age of 1 to about 5% for older ages – has been shown to result from 
intraplacental metastasis of leukemic clones that initiate in one identical twin 
and are passed to the other in utero through their shared blood system (30). 
This was shown by mapping the unique genetic breakpoints in translocations 
which were shown to be shared among affected twin pairs (24). Moreover,  
screening of newborn cord blood revealed that 1% of babies carry the 
ETV6/AML1 fusion (31), a frequency much higher than the actual prevalence of 
leukemia (about 1 in 10 000), providing a proof-of-principle that chromosomal 
translocations occur prenatally and are likely insufficient to cause leukemia. 
Other subtypes of ALL are expected to be initiated prenatally as well, but lack of 
genetic markers such as gene fusions precludes their identification. 
 
Cooperating Oncogenic Lesions 
While chromosomal alterations play an important role in driving the leukemic 
process by affecting molecular pathways that halt lymphoid progenitor cell 
differentiation and promote cell proliferation and survival, they are incapable, on 
their own, of causing full leukemic transformation (32). The observation that 
these abnormalities are often detected years before the onset of leukemia and 
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the use of experimental models to show that they do not alone result in 
leukemia (33) suggest the need for additional cooperating genetic mutations for 
full leukemic transformation. Greaves suggested that a minimum of two steps 
are required for leukemia development; the first genetic insult is expected to 
occur in utero during pregnancy, in perinatality or at the very least in early 
infancy, followed by a second postnatal genetic insult, that is required to induce 
overt leukemia (Figure 3). 
 
 
Figure 3. Greaves’ multi-stage model for the development of childhood 
ALL 
The most frequent genetic lesions in ALL are generated during normal fetal 
development and are fairly common events (31). Transition between covert pre-
leukemia and covert clinical leukemia occurs in only 1% of the cases and 
involves at least a second hit involving cooperating mutations that occur 
postnatally. 
Figure adapted from Greaves, 2006 (34). 
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Recent effort has gone into identifying the full complement of somatically 
acquired genetic alterations that contribute to acute leukemogenesis in children 
(35, 36). In addition to known recurrent chromosomal translocations, high 
frequency DNA copy number alterations, loss-of-heterozygosity events, 
deletions, amplifications and point mutations in genes involved in lymphoid 
differentiation, as well as in other critical cancer-related pathways such as cell 
cycle regulation, apoptosis, tumor suppression and xenobiotic metabolism have 
been identified in both B- and T-lineage ALL (37-39). Epigenetic analysis 
revealed that recurrent inactivation of tumor suppressor genes through DNA 
hypermethylation also contributes to oncogenesis in ALL (40, 41).  
 
The recurrent chromosomal abnormalities observed in childhood ALL define 
unique subtypes of the disease and together with cooperating genetic and 
epigenetic alterations shed light on the pathogenesis of ALL in children (35, 42). 
Many of these alterations are associated with disease outcome and have helped 
guide risk-stratified treatment regimes contributing to the success of modern day 
therapy in curing childhood ALL. But while it is likely that these distinct 
prognostic subgroups also reflect divergent disease etiologies, very little is 
known still of the underlying causes of childhood ALL. 
 
Risk Factors 
Acquired genetic changes (somatic mutations) are involved in the molecular 
pathogenesis of childhood ALL and its progression but do not explain the origin 
of the disease. It is the more elusive inherited germline variants that influence 
disease susceptibility, likely through the modulation of the response to 
environmental exposures. But while it is clear that both environmental and 
genetic factors have roles in the development of ALL in children, studies have 
thus far been inconsistent or incapable of providing unequivocal evidence for 
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implication in the etiology of ALL and the causes of the disease remain largely 
unknown. 
 
Evidence that childhood ALL has a genetic component stems in part from the 
fact that it is associated with other predisposing genetic syndromes. Inherited 
disorders such as Down‘s syndrome, Bloom‘s syndrome, ataxia-telangiectasia, 
and Nijmegen breakage syndrome are of the few established risk factors for 
childhood ALL however they account for a trivial proportion of cases (<5%) (43). 
Familial aggregation of childhood ALL is also rare and only a few pedigrees 
transmitting ALL have ever been recognized (43). There are five published 
reports of multigenerational ALL, possibly consistent with autosomal dominant 
inheritance, yet no clear susceptibility gene culprit has ever been identified 
within these families, and the small size and number of these pedigrees could 
be reminiscent of chance clustering rather than familial aggregation (43-46). 
Furthermore, very few reports of families with multiple affected children have 
been reported (47, 48), the incidence of childhood ALL among non-twinned 
siblings of probands is at most only weakly increased and could even be 
decreased (49-50), and long-term follow up studies of childhood ALL survivors 
indicate no increased risk of malignancy in their offspring as compared to the 
general population (51), not what one would expect if familial and highly 
penetrant leukemia susceptibility genes were involved in disease etiology. Thus, 
as opposed to other forms of hereditary cancers, such as certain forms of 
breast, prostate and colorectal cancer for example, that are inherited in a 
Mendelian fashion and are associated with highly penetrant germline mutations, 
childhood ALL is sporadic and inherited genetic susceptibility is multifactorial 
and likely involves the co-inheritance of multiple low penetrance variants that do 
not give rise to clear-cut familial patterns of inheritance. And unlike the search 
for ―the‖ gene that causes a Mendelian disorder, many different inherited 
susceptibility genes and many different environmental risk factors are likely 
going to be involved in the etiology of childhood ALL. 
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Environmental Exposures 
In conjunction with Greaves‘ multi-stage model for childhood ALL development, 
there are three critical windows during which exposure to environmental risk 
agents could potentially influence leukemogenesis; these are before conception, 
in utero during pregnancy, and after birth (Figure 4). Given that ALL is not a 
hereditary cancer in terms of a simple Mendelian inheritance, the notion that the 
mother and/or father may play an important role in ALL development in the 
offspring is somewhat counterintuitive, unless we think of it in terms of exposure 
and increased mutation burden. Exposure to carcinogenic agents during 
gametogenesis can incur germline mutations in the gametes of the parents 
preconception that are passed down to the offspring and could lead to increased 
genetic instability postconception. The role of the father in preconceptional ALL 
risk may be more important than the mother since spermatogenesis occurs 
throughout the entire lifetime of the male, offering greater opportunities for 
mutations to occur, whereas females bear their oocytes from birth. During 
pregnancy however, the mother may play a crucial role in disease development 
as she provides the prenatal environment and can influence her offspring‘s risk 
of disease through environmental exposures passed to the fetus via the 
placenta or through the effects of her own genes that can directly influence the 
intrauterine milieu (52). Finally, postnatal exposures of the child both directly 
and indirectly through the mother, for example in breast feeding, could be 
important determinants of childhood ALL.  
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Figure 4. Critical windows of exposure for childhood ALL 
Potential relationship between childhood ALL-inducing events and critical 
periods preconception, in utero and early after birth, during which exposure-
dependent risk factors could influence disease susceptibility. In concordance 
with the multi-stage model for ALL development, both mothers and fathers could 
potentially be involved in the initiating genetic event while mothers could 
contribute to the child‘s postnatal exposure-dependent risk through 
breastfeeding. The model can also be extended to include genetic risk factors 
(at the level of the child, mother and/or father) given that response to the 
environment is modulated by genetic components such as those involved in 
xenobiotic metabolism, DNA repair and cell cycle regulation.  
Figure adapted from Kim et al., 2006 (53). 
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Table 3 lists significant window-specific environmental exposures that have 
been associated with childhood ALL in the literature. The main classes of 
exposure-dependent risk factors identified for childhood ALL include ionizing 
radiation (preconception, in utero and postnatal), exposure to electromagnetic 
fields, chemicals (e.g. hydrocarbons such as benzene found in cigarette smoke, 
gasoline, solvents, paint thinners, air pollution and pesticide exposure either 
directly or via parental exposure), parental alcohol, cigarette and drug use, 
parental occupation, and certain dietary components. However contradictory 
results have been reported for most of these risk factors. Ionizing radiation 
appears to be the only significant environmental risk factor identified to date; 
most others (for example parental cigarette smoking and alcohol consumption) 
have been inconsistently associated with childhood ALL and their role in 
leukemogenesis remains very controversial. This stems mainly from the fact that 
exposures to environmental factors are often difficult to measure and assess 
and can suffer from high levels of uncertainty due to recall bias.  
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Table 3. Exposure-dependent risk factors reported to be significantly 
associated with childhood ALL 
Exposure 
window 
Exposure type Risk
a Odds ratio (sample size
b
); 
reference 
Preconception       
Fathers Occupational exposure   
 Plastic materials (polysterene) + 1.4 (1842 vs. 1986); (54) 
 Driving, exhaust fumes, inhaled particulate  
     hydrocarbons 
+ 13-1.4 (1461 vs. 2922); (55) 
 Electromagnetic fields + 2 (56) 
 Radiation exposure, X-rays ++ 1.9-2.6 (184 vs. 368); (57) 
2.2-3.8 (191 vs. 382); (58) 
 Cigarette smoking ++ 1.6 (203 vs. 406); (59) 
3.8 (110 vs. 110); (60) 
 Alcohol consumption + 1.4 (491 vs. 491); (61) 
 Medication/drug use   
 Amphetamines or diet pills + 2.2 (1842 vs. 1986); (62) 
 Mind-altering drugs (marijuana) + 1.3 (1842 vs. 1986); (62) 
Mothers Occupational exposure   
 Solvents/hydrocarbons (carbon tetrachloride) + 1.8 (1842 vs. 1986); (54) 
 Paints or thinners + 1.6 (1842 vs. 1986); (54) 
 Household pesticides + 1.7 (135 vs. 135); (63) 
 Medication/drug use, oral contraceptives + 1.3 (519 vs. 507); (64) 
 Food consumption   
 Vegetables − 0.5 (138 vs. 138); (65) 
 Protein − 0.4 (138 vs. 138); (65) 
Prenatal       
Mothers Occupational exposure   
 Solvents/hydrocarbons (freon, gasoline) ++ 1.6 (1842 vs. 1968); (54) 
1.7 (184 vs. 368); (57) 
1.7-2.3 (790 vs. 790); (66) 
 Paints or thinners ++ 1.7  (1842 vs. 1986); (54) 
3.2 (184 vs. 368); (57) 
2.4 (519 vs. 507); (67) 
 Pesticides + 3.5 (184 vs. 368); (57) 
 Organic dust (cotton, wool, synthetic fibers) + 5.5 (128 vs. 128); (68) 
 Electromagnetic fields + 2.5 (491 vs. 491) (69) 
 Household exposure   
 Pesticides ++ 1.7-1.8 (491 vs. 491); (70) 
2.3 (135 vs. 135); (63) 
 Paints + 1.7 (640 vs. 640); (71) 
 Radiation exposure, X-rays + 2.2 (519 vs. 507); (64) 
 Electric blanket, heating pad, humidifier + 1.4+1.6 (640 vs. 640); (72) 
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 Sewing machine − 0.8 (640 vs. 640); (72) 
 Cigarette smoking −− 0.7 (203 vs. 406); (59) 
0.7; (73) 
 Alcohol consumption + 
− 
1.4 (203 vs. 406); (59) 
0.7 (491 vs. 491); (61) 
 Medication/drug or supplement use   
 Vitamins − 0.7 (1842 vs. 1986); (62) 
 Iron or folate −− 0.4 (83 vs. 166); (74) 
0.9 (1842 vs. 1986); (62) 
 Antihistamines + 1.3 (1842 vs. 1986); (62) 
 Oral contraceptives + 1.5 (1842 vs. 1986); (75) 
 Pregnancy-maintaining drugs + 1.9 (519 vs. 507); (64) 
 Teratogenic medication (CNS depressants) + 1.3-1.4 (789 vs. 789); (76) 
 Antibiotics + 1.5 (477 vs. 484); (77) 
 Food consumption   
 Vegetables − 0.8 (131 vs. 131); (78) 
 Fruit − 0.7 (131 vs. 131); (78) 
 Fish and seafood − 0.7 (131 vs. 131); (78) 
 Sugars and syrups + 1.3 (131 vs. 131); (78) 
 Meat and meat products + 1.3 (131 vs. 131); (78) 
Postnatal       
Mothers Occupational exposure, plastic (polyvinyl 
chloride) 
+ 2.2 (1842 vs. 1986); (54) 
 Alcohol consumption − 0.5 (491 vs. 491); (61) 
Children Environmental exposure   
 Neighboring repair garages/gas stations 
(benzene) 
+ 3.6 (240 vs. 280); (79) 
 Chernobyl accident (radioactive 
contamination) 
+ 13.1 (98 vs. 151); (80) 
 High voltage power lines (electromagnetic 
fields) 
++ 2.00; (81) 
4 (101 vs. 412); (82) 
1.69; (83) 
 Household exposure   
 Pesticides ++ 1.4-1.8 (491 vs. 491); (70) 
1.7 (135 vs. 135); (63) 
 Artwork (organic solvents) + 4.1 (640 vs. 640); (71) 
 Electrical appliance usage (electric blanket, hair 
dryer, video game machines) 
+ 1.6-2.8 (640 vs. 640); (72) 
 Medication/drug use (chloramphenicol) + 1.8-10.7 (184 vs. 368); (57) 
 Supplementary oxygen exposure + 1.9 (603 vs. 3015); (84) 
  Radiation exposure, X-rays ++ 1.6 (491 vs. 491); (85) 
1.5 (701 vs. 701); (86) 
 Trihalomethanes in drinking water + 9.13 (491 vs. 491); (87) 
 High birth weight (>3800 g) ++ 1.3 (1905 vs. 9525); (88) 
1.8 (1455 vs. 816); (89) 
1.7 (603 vs. 3015); (84) 
2.5 (181 vs. 362); (90) 
2.2 (83 vs. 830); (91) 
3.8–4.6; (92) 
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Infection
c 
  
 
Early infection (in first 4 years of life) −− 0.4 (124 vs. 248); (93) 
0.1-0.8 (408 vs. 567);  (94) 
 
Ear infection − 0.3 (294 vs. 376); (95) 
 
Roseola/fever and rash (first year of life) − 0.3 (98 vs. 228); (96) 
 
Allergy history −− 0.6-0.7; (97) 
0.5-0.6 (1130 vs. 2957); 
(98) 
0.6 (255 vs. 760); (99) 
 
Vaccination
c 
  
 
Haemophilus influenza type b (Hib) −− 0.6 (439 vs. 439); (100) 
0.8 (282 vs. 409); (101) 
Bacille calmette-guérin (BCG) − 0.1 (63 vs. 126); (102) 
 Measles − 0.2 (63 vs. 126); (102) 
 Household density (>1 person/room)
c 
− 0.6; (103) 
 
Daycare attendence
c 
−− 0.5 (490 vs. 491); (77) 
0.7 (408 vs. 567); (94) 
0.4 (294 vs. 376); (95) 
 
Breastfeeding
c 
−− 
 
0.7 (491 vs. 491); (77) 
0.8 (1744 vs. 1879); (104)  
 
Only significant exposure-dependent risk factor associations are shown. This is 
not an exhaustive list; other postulated exposure risk factors for childhood ALL 
may have been investigated, inconclusive results are not shown. 
a Increased risk (odds ratio > 1) in one (+) or more (++) studies; decreased risk 
(odds ratio <1) in one (−) or more (−−) studies.  
b The total number of childhood ALL cases versus healthy controls analyzed in 
each reference. 
c Thought to be infection-related risk factors. 
Table adapted from Kim et al., 2006 (53).  
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Despite evidence that leukemogenesis is initiated in utero, high birth weight is 
one of the few birth-related factors that has been linked to ALL in children. Up to 
a 26% increase in ALL risk is associated with each kg increase in birth weight, 
which can perhaps simply be explained by the fact that larger babies have a 
higher number of lymphoid cells and therefore a higher number of cells at risk of 
leukemic transformation (88). On the other hand higher birth weight might 
indicate higher levels of circulating growth hormone which may induce 
proliferative stress on the bone marrow and indirectly be linked to leukemia 
(105). Other causative factors that have been proposed for childhood ALL 
include maternal (<20 years and >35 years) and paternal (>40 y ears) age, 
maternal reproductive history (miscarriage, abortion), high birth order (fourth 
born), long birth intervals (>5), race (white, Hispanic) and gender (male) 
however their associations with the disease remain highly speculative and the 
mechanisms through which they influence disease risk are unclear (53).  
 
Moreover, it has been hypothesized that childhood leukemia could be caused by 
infection-related factors. An aberrant immunological response to infection at a 
vulnerable time in the child‘s life when lymphoid cell proliferation is high could 
render the child more susceptible to genetic insults and to leukemia. The 
possibility that ALL may have an infectious etiology is supported by the higher 
prevalence of leukemia in modern, wealthy societies and the appearance of 
clusters of childhood ALL cases in small residential communities (106-108). Two 
infection-based models for ALL development have been proposed: Kinlen‘s 
population mixing hypothesis and Greaves‘ delayed-infection hypothesis. Kinlen 
postulated that clusters of ALL could result from prolonged population isolation 
and subsequent exposure to a common but otherwise non-pathogenic infection 
due to population mixing (109). Whereas Greaves suggested that individuals 
carrying pre-leukemic clones (Figure 3) that have spent their early years of life 
coddled in a sterile environment may exhibit a pathological response to a 
subsequent delayed exposure to common infections (34). While some 
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epidemiologic data do support the immune-response hypothesis – daycare 
attendance, increased household density, higher number of recorded common 
infections in early life, as well as breastfeeding and vaccination have all been 
shown to reduce the risk of ALL suggesting that increased social contact and 
potential exposure to infection and immune stimulation in early life protect 
against ALL (Table 3)– no causal infectious agents have yet been identified. 
 
Genetic Susceptibility Factors 
How these exposures affect an individual and their susceptibility to disease 
relies largely on their genetic makeup. Human phenotypic variation, be it in risk 
to disease, response to the environment, or with regard to physical 
characteristics such as height, is influenced by inherited differences in DNA 
sequence. Interindividual variation in the susceptibility to childhood ALL bears 
no exception. Assuming that genes modulate variability in the responses to 
exogenous and/or endogenous factors, they could thereby also influence an 
individual‘s risk of cancer. Childhood ALL is a complex disease in which both 
genes and the environment interact to confer a variable degree of risk on people 
who inherit predisposing genetic variants. Genetic susceptibility refers to an 
inherited increase in the risk of developing a disease, passed down from 
parental generations in the form of germline genetic variation. While the parental 
generation may not be at increased risk of disease, the combination of 
polymorphic variants they bestow upon their offspring could render the child 
more or less susceptible to developing disease. In order to unravel the complex 
etiology of childhood ALL one must therefore start by identifying the inherited 
genetic changes that influence an individual‘s risk of disease. 
 
To date, studies of genetic susceptibility to ALL have focused on the affected 
child and on common genetic variation in genes involved in biological pathways 
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such as folate metabolism, immune function, xenobiotic metabolism (including 
membrane transport, detoxification and biotransformation of drugs and 
chemicals), oxidative stress response, and DNA repair, under the presumed 
hypothesis that inherited genetic variants in genes functioning along these 
pathways could modify response to exposure-dependent risk factors and lead to 
genetic instability in lymphoid progenitor cells and thus influence a child‘s risk of 
developing ALL. Table 4 shows a summary of the genetic susceptibility factors 
shown to significantly modulate childhood ALL risk.  
 
These hypothesis-driven approaches are based on our imperfect understanding 
of the biological processes involved in leukemogenesis and often yield 
associations that are difficult to replicate. And despite two recent large-scale 
association studies that have convincingly vindicated the role for inherited 
genetic variation in childhood ALL predisposition (110, 111), the genetic 
component of childhood ALL remains largely undefined.  
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Table 4. Genetic risk factors reported to be significantly associated with 
childhood ALL 
Pathway, Gene DNA variant Risk 
Odds ratio (sample size); 
reference 
Folate metabolism       
MTHFR 677C>T −− 0.4 (71 vs. 71); (112) 
0.4 (52 vs. 88); (113) 
 1298A>C − 0.4 (270 vs. 300); (114) 
MTRR 66A>G − 0.8 (460 vs. 552); (115) 
Immune function       
HLA DPB1*0101 − 0.7 (982 vs. 864); (116) 
 DPB1*0201 + 1.8 (982 vs. 864); (116) 
 DPB1*0402 + 1.3 (982 vs. 864); (116) 
 DQA1*0101/*0104 + 2.3 (60 vs. 78); (117) 
 DQA1*05 − 0.6 (60 vs. 78); (117) 
Xenobiotic metabolism       
GSTM1 Null ++ 1.8 (174 vs. 304); (118) 
2.1 (118 vs. 188); (119) 
2.2 (47 vs. 102); (120) 
1.7 (107 vs. 320); (121) 
GSTP1 *B 1578A>G ++ 1.5 (278 vs. 303); (122) 
CYP1A1 *2A 6235T>C ++ 1.8 (170 vs. 299); (118) 
2.6-6.2 (118 vs. 118); (119) 
 m2 4889A>G + 2.2-4.3 (118 vs. 118); (119) 
CYP2E1 *5 1259G>C + 2.8 (174 vs. 302); (123) 
MDR1 3435C>T ++ 2.5 (396 vs. 192); (124) 
1.8 (113 vs. 175); (125) 
NAT1 *4 No mutation + 1.4 (155 vs. 306); (126) 
NAT2 *4 No mutation − 0.6 (176 vs. 291); (126) 
 *5C 341T>C & 
803A>G 
+ 3.1 (176 vs. 291); (126) 
 *7B 282C>T & 
857G>A 
+ 2.9 (176 vs. 291); (126) 
Oxydative stress response       
NQ01 *2 609C>T + 1.7 (174 vs. 323); (123) 
 *3 465C>T ++ 1.9 (174 vs. 323); (123) 
6.4 (72 vs. 185); (127) 
DNA repair       
XRCC1 Arg399Gln   + 1.9-2.4 (117 vs. 117); (128) 
 
Only significant genetic risk factor associations as of December 2006, which 
coincides with the beginning of my study, are shown. This is not an exhaustive 
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list; other postulated genetic variants have been tested for association with ALL 
but are not shown here due to inconclusive results.  
a Increased risk (odds ratio > 1) in one (+) or more (++) studies; decreased risk 
(odds ratio <1) in one (−) or more (−−) studies.  
b The total number of childhood ALL cases versus healthy controls analyzed in 
each reference. 
Table adapted from Kim et al., 2006 (53). 
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Thus, while it is likely that both genetic and environmental factors are involved in 
the etiology of childhood ALL very few definitive risk factors have been 
identified. This is in part be due to the complex nature of the disease and the 
fact that overall ALL risk is likely influenced by a complex interplay of multiple 
genetic, environmental, and perhaps infectious and other types of risk factors 
(e.g. birth weight, maternal age), acting at the level of the affected child as well 
as at the level of the parents. Identifying relevant interactions will likely be a 
challenging task however specific genetic variants shown to modify ALL risk 
associated with environmental exposures have already been reported (61, 70, 
86, 87, 129); examples include CYP2E1 and GSTM1 with maternal alcohol 
consumption (61), and CYP1A1 with pre- and postnatal exposure to pesticides 
(70). Furthermore, given the overwhelming evidence that childhood ALL is 
initiated in utero, attention must be paid to window-specific risk factors (Figure 
4), particularly those affecting the prenatal period, in order to better understand 
the underlying mechanisms of the leukemic process; from a genetic 
susceptibility point of view this has seldom been done to date. The identification 
of risk factors for childhood ALL is critical to understanding disease etiology. 
And while we cannot change a person‘s genes, the identification of genetic risk 
factors could help identify high-risk populations and aid in the identification of 
modifiable environmental factors involved in leukemogenesis and provide new 
avenues for prevention. 
 
DISSECTING THE GENETIC BASIS OF COMPLEX DISEASES 
 
Complex diseases, such as cancers, have a tremendous public health impact 
and much effort has gone into understanding their causes in order to better treat 
them and to ultimately prevent their effects before they arise by identifying 
individuals who are at increased predisposition. Genetic epidemiology aims to 
detect patterns of disease in families and in human populations and identify the 
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inherited genetic variants, and jointly acting environmental factors, that are 
associated with disease susceptibility, to better understand the etiology of the 
disease and better control it (130). The completion of the first draft sequence of 
the human genome (131, 132) has brought the field of genetic epidemiology to a 
new era and has opened up many new resources for the study of the genetic 
determinants of disease; yet with new opportunities come new challenges. In 
this section I describe how these resources can be used to dissect the genetic 
basis of complex diseases. 
 
The Landscape of Genetic Variation 
Genetic variation comes in all shapes and sizes. Common polymorphisms (>1% 
in the population) include variable number tandem repeats (minisatellites, 0.1-20 
kb; microsatellites, 2-100 nucleotides), large copy number variants, small 
segmental deletions/insertions (indels)/duplications, and single nucleotide 
polymorphisms (SNPs). SNPs are the most common form of variation, 
accounting for about 90% of all human genetic variation (Figure 5) (133). As of 
March 2010 a total of 23.4 million SNPs had been identified in the human 
genome (National Center for Biotechnology Information SNP database; dbSNP 
Build ID: 131, available from http://www.ncbi.nlm.nih.gov/snp) (134). SNPs 
occur on average once every 100-300 bps and are distributed throughout the 
genome with marked regional differences. SNPs can arise in coding regions of 
genes (exons), in the non-coding or regulatory regions of genes (introns, 5‘ and 
3‘ UTR and promoter regions) or between genes in regions known as gene 
deserts. Many of these SNPs result in silent, neutral changes not affecting 
protein function, however some of these variants fall in coding regions or 
flanking regulatory regions and could have important consequences on 
molecular and physiological processes that may lead to disease (Figure 6).  
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Figure 5. Single nucleotide polymorphism 
SNPs are the most common form of genetic variation. They occur when a single 
DNA nucleotide (A, C, T or G) is substituted (e.g. here a replacement of a 
guanine by an adenine G>A). Almost all SNPs are biallelic, that is they have two 
sequence forms, or  alleles, segregating in the population, however some have 
three (triallelic). In general the more common sequence form is called the major 
or wild-type allele, and the rare sequence variant is referred to as the minor 
allele. 
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Figure 6. Gene-based single nucleotide polymorphisms 
A SNP in a coding region of the gene (exons) may or may not affect the protein 
sequence encoded by the gene, due to degeneracy of the genetic code. A 
synonymous coding SNP (cSNP) will not change the amino acid sequence and 
is therefore silent however a nonsynonymous coding SNP can have a direct 
effect on protein structure and function by leading to a change in amino acid 
(missense cSNP) or by introducing a premature stop codon truncating the 
protein (nonsense cSNP). On the other hand, regulatory SNPs (rSNP) including 
intronic SNPs (iSNP), SNPs in the promoter and UTR regions can affect gene 
expression levels or alternative splicing.  
  
31 
 
 
While coding SNPs may have a direct effect on protein structure and function 
(qualitative change) by introducing changes in the amino acid sequence of the 
encoded protein or premature stop codons, it is thought that the softer, more 
subtle forms of regulatory variation (quantitative change) may play a more 
important role in complex diseases (135). Indeed, a large proportion of the 
susceptibility variants identified so far for a number of complex diseases 
including cancers, fall outside protein-coding regions. Cis-acting variants are 
commonly thought to involve regulatory elements such as promoters and 
enhancers which may lie immediately upstream of the gene, but can also be 
found hundreds of kilobases away (136). SNPs that lie within gene promoter 
regions can alter (change, destroy or create) recognition sites for transcription 
factor binding proteins (Figure 7). As a result, different transcription-regulatory 
proteins may be targeted to the promoter affecting temporal and/or spatial 
expression of the gene, or binding can be increased or decreased affecting 
gene dosage. Regulatory SNPs that alter gene expression are an important 
source of interindividual phenotypic variation and could play an important role in 
disease (Figure 8). Evidence of this has recently been demonstrated in humans 
where it was shown that common cis variants affecting gene regulation can 
explain over 50% of the observed population variation in gene expression (137).  
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Figure 7. The impact of a SNP in a transcription factor binding site (TFBS) 
A SNP that lies within a gene promoter can alter recognition sites for 
transcription factors (TF). In many instances, the SNP will not change TF 
binding affinity given that variation in the consensus sequence of the binding 
site is often allowed. However in some cases, a SNP may increase or decrease 
TF binding affinity leading to allele-specific gene expression. In rare cases, a 
SNP may destroy the TFBS or generate a novel binding site and consequently 
alter TF-induced control of gene expression. 
Figure adapted from Chorley et al., 2009 (138). 
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Figure 8. Rationale for rSNP discovery 
Regulatory variation (rSNP) may have a stronger impact on phenotypic diversity 
as compared to coding variation (cSNP); this is supported by the increasing 
number of human disease associations that have been identified for which no 
deleterious coding variants can be found. Functional regulatory SNPs in gene 
promoter regions leading to allele-specific differences in gene expression could 
impact the overall outcome of the metabolic pathway in which the gene lies and 
thereby positively or negatively influence disease risk. 
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The allelic architecture of complex diseases (number, type and frequency of 
susceptibility variants) is expected to be as diverse as the diseases themselves. 
Due to their sheer abundance and the fact that they are easily amenable to 
experimental interrogation, common SNPs have been the markers of choice in 
genetic susceptibility studies. However many other forms of genetic variation 
including rare SNPs, DNA copy-number variants (CNV), large duplications, 
deletions, or inversions ranging from one kilobase to several megabases in size 
that can engulf one or many genes, are proving to be an important source of 
genetic variation and human phenotypic diversity (139, 140) and have been 
implicated in a number of diseases including predisposition to cancer (141). 
Equally important are inherited epigenetic modifications that can affect gene 
expression changes through DNA methylation and chromatin structure (142). 
Though it is likely that other forms of genetic variation contribute to 
interindividual variability in the susceptibility to childhood ALL, they are not the 
focus of this study and will not be discussed further here. 
 
Identifying SNPs in the human genome has proven to be a relatively easy task 
compared to the complexity of determining which ones promote increased, or in 
certain instances decreased, susceptibility to disease. Considerable success 
has been achieved in finding genes responsible for Mendelian diseases (143). 
In contrast, we are still on the cusp of understanding genetic susceptibility to 
complex diseases. This lies mainly in the nature of the genetic variation involved 
in complex disorders. The human genome contains an estimated 20,000-25,000 
genes (132) and in a hereditary Mendelian disorder only one of these is affected 
by a predisposing highly-penetrant mutation and is sufficient to cause disease. 
Highly penetrant mutations are for the most part rare but their effect on risk is 
important, and when inherited they virtually guarantee expression of the trait. 
However low-penetrance susceptibility variants are more common and are likely 
to be carried by a large proportion of the general population. Individually, they 
may only contribute modestly to complex disease risk but collectively, low-
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penetrance susceptibility alleles could explain a large proportion of the disease. 
Hereditary cancers that exhibit familial clustering can involve both. For example 
in hereditary breast cancer, highly-penetrant mutations in the BRCA1/2 gene 
explain a substantial proportion of the disease while a number of low-penetrant 
genetic variants interact with BRCA1/2 to modify risk (144). It has long been 
thought that complex disease susceptibility is predominantly influenced by low-
penetrance genes and that the allelic frequency spectrum for complex diseases 
tends toward multiple common variants (minor allele frequency, MAF ≥5%) with 
modest effects on disease risk (145, 146). This paradigm, known as the 
common-disease common-variant (CDCV) hypothesis (146-149) has long 
dictated how we search for susceptibility genes in complex diseases. 
 
Genetic Association Studies  
Traditionally two different approaches have been applied to identify disease 
susceptibility genes or loci: i) linkage analysis, which involves mapping 
susceptibility genes to locations along the chromosomes that are inherited with 
the disease within families; ii) association studies which entail investigating the 
relationship between a genetic polymorphism and disease in the population 
(150, 151) (Figure 9).  
 
Linkage analysis relies on the principles of genetic recombination (crossing over 
of sister chromatids during meiosis) and identity by descent (IBD; refers to 
identical copies of the same ancestral allele) and always requires related 
individuals to identify genetic loci that cosegregate with the disease and that are 
physically linked to the putative susceptibility gene (i.e. on the same 
chromosome) (152). The rationale for linkage analysis is that related affected 
individuals will share more alleles at a particular locus if it is linked to the 
disease. Hence by finding genetic markers that are transmitted within families in 
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parallel with the disease, one can obtain an approximate idea of the 
chromosomal location of the true susceptibility gene. Different approaches 
include use of large family pedigrees or affected sib pairs to map tightly-linked 
markers to broad chromosomal regions which can then be narrowed down 
through additional fine-mapping in order to identify the disease gene more 
precisely. 
 
 
Figure 9. Disease mapping strategies 
Linkage analysis requires related individuals and allows disease loci to be 
physically mapped along the genome. While linkage analysis is extremely useful 
for identifying high-impact disease predisposing genes, association studies are 
more advantageous for identifying common, low-impact susceptibility alleles. 
Association analysis can be performed either on unrelated individuals or using 
family-based designs. 
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While linkage studies have been extremely useful in identifying high-impact 
genes responsible for predisposition to hereditary cancers (153-156), they are 
less useful in identifying common variants with weak effects on disease 
susceptibility. In which case association studies are more commonly used to 
compare patterns of genetic variation between individuals with and without the 
disease or trait (Figure 10A). Most genetic association studies are conducted 
using either a population-based case-control or a family-based design.  
 
Case-control Association Studies 
In population-based association studies, unrelated individuals are used to 
identify alleles that are overrepresented in affected individuals (cases) relative to 
unaffected individuals (controls), which would indicate presence of a risk-
enhancing gene, or that are underrepresented in affected individuals, which 
would indicate a protective effect against disease. In family-based association 
studies the control group is constructed from the genotypes of family members. 
Depending on the study design, different statistical methods are used to 
compare disease frequency (present or absent) between individuals with 
different risk factor characteristics (e.g. SNP alleles or genotypes) and to 
measure the strength of association.  
 
Two types of measures for the effect of a genetic variant on disease are 
available: measures of risk and measures of odds of disease (150). However 
measures of risk between exposed and unexposed individuals (more commonly 
known as the relative risk, RR) can only be measured if the disease frequencies 
are incidence rates and these can only be obtained through cohort studies. In a 
cohort study a group of at-risk individuals (currently free of the disease under 
study) is identified, characterized in terms of their risk factors (e.g. SNP 
genotypes), and then followed over time to identify individuals that develop the 
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disease (152). Unless the disease of interest is common however, a cohort 
study could be a long and costly endeavor; which is why the preferred design for 
population-based association studies has become the case-control design. 
However given that study subjects are ascertained based on their disease 
status the measure of association in a case-control study cannot be based on 
disease frequency differences. Rather, the odds of carrying a given risk factor 
among affected cases is compared to the odds of carrying a given risk factor 
among unaffected controls (150). See Appendix I for details on measures of 
genetic association and their significance tests. 
 
Linkage Disequilibrium 
Evidence of ―association‖ between disease outcome and the risk factor does not 
necessarily imply ―linkage‖ and provides no information on the physical distance 
between the marker variant and the veritable disease locus. Rather, association 
testing often relies on the concept of linkage disequilibrium to identify variants 
that are correlated with the true susceptibility gene (Figure 10B). Linkage 
disequilibrium (LD) refers to the tendency of a pair of alleles to be associated 
with each other in the population more than would be expected by chance (157). 
Association studies rely on the fact that, although the causal variant may not be 
directly probed, its effects on disease may still be detectable through the 
polymorphisms with which it is in strong LD. However, whether the underlying 
rationale is that the selected polymorphisms directly affect the disease trait or 
that they are in LD with the true causal loci, it is often not possible to directly 
distinguish whether the gene variant under study is itself responsible for the 
observed effect on disease or if it is in LD with the true susceptibility gene; 
further functional validation is usually required to identify the true causal variant. 
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Association studies of common genetic variants are facilitated by the fact that 
the human genome is segmentally partitioned into a haplotype block-like 
structure composed of long segments of strong LD, interrupted by regions of low 
LD, known as hotspots for recombination (158). An individual who carries a 
particular SNP allele at one site often predictably carries a specific allele at 
another nearby variant site if the two SNPs are highly correlated (are in strong 
LD) and are in the same haplotypic block. And when a new mutation arises in 
the population, i.e. a SNP, indel or structural variant, it initially falls upon a 
specific haplotype associated with a particular combination of alleles. In 
association testing, haplotypes can be used to capture the correlation structure 
of the SNPs in the region in order to identify putative causal variants, and 
perhaps more importantly to capture the combined effects of tightly linked cis-
acting variants (159). 
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A) 
 
B) 
 
Figure 10. Rationale for association studies 
A) Population-based association studies compare affected individuals (cases) to 
unaffected individuals (controls) that are presumed to be unrelated. Since we 
cannot trace transmission of the phenotype over generations (as in familial 
linkage analysis), we rely on correlations between current disease status or 
phenotype status with current marker alleles to infer statistical measures of 
disease association. Assuming that the causal disease locus has not been 
broken up by recombination over time, we should be able to identify groups of 
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individuals that share the susceptibility gene, provided they stem from a 
relatively recent common ancestor. See Appendix I for measures of association. 
B) In an association study, the causal variant may not be directly interrogated. 
However if the unobserved causal locus is in strong linkage disequilibrium with 
one or more of the SNPs that were genotyped in the study, then its effects may 
still be detected. Identifying the true susceptibility variant often requires 
additional functional assays to provide evidence of disease causality. Typed 
markers are shown in red. In the left panel, the typed locus is also the true 
causal locus; in the right panel, the typed markers serve as proxies to the true 
causal locus (shown in blue). 
Figure adapted from Balding, 2006 (160). 
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Family-Based Association Studies  
An alluring feature of family-based association tests is the fact that they allow 
both linkage and association to be tested for. In other words, association will 
only be detected with markers that are both physically linked and in LD with the 
causal gene. A commonly used family-based design in genetic association 
studies is the family-based case-parent-trio design consisting of the affected 
proband and both parents. Though the trio design requires more resources, 
given that a total of three individuals need to be genotyped for each case, it is 
robust against biases such as population substructure that can lead to spurious 
associations in case-control studies (161). Cryptic population structure occurs 
when an apparently homogeneous population is in fact subdivided into 
subpopulations with varying allele frequencies such that cases may be 
disproportionately overrepresented by a subpopulation with higher frequency of 
the risk allele leading to a false-positive association. In family-based designs, 
the association test is performed on the family unit thus eliminating any 
problems related to population structure. Association is measured by comparing 
the observed number of alleles transmitted to the affected offspring with those 
expected under Mendelian transmissions (see Appendix I for details). An excess 
of risk alleles among affected offspring indicates that a disease susceptibility 
locus is in linkage and in linkage disequilibrium with the marker (162). 
Conversely, under-transmission of an allele is indicative of a protective effect 
against the disease.  
 
Both population- and family-based designs have their uses in association 
testing. While case-parent-trios bar from unwanted population stratification, they 
can be more difficult to ascertain. It is usually much easier to recruit large 
numbers of unrelated cases and controls; though this may not be the case for 
pediatric disorders for which parents are usually available and more willing to 
participate. Family-based designs are of particular interest when studying 
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diseases with onset early in life, such as childhood ALL, in order to assess 
putative parental contributions to disease risk. However case-control designs 
are usually more efficient than family-based designs for detecting disease 
susceptibility genes (162-164). Main effects of environmental exposures on 
disease risk can only be estimated in a case-control design, while testing for 
interactions with environmental exposures could be facilitated in family designs 
(165, 166). Thus, both methods have their advantages and disadvantages and 
choosing an optimal study strategy relies largely on the specific questions being 
asked. It also often occurs that mixed sample types are ascertained, i.e. that 
parents of cases and unrelated control individuals are collected in parallel. In 
which case designs based solely on case-parent-triad data, or solely on case-
control data, could lead to considerable losses in efficiency to detect 
associations if available genotype data are disregarded. In these instances 
additional approaches are required to combine the information provided from 
both study designs (e.g. (167-169)).  
 
Hypothesis-Driven versus Hypothesis-Free Approaches 
Association studies are typically of either two types: genome-wide or candidate 
gene. In a candidate gene approach, a specific subset of genes and variants 
(typically up to 50 SNPs) is selected to test for association with disease, based 
on biological plausibility or on functional evidence. Because candidate gene 
approaches are hypothesis-driven, they allow targeted evaluation of specific 
SNPs that can be chosen based on putative functional relevance (for example 
missense coding SNPs, or regulatory SNPs in promoter regions). Such targeted 
approaches could offer advantages in comparison to the genome-wide strategy, 
specifically for testing associations with low-frequency variants or in small study 
samples, and could facilitate identification of the causal variant given that SNPs 
are chosen based on functionality (170). However, the difficulty in candidate 
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gene approaches is of course identifying worthwhile candidates, given the low 
prior probability that any particular gene is involved in disease susceptibility.  
 
At the other end of the spectrum is a more comprehensive genome-wide 
association approach which does not require any a priori information and allows 
surveying the entire genome for disease genes. With the advent of the 
International HapMap Project (171) and high-throughput genotyping 
technologies, it is now feasible and cost-efficient to capture most of the common 
genetic variation in a population using a limited, albeit large, number of SNPs. In 
a genome-wide association study (GWAS), up to a million SNPs can be 
assayed at a time, providing a powerful tool for investigating the genetic 
landscape of complex diseases. Due to their agnostic nature they are often 
referred to metaphorically as fishing expeditions. In other words, if we cast a 
large enough ―net‖ over the human genome, we are bound to find something, 
regardless of whether or not it is truly significant. Thus, stringent cutoffs for 
declaring significance have been set for genome-wide studies and replication of 
an association in independent studies is a prerequisite to bar from the 
potentially high number of false-positives that could ensue from testing such a 
large number of markers. Despite the potential drawbacks, whole-genome 
association studies have proven to be invaluable for the study of the genetic 
basis of human disease and since their first appearance in 2005 (172), GWAS 
have identified susceptibility loci involved in a number of cancers including 
prostate cancer (173), breast cancer (174), lung cancer (175-177), colorectal 
cancer (178, 179), and recently childhood ALL (110, 111). However given that 
GWAS identify regions of association, extensive fine-mapping is required to 
refine the risk loci and identify functional risk alleles along the associated 
haplotypes (180). Another important limitation of GWA screening is its 
insensitivity to rare variation. This is mainly due to the fact that whole genome 
association scans rely on SNP and LD maps which are strongly biased towards 
common variation (mostly MAF>5%) under the prevailing paradigm that 
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complex diseases are caused by common genetic variants. Consequently, 
although GWAS are an important advance in the study of the genetic 
architecture of complex diseases, they are not without their technical 
challenges. 
 
Finding the Missing Heritability 
A decade after decoding the human genome (132, 181), surprisingly little is 
known of the genetic architecture of complex diseases. While it was thought that 
the human genome would be opened up like a book and the genetic 
components of common traits and diseases such as cancer would be readily 
divulged, this has not been the case. And despite much of the enthusiasm 
surrounding GWAS, they have yet to explain but very little of the inherited 
susceptibility for most of the diseases investigated to date (182). Complex 
diseases have proven to be utterly more intricate and multifaceted than 
anticipated. Many explanations have been offered for this missing heritability in 
complex traits including a larger number of variants with small effects that  have 
yet to be identified (the so-called low hanging fruit as opposed to the higher 
impact loci that have so far been singled out by GWAS); rarer variants 
(MAF<5%) that aren‘t interrogated through many current candidate and GWA 
studies; structural variation such as copy number variants that have been paid 
little attention; more complex scenarios involving gene-gene and gene-
environment interactions; non-coding epigenetic changes; phenotype 
ascertainment issues (182, 183). In the case of pediatric disorders, another level 
of complexity which may hinder identification of susceptibility genes is the 
possibility that the parents‘ genes, particularly maternal genetic effects, may 
contribute to disease risk in the offspring. Therefore in a study of the genetic 
determinants of childhood ALL, it is unlikely that interrogating single, inherited 
DNA polymorphisms is going to reveal all or much of the underlying 
complexities of the disease.  
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Finding the so-called ―dark matter‖ of cancer susceptibility is a challenging task 
and while many other sources of missing heritability, such as rare variants and 
gene-environment interactions, are likely to explain part of the interindividual 
variability in the susceptibility to childhood ALL, they are beyond the scope of 
my research. In my thesis I focused on the possible contribution of gene-gene 
interactions, maternally-mediated genetic effects, and pathway-specific effects 
which may explain a proportion of the inherited risk of ALL among children. 
 
Epistasis 
Part of the complexity underlying the etiology of childhood ALL might be 
attributed to epistasis or gene-gene interaction which occurs when the effect of 
one gene is modified by the effect of another.  The term interaction can be 
interpreted in several ways (184) but essentially, it refers to the departure from 
independence of the effects of different loci in the way that they combine to 
cause disease (185). In this way, statistical interaction can be defined as the 
departure of the observed risk of disease from some model (e.g. additive or 
multiplicative, depending on the scale on which the effects are measured) for 
the main effects of two or more independent factors (152). It has been argued 
that gene-gene interactions are a ubiquitous component of the genetic 
architecture of human diseases and that epistasis may even be more important 
than the main effects of any single, inherited susceptibility variant (186). A 
number of interacting loci have been shown to influence cancer risk including 
prostate cancer (187), bladder cancer (188, 189), adult myeloid leukemia (189) 
as well as childhood ALL (126). The difficulty however lies in our capacity to link 
statistical interaction to biological interaction, for one does not directly imply the 
other. Biological interaction is the result of physical interactions between 
proteins within a gene regulatory network or a biochemical pathway that alter a 
phenotype in an individual (184, 190). In contrast, statistical epistasis describes 
the relationship between multilocus genotypes and their combined effects in 
phenotypic variation in a population. Both perspectives of epistasis, though 
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derived from and leading to different research strategies, are thought to play an 
important role in the etiology of common human diseases but the extent to 
which statistical interaction implies underlying biological interaction is still very 
much disputed and experimental support is often required to relate the two 
(191). 
 
Maternal Genetic Effects 
The genetic component of early onset diseases has an added level of 
complexity involving not only the affected individual‘s inherited genotype but 
also parentally mediated genetic mechanisms (169). In particular, the mother 
plays a crucial role as not only genetic contributor but also as fetal environment. 
A maternal allele can damage the fetus through its effect on the intrauterine 
milieu, regardless of whether it is transmitted (52). For example maternal 
exposures to environmental carcinogens and the efficiency of the mother‘s 
detoxification system, determined by the mother‘s genotype, could negatively 
affect the fetal environment and lead to increased susceptibility to disease for 
the growing fetus. Moreover there is increasing evidence that the nutritional, 
hormonal and metabolic environment of the mother may permanently 
programme the structure and physiology of her offspring and that adverse 
influences in utero might increase the risk of disease later on in adult life (192, 
193). The genetic risk associated with diseases originating in utero can 
therefore be influenced by the inherited genotype of the child and/or the prenatal 
environment, as determined by the maternal environment and her own 
genotype, or by joint maternal-gene and offspring-gene effects (194). 
Investigation into maternally-mediated genotype effects in the susceptibility to 
childhood ALL is therefore a prerequisite for unraveling the genetic complexities 
of this disease.  
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Candidate Cancer Pathways  
There is increasing interest in the use of pathways or networks to help guide 
association testing (195, 196). Given that genes function within complex 
molecular networks, rather than look at a single gene at a time (or on the 
contrary at all the genes at the same time, such as in a GWAS), it could be 
more biologically relevant to interrogate genetic variants along a given pathway, 
or in interconnecting or even conflicting pathways, in order to gain further insight 
on the molecular mechanisms involved in disease etiology. Pathway-driven 
approaches to studying complex diseases have primarily been used to select 
promising candidates for association testing but seldom has the information 
been carried through to the analysis stage (e.g.(197, 198)).  Methods for 
incorporating pathway information to guide statistical inference have been 
proposed (199-202) and can help not only in the identification of individual SNPs 
and entire pathways involved in disease, but also in the characterization of the 
underlying complexities of the disease process. 
 
Cancer, such as childhood ALL, is the end result of a network of multiple 
interacting genetic and environmental factors affecting common molecular 
routes that all converge toward oncogenesis. Biological pathways known to 
contribute to cancer susceptibility include xenobiotic metabolism, oxidative 
stress response, DNA damage control, cell cycle regulation and apoptosis 
(Figure 11). Dysregulation of any one of these pathways can lead to increased 
mutational burden, increased genomic instability and ultimately promote 
oncogenesis. My thesis work focused on the cell cycle control and DNA repair 
pathways. Genes encoding key regulators of DNA damage response and cell 
cycle progression are known as the caretakers and gatekeepers of the genome 
and inherited polymorphisms in either type of gene can predispose an individual 
to cancer. 
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Figure 11. Cellular responses to environmental exposures and cancer 
susceptibility 
Biological processes known to contribute to cancer susceptibility include those 
involved in modulating response to adverse environmental exposures : 
xenobiotic metabolism, oxidative stress response, DNA repair, cell cycle control 
and apoptosis. Dysregulation of these interconnected pathways can lead to 
increased genetic instability, increased mutation burden and eventually cancer. 
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The Cell Cycle and Cancer 
At the heart of these interconnected pathways is the cell cycle regulatory 
network (203, 204). The proliferative advantage of a cancer cell arises from its 
ability to bypass critical cell cycle checkpoints in response to external signals; 
loss of cell cycle control is a hallmark of oncogenesis. The cell cycle is a highly-
ordered and tightly-regulated process that is divided into four sequential phases: 
G1 is the growth phase during which cells integrate external information derived 
from mutagenic stimuli and nutrient availability to prepare for DNA replication 
which occurs during S phase; during the G2 gap phase the cell prepares for the 
M (mitosis) phase during which chromosomes are partitioned equally into two 
identical nuclei and cytokinesis occurs producing two identical daughter cells. 
Regulated progression through the cycle is ensured by cell cycle checkpoints, 
the main function of which is to ensure that the integrity of the genome remains 
intact. The checkpoints involve complex networks of signaling proteins that can 
sense aberrant or incomplete cell cycle events, and through a series of signal 
transduction pathways, can engage effector proteins that either invoke cell cycle 
arrest allowing time for the problem to be resolved, or if the damage is 
irreparable, invoke programmed cell death. Concerted action of a vast number 
of signaling molecules is required to ensure strict regulation of the checkpoint 
function. The G1/S transition checkpoint is a critical point in the cell cycle during 
which the cell irreversibly commits to a new round of division, it is also a major 
sensor of DNA damage and its proper function is crucial in order to maintain 
genomic integrity (Figure 12). Not surprisingly, somatic mutations in key 
regulators of G1/S phase progression and changes in expression of their protein 
products  have been reported in almost all human cancers, and germline 
polymorphisms have been associated with increased risk to a number of 
cancers, highlighting the importance of dysregulated cell cycle control in the 
initiation and progression of oncogenesis (204, 205).  
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Figure 12. Illustration of the G1/S cell cycle checkpoint 
The G1/S cell cycle checkpoint controls the passage of eukaryotic cells from 
gap phase G1 into the DNA synthesis phase (S). Two cyclin/cyclin-dependent 
kinase (CDK) complexes, CDK4/6-cyclin D and CDK2-cyclin E, and the 
transcription complex that includes RB and E2F are pivotal in controlling this 
checkpoint. During G1 phase, the RB-HDAC repressor complex binds to the 
E2F-DP1 transcription factors, inhibiting downstream transcription. 
Phosphorylation of RB by CDK4/6 and CDK2 dissociates the RB-repressor 
complex, permitting transcription of S-phase genes encoding for proteins that 
are required for DNA replication. Many different stimuli exert checkpoint control 
including the growth-inhibitory cytokine TGFB, DNA damage, contact inhibition, 
and growth factor withdrawal. The first three act by inducing cyclin-dependent 
kinase inhibitors (CDKIs) of the INK4 (p16/CDKN2A and p15/CDKN2B) and 
Cip/Kip (p21/CDKN1A and p27/CDKN1B) families. TGFB additionally inhibits 
the transcription of CDC25A, a phosphatase that activates the cell cycle 
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kinases. Cell cycle arrest in response to DNA damage is mediated through p53. 
Depending on the extent of the damage, p53 can trigger repair pathways or 
induce apoptotic cell death. The restriction point, R, is the crucial point at which 
the cell is irreversibly committed to undergo another round of division.  
Figure adapted from BioCarta 
(http://www.biocarta.com/pathfiles/h_g1Pathway.asp). 
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DNA Repair Pathways and Cancer 
Cellular responses to DNA damage constitute one of the most important 
processes in cancer research, first because DNA damage induces cancer, 
second because it is used to treat cancer and third because DNA damage is 
responsible for most of the side-effects attributable to cancer therapies, 
including second neoplasias, hair loss, immune deficiency (206). The integrity of 
the genome is constantly being threatened by endogenous (e.g. reactive oxygen 
species caused by normal metabolism, DNA replication errors) and exogenous 
(e.g. UV light, ionizing radiation, and genotoxic agents such as benzene in 
cigarette smoke) stressors. In response to the various types of DNA lesions that 
can occur, a variety of different DNA repair systems are in place to protect the 
genome: excision repair, mismatch repair (MMR), and double-strand break 
repair (DSBR) (Figure 13). Impaired DNA damage responses can lead to 
genetic instabilities which result in increased mutation in the genome and 
ultimately give rise to oncogenic transformation. Genomic instability due to 
impaired DNA damage responses is a hallmark of all cancers. The DSBR 
pathway is particularly relevant to childhood ALL given that double-strand 
breaks are at the origin of the chromosomal translocations observed in a large 
proportion of leukemia patients (24). Moreover, the identification of a number of 
cancer predisposing syndromes linked to defects in DNA repair pathways 
support the hypothesis that DNA repair-related genes play a key role in cancer 
development and progression (207, 208). Interindividual variability in the 
response to carcinogens associated with variations in DNA repair 
capacity/efficiency have also been linked to polymorphisms in a number of DNA 
repair genes and modulated risk of developing a number of sporadic cancers 
(209, 210). 
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Figure 13. DNA repair mechanisms 
A) Double-strand breaks (DSBs) can result from either exogenous factors such 
as ionizing radiation or genotoxic agents or from endogenous sources such as 
reactive oxygen species or spontaneously during replication or normal 
development of the immune system. Two major pathways exist for the repair of 
DSBs: homologous recombination (HR) and non-homologous end-joining 
(NHEJ) (211). HR uses homologous undamaged DNA from the intact sister 
chromatid and is therefore restricted to the S and G2 phases of the cell cycle. 
NHEJ functions in all phases by ligating broken, often noncompatible DNA ends, 
and is the dominant repair mechanism in mammalian cells. Deamination, 
oxidation, or alkylation of bases caused by oxidative stress, ionizing radiation or 
alkylating agents are repaired through base excision (BER). Pathway 
preference (long- or short-patch) depends on the type of lesion,  the state of the 
cell cycle and the differentiation state of the cell (212). UV exposure induces 
bulky, helix-distorting lesions in the DNA that are repaired through the 
MMR 
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nucleotide excision repair (NER) pathway (213). The two pathways of NER, 
global genome repair (GG-NER) and transcription-coupled repair (TC-NER), 
differ only in lesion recognition. 
Figure adapted from Mostoslavsky, 2008 (214).  
B) Mispairing of DNA bases can occur as a result of DNA polymerase errors or 
strand slippage during replication through microsatellite regions for example, 
and are usually repaired through the mismatch repair mechanism (MMR) (215).  
Figure adapted from Hsieh and Yamane, 2009 (215).  
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OBJECTIVES OF THE PROJECT 
 
The etiology of childhood ALL is likely explained by a combination of genetic 
susceptibility and environmental exposure during early development in fetal life 
and infancy. Assuming that genes modulate individual response to exogenous 
and/or endogenous factors, they would thereby also influence a child‘s risk of 
cancer. The goal of this study was to investigate the genetic basis of childhood 
ALL and to identify potential genetic risk factors. We postulated that a child‘s 
susceptibility to ALL is modulated, at least in part, by functional DNA variants in 
genes involved in the G1/S cell cycle checkpoint and in the cellular response to 
DNA damage. These carefully orchestrated processes are under strict 
regulatory control; it seems plausible that variation in gene dosage and activity 
of critical cell cycle control and/or DNA repair genes due to functional regulatory 
polymorphisms could have an important impact on the overall maintenance of 
genomic integrity and cell homeostasis, and thus influence disease.  
 
For my doctoral research, I wished to further elucidate the mechanisms through 
which genetic variants in these biological pathways might affect disease 
susceptibility and attempt to explain some of the observed interindividual 
variability in the risk to developing ALL among children. Using a unique study 
design consisting of case-parent trios as well as unrelated pre-B ALL cases and 
healthy controls from the established Quebec childhood ALL cohort, I conducted 
a candidate gene association study to investigate the putative role of 12 cell 
cycle control genes (CCND1, CDC25A, CDKN1A, CDKN1B, CDKN2A, 
CDKN2B, E2F1, HDAC1, MDM2, SMAD3, RB1, TGFB1) and 7 DNA repair 
genes (ATM, BRCA1, BRCA2, RAD51, XRCC4, XRCC5, XRCC6) in childhood 
ALL susceptibility. The specific aims of this study were:   
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1) investigate individual main effects including single-site allelic/genotypic as 
well as multilocus haplotypic effects, of candidate genes on the susceptibility to 
childhood ALL; 
2) investigate the combined effects of multiple genes/variants on disease risk 
through pathway-specific and gene-gene interaction effects; 
3) assess the role of maternally-mediated genetic effects in the susceptibility to 
childhood ALL. 
 
EXPECTED IMPACT OF THE PROJECT 
 
In this project I attempted to dissect the genetic factors that shape interindividual 
variability in the susceptibility to childhood ALL. In doing so, I hope to be able to 
offer new insight into the process of leukemogenesis and possibly provide novel 
targets for risk-based disease management or even novel therapeutic targets for 
disease treatment. The significance of this project lies in the unique opportunity 
to better understand the impact of regulatory genetic variation in cell cycle and 
DNA repair genes on the risk of pre-B ALL. This is one of only a few studies to 
assess the impact of entire biological pathways on childhood leukemogenesis 
and is the only one to have addressed the role the mother‘s genes play in the 
development of leukemia among children. The identification of genes that 
modify a child‘s risk of ALL, together with a better understanding of how genes 
interacting in biological pathways are involved in more complex disease 
mechanisms, will allow further elucidation of the genetic architecture of this 
disease and perhaps help refine our understanding of pediatric cancers in 
general. Ultimately the goal of a genetic epidemiology study such as this is to 
contribute to the overall improvement of population health, and be able to 
impact on policy and planning in the health sector, particularly, with regards to 
this study, in the fields of pediatric oncology and preventive medicine. 
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CHAPTER TWO 
INDIVIDUAL MAIN EFFECTS OF CANDIDATE 
GENES ON THE SUSCEPTIBILITY TO 
CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA 
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CANDIDATE GENE ASSOCIATION STUDIES 
 
My first objective was to investigate the putative main effects of selected gene 
variants on childhood ALL risk. A two-tier study design was used in which a 
population-based case-control study, conducted in 321 patients with pre-B ALL 
and 329 healthy controls, was performed in conjunction with a family-based 
analysis of 203 case-parent trios, to test for association. It should be noted 
however that cases used in the family-based association study were of the 321 
used in the case-control analysis therefore these two analyses were not 
independent (Figure 1).  
 
 
Figure 1. Design of the candidate gene association study 
A two-tier design was used in which 321 pre-B ALL cases and 329 healthy 
controls were used in a population-based case-control association study, and of 
these patients, 203 had additional parental data available and were enrolled in 
the family-based association study. All individuals were of French-Canadian 
origin from the province of Quebec. 
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Individuals participating in the study were from the Quebec childhood ALL 
(QcALL) cohort and were enrolled in the study at the Sainte-Justine Hospital, 
Montreal between 1985 and 2006. Patients were diagnosed and/or treated in 
the Division of Hematology-Oncology of the Sainte-Justine Hospital, Montreal 
and included 190 males and 131 females between the ages of 0 and 18 years 
with a median age of 4.3 years. Healthy controls included 183 males and 146 
females and were also recruited at the Sainte-Justin Hospital. The QcALL 
cohort consists of incident ALL cases, for which both normal and tumoral bio-
specimen are available, of case-parents as well as unrelated controls. Detailed 
demographic, clinical and histopathological data are also available for most of 
the patients (Table 1), providing a unique opportunity for the genetic 
characterization of childhood ALL and its subtypes. Only pre-B ALL cases (no T-
cell ALL) were investigated because of the higher prevalence of this subtype 
and also to decrease clinical heterogeneity. All study subjects were of French-
Canadian origin residing in the province of Quebec, Canada as judged by their 
names, languages and places of birth. The French-Canadian population is a 
relatively homogenous population due to particular demographic and historic 
characteristics . The virtues for using founder populations, such as the French-
Canadians, for genetic epidemiology studies include increased genetic and 
environmental homogeneity, potentially simpler genetic architectures for 
complex diseases, and longer stretches of linkage disequilibrium facilitating 
association testing. In recruiting only French-Canadian individuals diagnosed 
and/or treated at the Sainte-Justine Hospital, we reduced ethnic admixture and 
regional variability in the frequency of particular ethnic backgrounds. 
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Table 1. Characteristics of the pre-B ALL patients from the Quebec 
Childhood ALL cohort 
Patient characteristics Cases, n (%) 
Total number of patients* 321 
    
Gender   
Male 190 (59.2) 
Female 131 (40.8) 
    
Age group, years    
<= 1 8 (2.5) 
1-10 235 (73.2) 
> 10 53 (16.5) 
N/D 25 (7.8) 
    
Hyperdiploidy   
Positive
†
 113 (35.2) 
Negative 167 (52.0) 
N/D 41 (12.8) 
    
Chromosomal translocations   
Absence of translocation 97 (30.2) 
t(12;21)
†
 35 (10.9) 
Other 12 (3.7) 
N/D 177 (55.1) 
  
Normal ploidy and absence of 
chromosomal translocations 
43 (13.4) 
    
* Numbers are shown only for patients used in the candidate gene association 
studies presented here.  
† Hyperdiploidy and the t(12;21) translocation are virtually mutually exclusive; 
only a single patient in our cohort carries both. 
N/D indicates data not available. 
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Candidate genes were selected based on their key function in two cancer-
related pathways: G1/S checkpoint regulation and double-strand break repair. 
The 2kb proximal promoter regions of the candidate genes were screened for 
polymorphisms and only common promoter SNPs (MAF≥5% in at least one of 
the case or control groups) were kept for investigation. In total 26 promoter 
SNPs from 12 candidate cell cycle genes and 20 promoter SNPs from 7 double-
strand break repair genes were selected for analysis (Figure 2 and Table 2). 
Genotyping was performed using either the PCR-based allele-specific 
oligonucleotide (ASO) hybridization approach, or the allele-specific primer 
extension approach using the Luminex system. A 40 base pair deletion in the 
promoter region of the MDM2 gene was also included in the analysis and was 
genotyped using gel electrophoresis to separate the length polymorphism PCR 
products. Hardy-Weinberg equilibrium (HWE) was tested using the 𝑋2 goodness 
of fit test and the PedCheck Software was used to identify genotype 
incompatibilities using the familial data. 
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Figure 2. Candidate genes selected based on their function in two cancer-
related pathways 
This genetic association study focused on two candidate pathways A) The G1/S  
cell cycle checkpoint and B) DNA double-strand break damage repair (both 
homologous repair, HR, and non-homologous end-joining, NHEJ) pathways. A 
total of 26 promoter SNPs from 12 cell cycle genes and 20 promoter SNPs from 
7 DNA repair genes (shown in colour in the respective diagrams) were 
genotyped among pre-B ALL cases, their parents and unrelated controls of the 
QcALL cohort. See Table 2 for details. 
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Table 2. Characteristics of genes and corresponding DNA variants 
genotyped in the association studies 
Pathway, Gene (Chr.), 
DNA variant 
dbSP Position MAF (%) 
G1/S cell cycle checkpoint 
   
CCND1 (11q13) 
   
-1938T>C rs1944129 69,453,935 48.8 
-1537INS C rs36225395 69,454,336 45.2 
CDC25A (3p21) 
   
-2030G>T rs1903061 48,231,919 10.3 
CDKN1A (6p21.2) 
   
-1284T>C rs733590 36,645,203 36.2 
-899T>G rs762624 36,645,588 27.1 
-791T>C rs2395655 36,645,696 39.74 
CDKN1B (12p13) 
   
-1857C>T rs3759217 12,868,452 11.6 
-1608G>A rs35756741 12,868,701 8.6 
-373G>T rs36228499 12,869,936 43.4 
CDKN2A (9p21) 
   
-222T>A rs36228834 21,975,319 3.3 
CDKN2B (9p21) 
   
-1270C>T rs36229158 22,010,681 2.8 
-593A>T,C rs2069416 22,010,004 37.4/2.7 
-287G>C rs2069418 22,009,698 42.7 
E2F1 (20q11.2) 
   
-187C>T rs3213141 32,274,380 24.1 
HDAC1 (1p34.1) 
   
-1269T>C rs1741981 32,756,439 33.0 
-455T>C rs36212119 32,757,253 8.4 
MDM2 (12q14.3-q15) 
   
-1494A>G rs1144944 69,200,485 49.2 
-1174DEL AAAAAGC(40bp) rs3730485 69,200,806-69,200,845 40.5 
-182C>G rs937282 69,201,797 48.3 
+309T>G rs2279744 69,202,580 36.6 
SMAD3 (15q21-q22) 
   
-1938T>C rs36221701 67,356,489 12.8 
RB1(13q14.1-q14.2) 
   
-1554C>A rs1573601 48,876,357 24.8 
TGFB1 (19q13.1) 
   
-1886A>G rs2317130 41,861,674 31.4 
-1571G>A rs4803457 41,861,359 39.4 
-1550DEL AGG rs11466313 41,861,338-41,861,337 31.0 
-508G>A rs1800469 41,860,296 31.3 
DNA double-strand break repair 
   
ATM (11q22.3) 
   
-1206G>T rs4987876 108,092,637 9.6 
-635T>A rs228589 108,093,208 41.8 
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BRCA1 (17q21) 
   
-1890T>C rs4793204 41,279,298 32.4 
-708A>G rs799906 41,278,116 33.4 
-598INS ACA rs8176071 41,278,006-41,278,005 32.3 
-588A>G rs3092986 41,277,996 9.0 
BRCA2 (13q12.3) 
   
-1555C>A rs206114 32,888,062 41.3 
-1260DEL GTCTAA rs3072036 32,888,357-32,888,362 39.6 
-1144A>G rs206115 32,888,473 40.9 
-1134C>T rs206116 32,888,483 40.2 
-908C>T rs206117 32,888,709 39.7 
-254G>A rs3092989 32,889,363 20.5 
RAD51 (15q15.1) 
   
-1185A>T rs2619679 40,986,237 49.1 
XRCC4 (5q13-q14) 
   
-1864T>C rs3763063 82,371,453 49.5 
-1407C>G rs1993947 82,371,910 8.4 
XRCC5 (2q35) 
   
-1379G>T rs828907 216,972,732 47.1 
-297C>T rs11685387 216,973,814 25.6 
XRCC6 (22q11-q13) 
   
-1469C>T rs28384701 42,016,526 4.5 
-1296C>G rs2267437 42,016,699 38.6 
-731G>A rs132770 42,017,264 25.1 
 
DNA variant positions were numbered with respect to the first nucleotide of the 
first exon as +1, and the nucleotide immediately upstream as -1. Mapping of 
SNP positions is based on dbSNP build 130 and the GRCh37 human assembly 
(UCSC Genome Browser). Minor allele frequency (MAF) was calculated on a 
control cohort consisting of 329 healthy French-Canadian individuals from the 
QcALL cohort; overall frequencies are comparable to those to those reported for 
other populations of European descent. 
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Using both the case-control and case-parent trio data, we screened for 
associations with childhood ALL (allelic and genotypic). When applicable, 
haplotype-based association studies were performed to further capture the 
effects of cis-acting genetic variation in the promoter regions of these genes. 
Traditional statistical methods including chi-square or Fisher‘s exact tests (2-
sided) and unconditional logistic regression were used to compare 
allele/genotype/haplotype carriership and measure association in the case-
control design, and the family-based association test (FBAT), was used to test 
for deviations from random Mendelian transmission of alleles/haplotypes to 
affected offspring among case-parent trios. Together, these methods allowed 
efficient use of data from both unrelated individuals and available parents. Our 
sample size of 321 cases and roughly the same number of unrelated controls 
provided 80% power at the 5% level to detect a minimum odds ratio (OR) of 1.9 
with minor allele frequencies MAF≥0.05 and of 1.5 with MAF≥0.15 (Figure 3), 
while our family-based design consisting of 203 case-parent trios yielded 80% 
power at the 5% level to detect a minimum OR of 1.65 with MAF≥0.15 (Figure 
4). Note that a overlapping group of participants was used in both sets of power 
calculations, and that the case-control and family-based association tests were 
not independent and were used as complementary strategies in the 
identification of disease associations. See Appendix II for detailed power 
calculations. 
 
Functional validation of the regulatory polymorphisms was performed in 
collaboration with colleagues in the laboratory. Both gene reporter and 
electrophoretic mobility shift assays allowed us to identify allele-specific 
differential binding and/or expression providing some insight into the putative 
function of the genetic variants in disease.  
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Figure 3. Power calculations for main effects using a case-control design 
Power calculations when the measured locus M occurs with frequency PM and 
the ratio of frequencies between M and the disease locus D is given by PD : PM. 
The measure of linkage disequilibrium between M and P was set at D‘= 0.8. PM 
was set at 5% and 15%. PD varied from 1.5-times lower to 1.5-times higher than 
the marker allele frequency. A type I error rate of 0.05 (two-sided) was used for 
a sample size of N=321 and an unmatched case-control ratio of 1:1, assuming 
an overall disease prevalence rate of 0.0001. A multiplicative (log-additive) 
inheritance model was used and effect sizes (ORs) were allowed to vary from 
1.0 to 3.0. Horizontal reference line indicates 80% power. See Appendix II for 
detailed power calculations. 
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Figure 4. Power calculations for main effects using a family-based case-
parent trio design 
Recessive, dominant and multiplicative inheritance models were tested for 
minor allele frequencies (MAFs) of 0.05 and 0.15 and for main effect sizes 
(ORs) varying from 1.0 to 3.0. A type I error rate of 0.05 (two-sided) was used 
for a sample size consisting of 203 complete trios (father, mother and one 
affected child) and an overall disease prevalence rate of 0.0001. Horizontal 
reference line indicates 80% power. See Appendix II for detailed power 
calculations. 
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These initial studies lead to the publication of three articles which are presented 
in this chapter: 
― Promoter SNPs in G1/S checkpoint regulators and their impact on the 
susceptibility to childhood leukemia (Healy et al. (2007) Blood 
109(2):683-92); 
 
― No evidence for association between TGFB1 promoter SNPs and the risk 
of childhood pre-B acute lymphoblastic leukemia among French 
Canadians (Healy et al. (2009) Haematologica 94(7):1034-5); 
 
― Functional impact of sequence variation in the promoter region of TGFB1 
(Healy et al. (2009) International Journal of Cancer 125(6):1483-9). 
 
Tables and figures presenting the complete results of the association studies for 
all candidate genes/variants are available in Appendix II. 
 
GENOME-WIDE ASSOCIATION STUDIES 
 
In addition to this candidate gene association study, we have joined forces with 
a large group of international collaborators from Europe, Asia and the United 
States to form the International Acute Lymphoblastic Leukemia Genetics 
Consortium (IALLGC) whose aim is to identify and characterize low-penetrance 
susceptibility variants for childhood ALL through large-scale association-based 
analyses.  
 
91 
 
 
Two independent genome-wide association studies recently provided 
convincing evidence that common, inherited genetic variation contributes to 
childhood ALL susceptibility. Both studies identified overlapping variants in 
genes involved in transcriptional regulation and differentiation of B-cell 
progenitors that were associated with increased risk of childhood B-cell ALL. 
One of the immediate goals of the consortium is to provide opportunities for 
replication of genetic variants shown to be associated with childhood ALL. To 
this extent, we attempted to validate 15 of the initial GWAS signals from both 
studies in the QcALL cohort and successfully replicated the association of 5 
SNPs within the ARID5B gene. This publication is also presented in this 
chapter: 
― Replication analysis confirms the association of ARID5B with childhood 
B-cell acute lymphoblastic leukemia (Healy et al. (2010) Haematologica, 
Epub ahead of print, doi:10.3324/haematol.2010.022459). 
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Abstract 
 
Mutations leading to alteration of cell cycle checkpoint functions are a common 
feature of most cancers. Because of the highly regulated nature of the cell cycle, 
it seems likely that variation in gene dosage of key components due to 
functional regulatory polymorphisms could play an important role in cancer 
development. Here we provide evidence of the involvement of promoter SNPs 
(pSNPs) in cyclin-dependent kinase inhibitor genes CDKN2A, CDKN2B, 
CDKN1A and CDKN1B, in the etiology of childhood pre-B acute lymphoblastic 
leukemia (ALL). A case-control study conducted in 240 pre-B ALL patients and 
277 healthy controls combined with a family-based analysis using 135 parental 
trios, all of French-Canadian origin, were used to evaluate single site genotypic 
as well as multilocus haplotypic associations for a total of ten pSNPs. Using 
both study designs, we showed evidence of association between variants 
CDKN2A -222A, CDKN2B -593A and CDKN1B -1608A and an increased risk of 
ALL. These findings suggest that variable expression levels of cell cycle inhibitor 
genes CDKN2A, CDKN2B and CDKN1B due to regulatory polymorphisms could 
indeed influence the risk of childhood pre-B ALL and contribute to 
carcinogenesis.  
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Introduction 
 
Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer. The 
etiology of this hematologic malignancy might be explained by a combination of 
genetic susceptibility and environmental exposure during early development in 
fetal life and infancy. Assuming that genes modulate individual responses to 
exogenous and/or endogenous factors, they would thereby also influence an 
individual‘s risk of cancer (1). Consistent with this paradigm, it has been shown 
that childhood leukemogenesis is associated with genetic variability in 
xenobiotic metabolism (2-10), oxidative stress response (9, 11, 12) and DNA 
repair (13, 14) pathways. However, little is known about the impact of genetic 
polymorphisms in cell cycle components, despite the fact that the cell cycle is a 
highly orchestrated biological process frequently altered in human cancers (15). 
A critical point in the cell cycle is the G1/S transition checkpoint, during which 
the cell is irreversibly committed to a new round of division (16). The cyclin-
dependent kinase inhibitors (CDKIs) CDKN2A (p16INK4A), CDKN2B (p16INK4B), 
CDKN1A (p21Cip1/Waf1), and CDKN1B (p27kip1) are key regulators of the G1/S 
checkpoint, their concerted action preventing cells from undergoing subsequent 
division in response to oncogenic signaling or DNA damage (17). Accordingly, 
changes in their expression and/or activity due to polymorphisms might modify 
the susceptibility to cancer. Correlations between DNA variants in 
CDKN2A,CDKN2B,CDKN1A, andCDKN1B and cancer susceptibility have been 
reported, particularly in breast, prostate, and skin carcinomas (18-24). In 
addition, single-nucleotide polymorphisms (SNPs) in gene promoter sequences 
(pSNPs) have recently gained much importance because of their quantitative 
impact on gene expression (25, 26). Several studies have suggested that 
because protein levels regulate many biological pathways, including the cell 
cycle, pSNPs could influence the overall outcome of these biological processes 
and thereby modify disease risk (27-33). In this report we performed an 
association study using both a case-control and family-based design in order to 
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assess the impact of proximal promoter SNPs in CDKN2A, CDKN2B, CDKN1A, 
and CDKN1B on the susceptibility to childhood pre-B ALL. 
 
Patients, Materials, and Methods 
 
Study population  
The population under study and the inclusion criteria were described previously 
(6). Incident patients with childhood pre-B ALL (n = 240) were diagnosed in the 
Division of Hematology-Oncology of the Sainte-Justine Hospital in Montreal 
(QC, Canada), between October 1985 and November 2003. They comprised 
141 boys and 99 girls with a median age of 4.6 years (range, 5 months to 18 
years), all of French-Canadian descent, from the province of Quebec. A number 
of these patients (135), from whom parent DNA was available, were also 
enrolled in the family-based study. The healthy controls (n = 277) consisted of 
French-Canadian volunteers recruited while using clinical departments other 
than Hematology-Oncology of the Sainte-Justine Hospital. The CHU Sainte-
Justine Institutional Review Board approved the research protocol, and informed 
consent was obtained from all participating individuals and/or their parents. 
 
Genotyping of promoter SNPs  
DNA was isolated from either buccal epithelial cells, peripheral blood, or bone 
marrow in remission as described previously (34). DNA segments containing the 
polymorphic sites were amplified by polymerase chain reaction (PCR) using a 
―touchdown‖ thermal cycling protocol (35). The resulting PCR products were 
dot-blotted in duplicate on a nylon membrane and assayed for the presence or 
absence of variants by hybridization in parallel with allele-specific 
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oligonucleotides (ASOs) as described in Labuda et al (36). The amplimers and 
oligonucleotide probes used for ASO analysis are given in Table 1. 
 
EMSAs 
Double-stranded oligonucleotide probes corresponding to the sequences 
surrounding the polymorphic sites were radiolabeled and allowed to interact with 
nuclear extracts prepared from HepG2 (hepatoma), Jeg-3 (choriocarcinoma), 
and HeLa (cervical carcinoma) cells as described in Belanger et al (37). Briefly, 
protein was quantified with the Bradford protein assay (Bio-Rad, Mississauga, 
ON, Canada). Nuclear extracts (5 µg) were incubated with 35 fmol radiolabeled 
double-stranded DNA probes and a buffer containing 50 mM Tris-HCl (pH 7.5), 
5 mM MgCl2, 2.5 mM EDTA, 2.5 mM DTT, 250 mM NaCl, 0.25 µg/µL poly 
deoxyinosinate-deoxycytidylate, and 20% glycerol, in a total volume of 10 µL for 
20 minutes at room temperature. Complexes were separated in a 6% 
nondenaturing polyacrylamide gel (acrylamide-bisacrylamide, 60:1) in 0.5X Tris-
borate-EDTA buffer (190 V at 4°C). For competition of binding, a 50-fold molar 
excess of competitor (either the unlabeled probe oligo nucleotide or the 
corresponding mutant oligo) was included. The oligonucleotides used in the 
electrophoretic mobility shift assays (EMSAs) are as follows (only the 5‘-3‘ top 
strand of the double-stranded oligonucleotides are shown):  
CDKN2A –222T>A, ACAACCTTCC(T/A)AACTGCCAAATTGAATCGGGGTGT;  
CDKN2B –1270C>T, 
AATGCTACCCGGTTCCCTT(C/T)CCTGTCCAGGTGGATTT, –593A>T, C, 
GGATCTCAGATTCTTA(A/T/C)AGTATAATTTTTTTT, and –287C>G 
ATCTTAAGAAA(C/G)ACGGAGTTATTTTGA;  
CDKN1A –1284T>C, TTCTGTTTTT(T/C)AGTGGGATTT, –899T>G, 
TGGGGAAAC(T/G)GGGGCTC, and –791T>C, 
ACAGAAGAAA(T/C)CCCTGTGGTT;  
and CDKN1B –1857C>T, TACCACAGGCTCAAGA(C/T)AGCTGCATTTAA, 
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–1608G>A, GGTTTCCTGTCCAGG(G/A)ACATGCA, and –373G>T, 
TAAGCCCCGACCTCCCTCCCGCTCCTC(G/T)CCCGGGAAGCCGGGAC. 
 
Statistical analysis 
Hardy-Weinberg equilibrium was examined using the 𝑋2 test for goodness of fit. 
Fisher exact tests (2-sided) were used to compare allele/genotype/haplotype 
carriership in patients and controls. Crude odds ratios (ORs) are given with 95% 
confidence intervals (CIs). All analyses were carried out using STATA statistical 
software (release 9.1; StataCorp, College Station, TX). CDKN2B, CDKN1A, and 
CDKN1B haplotypes and corresponding frequencies were estimated using the 
PHASE software (version 2; University of Washington, Seattle) (38). Linkage 
disequilibrium between SNPs was tested with the Arlequin linkage utility 
software (version 2.00; University of Geneva, Switzerland) (39). An omnibus 𝑋2  
test, implemented in the Evolutionary-Based Haplotype Analysis Package (eHap 
version 2.0; Carnegie Mellon University and University of Pittsburgh, PA) (40) 
was used to examine overall haplotype associations with disease phenotype. 
Transmission disequilibrium from parents to children of individual SNPs and 
corresponding haplotypes was assessed with FBAT (family-based association 
test) software (version 1.5.1; Program for Population Genetics, Harvard School 
of Public Health, Boston, MA) (41). A multiallelic test was also carried out in 
FBAT to obtain the global haplotype association significance in the family-based 
setting. Correction for multiple testing errors was performed using the false 
discovery rate (FDR) principle (42), with a predetermined type I error rate set at 
10%. 
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Results 
 
Promoter SNPs 
The detection of proximal promoter variants in a population panel consisting of 
40 unrelated individuals (8 Africans, 8 Europeans, 8 Asians, 8 Middle-
Easterners, and 8 Amerindians) was performed by PCR-based denaturing high-
performance liquid chromatography (dHPLC) analysis followed by direct 
sequencing as described in Sinnett et al. (43). The targeted promoter region 
was arbitrarily defined as the 2-kb sequence upstream of the transcriptional 
initiation site. A total of 40 sequence variants were identified for the genes 
CDKN2A, CDKN2B, CDKN1A, and CDKN1B, including 21 that were previously 
reported in public databases (Figure 1). For the purpose of this study targeting 
French-Canadians, we considered only pSNPs that were common among 
Europeans; in other words, those that were found at least twice among the 8 
European patients initially screened. This led to the genotyping of 10 pSNPs: 
CDKN2A, −222T>A; CDKN2B, −1270C>T, −593A>T,C and −287C>G; 
CDKN1A, −1284T>C, −899T>G, and −791T>C; and CDKN1B, −1857C>T, 
−1608G>A, and−373G>T (Table 1). Of note, polymorphism −222T>A has been 
detected in the promoter region of CDKN2A in previous studies (19, 44, 45). 
The observed allele and genotype frequencies in children with ALL and in 
healthy controls are reported in Tables 2 and 3. In controls, the frequencies of 6 
of these pSNPs were in agreement with those reported in other populations of 
European descent as per the National Center of Biotechnology Information 
(NCBI) database of SNPs (dbSNP) (46) and the International Haplotype 
Mapping (HapMap) Project (47) databases. All distributions were in Hardy-
Weinberg equilibrium.  
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Predicted functional impact of the pSNPs 
The screening of the promoter region for predicted transcription factor–binding 
sites (TFBSs) using matInspector 
(http://www.genomatix.de/products/index.html) (48) led to the identification of 
pSNPs that might create and/or disrupt some of these TFBSs (Table 4). The 
putative impact of these pSNPs on DNA-protein–binding capacity was further 
validated by EMSAs. In the latter, double stranded oligonucleotide probes 
corresponding to the sequences surrounding the polymorphic sites (―Patients, 
materials, and methods‖) were radiolabeled and allowed to interact with nuclear 
extracts prepared from HepG2, Jeg-3, and HeLa cells, and differential allelic 
shifts were assessed (see Figure 2 for representative data). As indicated in 
Table 4, 7 of the tested pSNPs showed differential allelic shifts in at least 1 of 
the cell lines tested. 
 
Single-locus analysis 
First we assessed the involvement of the selected 10 pSNPs in childhood ALL 
by performing a case-control study. The estimated ORs and 95% CIs for the 
corresponding alleles and genotypes are given in Tables 2 and 3. The CDKN2A 
−222A allele was overrepresented in patients when compared with controls 
(7.5% versus 3.6%), as was the heterozygous −222TA genotype (13.2% versus 
6.5%). Evidence of an increased risk of ALL among carriers of the CDKN2A 
−222A variant was demonstrated (OR = 2.2, 95% CI, 1.2-4.0, P = .008) and 
remained significant after correction for potential multiple testing errors. In 
contrast, the CDKN2B −593T allele was underrepresented among patients 
(30.9% versus 37.9%), suggesting a protective effect of this variant (OR = 0.7, 
95% CI, 0.6-1.0, P = .02). The frequency of carriers of the −593T associated 
genotypes (AT, TT, and TC) was lower in patients with ALL compared with that 
in controls, but failed to reach statistical significance (Table 3). In CDKN1B, we 
found that −1608GA heterozygotes were more frequent among patients than 
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controls (21.4% versus 13.6%), conferring an increased risk of ALL in children 
(OR = 1.7, 95% CI, 1.0-2.8, P = .03), but this result did not remain significant 
after correction for multiple testing. The initial case-control assessment did not 
reveal any additional noteworthy associations for the other CDKN2B and 
CDKN1B variants, and the frequency of CDKN1A variants did not differ between 
patients and controls (Tables 2-3), indicating that these pSNPs alone do not 
appear to modify the risk of childhood pre-B ALL in our dataset. 
 
Haplotype analysis 
Because single variants in a candidate gene might not be sufficient to capture 
the genetic variability relative to a given phenotype, promoter haplotypes were 
constructed for CDKN2B, CDKN1A, and CDKN1B. Haplotype phase was 
estimated and the corresponding frequencies and distributions among patients 
with ALL and controls were assessed (Table 5). Omnibus 𝑋2 tests were 
performed to determine whether the effects of the haplotypes differed 
significantly between patients and controls. We found evidence for overall 
association between the 6 CDKN2B-derived haplotypes and ALL (𝑋2 = 19.1 [5 
degrees of freedom], P<.001), which remained significant after multiple testing 
corrections. When comparing individual haplotype distributions, the largest 
differences were observed for haplotypes 2B-2, 2B-3, and 2B-6. Haplotype 2B-2 
(CTG), carrying the protective −593T allele (Table 2), occurred at a lower 
frequency among patients with ALL (31.6% versus 37.9%), suggesting an 
inverse correlation with the disease (OR = 0.8, 95% CI, 0.6-1.0, P = .04). In 
contrast, haplotype 2B-3 (CAG), carrying the high-risk −593A allele, was 
overrepresented in patients as opposed to in controls (20.2% versus 13.2%) 
and was significantly associated with an increased risk of ALL (OR = 1.7, 95% 
CI, 1.2-2.4, P = .004). Interestingly, haplotype 2B-6 (TAC) was found exclusively 
in patients with ALL. For CDKN1A and CDKN1B, we were able to construct 7 
and 5 haplotypes, respectively, but the omnibus tests did not suggest overall 
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association, nor did any of the individual haplotypes show significant association 
with the risk of ALL (Table 5). 
 
Family-based analysis 
To further assess the impact of these polymorphisms on childhood pre-B ALL 
risk, we performed a family-based study by genotyping all 10 pSNPs in 148 
patient-parental trios. We either analyzed each variant independently (single-
marker; Table 6) or as haplotypes (Table 7) using FBATs. In the univariate 
FBATs, we found a significant preferential transmission of the high-risk 
CDKN2A −222A variant to affected offspring (Z = 2.60, P = .009; Table 6). The 
protective CDKN2B −593T allele was shown to be transmitted to affected 
patients less often than expected (Z = −2.64, P = .008), whereas the high-risk 
−593A allele was shown to be overtransmitted (Z = 2.778, P = .005; data not 
shown). In addition, these findings held true under the dominant and recessive 
models as well (data not shown). These results, which remained significant after 
correction for multiple testing, are consistent with the case-control results 
discussed in ―Single-locus analysis‖ (Tables 2-3). For CDKN1A and CDKN1B, 
no single variant was found to be significantly associated with childhood ALL 
using the additive model (Table 6). 
 
The global haplotype FBATs revealed no significant transmission disequilibrium 
of the promoter variants of CDKN2B, CDKN1A, and CDKN1B across all trios 
(Table 7). However FBAT analysis of individual haplotypes showed that 
CDKN2B-1 (CAC), bearing the high-risk A-593 allele, was preferentially 
transmitted to affected offspring (Z = 2.22, P = .03), whereas haplotype 2B-2 
(CTG) was associated with a protective effect and shown to be undertransmitted 
to patients with ALL (Z = −2.44, P = .01). No other significant associations were 
detected for the CDKN1A and CDKN1B promoter haplotypes under the additive 
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model (Table 7). Haplotype CDKN1B-2 (CGG) did show evidence of increased 
transmission under the recessive model (Z = 2.44, P = .01), suggesting the 
possibility that this haplotype carrying the variant −373G is associated with an 
increased risk of childhood ALL (data not shown). However, it should be noted 
that though the additive model is expected to perform well even when the true 
model is nonadditive, misspecification of a recessive or dominant mode of 
inheritance can lead to a decrease in power of the FBAT (49, 50). 
 
Discussion 
 
CDKIs are key regulators of the G1/S checkpoint (51). Their strict control and 
concerted action are crucial to maintain cell homeostasis and genomic integrity 
during cellular division. It is therefore plausible that variation in gene dosage of 
such critical cell cycle regulators due to functional regulatory polymorphisms 
could influence cancer susceptibility by altering cell cycle checkpoints. In the 
present study, we tested this hypothesis in childhood ALL by assessing the 
genotype and haplotype distributions associated with 10 common pSNPs found 
in the genes CDKN2A, CDKN2B, CDKN1A, and CDKN1B. This genetic 
epidemiology study was performed in French-Canadians, a population known 
for its relative genetic homogeneity due to particular demographic and historic 
characteristics (52). Using 2 distinct yet complementary study designs (case-
control and parental trios), we identified putative associations between pSNPs in 
CDKN2A (−222T>A), CDKN2B (−593A>T,C), and CDKN1B (−1608G>A) and a 
modified risk of childhood ALL, supporting the idea that DNA variants leading to 
variable CDKI levels might contribute at least to childhood leukemogenesis. 
 
In the case of CDKN2A, earlier work led to the identification of a critical region 
containing functional promoter activity within the 869 bases immediately 
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upstream of its coding domain (53). It is conceivable that the variant −222T>A 
might alter promoter function, perturbing CDKN2A expression and therefore cell 
cycle control. Interestingly, our in silico analysis showed that this pSNP leads to 
the loss of a predicted c-Myb binding site, a transcription factor required for 
proliferation, differentiation, and survival of hematopoietic cells (54, 55). 
Furthermore, reduced CDKN2A expression due to regulatory polymorphisms 
has been suggested to contribute to arrested lymphoblast differentiation, which 
is characteristic of leukemic disorders (56). Additional studies are required 
however to confirm whether this particular −222T>A nucleotide change has an 
effect on CDKN2A expression. We cannot rule out the possibility of other linked 
functional SNPs within (or beyond) the CDKN2A sequence that could influence 
childhood ALL predisposition and account for the observed association, 
especially given the fact that no haplotypic data were available in this particular 
study. To this effect, variant −222T>A has been shown to be in complete linkage 
disequilibrium with another common CDKN2A variant, an alanine-to-threonine 
substitution at codon 148 (Ala148Thr) shown to be associated with malignant 
melanoma (19, 44, 57-59).  
 
For CDKN2B, although we failed to show a significant positive association with 
−593AT heterozygous or −593AA homozygous individuals, the haplotype-
specific analysis did support evidence of an association between allele −593A 
and childhood leukemia. Haplotype 2B-3 (CAG) carrying the −593A allele was 
overrepresented among patients with ALL, and 2B-1 (CAC) was overtransmitted 
more frequently from parents to affected offspring, suggesting a potential 
positive association with the disease. The differential binding detected at the 
−593A>T,C site in both HeLa and HepG2 nuclear extracts further supports this 
hypothesis. The fact that these associations were observed for given haplotypes 
rather than at individual SNPs could reflect the benefit of haplotype-based 
analysis. Haplotypes provide an advantage because they contain more 
information as to the genetic variability in the surrounding locus when the 
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contributing SNPs are not all directly observed, providing they are within linkage 
units (haplotype blocks) with the SNP under study (60). Using the information 
generated by the International HapMap Project, we were able to confirm that the 
CDKN2B −593A>T, C variant is found within a 33-kb haplotype block alongside 
22 other tagged SNPs. It is possible that at least one of these SNPs in linkage 
disequilibrium with the −593 variant might contribute to the observed modified 
risk of childhood ALL. 
 
Both CDKN2A and CDKN2B are well-characterized tumor suppressors, and 
their implication in human cancers and various hematologic malignancies, 
including ALL (61), has been demonstrated. So far, deletion events have been 
the main cause of somatic inactivation of CDKN2A/2B in certain ALL subtypes 
(62), leading to deregulation of the cell cycle and subsequent tumor genesis. 
For the first time, we have provided evidence of the implication of CDKN2A and 
CDKN2B germline mutations in childhood leukemogenesis. 
 
CDKN1B also plays a critical role in regulating cell proliferation, and studies of 
knockout mice suggest that CDKN1B acts as a tumor suppressor as well (63-
66). Furthermore, a familial study on prostate cancer revealed an association 
with the regulatory SNP rs34330 found in the 5‘ untranslated region of CDKN1B, 
providing evidence that germline variants of this gene may indeed play a role in 
cancer susceptibility (18). In this report, we observed an increased risk of 
childhood ALL among carriers of the CDKN1B −1608GA genotype. However, 
the FBATs failed to corroborate this association, indicating random transmission 
of the −1608A allele from parents to affected children. To this effect, previous 
work by Labuda et al. (67) suggested that parental genetics might be important 
in predicting the risk of cancer (at least childhood leukemia). In other words, if at 
certain loci the parental genotypes rather than the offspring‘s own combination 
of genotypes are responsible for genetic susceptibility to a disease, analyses 
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such as FBAT would fail to detect the disease-susceptibility allele(s) since the 
parent-to-child transmission would essentially be random. We tested this 
hypothesis in our dataset for CDKN1B −1608G>A by substituting the parents for 
the patients and comparing fathers with male controls and mothers to female 
controls, but we failed to detect any significant associations (data not shown). 
Although this hypothesis remains speculative and requires further analysis to 
rule out the possibility that the observed case-control association is simply a 
spurious result, it illustrates the importance of considering the effect of parental 
genotypes and of combining various study designs when assessing complex 
disease susceptibility. 
 
In conclusion, our new findings suggest that germline variants in CDKI genes 
CDKN2A, CDKN2B, and CDKN1B may play a role in susceptibility to childhood 
leukemia. Also, we cannot rule out the possibility that these polymorphisms 
might act in combination with other disease modifiers in the same or any other 
related biological pathways. Further studies that evaluate interaction effects with 
genes involved in xenobiotic metabolism and DNA repair will be interesting 
because they may build upon previous findings of the implication of such 
disease-susceptibility genes in childhood leukemia and allow us to further 
understand the biological mechanism underlying the observed associations.  
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Figures 
 
Figure 1. Polymorphisms detected in the promoter regions of CDKN2A, 
CDKN2B, CDKN1A, and CDKN1B 
pSNPs that were genotyped in this report are identified by arrows; those 
reported in public databases are marked by an asterisk. The promoter positions 
were numbered with respect to the first nucleotide of the first exon as 1, and the 
nucleotide immediately upstream as −1. 
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Figure 2. EMSA illustrating allelic DNA-protein interactions in the promoter 
region of CDKN2B 
Labeled double-stranded oligonucleotide (ds-oligo) probes corresponding to the 
CDKN2B −287C>G alleles were incubated with HeLa nuclear extracts. Lanes 1 
to 3 represent labeled −287G ds-oligos; lanes 4 to 6, labelled −287C ds-oligos. 
The unlabeled probes used to compete DNA-protein interactions (in 50-fold 
molar excess) are indicated (+) at the top of each lane. Probe sequences are 
listed in Table 1. Fast migrating unbound probes can be seen at the bottom of 
the gel (NS indicates nonspecific), and the position of the DNA-protein 
complexes of slower mobility are marked by arrows. In this experiment, 3 
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distinct complexes were found following incubation of the probes with HeLa 
nuclear extract. Complex 1 was observed with both labeled ds-oligos −287G 
and −287C (lanes 1 and 4) but was competed by both unlabeled probes, 
indicating unstable DNA-protein interactions. Complex 2 was also found with 
both alleles; the −287C-derived complex was competed by both unlabeled 
probes; however, the −287G-derived complex seemed to be less affected by 
competitors and thus more stable, suggesting higher binding affinity. Complex 3 
appeared only when −287C was present (lane 4 vs lane 1). The specificity of 
this interaction was illustrated through competition with the specific unlabeled 
probe, which did not occur with the mismatched −287G probe (lane 6 vs lane 5). 
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Tables 
 
Table 1. Characteristics of the PCR primers and ASO probes used to genotype the selected pSNPs 
 
SNP ID indicates reference SNP identifier number from the NCBI dbSNP database (46). In the ASO probe sequences, 
uppercase characters indicate the polymorphic site.  
*45°C for the T-222 allele, 40°C for the A-222 allele.
111 
 
 
 
Table 2. Allele frequencies of promoter SNPs in CDKN2A, CDKN2B, 
CDKN1A, and CDKN1B in childhood pre-B ALL patients and controls 
 
Percentages indicate number of chromosomes with given allele/total number of 
chromosomes. OR indicates crude odds ratio; —, not applicable. 
*Remained significant following multiple test correction with an FDR of 10%. 
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Table 3. Distribution of CDKN2A, CDKN2B, CDKN1A, and CDKN1B 
promoter-based genotypes among childhood patients with pre-B ALL and 
controls 
 
Percentages indicate number of individuals with a given genotype/total number 
of genotyped individuals. OR indicates crude odds ratio; —, not applicable. 
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Table 4. Impact of promoter SNPs on predicted transcription factor binding sites 
 
Predicted impact of the pSNPs was estimated with the program matInspector. Gain and loss of transcription factor binding 
sites are specified for the minor allele with respect to the major allele. NA indicates not available; —, none. 
*Matrix similarity score. 
†Predictions for the minor allele −593T only are shown. In silico analysis for allele −593C was inconclusive.
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Table 5. Distribution of CDKN2B, CDKN1A, and CDKN1B promoter haplotypes in patients with pre-B ALL and 
controls 
 
The risk of ALL was evaluated for each haplotype compared with all other possible haplotypes combined. The 𝑋2 values 
represent overall haplotype frequency comparisons between ALL patients and control subjects for each gene. 
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Percentages indicate number of chromosomes with given haplotype/total number of chromosomes. OR indicates crude 
odds ratio; df, degrees of freedom; and —, not applicable. 
*𝑋𝑑𝑓=5
2  = 19.1, P < .001. 
†𝑋𝑑𝑓=6
2  = 5.0, P = .59. 
‡𝑋𝑑𝑓=4
2  = 3.7, P = .44. 
§Remained significant following multiple test correction with an FDR of 10%. 
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Table 6. Family-based association analysis of promoter SNPs in CDKN2A, CDKN2B, CDKN1A, and CDKN1B 
 
FBAT analyses were performed under the additive model. Only the results for the minor alleles are shown. MAF indicates 
minor (i.e., variant) allele frequency. 
*Number of informative families (i.e., families with at least one heterozygote parent). 
†Test statistic from FBAT for the observed number of transmitted alleles. 
‡Expected value of S under the null hypothesis (i.e., no linkage or association). 
§Variance of the test statistic S. 
¶Remained significant following multiple test correction with an FDR of 10%. 
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Table 7. FBAT analysis of promoter haplotypes in CDKN2B, CDKN1A, and CDKN1B 
 
Haplotype-specific FBAT analyses were performed under the additive model. df indicates degrees of freedom; —, not 
applicable due to lack of informative families (i.e., < 10). 
*Number of informative families (i.e., families with at least 1 heterozygote parent). 
†Test statistic from FBAT for the observed number of transmitted alleles. 
‡Expected value of S under the null hypothesis (i.e., no linkage or association). 
§Variance of the test statistic S. 
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Letter to the Editor 
 
TGFB1 is a potent growth inhibitor to a wide variety of cell types including 
hematopoietic cells and deregulation of the TGFB1 signaling pathway has been 
implicated in the development of several cancers (1). Functional regulatory 
polymorphisms of the TGFB1 gene have been directly associated with 
interindividual variability in TGFB1 plasma levels and modified risk of breast (2), 
lung (3), colorectal (4), and prostate (5) cancers. No studies, to date, have 
examined the association between genetic polymorphisms in TGFB1 and 
childhood leukemia. In this study we examined the role of TGFB1 promoter 
SNPs (pSNPs), −1886G>A, −1571A>G, −1550DEL/AGG, and −509C>T, as 
genetic modulators of childhood pre-B ALL susceptibility among the French 
Canadian population. 
 
In a case-control study, we investigated genotypic, haplotypic, as well as multi-
SNP combination associations with childhood pre-B ALL. The study population 
and inclusion criteria were described previously (6). Childhood pre-B ALL cases 
(n=321) consisted of 189 boys and 132 girls with a median age of 4.7 years. 
Parental DNA was available for 203 of these children. Healthy controls (n=329) 
were recruited at the Sainte-Justine Hospital. Study individuals were all French 
Canadian from the province of Quebec, Canada. Candidate pSNPs were 
previously identified (7) and were selected based on their frequency in the 
European population. A PCR-based allele-specific oligonucleotide hybridization 
approach was used to genotype samples, described previously (8).  
 
Hardy-Weinberg equilibrium was tested using the 𝑋2 goodness of fit test and 
PedCheck (Version 1.1) was used to identify genotype incompatibilities using 
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the familial data (9). Pearson‘s 𝑋2 test or Fisher‘s exact test, as appropriate, 
was used to compare allele/genotype/haplotype carriership in patients and 
controls. Crude odds ratios (ORs) were measured using logistic regression in 
STATA (Release 9.2) and are given with 95% confidence intervals (CIs). 
Haplotype frequencies were estimated using the FAMHAP Software (Version 
16) using parental data when available (10). A likelihood ratio test implemented 
in FAMHAP was used to examine global haplotype associations with disease 
status. Multimarker combinations were tested for association with disease using 
the method proposed by Becker and Knapp implemented in FAMHAP (11). 
Multiple testing was controlled for using the false discovery rate (12) with a type 
I error rate of 10%.  
 
Frequencies of pSNPs were in agreement with those previously reported in 
other populations of European descent and all distributions were in Hardy-
Weinberg equilibrium. TGFB1 pSNP distributions did not differ significantly 
between cases and controls (Table 1). Suggestive evidence of a reduced risk of 
childhood pre-B ALL was demonstrated when carriers of at least one variant 
−1886A allele were compared to homozygous individuals for the ancestral -
1886G allele (OR=0.58, 95% CI: 0.33-1.01, p=0.042). However these results did 
not sustain multiple testing corrections. A total of 12 promoter haplotypes 
(pHaps) were inferred but only haplotypes TGH*1, *2 and *3 had frequencies 
≥0.05 and represented 98% of the observed haplotypes in the population tested 
(Table 2). The remaining 2% of the chromosomes carried nine minor haplotypes 
that were grouped under TGH*. We found no significant difference in the overall 
distribution of the 12 TGFB1-derived pHaps between cases and controls (Global 
𝑋2= 10.85, 11 degrees of freedom, p=0.46) and found no evidence of 
association between individual haplotypes and the risk of pre-B ALL. 
Investigating multi-SNP combinations, the best result was obtained for marker 
combination −1886A/−1550AGG/−509C, which was associated with a 
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decreased risk of pre-B ALL (OR= 0.86) however the global test statistic failed 
to reach significance (p=0.15). 
 
Though the expected variability of TGFB1 expression levels due to promoter 
SNPs could indeed contribute to leukemogenesis, our data did not support a 
role for TGFB1 promoter variants −1886G>A, −1571A>G, −1550DEL/AGG or 
−509C>T in the etiology of childhood pre-B ALL, at least among the French 
Canadian population. Having screened 2kb upstream of the transcription start 
site in 40 individuals (7), a strength of this study was our ability to capture and 
survey most common genetic variation within the region under investigation with 
reasonable statistical power. Despite the relatively small size of this dataset, we 
had 80% power at the 5% level to detect a minimum OR of 1.5 with a minor 
allele frequency ≥15%. However it remains possible that other variants within 
the TGFB1 gene and surrounding regulatory sequences that were not assessed 
within the scope of this study could modify disease susceptibility. Additional 
analyses in independent datasets are required to further support the lack of 
association between these TGFB1 variants and childhood pre-B ALL since our 
study did have limited statistical power to detect associations involving weak 
effects or rarer variants. 
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Tables 
 
Table 1. Allele and genotype frequencies of pSNPs in TGFB1 in childhood 
pre-B ALL patients and controls. 
 
Percentages indicate number of individuals with a given genotype/total number 
of individuals in the dataset or the number of chromosomes with given 
allele/total number of chromosomes in the dataset. OR indicates crude odds 
ratio; —,not applicable.
 
 
 
 
1
3
1
 
 
Table 2. Distribution of TGFB1 promoter haplotypes in pre-B ALL patients and controls. 
 
The risk of ALL was evaluated for each haplotype compared with all other possible haplotypes combined. Percentages 
indicate number of chromosomes with given haplotype/total number of chromosomes. Haplotypes with relative 
frequencies <5% are grouped under TGH* and are represented as * combinations of the four DNA variants. A likelihood 
ratio test was performed in FAMHAP to compare global haplotype differences between cases and controls and is reported 
here as a Global X2 test with number of haplotype parameters different from zero-1 degrees of freedom. OR indicates 
crude odds ratio; df, degrees of freedom; and —, not applicable. 
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Abstract  
 
Pathological deregulation of the transforming growth factor, beta 1 (TGFB1) 
pathway has been implicated in the development of several major diseases, 
including cancers. Regulatory variation in the TGFB1 gene may lead to altered 
TGFB1 expression and activity, and thus, modulate an individual‘s susceptibility 
to disease. Here, we performed a study of the functional relevance of cis-acting 
regulatory variation in the proximal promoter region of the TGFB1 gene. In a 
previous study, 9 promoter polymorphisms were identified in the 2kb region 
upstream of the transcription start site and 9 distinct promoter haplotypes were 
inferred from a panel of individuals from 5 distinct continental population groups. 
Following experimental validation, we found that the 2 major haplotypes 
significantly influenced TGFB1 transcriptional activity in an allele-specific 
manner and that 3 of the SNPs (−1886G>A, −509C>T and −1550DEL/AGG) 
altered DNA-protein complex formation. Though the biological relevance of 
these findings remains to be verified, our study suggests that polymorphisms in 
the TGFB1 promoter could indeed influence gene expression and potentially 
contribute to the pathogenesis of TGFB1 related diseases. 
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Introduction 
 
Transforming growth factor, beta 1 (TGFB1) is a potent growth inhibitor to a 
wide variety of cell types, and plays a central role in regulating passage through 
the G1/S checkpoint. As a multifunctional cytokine, TGFB1 regulates a number 
of important cellular responses in addition to its role in cell cycle control 
including cell differentiation, apoptosis, cell migration, immune responses and 
angiogenesis (1, 2). Pathological deregulation of the TGFB1 signaling pathway 
has been extensively studied and has been shown to be implicated in the 
development of several major disease groups, including cancers (3), 
atherosclerosis (4), fibrotic diseases (5), and obesity (6). Its involvement in 
carcinogenesis is complex, having both tumour suppressor and oncogenic 
activities (7). A stage specific duality of function is the emerging paradigm for 
the role of TGFB1 in cancer (2): mutational inactivation or altered expression of 
the gene appears to be important in the early stages of cancer development in 
order for tumor cells to escape from its antiproliferative effects (8); whereas 
TGFB1 overexpression would be necessary in the later stages to enhance 
tumor progression and increase metastasis (9). Dose-dependent changes in 
gene expression of TGFB1, and of other downstream members of the pathway, 
are sufficient to disrupt signaling and promote tumorigenesis (7). Accordingly, 
DNA variation in gene promoter and/or regulatory sequences could impact 
TGFB1 expression levels and potentially play a role in disease etiology. In 
particular, one of the more commonly studied TGFB1 SNPs, −509C>T 
(rs1800469) located in the proximal promoter region has been associated with 
variability in TGFB1 plasma levels and modified risk of breast (10, 11), lung 
(12), colorectal (13, 14), and prostate (15) cancers. Here, we performed a 
comprehensive study of cis-acting regulatory variation in the TGFB1 promoter. 
Using in silico and in vitro approaches, we investigated the effects of TGFB1 
promoter SNPs (pSNPs) −1960C>T (rs11466311), −1886G>A (rs2317130), 
−1571A>G (rs4803457), −1550DEL/AGG (rs11466313), −1349INS/C 
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(rs36204367), −1146C>G (rs3087453), −800G>A (rs1800468), −509C>T 
(rs1800469), −448C>T (rs11466314) and 2kb TGFB1 promoter haplotypes 
(pHaps) on differential DNA-protein binding, and promoter activity. We showed 
that polymorphisms in the TGFB1 promoter can disrupt protein binding, and 
influence promoter activity in an allele-specific manner, suggesting that TGFB1 
promoter variation may be important in disease. 
 
Material and Methods 
 
Promoter SNP identification  
In a previous study, we screened the 2kb sequence upstream of the TGFB1 
transcription start site for polymorphisms on a population panel consisting of 39 
unrelated individuals from 5 continental groups (7 Africans, 8 Europeans, 8 
South East Asians, 8 Middle Easterners and 8 Amerindians) as well as a 
chimpanzee sample, obtained from the Granby Zoo (Granby, Canada), to infer 
ancestral alleles (refer Sinnett et al. (16) and Labuda et al. (17) for details). The 
targeted proximal promoter region of the TGFB1 gene was amplified 
sequentially in 7 overlapping fragments of ~350 bp for dHPLC analysis followed 
by direct sequencing. Primer sequences and detailed information on 
experimental conditions are available upon request. Polymorphism positions 
relative to the transcription start site were identified based on the RefSeq mRNA 
sequence NM_000660.1 with nucleotide +1 at position chr19:46,551,656 of the 
March 2006 human reference sequence (NCBI Build 36.1). 
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In silico analysis 
Computational haplotype reconstruction was performed using the PHASE 
software (Version 2.1) (18) and frequencies were estimated for each of the 5 
population groups in Labuda et al. (17). In silico analysis of the TGFB1 gene 
promoter sequence was performed using the MatInspector software (19) to 
predict the presence of putative transcription factor binding sites (TFBSs). For 
each pSNP under study, 50 bp of surrounding genomic sequence (25 bp 
upstream and 25 bp downstream of both the major and minor alleles) were 
analyzed using the optimized matrix similarity thresholds to predict gain and/or 
loss of a putative TFBS. 
 
Gene reporter assays  
Constructs. Four TGFB1 pHaps (TGH1, TGH2, TGH3 and TGH4) were selected 
for reporter gene assays. For the higher-frequency haplotypes (TGH1 and 
TGH2), genomic DNA of known heterozygous individuals were PCR amplified to 
obtain 2kb haplotype-specific fragments that were then subcloned into the 
promoterless pGL3-Basic Firefly luciferase reporter vector (Promega, Madison, 
WI). The lower-frequency haplotypes (TGH3 and TGH4) were generated by 
site-directed mutagenesis (Stratagen, Cedar Creek, TX) using TGH1 as 
template, following the manufacturer‘s instructions. The oligonucleotides used 
for site-directed mutagenesis were purchased from Integrated DNA 
Technologies (Coralville, IA). Sequences are available upon request. The 
resulting constructs were sequenced to confirm the presence of the expected 
polymorphic sites and then purified on QIAquick PCR purification columns 
(Qiagen, Mississauga, Ontario) prior to transfection. 
 
Transient transfections. Reporter gene expression was measured transiently in 
3 human cell lines: HepG2 (hepatoma), Jeg-3 (choriocarcinoma), HeLa (cervical 
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carcinoma) cells. For each, ~6–8 X 103 cells were plated-out and grown in 96-
well plates (30 mm2) to reach 80–90% confluence at the time of transfection. 
Cells were transfected with lipofectamine according to the manufacturer‘s 
protocol (Invitrogen, Burlington, Ontario). All 3 cell lines were co-transfected with 
100 ng of each haplotype-specific construct and 0.5 ng of a CMV-driven Renilla 
luciferase pRL-CMV plasmid (Promega, Madison, WI) (ratio 200:1) to control for 
transfection efficiency. Similar experiments were performed with a negative 
control consisting of the empty promoterless pGL3-Basic plasmid (Promega, 
Madison, WI) and also with a SV40-driven Firefly luciferase pGL3-Control 
plasmid (Promega, Madison, WI) as a positive control. Cells were harvested 
24hrs post-transfection and luciferase reporter gene activities were measured 
with the Dual-Luciferase Reporter Assay System according to the 
manufacturer‘s instructions (Promega, Madison, WI), in a Spectra Max 190 
luminometer (Molecular Devices, Sunnyvale, CA). The Renilla luciferase activity 
of the co-transfected pRL-CMV internal control was used to normalize the 
results of the Firefly luciferase activity. Results are expressed as the ratio of 
Firefly luciferase activity divided by the pRL-CMV Renilla activity and are 
represented as the relative luciferase activity of 4 independent replicates (Mean 
± SD). The promoterless pGL3-basic vector was used to measure basal 
expression levels in each cell line. Luciferase levels for promoter haplotypes 
TGH1, TGH2, TGH3 and TGH4 were normalized against the basal pGL3-basic 
expression level in each cell line to standardize results and help to differentiate 
any intrinsic cell-specific effects on promoter expression levels (Figure 2). A 
significant 1.5-fold difference in luciferase activity (p ≤ 0.05) over the empty 
vector was considered evidence for haplotype-specific promoter activity. Pairs of 
haplotypes were compared by Student‘s unpaired t-test using promoter 
haplotype TGH1 as reference against which relative expression was compared. 
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Electrophoretic mobility shift assays 
Electrophoretic mobility shit assays (EMSAs) were performed on the 4 most 
frequent pSNPs (−1886G>A, −1571A>G, −1550DEL/AGG and −509C>T). For 
each pSNP, doublestranded oligonucleotide probes corresponding to the 
sequences surrounding the polymorphic sites were radiolabeled and allowed to 
interact with nuclear extracts prepared from HepG2, Jeg-3 and HeLa cells as 
described in Belanger et al. (20), with the exception that, for binding 
competition, the EMSA was performed in the presence of 50-fold molar excess 
of the unlabeled probe oligonucleotide, the unlabeled corresponding mutant 
probe or 1 lg of calf thymus DNA (for variants −1886G>A, −1571A>G and 
−509C>T) or a random oligonucleotide (−1550DEL/AGG) as non-specific 
competitor. The oligonucleotides used in the electrophoretic mobility shift 
assays are as follows (only the 5‘-3‘ top strand of the double-stranded 
oligonucleotides are shown): 
−1886G>A, AATTACCACCATCT(G/A)ATCTACCCTATA; 
−1571A>G, GAAAGAAGGCCCTGGGCCCAAAG(A/G)GAGCAGGGCAG; 
−1550DEL/AGG, GGGACATGAGG(AGG/-)GAAGGCAG; 
−509C>T, CTGACCCTTCCATCC(C/T)TCAGGTGTCCTGT; 
Random oligonucleotide, GATCGAACTGACCGCTTGCGGCCCGT. 
 
Results 
 
The haplotype distributions among the 5 continental population groups are 
shown in Table 1 and Figure 1. (Adapted from Labuda et al. (17)). Haplotype 
structure analysis (refer (17)) showed that the 4 most frequent pSNPs 
(−1886G>A, −1571A>G, −1550DEL/AGG and −509C>T) split the TGFB1 
haplotypes into 2 clusters centered around the 2 major pHaps that together 
accounted for 87.2% of the total haplotypic diversity: TGH1 (46.2%) carrying 
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pSNPs −1886G>A and −1571A>G, and TGH2 (41.0%) carrying pSNPs 
−1550DEL/AGG and −509C>T. A third branch derived from the ancestral 
haplotype sequence consisted of African-specific polymorphisms only. 
 
To further assess the functional significance of DNA variation in the promoter 
region of TGFB1, we performed promoter activity analysis using luciferase gene 
reporter assays. Because of the observed inter-population differences in 
haplotypic diversity and frequency, we limited our analysis to mainly European-
specific haplotypes, that is haplotypes TGH1, TGH2, TGH3 and TGH4. For 
each of these haplotypes, the whole 2kb promoter sequence was subcloned in 
the promoterless pGL3-Basic Firefly luciferase reporter vector. The ability of 
each sequence to promote transcription of the luciferase gene was tested 
transiently in 3 human cell lines (HepG2, Jeg-3 and HeLa). As shown in Figure 
2, the HeLa cell line had overall lower expression levels (relative luciferase 
activity ranging from 0.3 to 1.8, following normalization with the empty pGL3-
Basic vector) compared to Jeg-3 and HepG2. HepG2 showed overall highest 
luciferase expression from the haplotype specific promoter constructs with 
relative luciferase activity ranging from 2.9 to 11.9. Promoter haplotype TGH1 
showed weak promoter activity in HeLa (1.7-fold over the empty vector), 
moderate promoter activity in Jeg-3 (3-fold over the empty vector) and strong 
activity in HepG2 (12-fold over the empty vector). Similarly, haplotypes TGH3 
and TGH4 showed intermediate to high promoter activity in Jeg-3 and HepG2 
but weak activity in HeLa. Haplotype TGH2 showed overall weaker promoter 
activity in all 3 cell lines.  
 
We compared each haplotype to the relative promoter activity of TGH1. 
Significant differences were found between the 2 major haplotypes, TGH1 and 
TGH2, across all 3 cell lines (Figure 2). Relative luciferase activity driven by 
TGH2 was 1.5-fold to 5-fold lower than the luciferase levels driven by its 
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counterpart TGH1, indicating allele-specific promoter activity. Comparison of 
pHaps TGH1 and TGH2 indicates that either the deletion at position −1550 or 
the variant T allele at pSNP −509 or the ancestral G and A alleles at positions 
−1886 and −1571, respectively, or a combination of these 4 genotypes, lowers 
the promoter activity by over 1.5-fold. On the contrary, the opposite alleles 
carried on TGH1 may act to increase promoter activity. Haplotypes TGH3 and 
TGH4 showed significant increased and decreased promoter activity, 
respectively, when compared to TGH1, in at least one of the cell lines tested, 
however, these differences were not consistent across cell lines. 
 
To further investigate the alleged effect of TGFB1 promoter variation on gene 
expression, we looked at the putative impact pSNPs could have on DNA-protein 
binding capacity. Depending on its position in a given regulatory region, a pSNP 
could potentially disrupt transcription factor recognition and thereby affect gene 
expression. The 4 most frequent variants, −1886G>A, −1571A>G, 
−1550DEL/AGG and −509C>T, were examined. Using in silico analysis, we first 
assessed the possibility that the pSNPs laid in consensus sequence elements 
for transcription factor recognition. Using the MatInspector software, we found 
that all 4 pSNPs had a predicted impact on TFBS motifs and that all 4 led to 
both the loss and/or gain of putative binding sites (Table 2), supporting a 
functional role for these pSNPs. These observations suggested that the 
haplotype-specific differences observed in the gene reporter assays could in 
fact be the consequence of polymorphic cis-elements in the promoter.  
 
In an attempt to identify the specific variants responsible for the changes in 
expression, pSNPs −1886G>A, −1571A>G, −1550DEL/AGG and −509C>T 
were further validated by EMSAs in 3 different cell lines. Representative data in 
Jeg-3 are shown in Figure 3. For variant −1886G>A, we observed 3 distinct 
slow-migrating DNA-protein complexes. Allele-specific differential binding was 
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observed for Complex 3 which showed high binding affinity for the −1886A allele 
(Figure 3, lane 6) but was hardly evident when incubated with Jeg-3 nuclear 
extract in the presence of the −1886G allele (Figure 3, lane 1). To confirm 
binding specificity to the −1886A allele, competition EMSAs were performed. In 
the presence of a 50-fold molar excess of the unlabeled −1886G probe, 
Complex 3 was still evident albeit at a much lower level, whereas the complex 
almost completely disappeared when competed with a 50-fold excess of the 
corresponding unlabeled −1886A allele (Figure 3, lane 7 vs. lane 8). The 
nuclear protein bound to the −1886A allele in Complex 3 appeared therefore to 
be a specific DNA-protein interaction that was weakened in the presence of the 
−1886G allele. We may speculate that the −1886G allele, found on the low 
expressing TGH2 haplotype may hinder protein binding within this region of the 
promoter, which in the context of transcription factor binding, could lead to 
decreased promoter activity, as observed in the luciferase gene reporter assay. 
Similar results were obtained for the −1886G>A variant with HeLa and HepG2 
nuclear extracts (Table 2), which both showed similar allele-specific complex 
formation. Promoter SNPs −1571A>G, −1550DEL/AGG and −509C>T were 
processed similarly and we found that −1550DEL/AGG also showed differential 
allelic shifts in all 3 cell lines tested (refer results for Jeg-3 in Figure 3), as did 
−509C>T, however, in HepG2 cells only (Table 2). The −509T allele disrupted 
complex formation in HepG2 cells also suggesting a potential implication for this 
variant in the observed differences in reporter gene expression, whereas in the 
presence of the −1550DEL/AGG allele, allele DNA-protein complexes were 
gained (Figure 3) suggesting that the deletion at position −1550 may lead, on 
the contrary, to novel TFBS motifs. 
 
 
 
 
146 
 
 
Discussion 
 
TGFB1 is a multifunctional cytokine that is ubiquitously expressed and plays a 
crucial role in normal cellular processes and disease. The TGFB1 signaling 
cascade is highly regulated and is sensitive to protein level variation (7). DNA 
variants that lie in putative TFBSs in the TGFB1 promoter could therefore 
potentially perturb transcription factor binding, alter gene expression levels, and 
have a number of pathological consequences. In this study, we set out to 
investigate the impact of functional diversity in the promoter region of TGFB1 on 
the transcriptional regulation of gene expression. Nine pSNPs were previously 
identified in the proximal promoter region of the TGFB1 gene and haplotype 
inference revealed a total of 9 distinct promoter haplotypes among 5 continental 
populations (17). Two major haplotypes, TGH1 and TGH2 represented, 
respectively, 46.2% and 41.0% of the observed worldwide haplotypic variability. 
Allele combinations −1886A/−1571G and −1550DEL/AGG/−509T were mutually 
exclusive, creating 2 distinct clusters around haplotypes TGH1 and TGH2. The 
ancestral promoter haplotype (‗‗ANC‘‘ in Figure 1) derived from chimpanzee 
DNA, was located between these 2 clusters. A third branch derived from the 
ancestral haplotype sequence consisted of African-specific polymorphisms only 
(refer haplotype network, Figure 1).  
 
These clusters could represent distinct phenotypic groups. Our in vitro functional 
assays supported this hypothesis. Using luciferase gene reporter assays and 
electrophoretic mobility shift assays, we provided evidence of allele-specific 
differences in promoter activity and DNA-protein complex formation. Three 
different human cell lines were used in these studies, HeLa (cervical 
carcinoma), Jeg-3 (choriocarcinoma) and HepG2 (hepatoma) cells, to assess 
tissue-specific effects. As expected, not all observations were consistent across 
cell lines, highlighting the importance of in vivo validation to determine the 
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biological relevance of these results. The luciferase gene reporter assays did, 
however, provide evidence of differential promoter activity between TGH1 and 
TGH2 that was consistent across all 3 cell lines. We observed decreased 
expression levels for pHap TGH2 when compared to TGH1. A previous report 
by Shah et al. also assessed diversity in the TGFB1 promoter region and 
reported similar results (21). While the authors examined an extended 
regulatory region which included exon 1, the haplotype patterns and frequencies 
from both studies are comparable (TGH1 vs. p003 and TGH2 vs. p001 of the 
Shah et al. study) and similarly, distinct phylogenetic clusters were identified for 
the 2 most common haplotypes p003 and p001. Interestingly, Shah et al. also 
examined multiple samples of various racial backgrounds and identified a 
number of novel African-American specific polymorphisms including SNPs 
−448C>T and −1146C>G that were observed uniquely among African 
individuals in our study. Though the impact of these variants on gene 
expression among this population was not investigated within the scope of this 
study, Shah et al. showed that variant −448C>T alters the binding affinity of 2 
unidentified transcription factor complexes which also translates into a 
significant difference in reporter gene expression (21). 
 
Our EMSAs showed that variants −1886G>A, −1550DEL/AGG and −509C>T 
perturbed protein binding. TGH2 alleles −1886G and −509T lead to the loss of 
specific DNA-protein complex formation while the AGG deletion lead to the gain 
of protein complex binding at position −1550. These results were corroborated 
by the in silico analysis, which predicted loss and gains of putative TFBS motifs 
at loci −1886G>A, −1550DEL/AGG and −509C>T. Variant −1886G>A was 
shown to lead to the predicted loss of 3 putative TFBSs, AP4, NeuroD/BETA2 
and GATA binding factors. Transcription factor AP4 acts as part of a repressor 
complex to negatively regulate expression of target genes and has been shown 
to directly repress expression of cyclin dependent kinase inhibitor 1A (CDKN1A) 
by occupying 4 CAGCTG motifs in the CDKN1A promoter and was shown to 
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interfere with cell cycle arrest during monoblast differentiation (22). 
NeuroD/BETA2, a basic helix-loop-helix transcription factor, has been shown to 
play a role in tissue-specific differentiation of pancreatic and enteroendocrine 
cells and regulates insulin gene expression and β-cell differentiation (23), while 
GATA transcription factors play a major role in regulating hematopoiesis and 
have been involved in many hematologic disorders (24). Variant −509C>T 
abrogated a putative olfactory neuron-specific transacting factor involved in the 
cell-specific expression of olfactory marker protein genes. The 3 bp deletion at 
position −1550 was predicted to lead to the loss of PAX and MAZ transcription 
factors. Both PAX4 and PAX6 are expressed in pancreatic islets and, along with 
NeuroD/BETA2, regulate endocrine fate in the pancreas (25) whereas Myc 
associated zinc finger transcription factors are speculated to have dual roles in 
transcription initiation and termination and have been shown to be expressed in 
all tissues except the kidney (26). However, the gel shift analysis showed 
appearance, rather than loss, of protein complexes in the presence of the 
deletion. The only transcription factor that was predicted to be gained by the 
−1550AGG deletion was the chorion-specific transcription factor GCMa, 
involved in the expression of multiple placenta-specific genes (27). Although the 
biological relevance of these predictions needs to be further investigated in the 
context of disease, the putative loss and/or gain of transcription factor binding 
motifs did translate into significant differences in reporter gene expression and 
disruption of DNA-protein complex formation. And though the identity of these 
protein complexes remains to be verified, it is possible that TGFB1 alleles 
−1886G, −1550DEL/AGG and −509T could contribute to the decreased 
expression levels observed for haplotype TGH2. 
 
This study was limited to the proximal promoter region (2kb region upstream of 
the transcription start site), and it is thus likely that other regulatory SNPs were 
missed. In this regard, previous studies characterizing the promoter region of 
TGFB1 identified sequences responsible for both promoting and inhibiting 
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transcriptional activity within the 3.1kb region upstream of the transcription start 
site and the first exon of the TGFB1 gene. An additional 9 polymorphisms were 
also identified within this extended region (21). According to these studies, 
variant −509C>T appeared to reside in a negative regulatory region (28) 
whereas variants −1550DEL/AGG and −1571A>G, and perhaps −1886G>A, 
were shown to lie in a distal enhancer region that dramatically increased TGFB1 
expression (21). Moreover, pSNPs −800G>A (rs1800466) and −448C>T 
(rs11466314), which were not thoroughly investigated here, have previously 
been associated with variations in gene expression, as have variants −387C>T 
(rs11466315) in the 5‘ UTR, SNP rs11466345 at the 3‘ end of TGFB1 and the 
Leu10Pro substitution at codon 10 (rs1800470), which were outside of the 
scope of this study (5, 13, 21, 29). Despite this limitation, it appears clear, by our 
study as well as previous reports, that regulatory variation within and around the 
TGFB1 sequence, can modulate transcriptional activity and potentially have 
important implications in disease. 
 
The −509C>T pSNP has been linked to inter-individual variations in TGFB1 
plasma levels to the extent where individuals that were homozygous for the 
−509T variant had almost double the level of circulating TGFB1 compared to 
−509CC carriers (30). A number of studies investigating the association of 
−509C>T with numerous diseases have been performed, however, they have 
yielded largely mixed results. Shah et al. were able to demonstrate exclusive in 
vivo and in vitro recruitment of AP1 to −509C leading to transcriptional 
repression of the TGFB1 gene. However, our in silico analysis failed to predict 
the gain and/or loss of this particular transcription factor binding motif at position 
−509 and we found that haplotype TGH2 which carries the −509T allele leads, 
on the contrary, to weaker promoter activity and decreased expression levels. 
This discrepancy reflects the limitations of computational tools that rely on prior 
knowledge for modeling and predicting biological processes, once again 
highlighting the importance of experimental validation. These discrepancies 
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could also be indicative of a haplotypic effect observed in our study, in which the 
combined effects on gene expression of a number of promoter sequence 
variants were accounted for, rather than focusing on a single polymorphism. 
 
The mechanisms that control TGFB1 expression remain unclear and there still 
remains much to be learned about the genetic and molecular implications of 
TGFB1 in disease before it can be used as a marker in prognosis and 
prevention. For example, the functional impact of many of the SNPs identified in 
this study, as well as others in extended regulatory regions need to be further 
explored and the population-specific effects of TGFB1 regulation warrant more 
ample investigation. This is especially true since a number of promoter SNPs 
investigated here and in previous reports appear to be African-specific. Though 
variation in TGFB1 plasma levels has been reported in a number of diseases 
including cancers, the role of TGFB1 promoter variation in modulating 
expression and in the modulation of disease risk remains unclear. Overall, this 
study should help further elucidate the impact of functional diversity in the 
promoter region of TGFB1 on transcriptional regulation and gene expression 
and be useful for future studies to determine the value of these TGFB1 promoter 
variants in the clinical setting. 
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Figures 
 
 
 
Figure 1. TGFB1 haplotype network 
This haplotype network was adapted from Labuda et al. (17). The area of the 
circle is proportional to the overall haplotype frequency, while colors indicate the 
distribution among continental groups. The solid lines connecting the haplotypes 
represent single mutations occurring without recombination, and correspond to 
the maximum parsimony tree for this network. ‗‗ANC‘‘ designates the ancestral 
promoter haplotype derived from chimpanzee DNA (refer to Labuda et al. for 
details (17)).
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Figure 2. Gene reporter assays evaluating promoter activity of 4 promoter haplotypes of TGFB1 
Relative luciferase activity (Mean ± SD) of TGFB1 promoter haplotypes was measured following transient transfection in 
HeLa, Jeg-3 and HepG2 cells. The ratio of Firefly: Renilla activity of each promoter was normalized against that of the 
empty promoterless pGL3-basic vector in each cell line. Promoter haplotype TGH1 was used as reference against which 
pairwise comparisons were made. Significant differences between haplotype expression are marked with an asterisk (*p < 
0.05; **p < 0.01).
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Figure 3. Representative EMSA analyses showing allelic DNA-protein 
interactions for pSNPs −1886G>A, −1571A>G, −I550DEL/AGG and −509C>T 
in Jeg-3 
The unlabeled probes used to compete DNA-protein interactions are indicated 
(+) at the top of each lane. Specific competitors corresponding to the unlabeled 
allele-specific probes were used in lanes 3, 4, 7 and 8 and non-specific calf 
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thymus DNA or a random oligonucleotide was used in lanes 5 and 9. The 
position of the DNA-protein complexes of slower mobility are marked by arrows 
and fast migrating unbound probes can be seen at the very bottom of the gel. 
NS refers to non-specific complexes.
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Tables 
 
Table 1. TGFB1 promoter haplotype distributions among five continental population groups 
 
A total of nine promoter haplotypes (TGH1 to 9) were inferred from the continental populations under study. The ancestral 
haplotype was derived from chimpanzee DNA and used as reference to identify polymorphic alleles, shown here in bold. 
−, none.
 
 
 
 
1
5
6
 
 
Table 2. Impact of pSNPs on predicted transcription factor binding sites and summary of EMSA results 
 
Predicted impact of the pSNPs was estimated with the Matlnspector software (Matrix Family Library Version 7.0). Gain 
and loss of transcription factor binding sites are specified for the variant allele with respect to the ancestral allele. 
Differential protein binding was further validated using electrophoretic mobility shift assays in three different cell lines. 
1Matrix similarity score.
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Abstract 
 
Although childhood acute lymphoblastic leukemia (ALL) is the most common 
pediatric cancer, its etiology remains poorly understood. In an attempt to 
replicate the findings of two recent genome-wide association studies in a 
French-Canadian cohort, we confirmed the association of five SNPs (rs7073837 
(p = 4.2 x 10-4), rs10994982 (p = 3.8 x 10-4), rs10740055 (p = 1.6 x 10-5), 
rs10821936 (p = 1.7 x 10-7) and rs7089424 (p = 3.6 x 10-7)) in the ARID5B gene 
with childhood ALL. We also confirmed a selective effect for B-cell ALL with 
hyperdiploidy and report a putative gender-specific effect of ARID5B SNPs on 
ALL risk in males. This study provides a strong rationale for more detailed 
analysis to identify the causal variants at this locus and to better understand the 
overall functional contribution of ARID5B to childhood ALL susceptibility. 
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Introduction 
 
Childhood acute lymphoblastic leukemia (ALL), the leading cause of cancer-
related deaths among children, is a heterogeneous disease with subtypes that 
differ markedly in their cellular and molecular characteristics. Advances in our 
understanding of the pathobiology of ALL have lead to risk-targeted treatment 
regimes and increased long-term survival rates (1). Yet, approximately 20% of 
patients do not respond to current treatment protocols, and over two-thirds of 
the survivors experience long-term treatment-related health problems (2). 
 
The etiology of pediatric ALL remains poorly understood. Initiation of 
leukemogenesis occurs during fetal life or in early infancy and is likely caused 
by multiple environmental and genetic factors (3). The assertion that ALL may 
have a genetic basis has long been pursued through association studies based 
on candidate genes; genes involved in xenobiotic metabolism (4), oxidative 
stress response (5), DNA repair (6), folate metabolism (7) and cell cycle 
regulation (8) have been associated with ALL. Two recent genome-wide 
association studies (GWAS) have provided convincing evidence that inherited 
genetic variation contributes to childhood ALL predisposition (9, 10). Using 
different genotyping platforms, Illumina Infinium HD Human 370Duo BeadChips 
(9) and Affymetrix 500K Arrays (10), both studies found strong associations 
between variants at 10q21.2 (ARID5B) and 7p12.2 (IKZF1) and childhood ALL 
risk. Both ARID5B and IKZF1 are involved in transcriptional regulation and 
differentiation of B-lymphocyte progenitors. These studies also pointed to 
CEBPE (14q11.2), DDC (7p12.2) and OR2C3 (1q44) as potential ALL 
susceptibility loci and indicated that common germline variants within the five 
loci identified may be associated with specific ALL subtypes. Follow-up studies 
confirmed that variants at loci 10q21.2, 7p12.2 and 14q11.2 are involved in B-
cell ALL (11). Variation in ARID5B was shown to contribute to ALL risk across 
167 
 
 
 
different racial groups (12) further highlighting the importance of this gene in the 
etiology of childhood ALL. 
 
We attempted to replicate 15 of the initial GWAS signals from the 
Papaemmanuil et al. and Trevino et al. studies in a French-Canadian cohort 
consisting of 284 B-precursor ALL cases and 270 healthy controls from the 
Quebec Childhood ALL (QcALL) study. We replicated the association of 5 SNPs 
within the ARID5B gene, further confirming the implication of this gene in B-cell 
ALL. Our work provides strong rationale for additional studies to identify the 
causal variants at this candidate risk locus. This is the first replication study that 
has attempted to replicate association signals from both initial GWASs in an 
independent population and the first to report a putative gender-specific effect of 
ARID5B on ALL risk in males. 
 
Design and Methods 
 
Study subjects  
Our cohort consisted of 284 childhood B-cell ALL patients and 270 healthy 
controls. In addition, parental DNA was available for 203 of the probands. Study 
subjects were French-Canadians of European descent from the established 
Quebec Childhood ALL (QcALL) cohort (see (4, 8)). Briefly, incident childhood 
pre-B ALL cases were diagnosed in the Hematology-Oncology Unit of Sainte-
Justine Hospital, Montreal, Canada, between October 1985 and November 
2006. The current study sample includes 170 males and 114 females with a 
median age of 4.2 years. This patient cohort is representative of the childhood 
pre-B ALL population; for clinical characteristics of cases, see Table 1. Healthy 
controls, 152 males and 118 females with a median age of 30.1 years, 
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consisted of a group of newborns and adults recruited through clinical 
departments other than the Hematology-Oncology Unit, Sainte-Justine Hospital. 
Peripheral blood or bone marrow (samples in remission) was collected from all 
participants and DNA was extracted as previously described (13). The 
Institutional Review Board approved the research protocol and informed 
consent was obtained from all participants and/or their parents.  
 
SNP genotyping and quality control checks 
SNPs were genotyped using the Luminex xMAP/Autoplex Analyser CS1000 
system (Perkin Elmer, Waltham, MA). The fifteen selected SNPs were amplified 
in a single multiplexed assay and hybridized to Luminex MicroPlex TM –xTAG 
Microspheres (14) for genotyping using allele-specific primer extension (ASPE). 
The PCR and TAG-ASPE primers are shown in Supplementary Table 1; 
amplification and reaction conditions are available upon request. Allele calls 
were assessed and compiled using the Automatic Luminex Genotyping software 
(M. Bourgey et al., manuscript submitted, 2009). The average genotype call rate 
for the 15 SNPs was 97.0%. Hardy-Weinberg equilibrium (HWE) was tested 
using the X2 goodness of fit test and PedCheck (Version 1.1) was used to 
identify genotype incompatibilities using the familial data (15); inconsistent case-
parent trios were removed from the analysis. 
 
Statistical analysis 
Statistical analyses were done using STATA/IC Version 10.1 (StataCorp, 
College Station, TX). Pearson‘s X2 test or Fisher‘s exact test, as appropriate, 
was used to compare allele/genotype/haplotype carriership in patients and 
controls. Crude odds ratios (ORs) were measured using logistic regression and 
are given with 95% confidence intervals (CIs). Pairwise linkage disequilibrium 
(LD) estimates were measured in STATA. We assessed gender-specific 
169 
 
 
 
associations through stratified analysis comparing male cases to male controls 
or female cases to female controls and the Mantel-Haenszel (MH) chi-square 
test of homogeneity was used to test for significant risk differences between 
males and females. Haplotype reconstruction was performed using the 
FAMHAP Software (Version 16), using parental data when available (16); 
incorporating genotype information of related individuals increases precision of 
haplotype reconstruction and frequency estimation (16-18). Logistic regression 
was used to estimate haplotype-specific ORs using the most common haplotype 
as reference and a likelihood ratio test implemented in FAMHAP was used to 
test for global haplotype association with disease status. Multiple testing 
corrections were performed using the Benjamini-Hochberg false discovery rate 
(FDR) method with a type I error rate of 5%; nominal p values are shown. 
 
Results and Discussion 
 
We genotyped the top ten SNPs from Papaemmanuil et al. (GWA1) (9) and five 
SNPs from Trevino et al. (GWA2) (10) in a French-Canadian cohort of European 
descent. The distribution of genotype frequencies in all 15 SNPs were in HWE 
(p > 0.05). Risk allele frequencies were similar to those observed in the 
European populations of both GWAS (9, 10) (Table 2).  
 
Univariate analysis showed highly significant allelic associations within 
chromosomal region 10q21.2. The five SNPs from this region annotated the 
ARID5B gene and were strongly associated with B-cell ALL risk in our cohort; 
OR estimates were in the same direction and were of similar strength as those 
previously reported (Table 2). SNPs rs10994982, rs10740055, rs10821936 and 
rs7089424 span a 42kb region in intron 3 of ARID5B whereas SNP rs7073837 
is located in intron 2. rs10821936, the strongest association signal from GWA2, 
was the most significant signal in our study (p = 1.7 x 10-7). rs10821936 (p =  
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3.6 x 10-7) is in strong LD with rs7089424 (r2 = 0.95), the second-strongest 
association signal in our study. SNPs rs10994982 (GWA1) and rs10740055 
(GWA2) were highly correlated (r2 = 0.93) and strongly associated with 
childhood B-cell ALL (p = 3.8 x 10-4 and p = 1.6 x 10-5, respectively). rs7073837 
was in moderate LD with SNP pairs rs10821936-rs7089424 and rs10994982-
rs10740055 (r2 of 0.65 and 0.72, respectively) and was also associated with 
disease (p = 4.2 x 10-4). These 5 SNP associations withstood multiple testing 
corrections and remained significant after controlling for a false discovery rate of 
5%. Using subtype analysis, we confirmed that ARID5B SNPs were significantly 
associated with B-hyperdiploid ALL (p values ≤ 2.0 x 10-4) (Table 2 and (9)).  
 
The direction and effect sizes were replicated for most of the SNPs tested; out 
of the 15 SNPs interrogated in this study only one (OR2C3 rs1881797) had an 
OR which tended in the opposite direction (93%; P= 0.00049; binomial 
probability). However the association signals at the IKZF1, DDC, CEBPE, and 
OR2C3 loci failed to reach statistical significance in our cohort (Table 2). Lack of 
confirmation of association with chromosomal region 7p12.2  was surprising 
given the strong statistical association observed in both original GWASs, and 
the convincing support of a recent follow-up study conducted in a large German 
case-control cohort for IKZF1 (11). Risk allele frequencies in cases did not differ 
between cohorts therefore failure to replicate is unlikely due to genetic 
heterogeneity. The most likely explanation for the lack of replication is the 
limited power of our study to detect loci with weaker effects. With our limited 
sample size, we had 80% power at the 5% level, to detect a minimum OR of 1.8 
with RAFs ≥ 20% and of 2.1 with RAFs ≥ 10%. Lack of replication could also 
partially reflect the complexity underlying ALL pathogenesis; for example, 
molecular characterization of the disease might differ across studies. Further 
association studies with larger case-control samples and detailed subgroup 
analysis are required to investigate whether the associations between 7p12.2 
(IKZF1 and DDC) and 14q11.2 (CEBPE) hold true.  
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To further describe the observed ARID5B associations and capture associations 
under various genetic models, we measured the corresponding genotype ORs 
in all samples, as well as in males and females separately. Carriers of a 
homozygous risk genotype at SNPs rs7073837, rs10994982 and rs10740055 
had over a 2-fold increase in B-cell ALL risk. A strong allele dose-dependent 
effect on risk was observed at loci rs10821936 and rs7089424 (ptrend = 7.4 x 
10-7 and 1.7 x 10-6, respectively) (Table 3). Significant risk differences were 
found between males and females at loci rs10994982 and rs10740055: a 3.8-
fold and 4.4-fold increase in risk was observed in male carriers of the 
homozygous risk genotypes, respectively, while no significant effect was 
observed in females (MH p values < 0.03) (Table 3). Although the effects of 
rs10821936 and rs7089424 were more marked in males, the gender difference 
was not significant at these loci (p values ≥ 0.15). 
 
We observed similar gender-biases among hyperdiploid ALL patients for 
variants rs10994982 (Males AA vs. GG:  OR(95%C.I.)= 6.25(2.40-17.49); 
Females AA vs. GG: OR(95%C.I.)= 1.12(0.33-3.96); MH p= 0.017), and 
rs10740055 (Males CC vs. AA:  OR(95%C.I.)= 6.90(2.43-22.18); Females CC 
vs. AA: OR(95%C.I.)= 1.66(0.49-6.14); MH p= 0.059) (data not shown). 
However, the wide confidence intervals caused by overstratification of the data 
emphasize the uncertainty of the risk estimates.  
 
Finally, we performed multivariate haplotype analysis for ARID5B 
(Supplementary Table 2). 15 different haplotypes could be inferred, but only four 
haplotypes had frequencies ≥ 0.05 and represented ~96% of the observed 
haplotypes in our sample. The remaining 4% of the chromosomes carried 
eleven minor haplotypes. We found a significant difference in the overall 
distribution of the 15 ARID5B-derived haplotypes between B-cell ALL cases and 
controls (Global X2 = 45.03, 14 degrees of freedom, p = 4.0 x 10-5). The most 
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frequent haplotype among controls (50%) carried non-risk alleles at all five of 
the ARID5B loci (CGATT) whereas the complementary haplotype, formed by the 
risk alleles of these polymorphisms (AACCG), was the most abundant haplotype 
among cases (46.25%). Through haplotype-specific tests we showed that the 
risk haplotype AACCG was associated with a near 2-fold increase in B-cell ALL 
susceptibility (OR(95%CI) = 1.93(1.47-2.53), p = 7.6 x 10-7) (Supplementary 
Table 2). And when stratified by gender, similar results were observed in the 
male subgroup only. The haplotype analysis further demonstrates that the 
associations observed at the 5 individual ARID5B loci are not independent and 
likely reflect a single association signal.  
 
rs10821936 was the strongest association signal in our study (p = 1.7 x 10-7). To 
further verify that the associations detected at ARID5B are not independent, we 
performed logistic regression analysis on each of the additional SNPs, adjusting 
for the effect of variant rs10821936 (data not shown). No residual association 
was provided by the remaining four SNPs after accounting for the effect of 
rs10821936 and the likelihood ratio tests, comparing the reduced univariate 
rs10821936 model to each of the extended 2-SNP models, were all non-
significant (p > 0.12), suggesting no evidence of multiple effects operating 
across the ARID5B SNPs. 
 
Our replication data confirms that ARID5B is a novel susceptibility factor for 
childhood B-cell ALL and corroborate previous findings of a putative selective 
effect for B-cell precursor ALL with hyperdiploidy. We also report a gender-
specific effect of ARID5B SNPs on ALL risk in males. ARID5B plays a vital role 
in the regulation of embryonic development and cell growth and differentiation 
through tissue-specific repression of differentiation-specific gene expression 
(19, 20). Aberrant ARID5B expression in the developing fetus could halt B-
lymphocyte maturation and contribute to leukemogenesis.  B-cell ALL incidence 
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is higher in males and though our data suggest a gender bias in the effect of 
ARID5B variation on disease risk, the link between ARID5B and increased risk 
of leukemia among males remains to be determined. Given the combined 
statistical significance of association of this region, re-sequencing and functional 
analyses are now required to identify the causal variants at the 10q21.2 locus. 
Better elucidation of the mechanisms through which ARID5B variants are 
involved in childhood ALL could be of great diagnostic value and help guide risk-
directed therapy, ultimately improving disease management and outcome. 
 
 
  
174 
 
 
 
Tables  
 
Table 1. Characteristics of the B-cell ALL patients from the Quebec 
Childhood ALL cohort 
Patient Characteristics Cases, n (%) 
Total number of subjects 284 
    
Gender   
Male 170 (59.9) 
Female 114 (40.1) 
    
Age group, years    
<= 1 6 (2.1) 
1-10 201 (70.8) 
> 10 41 (14.4) 
N/D 36 (12.7) 
    
Hyperdiploid   
Positive 106 (37.3) 
Negative 156 (54.9) 
N/D 22 (7.7) 
    
Chromosomal translocations   
Absence of translocation 92 (32.4) 
t(12;21) 35 (12.3) 
Other 12 (4.2) 
N/D 145 (51.1) 
      N/D indicates no data available 
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Table 2. Replication analysis in the Quebec Childhood ALL cohort of germline SNPs whose allele frequencies 
differed between children with ALL and control groups in two genome-wide association studies 
 
RAF Subgroup OR (95% CI) p  value RAF Subgroup OR (95% CI) p  value RAF Subgroup OR (95% CI) p  value
ARID5B  (10q21.2)
rs7073837 A 0.34 B-cell 1.54 ( 1.21-1.97) 4.2E-04 0.40 ― 1.58 (1.35-1.89) 4.7E-16
B-hyperdip 2.10 (1.51-2.93) 9.6E-06 B-cell 1.59 (1.48-1.71) 1.0E-15
rs10994982 A 0.48 B-cell 1.55 ( 1.22-1.97) 3.8E-04 0.47 ― 1.71 (1.43-2.05) 1.2E-09
B-hyperdip 1.87 (1.34-2.60) 2.0E-04 B-hyperdip 1.71 (1.19-2.46) 0.0025
rs10740055 C 0.49 B-cell 1.71 (1.34-2.19) 1.6E-05 0.50 ― 1.53 (1.41-1.64) 5.4E-14
B-hyperdip 2.06 (1.46-2.90) 3.0E-05 B-cell 1.57 (1.45-1.81) 1.6E-14
rs10821936 C 0.33 B-cell 1.93 (1.51-2.48) 1.7E-07 0.33 ― 2.00 (1.68-2.38) 2.8E-16a
B-hyperdip 2.91 (2.08-4.07) 2.0E-10 B-hyperdip 2.12 (1.49-3.01) 9.7E-06
rs7089424 G 0.43 B-cell 1.91 (1.49-2.45) 3.6E-07 0.34 ― 1.65 (1.54-1.76) 6.7E-19
B-hyperdip 2.87 (2.04-4.04) 8.2E-10 B-cell 1.70 (1.58-1.81) 1.4E-19
B-hyperdip ― 3.8E-06b
IKZF1  (7p12.2)
rs6964823 G 0.54 B-cell 1.15 ( .90-1.46) 0.27 0.50 ― 1.52 (1.41-1.64) 6.0E-14
B-cell 1.53 (1.42-1.65) 1.9E-13
rs11978267 G 0.31 B-cell 1.27 (.99-1.65) 0.065 0.27 ― 1.69 (1.4-1.9) 8.8E-11
rs4132601 G 0.31 B-cell 1.26 ( .98-1.62) 0.075 0.28 ― 1.69 (1.58-1.81) 1.2E-19c
B-cell 1.73 (1.61-1.85) 9.3E-20
rs6944602 A 0.24 B-cell 1.17 ( .89-1.55) 0.27 0.21 ― 1.64 (1.37-2.07) 3.4E-15
B-cell 1.69 (1.56-1.81) 1.5E-15
Gene (Chr.),
   DNA variant
Risk
allele
QcALL replication study GWA1 - Papaemmanuil et al. GWA2 - Trevino et al.
―
―
―
―
―
―
―
―
―
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Results are shown for allelic case-control association tests; p values in bold remain significant after FDR adjustment for 
multiple testing at the 5% level. The Quebec Childhood ALL (QcALL) replication cohort consisted of 284 B-cell ALL cases 
and 270 controls; logistic regression was applied to either the full dataset or to a restricted subgroup of patients as 
specified. GWA1; the Papaemmanuil et al. study comprised 907 cases (824 B-cell, 83 T-cell) and 2,398 controls; logistic 
regression was applied to either the full dataset or to a restricted subgroup of patients as specified; P values denote 
Cochran-Armitage trend test statistics. GWA2; the Trevino et al. study consisted of a discovery cohort of 317 cases (274 
B-cell, 43 T-cell) and 17,958 controls; logistic regression was used and subgroup analysis was performed by comparing 
allele frequencies between single ALL subgroups and all other subgroups combined. RAF indicates risk allele frequency 
in controls; OR,odds ratio; CI, confidence interval; –, not applicable. 
a Strongest association signal from the Trevino et al. study. 
b p value denotes case-only logistic regression analysis. 
c Strongest association signal from the Papaemmanuil et al. study. 
DDC  (7p12.2)
rs7809758 G 0.41 B-cell 1.02 (.80-1.30) 0.9 0.37 ― 1.44 (1.32-1.54) 2.4E-10
B-cell 1.48 (1.37-1.60) 2.9E-11
rs880028 C 0.25 B-cell 1.04 (.79-1.36) 0.79 0.22 ― 1.43 (1.30-1.56) 1.3E-07
B-cell 1.49 (1.36-1.61) 1.4E-09
rs3779084 C 0.25 B-cell 1.01 ( .77-1.33) 0.92 0.22 ― 1.44 (1.32-1.56) 8.8E-09
B-cell 1.50 (1.37-1.63) 6.5E-10
rs2242041 G 0.11 B-cell 1.40 (.99-2.00) 0.059 0.09 ― 1.72 (1.3-2.1) 9.9E-07
CEBPE  (14q11.2)
rs2239633 G 0.53 B-cell 1.19 ( .94-1.52) 0.15 0.52 ― 1.34 (1.22-1.45) 2.9E-07
B-cell 1.37 (1.26-1.49) 5.6E-08
OR2C3  (1q44)
rs1881797 C 0.17 B-cell 0.95 ( .66-1.35) 0.77 0.16 ― 1.52 (1.2-1.8) 7.3E-06
t(12;21) 1.31 (.53-3.24) 0.57 t(12;21) 2.08 (1.1-3.8) 0.021
―
―
―
―
―
―
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Table 3. Distribution of ARID5B genotypes among B-cell ALL cases and controls from the Quebec Childhood ALL 
cohort and gender-specific genotype risks estimates 
B-cell ALL
Cases
Controls
B-cell ALL
Cases
Controls Males Females
rs7073837
CC 67 (24.81) 93 (35.23) 1 (referent) – 39 (23.8)/28 (26.4) 59 (39.9)/34 (29.6) 1 (referent) 1 (referent) –
CA 128 (47.41) 127 (48.11) 1.40 (0.94-2.08) 0.1 75 (45.7)/53 (50.0) 65 (43.9)/61 (53.0)  1.75 (1.00-3.05)  1.05 (.54-2.06) 0.22
AA 75 (27.78) 44 (16.67) 2.37 (1.45-3.85) 4.8E-04 50 (30.5)/25 (23.6) 24 (16.2)/20 (17.4)  3.15 (1.60-6.25) 1.52 (.65-3.53) 0.15
rs10994982
GG 50 (18.18) 72 (27.27) 1 (referent) – 28 (16.8)/22 (20.4) 50 (33.1)/22 (19.6) 1 (referent) 1 (referent) –
GA 125 (45.45) 129 (48.86) 1.39 (0.90-2.16) 0.14 71 (42.5)/54 (50.0) 69 (45.7)/59 (52.7)  1.84 (1.00-3.39)  .92 (.43-1.95) 0.13
AA 100 (36.36) 63 (23.86) 2.29 (1.42-3.69) 6.6E-04 68 (40.7)/32 (29.6) 32 (21.2)/31 (27.7)  3.79 (1.94-7.45) 1.03 (.45-2.39) 0.01
rs10740055
AA 41 (15.41) 67 (25.48) 1 (referent) – 22 (13.7)/19 (18.1) 44 (29.3)/23 (20.5) 1 (referent) 1 (referent) –
AC 117 (43.98) 132 (50.19) 1.45 (0.91-2.30) 0.12 65 (40.4)/52 (49.5) 72 (48.0)/59 (52.7)  1.81 (.94-3.51) 1.07 (.49-2.32) 0.27
CC 108 (40.60) 64 (24.33) 2.76 (1.68-4.53) 5.0E-05 74 (46.0)/34 (32.4) 34 (22.7)/30 (26.8) 4.35 (2.16-8.84) 1.37 (.58-3.23) 0.03
rs10821936
TT 76 (27.94) 127 (48.47) 1 (referent) – 42 (25.8)/34 (31.2) 72 (48.3)/55 (49.1) 1 (referent) 1 (referent) –
TC 129 (47.43) 99 (37.79) 2.18 (1.48-3.20) 7.2E-05 73 (44.8)/56 (51.4) 56 (37.6)/42 (37.5)   2.23 (1.29-3.87)  2.16 (1.15-4.04) 0.93
CC 67 (24.63) 36 (13.74) 3.11 (1.90-5.10) 4.8E-06 48 (29.4)/19 (17.4) 21 (14.1)/15 (13.4) 3.92 (1.98-7.84) 2.05 (.85-4.95) 0.21
rs7089424
TT 62 (23.85) 115 (45.28) 1 (referent) – 34 (21.7)/28 (27.2) 64 (44.1)/51 (47.2) 1 (referent) 1 (referent) –
TC 131 (50.38) 99 (38.98) 2.45 (1.63-3.68) 1.1E-05 75 (47.8)/56 (54.4) 59 (40.7)/39 (36.1)  2.39 (1.35-4.25) 2.62 (1.35-5.08) 0.83
CC 67 (25.77) 40 (15.75) 3.11 (1.89-5.12) 6.1E-06 48 (30.6)/19 (18.4) 22 (15.2)/18 (16.7)  4.11 (2.04-8.35)  1.92 (.81-4.58) 0.15
p  valuea
Males/Females (%) OR (95% CI)
DNA variant,
    Genotype
No. (%)
OR (95% CI) p value
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Logistic regression was used to estimate ORs in either the full dataset or in restricted subgroups stratified by gender, 
comparing male cases to male controls or female cases to female controls. Percentages indicate number of individuals 
with a given genotype/total number of genotyped individuals. p values in bold remain significant after FDR adjustment for 
multiple testing at the 5% level. OR indicates odds ratio; CI, confidence interval; –, not applicable. 
a p value denotes the Mantel-Haenszel chi-square test of homogeneity for risk differences between males and females. 
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Supplementary Table 1. Summary of primers used in the PCR and allele-specific primer extension (ASPE) assays 
for SNP genotyping 
 
a SNP position relative to the UCSC Genome Browser Human May 2004 Assembly (hg17)
Gene (Chr)
DNA
variant
Position PCR primers
Product
size (bp)
Allele TAG-ASPE primers
ARID5B (10q21.2)
rs7073837 63,369,901 F: ACCAGAATGCACACAGTCTCCTTGC 241 A TCATTTACCTTTAATCCAATAATCTGGAGAGTGGATCATTTCCCTCA
R: GGTCCAGCGTGGAAGCCACA C TCAATTACCTTTTCAATACAATACGGAGAGTGGATCATTTCCCTCC
rs10994982 63,380,110 F: ACCTCGTGATCTGCCCGCCT 204 A CTAATTACTAACATCACTAACAATCATGGTCTTTTAAATATCTTTTGAGAATGCAA
R: CCACCTCGGCCTTCCGGAGT G TCAATTACTTCACTTTAATCCTTTCATGGTCTTTTAAATATCTTTTGAGAATGCAG
rs10740055 63,388,485 F: ACCACTATGCACTTATCGGAGACAACA 278 G CAATAAACTATACTTCTTCACTAACACAGGGTTTCTATTTGGAAAGCTGG
R: GCCCGGCCGTGACCTCTTTT T CTTTAATCCTTTATCACTTTATCACACAGGGTTTCTATTTGGAAAGCTGT
rs10821936 63,393,583 F: ACCAGCTCGGCAGAGCATCC 257 C TCATAATCTCAACAATCTTTCTTTCTTCTGTGTGCAGTTACTATAGTTGTAC
R: CCCCGGTGCCTTGAACACACT T TCATCAATCAATCTTTTTCACTTTCCTTCTGTGTGCAGTTACTATAGTTGTAT
rs7089424 63,422,165 F: TGGCTCCCGGTCGTGGCTTA 271 G TACACTTTCTTTCTTTCTTTCTTTGGTAGCAGTGTTTGGTTATAGTTTAGTTG
R: CCCAAAACCAAGGGTTTGAACCAGC T CAATTTCATCATTCATTCATTTCAGGTAGCAGTGTTTGGTTATAGTTTAGTTT
IKZF1  (7p12.2)
rs6964823 50,234,305 F: CTGTCCCTGCAGCGTCTGGC 289 C TCATCAATCTTTCAATTTACTTACGACGAATGGTCTTGTTCTTCTTCTTC
R: AGGCCTGGCCGGCTTCTCAG T TTACTTCACTTTCTATTTACAATCAGACGAATGGTCTTGTTCTTCTTCTTT
rs11978267 50,240,513 F: ACTGGCAAGACTGCGGCTGTG 298 C CAATTCAAATCACAATAATCAATCAGGGGAGGGTAGGTAGAAGTTTATGC
R: GCTCTCATGGCACGCTCCCC T AATCCTTTCTTTAATCTCAAATCACTAGGGGAGGGTAGGTAGAAGTTTATGT
rs4132601 50,244,813 F: GGGTGTGGCATTTGGAAACGGGA 231 G TCAAAATCTCAAATACTCAAATCATCACAGAGAAAGATGCGCCTG
R: ACCAACTGACTCAGGGGGATGGA T CAATTAACTACATACAATACATACATCACAGAGAAAGATGCGCCTT
rs6944602 50,247,960 F: ACACAGCTTCACGGTGTGACCC 184 A TACACAATCTTTTCATTACATCATCCAGCGGGCATTACACTCA
R: ATTGCTGCACGGGGGTCTGC G ATCATACATACATACAAATCTACACCAGCGGGCATTACACTCG
DDC  (7p12.2)
rs7809758 50,347,542 F: TGTCCAGCCCAGCCACCTGT 180 C CTTTATCAATACATACTACAATCAAAGCTGGTGAGACGAACCTTCC
R: CCCCAGTTCGAGACCTTTGTGGC T ATACTACATCATAATCAAACATCAAAAGCTGGTGAGACGAACCTTCT
rs880028 50,344,345 F: ACTTGGCCCAGGGGACAGCA 106 A AATCTTACTACAAATCCTTTCTTTGCCCTTTAAATCCGATAGCCCTA
R: TCCTGGCCAGTAGCTGGCTGAT G CTTTTCATCAATAATCTTACCTTTGCCCTTTAAATCCGATAGCCCTG
rs3779084 50,342,944 F: GGGATGCATGGAGCTGTGGGC 190 A CTTTTCAAATCAATACTCAACTTTGGCCCATCTAGGAACCAGGCA
R: CCCCACTGAGGCAGCCTTGC G CTACAAACAAACAAACATTATCAAGCCCATCTAGGAACCAGGCG
rs2242041 50,303,658 F: ACAGCGGTACTTTCCCTCCCCT 99 C CTATCTTTAAACTACAAATCTAACGTCTTATGCTGAGAGCAATGGAATAAC
R: CTCAAGCATCTCTGGAAGGTAGTGGGG G CTAACTAACAATAATCTAACTAACGTCTTATGCTGAGAGCAATGGAATAAG
CEBPE  (14q11.2)
rs2239633 22,658,897 F: TGCTGGGCTCCACCTACCCC 159 A TCATTTCACAATTCAATTACTCAATAGGTCCTAGGAACAAGCTCTACACA
R: CTCTGGAGCACCACGCAGGC G CAATTCATTTACCAATTTACCAATTAGGTCCTAGGAACAAGCTCTACACG
OR2C3 (1q44)
rs1881797 244,015,573 TGTGCACAGCATGTGTTGAGATGA 292 C CTACTATACATCTTACTATACTTTTGGGTTAGTTTCTGAATTCTTGCATTC
GCACTGGACACAGCTTCTGCCT T TTACCTTTATACCTTTCTTTTTACTGGGTTAGTTTCTGAATTCTTGCATTT
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Supplementary Table 2. Distribution of ARID5B haplotypes among B-cell ALL cases and controls from the 
Quebec Childhood ALL cohort and gender-specific haplotype risks estimates 
 
Logistic regression was used to estimate haplotype-specific ORs in either the full dataset or in restricted subgroups 
stratified by gender, comparing male cases to male controls or female cases to female controls. The most common 
haplotype was used as reference. p values in bold remain significant after FDR adjustment for multiple testing at the 5% 
level. Percentages indicate number of chromosomes with given haplotype/total number of chromosomes. Haplotypes with 
relative frequencies <5% are grouped under ARID5B* and are represented as * combinations of the four DNA variants.
B-cell ALL
Cases
Controls
rs7073837 rs10994982 rs10740055 rs10821936 rs7089424
ARID5B*1 C G A T T 224 (38.23) 268 (50.00) 1 (referent) –
ARID5B*2 A A C C G 271 (46.25) 168 (31.34) 1.93 (1.47-2.53) 7.6E-07
ARID5B*3 A A C T T 31 (5.29) 46 (8.58) 0.81 (.48-1.35) 0.39
ARID5B*4 C A C T T 37 (6.31) 34 (6.34) 1.30 ( .77-2.21) 0.30
ARID5B* ― ― ― ― ― 23 (3.92) 20 (3.73) 1.38 (.70-2.71) 0.31
ARID5B*1 C G A T T 120 (34.29) 159 (52.65) 1 (referent) –
ARID5B*2 A A C C G 170 (48.57) 92 (30.46)  2.45 (1.70-3.52) 3.41E-07
ARID5B*3 A A C T T 19 (5.43) 21 (6.95)  1.20 (.58-2.46) 0.59
ARID5B*4 C A C T T 26 (7.43) 15 (4.97)   2.30 (1.11-4.87) 0.014
ARID5B* ― ― ― ― ― 15 (4.29) 15 (4.97) 1.32 (.58-3.03) 0.46
ARID5B*1 C G A T T 104 (44.07) 108 (46.35) 1 (referent) –
ARID5B*2 A A C C G 99 (41.95) 75 (32.19)  1.37 (.90-2.09) 0.120
ARID5B*3 A A C T T 13 (5.51) 24 (10.30)  0.56 (.25-1.22) 0.120
ARID5B*4 C A C T T 11 (4.66) 20 (8.58) 0.57 (.23-1.33) 0.16
ARID5B* ― ― ― ― ― 9 (3.81) 6 (2.58)  1.56 (.47-5.50) 0.41
Total (%)
Males (%)
Females (%)
36.95 (16) 2.13E-03
21.45 (9) 0.011
Global
p value
45.03 (14) 4.04E-05
Haplotype
DNA variant
OR (95% CI) p value
Global
X 2 (df)
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A likelihood ratio test was performed in FAMHAP to compare global haplotype differences between cases and controls 
and is reported here as a Global chi-square test with number of haplotype parameters different from zero-1 degrees of 
freedom. OR indicates crude odds ratio; df, degrees of freedom; and —, not applicable. 
a Significant risk difference between males and females based on Mantel-Haenszel chi-square test of homogeneity: X2= 
7.31 (1df); p value= 0.0069. 
 
182 
 
 
 
References 
 
1. Pieters R, Carroll WL. Biology and treatment of acute lymphoblastic 
leukemia. Pediatr Clin North Am. 2008 Feb;55(1):1-20, ix. 
2. Mody R, Li S, Dover DC, Sallan S, Leisenring W, Oeffinger KC, et al. 
Twenty-five-year follow-up among survivors of childhood acute lymphoblastic 
leukemia: a report from the Childhood Cancer Survivor Study. Blood. 2008 Jun 
15;111(12):5515-23. 
3. Greaves M. Molecular genetics, natural history and the demise of 
childhood leukaemia. Eur J Cancer. 1999 Dec;35(14):1941-53. 
4. Krajinovic M, Labuda D, Richer C, Karimi S, Sinnett D. Susceptibility to 
childhood acute lymphoblastic leukemia: influence of CYP1A1, CYP2D6, 
GSTM1, and GSTT1 genetic polymorphisms. Blood. 1999 Mar 1;93(5):1496-
501. 
5. Krajinovic M, Sinnett H, Richer C, Labuda D, Sinnett D. Role of NQO1, 
MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood 
acute lymphoblastic leukemia. Int J Cancer. 2002 Jan 10;97(2):230-6. 
6. Batar B, Guven M, Baris S, Celkan T, Yildiz I. DNA repair gene XPD and 
XRCC1 polymorphisms and the risk of childhood acute lymphoblastic leukemia. 
Leuk Res. 2009 Jun;33(6):759-63. 
7. Petra BG, Janez J, Vita D. Gene-gene interactions in the folate metabolic 
pathway influence the risk for acute lymphoblastic leukemia in children. Leuk 
Lymphoma. 2007 Apr;48(4):786-92. 
8. Healy J, Belanger H, Beaulieu P, Lariviere M, Labuda D, Sinnett D. 
Promoter SNPs in G1/S checkpoint regulators and their impact on the 
susceptibility to childhood leukemia. Blood. 2007 Jan 15;109(2):683-92. 
9. Papaemmanuil E, Hosking FJ, Vijayakrishnan J, Price A, Olver B, 
Sheridan E, et al. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk 
of childhood acute lymphoblastic leukemia. Nat Genet. 2009 Sep;41(9):1006-10. 
10. Trevino LR, Yang W, French D, Hunger SP, Carroll WL, Devidas M, et al. 
Germline genomic variants associated with childhood acute lymphoblastic 
leukemia. Nat Genet. 2009 Sep;41(9):1001-5. 
183 
 
 
 
11. Prasad RB, Hosking FJ, Vijayakrishnan J, Papaemmanuil E, Kohler R, 
Greaves MF, et al. Verification of the susceptibility loci on 7p12.2, 10q21.2 and 
14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood. Blood. 
2009 Dec 30. 
12. Yang W, Trevino LR, Yang JJ, Scheet P, Pui CH, Evans WE, et al. 
ARID5B SNP rs10821936 is associated with risk of childhood acute 
lymphoblastic leukemia in blacks and contributes to racial differences in 
leukemia incidence. Leukemia.  Jan 7. 
13. Baccichet A, Qualman SK, Sinnett D. Allelic loss in childhood acute 
lymphoblastic leukemia. Leuk Res. 1997 Sep;21(9):817-23. 
14. Koo SH, Ong TC, Chong KT, Lee CG, Chew FT, Lee EJ. Multiplexed 
genotyping of ABC transporter polymorphisms with the Bioplex suspension 
array. Biol Proced Online. 2007;9:27-42. 
15. O'Connell JR, Weeks DE. PedCheck: a program for identification of 
genotype incompatibilities in linkage analysis. Am J Hum Genet. 1998 
Jul;63(1):259-66. 
16. Becker T, Knapp M. Maximum-likelihood estimation of haplotype 
frequencies in nuclear families. Genet Epidemiol. 2004 Jul;27(1):21-32. 
17. Schaid DJ. Relative efficiency of ambiguous vs. directly measured 
haplotype frequencies. Genet Epidemiol. 2002 Nov;23(4):426-43. 
18. Schouten MT, Williams CK, Haley CS. The impact of using related 
individuals for haplotype reconstruction in population studies. Genetics. 2005 
Nov;171(3):1321-30. 
19. Huang TH, Oka T, Asai T, Okada T, Merrills BW, Gertson PN, et al. 
Repression by a differentiation-specific factor of the human cytomegalovirus 
enhancer. Nucleic Acids Res. 1996 May 1;24(9):1695-701. 
20. Wilsker D, Patsialou A, Dallas PB, Moran E. ARID proteins: a diverse 
family of DNA binding proteins implicated in the control of cell growth, 
differentiation, and development. Cell Growth Differ. 2002 Mar;13(3):95-106. 
 
  
184 
 
 
 
Reprint Permissions 
 
 
 
  
  
 
 
 
 
 
 
 
CHAPTER THREE 
COMBINED PATHWAY EFFECTS AND GENE-
GENE INTERACTIONS IN THE 
SUSCEPTIBILITY TO CHILDHOOD ACUTE 
LYMPHOBLASTIC LEUKEMIA 
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In previous analyses, I selected a subset of promoter SNPs (pSNPs) in genes 
that play a key role in maintaining genomic integrity and cell homeostasis and 
performed a candidate gene association study to identify single variants and/or 
haplotypes that may modulate gene expression and thereby influence ALL risk 
in children. Several of these variants, as well as their associated promoter 
haplotypes, were shown to be associated with ALL supporting a role for both 
G1/S cell cycle checkpoint and DNA double-strand break repair mechanisms in 
disease etiology. However these genes and corresponding pSNPs are not likely 
to act alone to confer disease susceptibility but rather interact with a number of 
genes, and possibly environmental factors, and operate through complex 
biological mechanisms to increase susceptibility. Although we cannot be certain 
that the identified pSNPs play a functional role in the biological process in which 
the corresponding gene products are implicated, our genetic data and functional 
studies suggest that they are likely to affect the overall outcome of the pathways 
in which they lie. In which case, each individual variant may only have a small 
incremental effect on disease risk but the genetic effect of combinations of 
functionally relevant SNPs among several pathway components could lead to 
dysregulation of the corresponding pathway and contribute to modified 
childhood ALL risk. The effects of gene-gene or epistatic interactions, whereby 
the effect of a gene can be altered by one or several other genes, could also 
dictate disease outcome over the independent effects of any one susceptibility 
gene. 
 
In the second aim of my study, I used a comprehensive pathway-driven 
approach to identify genes and pathways that are strongly associated with 
childhood ALL. In an attempt to better explain the underlying complexities of 
disease etiology, I also investigated putative gene-gene interaction effects. I 
applied a semi-Bayesian method which involved the use of hierarchical models 
to integrate relevant biological and functional information directly into the 
analytical framework to inform association testing. This is the first time this 
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approach has been used to successfully identify biological pathways involved in 
childhood ALL susceptibility, shedding light on the genetic underpinnings of this 
disease. This work has recently been submitted for publication and is presented 
in this chapter: 
― Promoter variants in genes involved in the cell cycle and DNA repair 
pathways and the susceptibility to childhood acute lymphoblastic 
leukemia (Healy et al. (2010) Cancer Research, submitted); 
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Abstract  
 
Childhood acute lymphoblastic leukemia (ALL) is likely caused by multiple 
genetic and environmental factors however the identification of established 
genetic risk factors for ALL has been impeded by its complex and 
heterogeneous nature. In this study, we postulated that a combination of cis-
acting sequence variants in multiple genes sharing functions in the G1/S cell 
cycle checkpoint and DNA double-strand break repair pathways could influence 
interindividual variability in the susceptibility to childhood ALL by modulating 
gene expression and affecting the overall outcome of these core regulatory 
processes. Hierarchical modeling was used to investigate gene- and pathway-
based associations between 46 promoter SNPs in 12 cell cycle genes and 7 
DNA repair genes with childhood ALL and to explore putative gene-gene 
interactions, while integrating prior biological and functional information into the 
analysis. We found that variants in genes CDKN2A (rs36228834), CDKN2B 
(rs2069416), HDAC1 (rs1741981), BRCA1 (rs3092986), XRCC4 (rs3763063), 
and XRCC5 (rs11685387) are associated with modified risk of disease, and 
pathway analysis supported a role for both biological processes in 
leukemogenesis (cell cycle OR(95%CI)= 1.21(1.07-1.38); DNA repair 
OR(95%CI)= 1.28(1.10-1.47)). This study warrants further elucidation of the 
mechanisms through which aberrant cell cycle control and double-strand break 
repair may be involved in childhood ALL susceptibility. 
 
  
191 
 
 
 
Introduction 
 
B-cell precursor acute lymphoblastic leukemia (pre-B ALL) is the most common 
paediatric cancer. The origins of childhood ALL can likely be explained by a 
combination of inherited genetic predisposition and environmental exposure 
during early development in fetal life and infancy. The assertion that ALL may 
have a genetic basis has long been pursued through candidate gene 
association studies (1-5) and recently, genome-wide association studies (6-9) 
(GWAS) have vindicated the role of common inherited genetic variation in 
childhood ALL susceptibility; still few established genetic risk factors for ALL 
have been identified.  
 
In this study, we postulated that a child‘s susceptibility to ALL may be influenced 
by a combination of sequence variants in multiple genes sharing functions in at 
least two core biological pathways: G1/S cell cycle checkpoint control and DNA 
double-strand break repair (DSBR). Strict regulation of the G1/S cell cycle 
checkpoint and concerted activation of DNA damage repair pathways is critical 
to maintain genomic integrity and cell homeostasis and protect against 
malignant transformation (10). Not surprisingly somatic inactivation of genes 
regulating DNA repair and cell cycle control are common features of most 
cancers in both adults and children (10-12). While there is well-established 
evidence for the role of these biological pathways in driving leukemogenesis 
(13, 14), their relevance in disease predisposition remains elusive. Because of 
the highly regulated nature of these pathways, it seems plausible that variation 
in gene expression levels due to regulatory polymorphisms, could perturb G1/S 
checkpoint activation and preclude proper DNA damage repair, leading to 
increased genomic instability and increased mutational burden resulting in 
leukemic transformation. 
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We hypothesized that cis-acting polymorphisms in the promoter regions 
(pSNPs) of genes encoding key players of the G1/S cell cycle checkpoint 
(CCND1, CDC25A, CDKN1A, CDKN1B, CDKN2A, CDKN2B, E2F1, HDAC1, 
MDM2, SMAD3, RB1, TGFB1) and DSBR pathway (ATM, BRCA1, BRCA2, 
RAD51, XRCC4, XRCC5, XRCC6), could influence susceptibility to ALL. In an 
attempt to better understand the biological mechanisms underlying ALL 
predisposition, we applied a pathway-driven approach in which hierarchical 
modeling (HM) was used to perform a case-control association study and 
assess the effects of the above genes on childhood ALL risk either 
independently or collectively by assessing putative pathway-specific effects. An 
interesting feature of HM is that it allows prior information to be readily 
incorporated into the analytical framework, providing more accurate and stable 
risk estimates and reducing false-positive associations (15-17). Given that the 
promoter variants in our study were selected based on their putative impact on 
gene expression, we included prior information relevant to the functional 
regulatory potential of each variant such as in silico predictions regarding 
transcription factor (TF) binding as well as data from in vitro functional assays. 
This is the first study to directly incorporate prior biological and functional 
knowledge in a candidate gene association study on childhood ALL. 
 
Material and Methods 
 
Study subjects  
Our cohort consisted of 321 childhood pre-B ALL patients and 329 healthy 
controls. Parental DNA was available for 203 of the probands. Study subjects 
were French-Canadians of European descent from the established Quebec 
Childhood ALL (QcALL) cohort (18). Incident cases were diagnosed in the 
Hematology-Oncology Unit of Sainte-Justine Hospital, Montreal, Canada, 
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between October 1985 and November 2006. The current study sample included 
190 males and 131 females with a median age of 4.3 years. Healthy controls, 
182 males and 146 females with a median age of 30.1 years, consisted of a 
group of newborns and adults recruited at Sainte-Justine Hospital. Peripheral 
blood or bone marrow (samples in remission) was collected from all participants 
and DNA was extracted as previously described (19). The Institutional Review 
Board approved the research protocol and informed consent was obtained from 
all participants and/or their parents. 
 
SNP genotyping and quality control filters 
A total of 46 promoter (defined as the 2kb region upstream of the transcription 
start site (20)) SNPs (pSNPs) in 19 genes were selected for genotyping (Table 
1). SNPs were genotyped using the Luminex xMAP/Autoplex Analyser CS1000 
system (Perkin Elmer, Waltham, MA). Groups of SNPs were amplified in 
multiplex PCR assays and hybridized to Luminex MicroPlexTM–xTAG 
Microspheres for genotyping using allele-specific primer extension (ASPE) (21). 
The PCR and TAG-ASPE primers as well as amplification and reaction 
conditions are available upon request. Allele calls were assessed and compiled 
using the Automatic Luminex Genotyping software (M. Bourgey et al., 
manuscript under review). Hardy-Weinberg equilibrium (HWE) was tested in 
cases and controls separately using the chi-square goodness of fit test, and 
PedCheck (Version 1.1) was used to identify genotype incompatibilities using 
the familial data (22); inconsistent case-parent trios were sequenced for 
genotype validation and those that remained inconsistent were removed from 
the analysis. 
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Preliminary statistical analysis 
Unless otherwise stated, statistical analyses were performed in STATA/IC 
version 10.1 (StataCorp, College Station, TX). Preliminary analysis was 
performed to dichotomize genotypes into two categories based on frequency 
distribution of the pSNP alleles, combining risk versus nonrisk genotypes. 
Logistic regression was used to compare genotype carriership in patients and 
controls and to estimate odds ratios (ORs) and 95% confidence intervals (CIs) 
for all 46 pSNPs (Supplementary Table 1). The direction of the measured effect 
was used to identify risk genotype combinations defined as having OR>1; 
therefore minor alleles were not necessarily assumed to confer an increased 
risk.  
 
To reduce redundancy and overfitting in the regression models we chose a 
minimal subset of informative haplotype-tagging pSNPs for subsequent 
analyses. For genes with multiple markers, we reconstructed haplotypes using 
the expectation-maximization algorithm within FAMHAP (Version 16) (23), using 
parental data when available. The ‗htsearch‘ program implemented in STATA 
(http://www-gene.cimr.cam.ac.uk/clayton/software/) with a pair-wise linkage 
disequilibrium threshold of r2>0.8 was used to select informative tag pSNPs 
among cases and controls combined. Tag pSNPs and their associated high-risk 
genotypes are shown in Table 2. 
 
Parental data and haplotype phase information, when available, were used to 
impute missing genotype data in the offspring. Only cases and controls with 
complete genotypic information at all loci (observed or imputed) were retained in 
subsequent analyses. 
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Hierarchical modeling 
A two-stage hierarchical modeling (HM) approach was used to test for 
association between selected genes and childhood pre-B ALL. The hierarchical 
model was described previously (16, 17, 24). Briefly, we used a conventional 
logistic regression model as the first stage: 
 
                                ln  
P
1−P
 =  𝛼 + 𝐗β                                                  (A) 
 
where 𝐗 is a matrix with row number equal to the number of individuals and 
column number equal to the number of genetic markers (𝑛), and β  is a column 
vector of regression coefficients representing the effects of each particular 
marker, on a log scale.  
 
In the second-stage of the hierarchical model we used the following linear model 
to improve the estimation of the β coefficients: 
 
                                               β   =  𝒁π  +  δ                                                                         (B) 
                                                    δ𝑖  ~ 𝑁(0, τ
2)                                                                            
 
where 𝒁 is the prior covariate matrix with the 𝑖th row containing second-stage 
covariates (𝑝) for the 𝑖th genetic marker, π is the corresponding column vector 
of 𝑝 prior coefficients representing the linear effects of the second-stage 
covariates on 𝛽𝑖 . The 𝑛-by-𝑝 𝒁 matrix reflects the similarities between the first-
stage factors. The elements of δ  (𝛿𝑖) are the residual effects of the 𝑖 genetic 
markers and are independent normal random variables with zero means and 
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variances τ2. The prior or second-stage variance, τ2, reflects the range of the 
potential residual effect that remains after accounting for all first- and second-
stage covariates. In other words, the standard deviation, τ, is a measure of the 
prior uncertainty of 𝛽𝑖 . For example τ = 0.5 corresponds to being 95% certain a 
priori that the OR of a given genetic marker lies within a 7-fold range (exp(3.92τ) 
= exp(3.92*0.5) = 7) (15).  
 
Substituting equation B into A gives the following mixed model: 
 
                                          ln  
P
1−P
 =  𝛼  +  𝐗(𝒁π  +  δ)                                                        (C) 
                                                            =  𝛼  +  𝐗𝒁π  +  𝐗δ 
 
in which π is a vector of fixed coefficients and δ is treated as a vector of random 
coefficients with mean 0 and variance τ2.  Conventional maximum-likelihood 
estimation is equivalent to using a model (C) with no constraint on the residual 
effects (τ2 = ∞) and could result in overfitting of the data, conversely, τ2 = 0 
implies no uncertainty about the residual effects and can lead to 
underdispersion of the HM estimates, compared to the constrained (τ2 < ∞) 
multilevel approach (25). 
 
Specification of the second-stage covariates 
We constructed the 𝒁 matrix using prior information pertaining to the biological 
function of the gene and the potential significance of its pSNPs (Table 2). First, 
an indicator column was created to represent each biological pathway (G1/S cell 
cycle checkpoint and DSBR) and a score of 1 was assigned to the genetic risk 
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variant if the corresponding gene was involved in the pathway or 0 if it was not; 
we assumed that the pathways were mutually exclusive. Genes assigned to a 
similar pathway were therefore assumed to be interchangeable and their effects 
to arise from a common distribution. 
 
Second, we included prior information relevant to the functional regulatory 
impact of each polymorphism on gene expression. The putative effect of each 
pSNP on transcription factor (TF) binding was evaluated through cis-regulatory 
module (CRM) predictions (26-28). In silico analysis was performed using the 
PreMod database (http://genomequebec.mcgill.ca/PReMod) to evaluate the 
presence of CRMs; genomic regions with significant module scores (P-values < 
5x10-5) reported in PReMod reflect the presence, in a region of 100-1000bp, of 
a large number of conserved TF binding sites (29). pSNPs falling in such 
regions were assigned the corresponding module score in the 𝒁 matrix; a score 
of 0 was assigned if no significant CRM was identified in the 1kb region 
surrounding the polymorphism. In vitro analyses were carried out to assess the 
functional significance of the variants on DNA-protein binding using 
electrophoretic mobility shift assays (EMSA), and on allele-specific promoter 
activity using luciferase gene reporter assays. Experimental validation was 
performed in three different cell lines (HepG2, Jeg-3 and HeLa) as described 
previously (30). A score of 1 was assigned to a variant in the 𝒁 matrix if the 
EMSA showed appearance and/or disappearance of a DNA-protein complex in 
the presence of the risk allele in at least one of the three cell lines while a score 
of 0 was assigned if there was no change in DNA-protein complex formation. 
Similarly, a score of 1 was assigned to a variant if a significant effect on 
promoter activity (increase or decrease of reporter gene expression) was 
observed for the risk allele/haplotype compared to the non-risk allele/haplotype 
in at least one of the cell lines tested; a score of 0 was assigned if no change in 
reporter gene expression was observed. To include the maximal amount of prior 
information in the analysis we used a conservative approach and assumed that 
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variants with missing data had no relevant functional significance, in which case 
a score of 0 was assigned to the corresponding 𝒁 matrix column for that variant.  
 
The resulting second-stage 𝒁 matrix had 5 columns for each of the prior 
covariates (DSBR pathway, cell cycle pathway, CRM score, differential DNA-
protein binding, and allele-specific promoter activity) (Table 2). Two variations of 
this prior matrix were used in the HM analysis: a reduced model including only 
the two pathway indicators and the full model including both the pathway 
indicators and functional covariates. 
 
Specification of the second-stage variance 
We performed sensitivity analysis to select an appropriate range of residual 
main effects, τ2. Hierarchical modeling was performed with pathway indicators 
only and τ2  set to 0.01, 0.04, 0.1225, 0.25, 0.4 or 1 which corresponds to being 
95% certain a priori that an OR lies in a 1.5-fold, 2.2-fold, 4-fold, 7-fold, 12-fold 
and 50-fold range, respectively. We set all τ2 to a single value, implying equal 
uncertainty about all residual effects. Given that the second-stage model 
contained only limited prior information on the biological relevance of the genes 
and the functional significance of their polymorphisms, the existence of a large 
residual effect is theoretically possible. However most common susceptibility 
variants identified so far have only low to intermediate effects on risk (31), 
therefore it seems unlikely that any of the variants under investigation would 
confer a particularly large increment in disease risk. Consequently, for 
association testing of main genetic effects we set τ2 to a moderate value of 0.04 
which would allow a 2.2-fold variation in the effect of the gene variant. 
Nonetheless, even when τ2 was as large as 1 (implying a prior 95% CI covering 
a 50-fold range) results were similar (Supplementary Table 2). 
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Association testing using hierarchical modeling and conventional logistic 
regression 
We used the SAS macro GLIMMIX for multilevel modeling (SAS version 9.00, 
SAS Institute Inc., Cary, NC) in conjunction with the SAS IML matrix language 
(source code provided by Witte et al. (25); 
http://www.epibiostat.ucsf.edu/witte_lab/glimmix.htm) for two-stage hierarchical 
modeling of the childhood pre-B ALL case-control data.  
 
To evaluate the performance of our model, we compared the results based on 
HM to those from conventional maximum-likelihood analysis. We either treated 
all genetic factors independently and constructed logistic regression models with 
a single marker in each regression (Conventional model 1); or included all 
markers in one single logistic regression model (Conventional model 2). 
Pathway effects were further validated using the pathway genetic load (PGL) 
method described in Huebinger et al. (32). Individuals were assigned a score 
based on the number of risk genotypes they carried across all loci of a given 
pathway. Scores for the genetic load for the cell cycle pathway could range from 
0 to 20 and from 0 to 14 for the DSBR pathway. Logistic regression was used, 
with PGL as independent variable, to measure the risk associated with carrying 
an increasing number of risk genotypes in a given pathway. 
 
Gene-gene interaction effects 
To explore possible epistasis effects in the hierarchical modeling framework, we 
added product terms of pair-wise interactions to the first-stage model of the 
form: 
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                                       ln  
P
1−P
 =  𝛼 + X𝑖𝛽𝑖 +  X𝑗𝛽𝑗 + (Xi ∗  Xj)𝛽𝑖𝑗                                  (D) 
 
An extra row was added to the 𝒁 matrix for each gene-gene product term and 
each interaction parameter was assigned a score of 1 in the relevant biological 
pathway columns. Given that the functional data was relevant to each individual 
pSNP and no measures of the putative biological effects of statistical 
interactions between pSNPs on disease were available, we included only 
pathway information in the gene-gene interaction analysis; the 𝒁 matrix is 
available upon request. 
 
Consistent with the main effects, we performed a sensitivity analysis to select an 
appropriate range of residual gene-gene interaction effects (Supplementary 
Table 3). We selected a slightly wider range and set τ2 = 0.1225 allowing a 4-
fold variation in the effect of the gene x gene product term on childhood B-cell 
ALL risk. 
  
The SAS macro GLIMMIX was used to test for gene-gene interactions in the HM 
framework, as described previously. We compared the HM estimates to those 
obtained through conventional gene-gene interaction analyses. We performed 
maximum-likelihood analysis using logistic regression with either a single gene x 
gene (or effectively a SNP x SNP) product term and both significant main effects 
in each regression model (Conventional GxG model 1), or all significant main 
effects and all relevant pair-wise SNP x SNP product terms in one single model 
(Conventional GxG model 2). We performed multiple logistic regressions in a 
backward stepwise manner (Backward stepwise model) forcing all significant 
main effects into the model and using a significance level for removal from the 
model of P≤0.05 and a significance level for addition to the model of P≤0.10. 
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Results  
 
A total of 46 pSNPs in 19 genes were genotyped among 321 unrelated cases 
(including 203 case-parent trios) and 329 controls. All of the SNP allele 
frequencies were in HWE (P<0.01) except for variants CCND1-1537INS/C and 
XRCC6-1469C>T which significantly deviated from HWE in the control group 
and were therefore excluded from the analysis. We also removed individuals for 
which Mendelian inconsistencies could not be reconciled by sequencing; on 
average, two families were removed at each locus. The percentage of missing 
case genotypes was well below 10% for all variants except ATM-635T>A 
(12.1%). Following imputation using parental data and LD information, the 
percentage of missing data dropped to less than 3.4% across all loci. Imputation 
had no effect on the significance or directionality of the associations therefore 
ATM-635T>A was retained in the analysis. Variant genotypes were 
dichotomized as risk versus nonrisk, assuming that the risk genotype 
combination was associated with a positive effect (OR>1) on disease 
susceptibility (Supplementary Table 1). Following data quality control and 
imputation a total of 286 childhood pre-B ALL cases and 297 healthy controls 
were fully genotyped at 34 tag-pSNPs from 19 genes (Table 2). The distribution 
of demographic and clinical characteristics of cases retained in the analysis are 
given in Table 3. 
 
We first measured the main effects of the pSNPs on pre-B ALL risk (Table 4). 
For each variant, four risk estimates (OR(95%CI)) are shown. The conventional 
single marker analysis suggested that seven pSNPs were associated with pre-B 
ALL risk when considered independently: CDKN2A-222T>A, CDKN2B-
593A>T,C, TGFB1-1886A>G, BRCA1-588A>G, XRCC4-1864T>C, XRCC4-
1407C>G, and XRCC5-297C>T. Association with three of these variants 
(TGFB1-1886A>G, XRCC4-1407C>G, and XRCC5-297C>T) was lost using 
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multivariate analysis. The HM procedure with pathway indicators only, 
confirmed the association of variants CDKN2A-222T>A, CDKN2B-593A>T,C, 
BRCA1-588A>G, XRCC4-1864T>C, and XRCC5-297C>T and an additional 
effect was observed for HDAC1-1269T>C, but the latter was lost when we 
included functional data in the prior covariate matrix. Hierarchical regression 
increased the precision of the risk estimates as CIs were narrower when 
compared to conventional estimates, and estimates were more stable: more 
extreme values in the conventional analysis, such as the risk estimate for 
CDKN2A-222TA/AA (Conventional model 1: OR(95%CI)= 2.38(1.34-4.22)), 
experienced notable shrinkage (Hierarchical model 1: OR(95%CI)= 1.40(1.00-
1.96)); moderate, stable risk estimates however, such as XRCC4-1864T>C 
(Conventional model 1: OR(95%CI)= 1.61(1.13-2.30)) remained much the same 
((Hierarchical model 1: OR(95%CI)= 1.42(1.07-1.88)). Results for Hierarchical 
model 2 (pathway indicators and functional assays) were more unstable and 
had larger variances than those obtained including pathway information only. 
This may be due to the fact that functional information was lacking for several of 
the pSNPs. 
 
Rather than limit the analysis to individual genes, we investigated the combined 
action of multiple genes within the same pathway. Assuming that the effects of 
the SNPs from a similar pathway are interchangeable and are drawn from the 
same distribution, we could extract the second-stage coefficients (π) from the 
HM model to measure pathway-specific effects on disease outcome. Both the 
DSBR and G1/S cell cycle control pathways were associated with increased risk 
of pre-B ALL among children (Hierarchical model 1: OR(95%CI)= 1.28(1.10-
1.47) and 1.21(1.07-1.38), respectively) (Table 4). Similar results were obtained 
when the pSNPs were combined into a pathway genetic load score; significant 
associations were confirmed with both the cell cycle control (OR(95%CI)=  
1.19(1.10-1.29), P=2.10x10-5) and DSBR pathways (OR(95%CI)=  1.27(1.15-
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1.39), P=3.61x10-7), and increased risk of ALL was associated with increasing 
numbers of risk genotypes within a given pathway. 
 
Finally, we investigated the putative effects of gene-gene interactions on pre-B 
ALL risk using both conventional maximum-likelihood estimation and 
hierarchical modeling (Supplementary Table 4). A fully saturated model 
including all main effects and all possible pair-wise interactions resulted in 
model instability due to sparse data. Therefore we limited the gene-gene 
interaction analysis to variants with significant main effects only. Three 
conventional maximum-likelihood testing procedures for detecting gene-gene 
interactions were compared to HM in which product terms for the 15 pair-wise 
interactions were included in the first-stage regression model and pathway 
indicators informed the second-stage regression. HM provided overall more 
stable values, however no evidence of interaction could be detected in this 
dataset. We also tested all possible pair-wise interaction effects between the 34 
pSNPs using conventional logistic regression (561 tests in total); as expected, 
none of the significant interactions withstood multiple testing corrections (data 
not shown). In addition, we modeled pathway-specific interactions by restricting 
the analysis to genes acting within the same pathway, since these are likely to 
be biologically more relevant, yet no further evidence of interaction was 
observed (data not shown). 
 
Discussion 
 
Using a comprehensive hierarchical modeling approach, we incorporated 
biological knowledge as well as in silico and in vitro functional data into the 
association analysis, and successfully identified individual variants in two 
biologically relevant pathways that were associated with an increased risk of 
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ALL: CDKN2A-222TA/AA (rs36228834), CDKN2B-593AA/AC (rs2069416), and 
HDAC1-1269TT (rs1741981) involved in the G1/S cell cycle checkpoint, and 
BRCA1-588AA (rs3092986), XRCC4-1864TT (rs3763063), and XRCC5-
297CT/TT (rs11685387) involved in DNA double-strand break repair.  
 
CDKN2A and CDKN2B are well-characterized tumor suppressors that map to 
chromosomal region 9p21. They negatively regulate cell cycle progression 
through the G1/S checkpoint and are frequently inactivated in B-cell ALL (33). 
The implication of these genetic variants in ALL susceptibility has previously 
been demonstrated in a candidate-gene study on the same cohort (5). 
Furthermore, a recent GWAS identified a variant (rs3731217) within the 
CDKN2A gene region that was strongly associated with childhood ALL in a large 
case-control replication series including French-Canadian patients from the 
QcALL cohort (8). This variant lies 9.3kb downstream from the CDKN2A 
association signal identified here. Unfortunately we are currently unable to 
describe LD levels between these two SNPs therefore it is unknown to us 
whether or not these CDKN2A signals represent the same association. However 
LD between variants CDKN2A-222T>A and CDKN2B-593A>T,C in the present 
study is low (D‘= 0.81, R2= 0.02), and based on data from European individuals 
genotyped in the 1000 Genomes Project, pairwise LD between variants 
CDKN2A rs3731217 from the GWAS and CDKN2B-593A>T,C from this study, is 
also expected to be low (D‘= 0.32 and R2= 0.01), suggesting independence of 
the CDKN2A and CDKN2B association signals. While Sherborne et al. found no 
SNPs in LD with variant rs3731217 in any of the coding regions of CDKN2A or 
in any of the other adjacent genes (CDKN2B, MTAP, ANRIL), nor did they 
identify any regulatory regions surrounding rs3731217 or effects on gene 
expression (8), our in vitro data did show differential DNA-protein binding within 
the promoter region of CDKN2A and allele-specific promoter activity associated 
with the variant -222T>A (rs36228834) in our study. Additional functional data 
including allele-specific promoter activity associated with promoter haplotypes 
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carrying the risk alleles for CDKN2A-222A and CDKN2B-593A, in conjunction 
with the differential DNA-protein binding observed for allele CDKN2A-222A (no 
complex-binding differences were observed for CDKN2B-593A>T,C), further 
support the putative role of these variants in modulating gene expression and 
perhaps disease risk. Yet fine-mapping and additional functional studies are 
imperative to better define the causal basis of the 9p21 associations with 
childhood pre-B ALL. 
 
Furthermore, histone deacetylase HDAC1 plays a key role in lineage 
specification during hematopoiesis and is overexpressed in acute myeloid 
leukemia where it has been shown to contribute to leukemogenesis by 
perturbing differentiation (34). In our gene reporter assays, variant -1269T in 
HDAC1 was associated with increased promoter activity in HeLa cells (no 
EMSAs were available). BRCA1 is a master regulator of genome integrity due to 
its roles in both cell cycle checkpoint control and DSBR through homologous 
recombination (35). Inactivation of BRCA1 has been shown to increase risk for 
leukemia by allowing the number of cells with errors in DSBR to survive (36); in 
fact BRCA1 is nearly undetectable in leukemia cells from patients with chronic 
myelocytic leukemia (37). The in silico analysis was highly indicative of a CRM 
within the 1kb surrounding the BRCA1-588A>G variant and functional validation 
showed differential DNA-protein complex formation and gene reporter assays 
suggested allele-specific gene expression associated with promoter haplotypes 
carrying the BRCA1-588A allele. Conversely, XRCC4 and XRCC5 are involved 
in the error-prone nonhomologous end joining repair of double strand breaks. 
Overactivity of this pathway and concomitant DNA misrepair has been shown to 
lead to increased chromosomal instability and contribute to leukemia (38). 
Though no EMSAs were available, luciferase gene reporter assays did provide 
evidence for allele-specific promoter activity associated with pSNP XRCC5 -
297C>T with the high-risk -297T allele showing increased activity in vitro. 
Promoter SNPs in XRCC4 have recently been associated with increased 
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childhood leukemia risk in a Taiwanese population (39); yet unfortunately no 
functional data were available for variant XRCC4 -1864.  
 
Our pathway-based analysis further supported a role for the G1/S cell cycle 
checkpoint and DSBR systems in ALL susceptibility perhaps via increased 
tolerance to genomic instability associated with impaired differentiation and 
deregulated proliferation. Risk was shown to significantly increase with 
increasing numbers of risk alleles within a given pathway, as demonstrated by 
the PGL analysis. Thus, based on the observed associations and in vitro 
functional evidence, one could speculate that modulated expression levels of 
G1/S cell cycle regulators CDKN2A, CDKN2B and HDAC1, and of DSBR genes 
BRCA1, XRCC4 and XRCC5, due to the corresponding promoter 
polymorphisms, could influence a child‘s susceptibility to develop ALL either 
through the individual effects of their variants or via global pathway 
deregulation. However the functional significance of the observed associations 
remains speculative and requires further validation to confirm association and 
better describe the mechanistic role of these pSNPs and respective pathways in 
childhood pre-B ALL susceptibility.  
 
This is the first time HM was applied in the study of childhood leukemia, and to 
the best of our knowledge, this is the first time functional data have efficiently 
been integrated in a case-control genetic association study to inform risk 
estimation. HM allowed us to increase the precision of the risk estimates and 
reduced the likelihood of false-positives by shrinking effect sizes toward a prior 
mean. Though a more comprehensive modeling approach within both the 
conventional and hierarchical framework would include main effects and 
putative gene-gene interactions between factors that act jointly within a pathway 
or that operate in interconnecting pathways, we were unable to detect any 
significant gene-gene interaction effects in this study, which suffered from small 
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sample sizes. Still epistasis likely plays an important role in determining disease 
predisposition and warrants further investigation in larger childhood pre-B ALL 
study samples. Additional limitations to the hierarchical model used in this study 
include the dichotomization of the SNP genotypes into risk versus nonrisk 
classes, which may not have reflected the underlying genetic model of 
inheritance. Second, in the design of the 𝒁 matrix, prior functional information 
was missing for some of the variants and was considered equivalent to a 
negative result. Moreover, use of 0 and 1 in the 𝒁 matrix to describe EMSA and 
gene reporter data, is unlikely to capture the precise differences between the 
genetic factors. Third, in using a single common prior variance, τ2, for all 
markers, we assumed that the effects of individual SNPs and gene-gene 
interactions from a similar pathway were drawn from a single distribution and 
that their effect sizes should be shrunk toward a single prior mean; however in 
practice, this may not hold true. Nonetheless, our results suggest that the 
pathway-based model was relatively robust and that a 𝒁 matrix that is 
reasonable in its biological interpretation of the functional significance of genetic 
variants can be helpful in improving risk estimation. Finally, even though the HM 
model used in this study obviously represented an incomplete picture of the 
underlying disease process, it still provided insight into the mechanisms that 
may be driving leukemogenesis, suggesting a role for both the cell cycle and 
DNA double-strand break repair pathways, and allowed for individual gene 
variants associated with disease to be identified.  
 
In conclusion, using a comprehensive hierarchical modeling approach, we 
provide evidence that genes involved in mediating the cellular response to DNA 
damage, including G1/S cell cycle inhibition and DSBR, are associated with 
modified risk of pre-B ALL among children. However, replication in larger 
cohorts is imperative and further association testing and functional validation will 
also be required to identify the causal variants at the suggested loci and validate 
their implication in disease. This is especially true given that tag SNPs were 
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used in the analysis and that these SNPs are in linkage disequilibrium with a 
number of SNPs that may or may not have been genotyped in this study. 
Considering that new therapeutic development in cancer may lie in the 
discovery of agents that target the physiologic effects of altered biologic 
pathways rather than their individual gene components (40), better elucidation 
of the mechanisms through which aberrant cell cycle control and DSBR are 
involved in childhood ALL susceptibility could be of great diagnostic value and 
provide the data required to help guide risk-directed therapy, ultimately 
improving disease management and outcome.  
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Tables 
 
Table 1. Genes and DNA variants genotyped in B-cell ALL patients, their 
parents, and healthy controls 
Pathway: Gene (Chr.), 
DNA variant 
dbSNP Position MAF (%) 
G1/S cell cycle control: 
   
CCND1 (11q13) 
   
-1938T>C rs1944129 69,453,935 48.8 
-1537INS C rs36225395 69,454,336 45.2 
CDC25A (3p21) 
   
-2030G>T rs1903061 48,231,919 10.3 
CDKN1A (6p21.2) 
   
-1284T>C rs733590 36,645,203 36.2 
-899T>G rs762624 36,645,588 27.1 
-791T>C rs2395655 36,645,696 39.74 
CDKN1B (12p13) 
   
-1857C>T rs3759217 12,868,452 11.6 
-1608G>A rs35756741 12,868,701 8.6 
-373G>T rs36228499 12,869,936 43.4 
CDKN2A (9p21) 
   
-222T>A rs36228834 21,975,319 3.3 
CDKN2B (9p21) 
   
-1270C>T rs36229158 22,010,681 2.8 
-593A>T,C rs2069416 22,010,004 37.4/2.7 
-287G>C rs2069418 22,009,698 42.7 
E2F1 (20q11.2) 
   
-187C>T rs3213141 32,274,380 24.1 
HDAC1 (1p34.1) 
   
-1269T>C rs1741981 32,756,439 33.0 
-455T>C rs36212119 32,757,253 8.4 
MDM2 (12q14.3-q15) 
   
-1494A>G rs1144944 69,200,485 49.2 
-1174DEL AAAAAGC(40bp) rs3730485 69,200,806-69,200,845 40.5 
-182C>G rs937282 69,201,797 48.3 
+309T>G rs2279744 69,202,580 36.6 
SMAD3 (15q21-q22) 
   
-1938T>C rs36221701 67,356,489 12.8 
RB1(13q14.1-q14.2) 
   
-1554C>A rs1573601 48,876,357 24.8 
TGFB1 (19q13.1) 
   
-1886A>G rs2317130 41,861,674 31.4 
-1571G>A rs4803457 41,861,359 39.4 
-1550DEL AGG rs11466313 41,861,338-41,861,337 31.0 
-508G>A rs1800469 41,860,296 31.3 
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DNA double-strand break repair: 
   
ATM (11q22.3) 
   
-1206G>T rs4987876 108,092,637 9.6 
-635T>A rs228589 108,093,208 41.8 
BRCA1 (17q21) 
   
-1890T>C rs4793204 41,279,298 32.4 
-708A>G rs799906 41,278,116 33.4 
-598INS ACA rs8176071 41,278,006-41,278,005 32.3 
-588A>G rs3092986 41,277,996 9.0 
BRCA2 (13q12.3) 
   
-1555C>A rs206114 32,888,062 41.3 
-1260DEL GTCTAA rs3072036 32,888,357-32,888,362 39.6 
-1144A>G rs206115 32,888,473 40.9 
-1134C>T rs206116 32,888,483 40.2 
-908C>T rs206117 32,888,709 39.7 
-254G>A rs3092989 32,889,363 20.5 
RAD51 (15q15.1) 
   
-1185A>T rs2619679 40,986,237 49.1 
XRCC4 (5q13-q14) 
   
-1864T>C rs3763063 82,371,453 49.5 
-1407C>G rs1993947 82,371,910 8.4 
XRCC5 (2q35) 
   
-1379G>T rs828907 216,972,732 47.1 
-297C>T rs11685387 216,973,814 25.6 
XRCC6 (22q11-q13) 
   
-1469C>T rs28384701 42,016,526 4.5 
-1296C>G rs2267437 42,016,699 38.6 
-731G>A rs132770 42,017,264 25.1 
DNA variant positions were numbered with respect to the first nucleotide of the 
first exon as +1, and the nucleotide immediately upstream as -1. Mapping of 
SNP positions is based on dbSNP build 130 and the GRCh37 human assembly 
(UCSC Genome Browser). Minor allele frequency (MAF) indicates minor allele 
frequency and was calculated on a control cohort consisting of 329 healthy 
French-Canadian individuals from the QcALL cohort; overall frequencies are 
comparable to those reported for other populations of European descent. SNPs 
that were included in the analysis had a MAF≥5% in at least the pre-B ALL 
patients or the control group. 
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Table 2. Prior matrix used in the hierarchical model 
Gene tag pSNP High-risk genotype DSBR 
Cell 
cycle 
CRM 
score 
Differential 
DNA-protein 
binding 
Allele-specific 
promoter activity 
CCND1  -1938T>C -1938CC 0 1 33.83 0 0 
CDC25A  -2030G>T -2030GG 0 1 0 1 1 
CDKN1A  -1284T>C -1284TC/CC 0 1 0 1 1 
  -899T>G -899TT 0 1 0 1 1 
CDKN1B  -1857C>T -1857CC 0 1 0 0 0 
  -1608G>A -1608GA/AA 0 1 0 0 0 
  -373G>T -373GG/GT 0 1 38.14 0 1 
CDKN2A  -222T>A -222TA/AA 0 1 0 1 1 
CDKN2B  -593A>T,C -593AA/AC 0 1 0 0 1 
  -287G>C -287GG 0 1 0 1 1 
E2F1  -187C>T -187CC 0 1 0 0 0 
HDAC1  -1269T>C -1269TT 0 1 0 0 1 
  -455T>C -455TC/CC 0 1 0 0 1 
SMAD3  -1938T>C -1938TT 0 1 0 0 1 
MDM2  -1494A>G -1494AG/GG 0 1 0 1 1 
  
-1174DEL 
AAAAAGC(40bp) 
-1174AAAAAGC-/-- 0 1 0 0 1 
  +309T>G +309TT 0 1 0 0 1 
RB1 -1554C>A -1554CC 0 1 0 1 0 
TGFB1  -1886A>G -1886GG 0 1 0 1 1 
  -1571G>A -1571AA 0 1 0 0 1 
ATM  -1206G>T -1206GT/TT 1 0 25.37 0 1 
  -635T>A -635TT 1 0 25.37 0 1 
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BRCA1  -598INS ACA -598-ACA/ACA ACA 1 0 56.67 1 1 
  -588A>G -588AA 1 0 56.67 1 1 
BRCA2  -1260DEL GTCTAA -1260-- 1 0 0 0 1 
  -1144A>G -1144GG 1 0 0 1 1 
  -254G>A -254GG 1 0 0 0 1 
RAD51  -1185A>T -1185TT 1 0 0 0 0 
XRCC4  -1864T>C -1864TT 1 0 0 0 0 
  -1407C>G -1407CG/GG 1 0 0 0 0 
XRCC5  -1379G>T -1379GG 1 0 0 0 1 
  -297C>T -297CT/TT 1 0 0 0 1 
XRCC6  -1296C>G -1296GG 1 0 0 0 0 
  -731G>A -731GG 1 0 0 0 0 
 
The 𝒁 matrix used in the second stage of the hierarchical model included pathway information (DSBR double strand break 
repair; cell cycle control) as well as prior information on potential pSNP function based on cis-regulatory modulation 
potential (CRM score), on disruption of DNA-protein binding as evidenced by electrophoretic mobility shift assays (EMSA), 
and on allele-specific promoter activity as evidenced by gene reporter assays. Results for the EMSA and reporter gene 
expression assay were dichotomized: 1= appearance and/or disappearance of DNA-protein complex in the presence of 
the risk allele or significant increase or decrease of gene expression for the risk allele/haplotype compared to the non-risk 
allele/haplotype; 0= no change in DNA-protein complex formation in the presence of the risk allele or no change in 
reporter gene expression for the risk allele/haplotype. High risk alleles were presumed to have a positive effect on disease 
risk and therefore minor alleles were not necessarily assumed to confer an increased risk. 
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Table 3. Characteristics of the French-Canadian pre-B ALL patients from 
the Quebec Childhood ALL cohort that were retained in the analysis 
Patient Characteristics Cases, n (%) 
Total number of subjects 286 
    
Gender   
Male 168 (58.7) 
Female 118 (41.3) 
    
Age group, years    
<= 1 6 (2.1) 
1-10 220 (76.92) 
> 10 42 (14.69) 
N/D 18 (6.29) 
    
Hyperdiploidy   
Positive 109 (38.1) 
Negative 150 (52.5) 
N/D 27 (9.4) 
    
Chromosomal translocations   
Absence of translocation 92 (32.2) 
t(12;21) 32 (11.2) 
Other 10 (3.4) 
N/D 152 (53.2) 
    
Normal ploidy and absence of 
chromosomal translocations 
39 (13.6) 
                                  
Frequencies based on the total number patients that were fully genotyped at all 
tag-pSNPs following data quality control and imputation. N/D indicates no data 
available. 
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Table 4. Main effects of pSNPs on pre-B ALL risk among children, as estimated by conventional maximum-
likelihood analysis and hierarchical modeling 
Gene tag pSNP 
High-risk 
genotype 
Case 
no. 
(n= 286) 
Control 
no. 
(n= 297) 
Conventional 1, 
OR (95% CI) 
Conventional 2, 
OR (95% CI) 
Pathway HM 1, 
OR (95% CI) 
Pathway and 
functional HM 2, 
OR (95% CI) 
CCND1  -1938T>C -1938CC 67 60 1.21 (.82-1.79) 1.26 (0.82-1.93) 1.23 (.92-1.66) 1.24 (.88-1.74) 
CDC25A  -2030G>T -2030GG 237 239 1.17 (.77-1.79) 1.24 (.78-1.96) 1.24 (.91-1.69) 1.27 (.92-1.75) 
CDKN1A  -1284T>C -1284TC/CC 181 178 1.15 (.83-1.61) 1.28 (.85-1.93) 1.23 (.93-1.63) 1.26 (.94-1.69) 
  -899T>G -899TT 160 161 1.07 (.77-1.49) 1.22 (.81-1.82) 1.21 (.91-1.60) 1.24 (.92-1.66) 
CDKN1B  -1857C>T -1857CC 228 229 1.17 (.79-1.73) 1.16 (.74-1.83) 1.23 (.91-1.65) 1.21 (.89-1.65) 
  -1608G>A -1608GA/AA 56 50 1.20 (.79-1.83) 1.14 (.71-1.84) 1.17 (.87-1.59) 1.16 (.85-1.59) 
  -373G>T  -373GG/GT 241 247 1.08 (.70-1.68) 1.04 (.63-1.71) 1.14 (.84-1.56) 1.15 (.81-1.63) 
CDKN2A  -222T>A -222TA/AA 40 19 2.38 (1.34-4.22) 1.98 (1.05-3.72) 1.40 (1.00-1.96) 1.44 (1.01-2.04) 
CDKN2B  -593A>T,C -593AA/AC 136 113 1.48 (1.06-2.05) 1.48 (1.01-2.18) 1.38 (1.05-1.81) 1.36 (1.03-1.79) 
  -287G>C -287GG 96 94 1.09 (.77-1.54) 1.20 (.80-1.81) 1.23 (.93-1.63) 1.25 (.93-1.67) 
E2F1  -187C>T -187CC 166 170 1.03 (.74-1.44) 1.03 (.72-1.47) 1.13 (.86-1.47) 1.12 (.85-1.47) 
HDAC1  -1269T>C -1269TT 147 131 1.34 (.97-1.86) 1.43 (.99-2.06) 1.31 (1.00-1.71) 1.30 (.99-1.70) 
  -455T>C -455TC/CC 54 48 1.21 (.79-1.85) 1.18 (.74-1.89) 1.19 (.88-1.62) 1.18 (.86-1.61) 
SMAD3  -1938T>C -1938TT 224 226 1.14 (.77-1.67) 1.17 (.77-1.79) 1.18 (.88-1.58) 1.17 (.87-1.57) 
MDM2  -1494A>G -1494AG/GG 224 226 1.14 (.77-1.67) 0.95 (.51-1.80) 1.08 (.79-1.48) 1.12 (.80-1.56) 
  -1174DEL AAAAAGC(40bp) -1174AAAAAGC-/-- 191 190 1.13 (.80-1.59) 1.06 (.60-1.87) 1.09 (.81-1.46) 1.07 (.79-1.44) 
  +309T>G +309TT 127 111 1.34 (.96-1.86) 1.34 (.89-1.94) 1.26 (.96-1.65) 1.24 (.94-1.64) 
RB1 -1554C>A -1554CC 162 161 1.10 (.80-1.53) 1.15 (.81-1.64) 1.18 (.90-1.54) 1.20 (.90-1.61) 
TGFB1  -1886A>G -1886GG 37 23 1.77 (1.02-3.06) 2.57 (1.00-6.56) 1.32 (.93-1.85) 1.36 (.95-1.96) 
  -1571G>A -1571AA 48 41 1.26 (.80-1.98) 0.69 (.31-1.53) 1.15 (.83-1.59) 1.12 (.80-1.57) 
ATM  -1206G>T -1206GT/TT 52 52 1.05 (.69-1.60) 0.96 (.60-1.54) 1.15 (.84-1.56) 1.14 (.83-1.58) 
  -635T>A -635TT 121 109 1.26 (.91-1.76) 1.33 (.91-1.93) 1.27 (.97-1.67) 1.28 (.97-1.69) 
BRCA1  -598INS ACA -598-ACA/ACA ACA 164 158 1.18 (.85-1.64) 1.12 (.78-1.61) 1.21 (.93-1.59) 1.23 (.93-1.63) 
  -588A>G -588AA 256 246 1.77 (1.09-2.87) 1.84 (1.10-3.10) 1.45 (1.05-2.00) 1.54 (1.02-2.32) 
BRCA2  -1260DEL GTCTAA -1260-- 59 47 1.38 (.91-2.11) 1.47 (.88-2.46) 1.33 (.97-1.82) 1.32 (.96-1.83) 
  -1144A>G -1144GG 63 51 1.36 (.90-2.05) 1.38 (.84-2.28) 1.29 (.95-1.76) 1.33 (.96-1.85) 
  -254G>A -254GG 199 187 1.35 (.95-1.90) 1.10 (.72-1.70) 1.21 (.92-1.60) 1.20 (.90-1.59) 
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RAD51  -1185A>T -1185TT 71 68 1.11 (.76-1.63) 1.11 (.73-1.67) 1.17 (.88-1.57) 1.17 (.87-1.57) 
XRCC4  -1864T>C -1864TT 102 76 1.61 (1.13-2.30) 1.53 (1.04-2.27) 1.42 (1.07-1.88) 1.41 (1.06-1.87) 
  -1407C>G -1407CG/GG 67 50 1.51 (1.00-2.27) 1.31 (.83-2.05) 1.30 (.96-1.76) 1.29 (.95-1.75) 
XRCC5  -1379G>T -1379GG 91 78 1.31 (.91-1.88) 1.17 (.78-1.78) 1.23 (.92-1.63) 1.22 (.92-1.63) 
  -297C>T -297CT/TT 158 136 1.46 (1.05-2.02) 1.39 (.96-2.01) 1.33 (1.02-1.74) 1.32 (1.00-1.73) 
XRCC6  -1296C>G -1296GG 50 39 1.40 (.89-2.21) 1.37 (.81-2.32) 1.30 (.95-1.78) 1.29 (.93-1.78) 
  -731G>A -731GG 178 170 1.23 (.88-1.71) 1.17 (.79-1.71) 1.22 (.93-1.60) 1.21 (.92-1.59) 
                  
Pathway estimation               
DSBR           1.28 (1.10-1.47) 1.25 (1.05-1.50) 
Cell cycle           1.21 (1.07-1.38) 1.19 (.97-1.44) 
 
Conventional model 1, logistic regression with a single marker in each regression; Conventional model 2, logistic 
regression with all markers in one single model; Pathway HM 1, hierarchical modeling with τ2 set to 0.04 and pathway 
indicators only; Pathway and functional HM 2, hierarchical modeling with τ2 set to 0.04, pathway indicators and functional 
covariates including CRM scores, as well as indicator variables for differential DNA-protein binding and allele-specific 
gene expression. Significant results are shown in bold. 
HM, hierarchical modeling; OR, odds ratio; CI, confidence interval; DSBR, double strand break repair. 
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Supplementary Table 1. Distribution of DNA repair and cell cycle 
genotypes among B-cell ALL cases and controls from the Quebec 
Childhood ALL cohort and their effect on ALL risk, as estimated by 
logistic regression 
Pathway: 
Gene,   
DNA variant 
db SNP Genotype 
No. (%) 
OR (95% CI) P 
ALL patients Controls 
G1/S cell cycle control: 
     
CCND1  
      
-1938T>C rs1944129 TT 78 (25.1) 74 (23.0) 1 (referent) ― 
  
 
TC 162 (52.1) 182 (56.5) 0.84 (.58-1.24) .39 
  
 
CC 71 (22.8) 66 (20.5) 1.02 (.64-1.62) .93 
  
      
-1537INS C rs36225395 -/- 85 (27.3) 85 (26.2) 1 (referent) ― 
  
 
-/C 163 (52.4) 186 (57.2) 0.88 (.61-1.26) .48 
  
 
CC 63 (20.3) 54 (16.6) 1.17 (.73-1.87) .52 
CDC25A  
      
-2030G>T rs1903061 GG 253 (83.5) 262 (80.4) 1 (referent) ― 
  
 
GT 47 (15.5) 61 (18.7) 0.80 (.52-1.21) .29 
  
 
TT 3 (1.0) 3 (0.9) 1.04 (.21-5.18) .97 
CDKN1A  
      
-1284T>C rs733590 TT 108 (35.9) 126 (39.6) 1 (referent) ― 
  
 
TC 154 (51.2) 154 (48.4) 1.17 (.83-1.64) .89 
  
 
CC 39 (12.9) 38 (11.9) 1.20 (.72-2.00) .68 
  
      
-899T>G rs762624 TT 160 (54.4) 168 (53.3) 1 (referent) ― 
  
 
TG 113 (38.4) 123 (39.0) 0.96 (.69-1.35) .83 
  
 
GG 21 (7.1) 24 (7.6) 0.92 (.49-1.71) .79 
  
      
-791T>C rs2395655 TT 94 (31.5) 112 (35.6) 1 (referent) ― 
  
 
TC 155 (52.0) 156 (49.5) 1.18 (.83-1.68) .35 
  
 
CC 49 (16.5) 47 (14.9) 1.24 (.76-2.02) .38 
CDKN1B  
      
-1857C>T rs3759217 CC 238 (79.6) 243 (77.1) 1 (referent) ― 
  
 
CT 58 (19.4) 71 (22.5) 0.83 (.56-1.23) .36 
  
 
TT 3 (1.0) 1 (0.3) 3.06 (.32-29.65) .33 
  
      
-1608G>A rs35756741 GG 245 (80.3) 267 (84.0) 1 (referent) ― 
  
 
GA 60 (19.7) 47 (14.8) 1.39 (.91-2.11) .12 
  
 
AA 0 (0.0) 4 (1.2) ― ― 
  
      
-373G>T rs36228499 GG 93 (31.2) 99 (31.0) 1 (referent) ― 
  
 
GT 159 (53.4) 163 (51.1) 1.04 (.73-1.48) .84 
  
 
TT 46 (15.4) 57 (17.9) 0.86 (.53-1.39) .54 
CDKN2A  
      
-222T>A rs36228834 TT 266 (86.6) 298 (93.7) 1 (referent) ― 
  
 
TA 39 (12.7) 19 (6.0) 2.30 (1.30-4.08) .004 
  
 
AA 2 (0.7) 1 (0.3) 2.24 (.20-24.85) .51 
CDKN2B  
      
-1270C>T rs36229158 CC 277 (91.4) 302 (94.7) 1 (referent) ― 
  
 
CT 24 (7.9) 16 (5.0) 1.64 (.85-3.14) .14 
  
 
TT 2 (0.7) 1 (0.3) 2.18 (.20-24.18) .52 
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-593A>T,C rs2069416 AA 129 (43.1) 107 (34.1) 1 (referent) ― 
  
 
AT 124 (41.5) 150 (47.8) 0.69 (.48-.97) .034 
  
 
AC 11 (3.7) 12 (3.8) 0.60 (.35-1.03) .07 
  
 
TT 29 (9.7) 40 (12.7) 0.76 (.32-1.79) .53 
  
 
TC 6 (2.0) 5 (1.6) 0.99 (.30-3.35) .99 
  
 
CC 0 0 ― ― 
  
      
-287G>C rs2069418 GG 102 (34.1) 97 (30.7) 1 (referent) ― 
  
 
GC 141 (47.2) 168 (53.2) 0.80 (.56-1.14) .22 
  
 
CC 56 (18.7) 51 (16.1) 1.04 (.65-1.67) .86 
E2F1  
      
-187C>T rs3213141 CC 172 (57.5) 180 (57.0) 1 (referent) ― 
  
 
CT 119 (29.8) 120 (38.0) 1.04 (.75-1.44) .82 
  
 
TT 8 (2.7) 16 (5.1) 0.52 (.22-1.25) .15 
HDAC1  
      
-1269T>C rs1741981 TT 151 (49.8) 143 (44.1) 1 (referent) ― 
  
 
TC 133 (43.9) 148 (45.7) 0.85 (.61-1.18) .33 
  
 
CC 19 (6.3) 33 (10.2) 0.54 (.30-1.00) .051 
  
      
-455T>C rs36212119 TT 261 (83.4) 277 (84.2) 1 (referent) ― 
  
 
TC 49 (15.6) 49 (14.9) 1.06 (.69-1.63) .79 
  
 
CC 3 (1.0) 3 (0.9) 1.06 (.21-5.30) .94 
MDM2  
      
-1494A>G rs1144944 AA 73 (23.2) 82 (24.9) 1 (referent) ― 
  
 
AG 165 (52.4) 170 (51.7) 1.09 (.74-1.60) .66 
  
 
GG 77 (24.4) 77 (23.4) 1.12 (.72-1.76) .61 
  
      
-1174DEL rs3730485 AAAAAGC 104 (33.6) 119 (36.4) 1 (referent) ― 
  AAAAAGC(40bp) 
 
AAAAAGC/- 156 (50.5) 151 (46.2) 1.18 (.84-1.67) .34 
  
 
-/- 49 (15.9) 57 (17.4) 0.98 (.62-1.56) .94 
  
      
-182C>G rs937282 CC 78 (24.9) 84 (25.6) 1 (referent) ― 
  
 
CG 164 (52.4) 171 (52.1) 1.03 (.71-1.50) .87 
  
 
GG 71 (22.7) 73 (22.3) 1.05 (.67-1.64) .84 
  
      
+309T>G rs2279744 TT 141 (45.1) 125 (38.5) 1 (referent) ― 
  
 
TG 139 (44.4) 162 (49.8) 0.76 (.55-1.06) .11 
  
 
GG 33 (10.5) 38 (11.7) 0.77 (.45-1.30) .33 
SMAD3  
      
-1938T>C rs36221701 TT 246 (78.8) 254 (77.2) 1 (referent) ― 
  
 
TC 62 (19.9) 66 (20.1) 0.97 (.66-1.43) .88 
  
 
CC 4 (1.3) 9 (2.7) 0.46 (.14-1.51) .20 
RB1 
      
-1554C>A rs1573601 CC 175 (58.1) 176 (55.3) 1 (referent) ― 
  
 
CA 112 (37.2) 126 (39.6) 0.89 (.64-1.24) .51 
  
 
AA 14 (4.7) 16 (5.0) 0.88 (.42-1.86) .74 
TGFB1  
      
-1886A>G rs2317130 AA 138 (44.2) 144 (50.0) 1 (referent) ― 
  
 
AG 135 (43.3) 151 (47.2) 0.93 (.67-1.30) .68 
  
 
GG 39 (12.5) 25 (7.8) 1.63 (.94-2.83) .09 
  
      
-1571G>A rs4803457 GG 105 (34.3) 113 (35.3) 1 (referent) ― 
  
 
GA 150 (49.0) 162 (50.6) 1.00 (.70-1.41) .98 
  
 
AA 51 (16.7) 45 (14.1) 1.22 (.75-1.97) .42 
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-1550DEL AGG rs11466313 AGG/AGG 140 (45.4) 149 (46.1) 1 (referent) ― 
  
 
AGG/- 133 (43.2) 148 (45.8) 0.96 (.69-1.33) .79 
  
 
-/- 35 (11.4) 26 (8.1) 1.43 (.82-2.50) .21 
  
      
-508G>A rs1800469 GG 138 (44.4) 147 (45.5) 1 (referent) ― 
  
 
GA 136 (43.7) 150 (46.4) .97 (.70-1.34) .84 
  
 
AA 37 (11.9) 26 (8.1) 1.52 (.87-2.63) .14 
DNA double-strand break repair: 
    
ATM  
      
-1206G>T rs4987876 GG 231 (79.9) 261 (82.3) 1 (referent) ― 
  
 
GT 54 (18.7) 51 (16.1) 1.20 (.78-1.82) .29 
  
 
TT 4 (1.4) 5 (1.6) 0.90 (.24-3.41) .88 
  
      
-635T>A rs228589 TT 111 (39.4) 111 (35.1) 1 (referent) ― 
  
 
TA 137 (48.6) 146 (46.2) 0.94 (.66-1.33) .68 
  
 
AA 34 (12.0) 59 (18.7) 0.58 (.35-.95) .03 
BRCA1  
      
-1890T>C rs4793204 TT 130 (42.6) 149 (46.4) 1 (referent) ― 
  
 
TC 144 (47.2) 136 (42.4) 1.21 (.87-1.69) .25 
  
 
CC 31 (10.2) 36 (11.2) 0.99 (.58-1.68) .96 
  
      
-708A>G rs799906 AA 124 (40.9) 145 (44.6) 1 (referent) ― 
  
 
AG 146 (48.2) 143 (44.0) 1.19 (.86-1.66) .30 
  
 
GG 33 (10.9) 37 (11.4) 1.04 (.61-1.77) .88 
  
      
-598INS ACA rs8176071 -/- 130 (42.5) 151 (46.2) 1 (referent) ― 
  
 
-/ACA 145 (47.4) 141 (43.1) 1.19 (.86-1.66) .29 
  
 
ACA/ACA 31 (10.1) 35 (10.7) 1.03 (.60-1.76) .92 
  
      
-588A>G rs3092986 AA 272 (89.5) 268 (82.7) 1 (referent) ― 
  
 
AG 31 (10.2) 54 (16.7) 0.56 (.35-.91) .018 
  
 
GG 1 (0.3) 2 (0.6) 0.49 (.04-5.47) .56 
BRCA2  
      
-1555C>A rs206114 CC 112 (35.5) 116 (35.3) 1 (referent) ― 
  
 
CA 133 (42.2) 154 (46.8) 0.89 (.63-1.27) .53 
  
 
AA 70 (22.2) 59 (17.9) 1.23 (.80-1.89) .35 
  
      
-1260DEL  rs36221753 GTCTAA/GTCTAA 115 (36.7) 117 (35.8) 1 (referent) ― 
 GTCTAA 
 
GTCTAA/- 137 (43.8) 161 (49.2) .86 (.61-1.22) .41 
  
 
-/- 61 (19.5) 49 (15.0) 1.27 (.80-2.00) .31 
  
      
-1144A>G rs206115 AA 97 (32.5) 110 (34.5) 1 (referent) ― 
  
 
AG 134 (45.0) 157 (49.2) .97 (.68-1.38) .86 
  
 
GG 67 (22.5) 52 (16.3) 1.46 (.93-2.30) .10 
  
      
-1134C>T rs206116 CC 105 (36.3) 111 (35.1) 1 (referent) ― 
  
 
CT 122 (42.2) 156 (49.4) 0.83 (.58-1.18) .30 
  
 
TT 62 (21.5) 49 (15.5) 1.34 (.84-2.12) .21 
  
      
-908C>T rs206117 CC 108 (35.5) 115 (35.8) 1 (referent) ― 
  
 
CT 135 (44.4) 157 (48.9) 0.91 (.64-1.30) .62 
  
 
TT 61 (20.1) 49 (15.3) 1.32 (.84-2.10) .23 
  
      
-254G>A rs3092989 GG 220 (69.4) 205 (62.3) 1 (referent) ― 
  
 
GA 89 (28.1) 113 (34.3) 0.73 (.52-1.03) .07 
  
 
AA 8 (2.5) 11 (3.3) 0.68 (.27-1.72) .41 
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RAD51  
      
-1185A>T rs2619679 AA 76 (24.3) 81 (25.0) 1 (referent) ― 
  
 
AT 161 (51.4) 168 (51.9) 1.02 (.70-1.49) .91 
  
 
TT 76 (24.3) 75 (23.1) 1.08 (.69-1.69) .74 
XRCC4  
      
-1864T>C rs3763063 TT 98 (33.0) 79 (24.6) 1 (referent) ― 
  
 
TC 140 (47.1) 166 (51.7) 0.68 (.47-.98) .042 
  
 
CC 59 (19.9) 76 (23.7) 0.63 (.40-.98) .042 
  
      
-1407C>G rs1993947 CC 229 (78.7) 266 (83.9) 1 (referent) ― 
  
 
CG 59 (20.3) 49 (15.5) 1.40 (.92-2.12) .12 
  
 
GG 3 (1.0) 2 (0.6) 1.74 (.29-10.52) .54 
XRCC5  
      
-1379G>T rs828907 GG 101 (32.2) 88 (26.8) 1 (referent) ― 
  
 
GT 153 (48.7) 171 (52.1) 0.78 (.54-1.12) .17 
  
 
TT 60 (19.1) 69 (21.1) 0.76 (.48-1.19) .22 
  
      
-297C>T rs11685387 CC 140 (44.9) 178 (54.3) 1 (referent) ― 
  
 
CT 139 (44.5) 132 (40.2) 1.34 (.97-1.85) .08 
  
 
TT 33 (10.6) 18 (5.5) 2.33 (1.26-4.31) .007 
XRCC6  
      
-1469C>T rs28384701 CC 267 (86.7) 297 (92.2) 1 (referent) ― 
  
CT 41 (13.3) 21 (6.5) 2.17 (1.25-3.77) .006 
  
TT 0 (0.0) 4 (1.2) ― ― 
       
-1296C>G rs2267437 CC 97 (31.5) 115 (35.9) 1 (referent) ― 
  
 
CG 155 (50.3) 163 (50.9) 1.13 (.80-1.60) .50 
  
 
GG 56 (18.2) 42 (13.1) 1.58 (.98-2.56) .06 
  
      
-731G>A rs132770 GG 197 (62.5) 189 (57.8) 1 (referent) ― 
  
 
GA 104 (33.0) 112 (34.2) 0.89 (.64-1.24) .50 
  
 
AA 14 (4.5) 26 (8.0) 0.52 (.26-1.02) .06 
 
Percentages indicate number of individuals with a given genotype/total number 
of genotyped individuals. Nominally significant results are shown in bold. 
Directionality of the association, as measured by the ORs, was used to define 
risk versus nonrisk genotype combinations. 
OR indicates odds ratio; CI, confidence interval; –, not applicable. 
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Supplementary Table 2. Main effects of pSNPs on ALL risk among children, as estimated by hierarchical 
modeling with a range of second-stage residual variance values 
Gene 
High-risk 
genotype 
of tag pSNP 
Case 
no. 
(n= 286) 
Control 
no. 
(n= 297) 
HM ORs (95% CIs) when second-stage variance equals: 
𝛕𝟐= 0.01 𝛕𝟐= 0.04 𝛕𝟐= 0.1225 𝛕𝟐= 0.25 𝛕𝟐= 0.4 𝛕𝟐= 1 
CCND1  -1938CC 67 60 1.21 (1.00-1.47) 1.23 (.92-1.66) 1.25 (.86-1.80) 1.25 (.84-1.87) 1.26 (.83-1.89) 1.26 (.82-1.93) 
CDC25A  -2030GG 237 239 1.22 (1.00-1.49) 1.24 (.91-1.69) 1.24 (.84-1.83) 1.24 (.81-1.89) 1.24 (.79-1.91) 1.24 (.78-1.96) 
CDKN1A  -1284TC/CC 181 178 1.21 (1.00-1.47) 1.23 (.93-1.63) 1.25 (.88-1.77) 1.26 (.86-1.84) 1.26 (.85-1.88) 1.27 (.84-1.92) 
  -899TT 160 161 1.21 (1.00-1.46) 1.21 (.91-1.60) 1.21 (.86-1.71) 1.21 (.83-1.76) 1.21 (.82-1.78) 1.21 (.81-1.82) 
CDKN1B  -1857CC 228 229 1.22 (1.00-1.48) 1.23 (.91-1.65) 1.22 (.84-1.78) 1.21 (.80-1.82) 1.20 (.78-1.84) 1.18 (.75-1.85) 
  -1608GA/AA 56 50 1.19 (.98-1.45) 1.17 (.87-1.59) 1.15 (.78-1.70) 1.15 (.75-1.76) 1.14 (.73-1.79) 1.14 (.71-1.83) 
  -373GG/GT 241 247 1.18 (.97-1.44) 1.14 (.84-1.56) 1.10 (.74-1.65) 1.08 (.69-1.69) 1.07 (.67-1.71) 1.05 (.64-1.73) 
CDKN2A  -222TA/AA 40 19 1.27 (1.03-1.55) 1.40 (1.00-1.96) 1.58 (.99-2.51) 1.70 (1.00-2.89) 1.77 (1.01-3.12) 1.88 (1.02-3.45) 
CDKN2B  -593AA/AC 136 113 1.27 (1.06-1.54) 1.38 (1.05-1.81) 1.45 (1.04-2.02) 1.47 (1.03-2.11) 1.48 (1.02-2.15) 1.49 (1.01-2.19) 
  -287GG 96 94 1.21 (1.00-1.47) 1.23 (.93-1.63) 1.24 (.87-1.75) 1.23 (.85-1.80) 1.23 (.83-1.81) 1.22 (.81-1.83) 
E2F1  -187CC 166 170 1.17 (.97-1.41) 1.13 (.86-1.47) 1.09 (.79-1.50) 1.07 (.76-1.50) 1.06 (.74-1.50) 1.04 (.73-1.49) 
HDAC1  -1269TT 147 131 1.25 (1.03-1.50) 1.31 (1.00-1.71) 1.36 (.99-1.88) 1.39 (.98-1.95) 1.40 (.98-1.99) 1.42 (.98-2.04) 
  -455TC/CC 54 48 1.20 (.98-1.46) 1.19 (.88-1.62) 1.18 (.80-1.75) 1.18 (.77-1.81) 1.18 (.75-1.84) 1.18 (.74-1.88) 
SMAD3  -1938TT 224 226 1.19 (.98-1.44) 1.18 (.88-1.58) 1.17 (.82-1.68) 1.17 (.79-1.73) 1.17 (.78-1.75) 1.17 (.77-1.78) 
MDM2  -1494AG/GG 224 226 1.15 (.95-1.39) 1.08 (.79-1.48) 1.03 (.67-1.59) 1.00 (.60-1.67) 0.99 (.57-1.71) 0.97 (.53-1.78) 
  -1174AAAAAGC-/-- 191 190 1.14 (.95-1.38) 1.09 (.81-1.46) 1.06 (.71-1.58) 1.05 (.66-1.68) 1.05 (.64-1.74) 1.05 (.61-1.82) 
  +309TT 127 111 1.22 (1.01-1.46) 1.26 (.96-1.65) 1.30 (.93-1.82) 1.32 (.92-1.90) 1.33 (.92-1.93) 1.34 (.91-1.97) 
RB1 -1554CC 162 161 1.19 (.99-1.44) 1.18 (.90-1.54) 1.17 (.85-1.61) 1.16 (.83-1.63) 1.16 (.82-1.64) 1.16 (.81-1.65) 
TGFB1  -1886GG 37 23 1.23 (1.01-1.51) 1.32 (.93-1.85) 1.48 (.89-2.46) 1.66 (.89-3.10) 1.80 (.89-3.64) 2.10 (.92-4.79) 
  -1571AA 48 41 1.19 (.97-1.45) 1.15 (.83-1.59) 1.06 (.67-1.68) 0.97 (.56-1.69) 0.91 (.49-1.68) 0.81 (.40-1.64) 
ATM  -1206GT/TT 52 52 1.22 (1.00-1.50) 1.15 (.84-1.56) 1.07 (.72-1.58) 1.03 (.67-1.58) 1.01 (.64-1.57) 0.98 (.61-1.57) 
  -635TT 121 109 1.27 (1.05-1.54) 1.27 (.97-1.67) 1.29 (.93-1.78) 1.29 (.91-1.84) 1.30 (.91-1.87) 1.31 (.90-1.91) 
BRCA1  
-598-ACA/ACA 
ACA 
164 158 1.25 (1.03-1.51) 1.21 (.93-1.59) 1.17 (.85-1.62) 1.15 (.82-1.62) 1.14 (.81-1.62) 1.13 (.79-1.63) 
  -588AA 256 246 1.33 (1.08-1.64) 1.45 (1.05-2.00) 1.60 (1.05-2.43) 1.68 (1.06-2.68) 1.73 (1.06-2.81) 1.79 (1.07-2.99) 
BRCA2  -1260-- 59 47 1.29 (1.05-1.58) 1.33 (.97-1.82) 1.39 (.92-2.08) 1.42 (.90-2.24) 1.44 (.89-2.32) 1.46 (.88-2.42) 
  -1144GG 63 51 1.28 (1.05-1.56) 1.29 (.95-1.76) 1.32 (.89-1.97) 1.34 (.86-2.09) 1.36 (.85-2.16) 1.37 (.84-2.24) 
  -254GG 199 187 1.25 (1.04-1.51) 1.21 (.92-1.60) 1.17 (.82-1.66) 1.14 (.78-1.68) 1.13 (.76-1.69) 1.12 (.73-1.71) 
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RAD51  -1185TT 71 68 1.23 (1.01-1.50) 1.17 (.88-1.57) 1.13 (.79-1.62) 1.11 (.76-1.64) 1.11 (.74-1.65) 1.11 (.73-1.67) 
XRCC4  -1864TT 102 76 1.33 (1.10-1.62) 1.42 (1.07-1.88) 1.49 (1.06-2.09) 1.51 (1.05-2.19) 1.52 (1.04-2.23) 1.53 (1.03-2.27) 
  -1407CG/GG 67 50 1.29 (1.06-1.57) 1.30 (.96-1.76) 1.30 (.89-1.90) 1.30 (.86-1.96) 1.30 (.84-1.99) 1.30 (.83-2.03) 
XRCC5  -1379GG 91 78 1.26 (1.04-1.52) 1.23 (.92-1.63) 1.20 (.84-1.71) 1.19 (.81-1.74) 1.18 (.79-1.76) 1.18 (.78-1.78) 
  -297CT/TT 158 136 1.30 (1.07-1.56) 1.33 (1.02-1.74) 1.36 (.98-1.88) 1.37 (.97-1.95) 1.38 (.96-1.98) 1.38 (.95-2.01) 
XRCC6  -1296GG 50 39 1.28 (1.04-1.56) 1.30 (.95-1.78) 1.34 (.88-2.03) 1.36 (.85-2.16) 1.37 (.84-2.23) 1.37 (.82-2.30) 
  -731GG 178 170 1.25 (1.03-1.51) 1.22 (.93-1.60) 1.19 (.86-1.66) 1.18 (.83-1.69) 1.18 (.81-1.70) 1.17 (.80-1.72) 
           
Pathway estimation 
        
DSBR 
   
1.27 (1.14-1.42) 1.28 (1.10-1.47) 1.28 (1.04-1.58) 1.28 (.97-1.70) 1.28 (.91-1.82) 1.29 (.75-2.19) 
Cell cycle  
  
1.20 (1.09-1.33) 1.21 (1.07-1.38) 1.22 (1.02-1.46) 1.23 (.96-1.56) 1.23 (.92-1.65) 1.23 (.79-1.93) 
 
Hierarchical modeling with pathway indicators only and τ2 set to 0.01, 0.04, 0.1225, 0.25, 0.4 or 1 which corresponds to 
being 95% certain a priori that an OR lies in a 1.5-fold, 2.2-fold, 4-fold, 7-fold, a 12-fold and 50-fold range, respectively 
(note that exp(3.92τ) = 2.2 if τ2 = 0.04). Significant results are shown in bold. 
HM, hierarchical model; OR, odds ratio; CI, confidence interval; DSBR, double strand break repair. 
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Supplementary Table 3. Gene-gene interaction effects of selected polymorphisms on ALL risk among children, as 
estimated by hierarchical modeling with a range of second-stage residual variance 
Gene, 
gene-gene interactions 
Case no. 
(n= 286) 
Control 
no. 
(n= 297) 
HM ORs (95% CIs) when second-stage variance equals: 
𝛕𝟐= 0.01 𝛕𝟐= 0.04 𝛕𝟐= 0.1225 𝛕𝟐= 0.25 𝛕𝟐= 0.4 𝛕𝟐= 1 
CDKN2A-222TA/AA 40 19 1.10 (.89-1.35) 1.18 (.82-1.69) 1.32 (.74-2.36) 1.50 (.68-3.28) 1.67 (.64-4.35) 2.19 (.55-8.68) 
CDKN2B-593AA/AC 136 113 1.07 (.88-1.29) 1.10 (.80-1.51) 1.20 (.74-1.95) 1.33 (.72-2.47) 1.46 (.72-2.96) 1.81 (.76-4.34) 
HDAC1-1269TT  147 131 1.04 (.86-1.26) 1.03 (.75-1.41) 1.03 (.63-1.67) 1.03 (.55-1.91) 1.03 (.51-2.10) 1.06 (.45-2.53) 
BRCA1-588AA  256 246 1.14 (.93-1.40) 1.18 (.85-1.65) 1.23 (.76-1.98) 1.28 (.71-2.32) 1.35 (.69-2.65) 1.57 (.68-3.65) 
XRCC4-1864TT   102 76 1.13 (.93-1.36) 1.17 (.85-1.62) 1.29 (.78-2.14) 1.45 (.76-2.77) 1.61 (.76-3.40) 2.05 (.80-5.21) 
XRCC5-297CT/TT   158 136 1.12 (.93-1.35) 1.15 (.84-1.58) 1.24 (.77-2.00) 1.36 (.74-2.49) 1.47 (.73-2.95) 1.76 (.74-4.16) 
CDKN2A-222TA/AA*CDKN2B-593AA/AC  25 12 1.07 (.86-1.32) 1.07 (.74-1.55) 1.03 (.58-1.83) 0.96 (.46-2.01) 0.91 (.39-2.10) 0.78 (.28-2.16) 
CDKN2A-222TA/AA*HDAC1-1269TT  15 7 1.06 (.85-1.31) 1.05 (.72-1.54) 1.01 (.55-1.84) 0.96 (.45-2.06) 0.92 (.39-2.18) 0.84 (.30-2.37) 
CDKN2A-222TA/AA*BRCA1-588AA  38 18 1.22 (1.00-1.49) 1.29 (.90-1.85) 1.40 (.78-2.49) 1.48 (.68-3.24) 1.55 (.60-3.96) 1.61 (.43-6.04) 
CDKN2A-222TA/AA*XRCC4-1864TT    16 4 1.20 (.98-1.48) 1.26 (.86-1.85) 1.35 (.73-2.49) 1.45 (.66-3.19) 1.52 (.61-3.78) 1.67 (.54-5.13) 
CDKN2A-222TA/AA*XRCC5-297CT/TT   17 12 1.15 (.94-1.42) 1.06 (.73-1.54) 0.87 (.48-1.56) 0.70 (.33-1.46) 0.59 (.25-1.37) 0.43 (.16-1.17) 
CDKN2B-593AA/AC*HDAC1-1269TT  69 51 1.05 (.86-1.27) 1.04 (.75-1.44) 1.04 (.65-1.64) 1.03 (.60-1.77) 1.03 (.58-1.85) 1.02 (.54-1.94) 
CDKN2B-593AA/AC*BRCA1-588AA  120 93 1.18 (.98-1.42) 1.17 (.85-1.61) 1.12 (.69-1.81) 1.05 (.57-1.92) 0.99 (.50-1.96) 0.85 (.37-1.95) 
CDKN2B-593AA/AC*XRCC4-1864TT    45 30 1.15 (.95-1.40) 1.09 (.77-1.53) 0.98 (.60-1.61) 0.90 (.50-1.62) 0.85 (.45-1.60) 0.76 (.38-1.54) 
CDKN2B-593AA/AC*XRCC5-297CT/TT     70 48 1.16 (.99-1.41) 1.13 (.81-1.56) 1.08 (.68-1.72) 1.05 (.61-1.80) 1.03 (.58-1.85) 0.99 (.52-1.89) 
HDAC1-1269TT*BRCA1-588AA  133 106 1.19 (.99-1.43) 1.23 (.90-1.69) 1.31 (.81-2.10) 1.37 (.76-2.50) 1.42 (.72-2.80) 1.49 (.66-3.38) 
HDAC1-1269TT*XRCC4-1864TT    56 38 1.16 (.96-1.41) 1.13 (.80-1.58) 1.07 (.66-1.74) 1.02 (.58-1.81) 0.99 (.53-1.84) 0.94 (.47-1.86) 
HDAC1-1269TT*XRCC5-297CT/TT   81 62 1.14 (.95-1.38) 1.09 (.79-1.50) 1.00 (.64-1.58) 0.94 (.56-1.61) 0.91 (.51-1.61) 0.85 (.45-1.60) 
BRCA1-588AA*XRCC4-1864TT    90 64 1.12 (.92-1.35) 1.11 (.80-1.54) 1.08 (.65-1.77) 1.02 (.54-1.91) 0.96 (.47-1.98) 0.83 (.34-1.99) 
BRCA1-588AA*XRCC5-297CT/TT   141 113 1.12 (.94-1.35) 1.14 (.84-1.55) 1.14 (.72-1.83) 1.12 (.62-2.03) 1.09 (.56-2.14) 1.00 (.44-2.28) 
XRCC4-1864TT *XRCC5-297CT/TT   55 35 1.11 (.91-1.35) 1.10 (.79-1.54) 1.09 (.67-1.76) 1.06 (.60-1.88) 1.04 (.56-1.93) 0.98 (.50-1.95) 
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Hierarchical modeling of significant main effects plus pair-wise gene-gene interaction effects using pathway indicators 
only and with τ2  set to 0.01, 0.04, 0.1225, 0.25, 0.4 or 1 which corresponds to being 95% certain a priori that an OR lies 
in a 1.5-fold, 2.2-fold, 4-fold, 7-fold, 12-fold and 50-fold range, respectively (note that exp(3.92τ) = 4 if τ2 = 0.1225). 
Significant results are shown in bold. 
HM, hierarchical model; OR, odds ratio; CI, confidence interval 
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Supplementary Table 4. Gene-gene interaction effects on pre-B ALL risk among children, as estimated by 
conventional maximum-likelihood analysis and hierarchical modeling 
Gene, high-risk genotype 
gene-gene interaction 
Case no. 
(n= 286) 
Control no. 
(n= 297) 
Conventional 
GxG 1, 
OR (95% CI) 
Conventional 
GxG 2, 
OR (95% CI) 
Backward 
stepwise, 
OR (95% CI) 
Pathway HM 1, 
OR (95% CI) 
CDKN2A-222TA/AA 40 19 2.38 (1.34-4.22) 6.92 (.33-144.02) 4.39 (1.79-10.73) 1.32 (.74-2.36) 
CDKN2B-593AA/AC 136 113 1.48 (1.06-2.05) 3.02 (.94-9.74) 1.46 (1.03-2.05) 1.20 (.74-1.95) 
HDAC1-1269TT  147 131 1.34 (.97-1.86) 1.15 (.38-3.49) 1.35 (.96-1.89) 1.03 (.63-1.67) 
BRCA1-588AA  256 246 1.77 (1.09-2.87) 2.54 (.79-8.22) 1.72 (1.05-2.83) 1.23 (.76-1.98) 
XRCC4-1864TT   102 76 1.61 (1.13-2.30) 3.53 (1.02-12.20) 1.70 (1.20-2.42) 1.29 (.78-2.14) 
XRCC5-297CT/TT   158 136 1.46 (1.05-2.02) 2.75 (.89-8.51) 1.70 (1.20-2.42) 1.24 (.77-2.00) 
CDKN2A-222TA/AA * CDKN2B-593AA/AC  25 12 0.67 (.21-2.20) 0.55 (.16-1.96) − 1.03 (.58-1.83) 
CDKN2A-222TA/AA * HDAC1-1269TT  15 7 0.72 (.22-2.33) 0.68 (.19-2.48) − 1.01 (.55-1.84) 
CDKN2A-222TA/AA * BRCA1-588AA  38 18 0.62 (.05-7.65) 0.90 (.05-15.81) − 1.40 (.78-2.49) 
CDKN2A-222TA/AA * XRCC4-1864TT    16 4 1.63 (.43-6.12) 1.82 (.44-7.57) − 1.35 (.73-2.49) 
CDKN2A-222TA/AA * XRCC5-297CT/TT   17 12 0.26 (.08-.84) 0.26 (.08-.89) 0.26 (.08-.85) 0.87 (.48-1.56) 
CDKN2B-593AA/AC * HDAC1-1269TT  69 51 0.89 (.46-1.72) 0.97 (.48-1.96) − 1.04 (.65-1.64) 
CDKN2B-593AA/AC * BRCA1-588AA  120 93 0.82 (.31-2.18) 0.58 (.20-1.70) − 1.12 (.69-1.81) 
CDKN2B-593AA/AC * XRCC4-1864TT    45 30 0.74 (.36-1.53) 0.62 (.29-1.35) − 0.98 (.60-1.61) 
CDKN2B-593AA/AC * XRCC5-297CT/TT     70 48 0.93 (.48-1.80) 0.92 (.45-1.85) − 1.08 (.68-1.72) 
HDAC1-1269TT * BRCA1-588AA  133 106 1.57 (.60-4.14) 1.55 (.55-4.33) − 1.31 (.81-2.10) 
HDAC1-1269TT * XRCC4-1864TT    56 38 0.90 (.44-1.85) 0.85 (.40-1.79) − 1.07 (.66-1.74) 
HDAC1-1269TT * XRCC5-297CT/TT   81 62 0.88 (.46-1.70) 0.77 (.39-1.53) − 1.00 (.64-1.58) 
BRCA1-588AA * XRCC4-1864TT    90 64 0.71 (.25-2.03) 0.57 (.18-1.79) − 1.08 (.65-1.77) 
BRCA1-588AA * XRCC5-297CT/TT   141 113 0.91 (.34-2.40) 0.75 (.26-2.15) − 1.14 (.72-1.83) 
XRCC4-1864TT  * XRCC5-297CT/TT   55 35 0.91 (.44-1.85) 0.86 (.41-1.81) − 1.09 (.67-1.76) 
 
Conventional GxG model 1, logistic regression with a single marker in each regression model or both main effects and the 
product interaction term in which case interaction ORs (95% CIs) are shown; Conventional GxG model 2, logistic
  
 
2
2
5
 
regression with all markers and product interaction terms in one single model; Backward stepwise, backward stepwise 
logistic regression forcing all significant main effects into the model and using P≤0.05 for removal from and P≤0.10 for 
addition to the model; Pathway HM 1; hierarchical modeling with τ2 set to 0.1225 and pathway indicators only. Significant 
results are shown in bold. 
GxG, gene-gene interaction; HM, hierarchical modeling; OR, odds ratio; CI, confidence interval. 
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CHAPTER FOUR 
THE ROLE OF MATERNALLY-MEDIATED 
GENETIC EFFECTS IN THE 
SUSCEPTIBILITY TO CHILDHOOD ACUTE 
LYMPHOBLASTIC LEUKEMIA 
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Another complex biologic mechanism that is important to consider in the study 
of diseases that originate during fetal life is the possible role that the mother‘s, 
and to a lesser extent the father‘s, genetics could play in disease development. 
Exposure and genetic make-up of the father could lead to increased mutational 
burden at the level of the gametes, affecting offspring risk at a prezygotic stage. 
More importantly perhaps, the mother plays a crucial role as not only the genetic 
donor but also as fetal environment. Thus a susceptibility allele acting through 
the mother‘s genotype could have an effect on the fetus by shaping the 
intrauterine milieu, regardless of whether the allele was passed on to the fetus. 
Discriminating between maternal genotype effects and inherited genetic effects 
acting through the child or from joint fetomaternal effects, is important to better 
understand the underlying disease mechanisms, however this is complicated by 
the inherent fact that case genotype effects can alias maternal genotype effects 
due to simple Mendelian inheritance. 
 
In this third objective, I built upon existing methods of analysis to explore 
maternally-mediated genetic effects and fetomaternal relationships in childhood 
ALL susceptibility. Simulation studies were performed in collaboration with 
colleagues in the laboratory, to show how existing methods can be adapted to 
mixed data sets composed of unrelated cases and controls, as well as case-
parent triads. We also showed how these methods perform when the 
assumption of mating symmetry (i.e. equal allele frequencies between mothers 
and fathers mating in the population, an assumption that is required to bar from 
spurious maternal genotype associations), cannot be directly verified. Finally I 
evaluated the role of maternal genetic effects in the susceptibility to childhood 
ALL and showed, for the first time, that the mother‘s genotype can influence the 
risk of leukemia among her offspring, further corroborating the importance of 
parental genetic contributions to the susceptibility to early-onset disorders such 
as childhood leukemia. This work lead to the publication of a manuscript which 
is presented in this chapter: 
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― Detection of fetomaternal genotype associations in early-onset disorders: 
evaluation of different methods and their application to childhood 
leukemia (Healy et al. (2010) Journal of Biomedicine and Biotechnology, 
doi:10.1155/2010/369534). 
 
Tables and figures presenting the results of the fetomaternal association studies 
for the DNA double-strand break repair genes are available in Appendix III. 
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Abstract 
 
Several designs and analytical approaches have been proposed to dissect 
offspring from maternal genetic contributions to early-onset diseases. However, 
lack of parental controls halts the direct verification of the assumption of mating 
symmetry (MS) required to assess maternally-mediated effects. In this study, we 
used simulations to investigate the performance of existing methods under 
mating asymmetry (MA) when parents of controls are missing. Our results show 
that the log-linear, likelihood-based framework using a case-triad/case-control 
hybrid design provides valid tests for maternal genetic effects even under MA. 
Using this approach, we examined fetomaternal associations between 29 SNPs 
in 12 cell cycle genes and childhood pre-B acute lymphoblastic leukemia (ALL). 
We identified putative fetomaternal effects at loci CDKN2A rs36228834 (P = 
.017) and CDKN2B rs36229158 (P = .022) that modulate the risk of childhood 
ALL. These data further corroborate the importance of the mother‘s genotype on 
the susceptibility to early-onset diseases. 
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Introduction 
 
The risk for early-onset disorders can be influenced both by the inherited 
genotype of the child as well as by parentally-mediated genetic effects (1). The 
mother has a crucial role in early-onset disease predisposition as she provides 
the prenatal environment (2, 3) and can influence her offspring‘s risk of disease 
not only as a genetic donor but also through the effects of her genes acting 
directly on the intrauterine milieu or indirectly through fetomaternal gene-gene 
interactions (1, 4-6). Given the important role the mother can play in shaping 
disease susceptibility in her offspring, focusing solely on the genotype of the 
child in association testing could, in certain instances, be misleading. 
 
Several family-based tests have been proposed to dissect offspring and 
maternal genetic contributions to early-onset disorders including the case-parent 
designs of Wilcox et al. (1) and Weinberg et al. (3) using a log-linear framework, 
and of Cordell et al. (7, 8), which uses a conditional logistic regression 
framework. Designs using alternative family structures have also been 
suggested: the hybrid design based on augmenting a set of case-parent trios 
with a set of parents of unrelated controls (9), the ―pent‖ design consisting of the 
affected child, mother, father, and maternal grandparents (2), the case-
mother/control-mother dyad design (10) or the design consisting of case-parent 
triads supplemented by control-mother dyads (11). However, the use of these 
alternative designs can be limited by the difficulty of obtaining grandparental 
data or sufficiently large samples of parents of unaffected children, and by the 
increase in costs incurred for genotyping these additional sets of individuals. On 
the other hand, in many ongoing genetic association studies it often occurs that 
parents of cases and unrelated control individuals are collected in parallel, in 
which case designs based solely on case-triad data could lead to considerable 
losses in power if unrelated case-control data are disregarded. In the event that 
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both case-parent triads as well as case-control data are ascertained, additional 
designs/analytical strategies are needed for fetomaternal genotype association 
testing. 
 
The first aim of this study was to evaluate the adaptability of existing methods to 
deal with mixed data sets consisting of both case-parent triads and case-control 
data. We used simulations to investigate the validity and power of 1) Weinberg 
and Umbach‘s hybrid design (9) treating parents of controls as missing (HD-
NPC) and 2) a classic case-control test in conjunction with Cordell et al.‘s 
conditional logistic regression method (7) (CC+CLR), to distinguish between 
offspring and maternal genetic contributions to disease. Given that Cordell et 
al.‘s approach relies solely on the use of case-parent triads, combining it with a 
case-control test will allow us to maximize the use of available genotype 
information. Finally, we compared both these approaches to a third hypothetical, 
ideal situation, in which genotype data from parents of controls would be 
available and Weinberg and Umbach‘s hybrid design could be used (HD) as 
described in (9).  
 
However lack of parents of controls in HD-NPC and CC+CLR precludes the 
direct verification of the assumption of mating symmetry (MS) that is required to 
assess maternally-mediated effects. Mating symmetry (MS) refers to the 
hypothesis that for a parental genotype pair, the frequency in the population for 
a given mother-father genotype assignment is the same as for the reverse 
father-mother assignment (1, 12). Departures from this symmetry could lead to 
genotype frequency differences among males and females mating in the 
population which, in the context of fetomaternal association testing, could lead 
to confounding and spurious maternal associations. As such, the HD approach, 
using an auxiliary sample of parents of controls to obtain direct information on 
mating frequencies (9), is the only method that allows for the assumption of 
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symmetry to be directly tested and readily accommodated. It is unclear however 
how this method performs when parents of controls are missing and MA is 
present. And since parents of unaffected controls are not available in most 
ongoing studies, it is important to assess the robustness of these fetomaternal 
association tests under such circumstances. Therefore, we evaluated type I 
error rates and power of the three methods (HD, HD-NPC and CC+CLR) under 
varying degrees of MA, and genotypic risk models involving child, mother or 
both child and mother jointly, in order to identify the analytical approach that is 
most reliable for dissecting child and maternal genetic contributions to early-
onset diseases in the absence of parents of controls. 
 
Another aim of this study was to use these methods to investigate fetomaternal 
associations in a real mixed dataset of childhood pre-B acute lymphoblastic 
leukemia (ALL) patients. ALL is a hematological malignancy resulting from 
chromosomal alterations and mutations that affect molecular pathways that 
disrupt lymphoid progenitor cell differentiation (13, 14). There is well-established 
evidence for prenatal initiation of the leukemogenesis process in children (15-
18). Moreover, parental exposures to environmental carcinogens or use of 
medication have been identified as potential risk factors for childhood leukemia 
(19-23) and transplacental carcinogen exposure has been involved in the 
development of certain subtypes of ALL (24). Although the risk of leukemia from 
environmental exposures in utero or in early childhood is likely to be influenced 
by genetic variation at both the level of the child and the mother, the role of 
maternally-mediated genetic effects in childhood leukemia susceptibility remains 
undefined. Here we performed a candidate gene association study using both 
ALL case-parent triads and unrelated controls to assess the impact of 29 SNPs 
from 12 cell cycle genes in both mother and child on childhood pre-B ALL risk. 
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Materials and Methods 
 
Methods used to test for fetomaternal genotype associations 
We compared three analytical approaches for the detection of early-onset 
disease associations. In the event that both case-parent triads and unrelated 
case-control data are available, we tested 1) a combined method in which a 
case-control genotypic test was carried out in conjunction with the conditional 
logistic regression test of Cordell et al. to detect associations at the level of the 
child and mother, respectively (CC+CLR); and 2) the log-linear, likelihood-based 
approach of Weinberg and Umbach (9) using an additional set of unrelated 
cases and unrelated controls as proxies for parental control genotype 
information (HD-NPC). We also compared these two approaches to 3) one in 
which parents of controls are also available and therefore the hybrid design 
(case-parent/parents of controls) can be used through log-linear, likelihood-
based analysis (HD).  
 
It should be noted that the combined CC+CLR approach is not a modification of 
the conditional logistic regression approach of Cordell et al. but rather an 
adaptation in its use to detect fetomaternal associations. Cordell et al.‘s 
approach relies solely on the use of case-parent triads. Since disregarding any 
available unrelated case-control genotype data reduces power, we used 
Pearson‘s chi-square tests or Fisher‘s exact tests (CC), as appropriate, and 
conditional logistic regression (CLR) in parallel on partially overlapping data. 
The former were used on all available cases to identify genotype associations at 
the level of the child whereas the latter was used on case-parent triads to 
identify maternally-contributed effects. Results from the two tests were not 
combined, rather if a significant association was found in the child CC test then 
the CLR test was used (albeit on a reduced case set) in order to dissect 
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offspring and maternal effects. Similarly, if a significant result was found for the 
mother test using CLR, then CLR was further used to distinguish a main effect 
of the mother from a joint fetomaternal effect (see likelihood-ratio testing below).  
 
Likelihood-ratio testing to dissect child from maternal genetic effects 
Given that the offspring will be enriched for the risk allele by simple Mendelian 
inheritance (25),  it is important to discriminate between direct effects of a 
maternal genotype or of a child genotype from a joint fetomaternal effect. To do 
so, we used a forward stepwise likelihood-ratio testing procedure. In the first 
step, we performed two single-step tests to investigate associations at the level 
of the child and mother separately (Table 1). For CC+CLR, Pearson‘s chi-
square or Fisher‘s exact tests were performed in R (version 2.6.2), to compare 
genotype distributions in cases (unrelated and triad cases) vs. controls. In 
parallel, we used case-parent triads and logistic regression conditioning on 
exchangeable parental genotypes (CEPG) (7, 8), using the DGCgenetics 
package for R developed by D. Clayton (available at http://www-
gene.cimr.cam.ac.uk/clayton/software/DGCgenetics_1.0.tar.gz) to test for 
maternally-mediated associations through a two degree-of-freedom likelihood-
ratio test (Mother vs. Null). For HD-NPC and HD, log-linear regression analysis 
was performed using the LEM software (Log-linear and event history analysis 
with missing data using the EM algorithm) (26) and LEM script files provided by 
Weinberg et al. (available at 
http://www.niehs.nih.gov/research/resources/software/hybrid/index.cfm (9, 26)). 
Two degree-of-freedom likelihood-ratio tests were performed to independently 
test for offspring (Child vs. Null) and maternal (Mother vs. Null) associations in 
the log-linear framework. 
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In the second step, if a significant effect was found in the first step (based on a 
Bonferroni correction of P < 0.025 for the 2 tests performed), then the most 
significant model was tested against a joint effects model (Child+Mother vs. 
Child or Child+Mother vs. Mother) in a two degree-of-freedom likelihood-ratio 
test (Table 1). For CC+CLR this meant that conditional logistic regression was 
used on the reduced case-triad data set to test either Child+Mother vs. Child or 
Child+Mother vs. Mother depending on the results from step one. Whereas log-
linear regression analysis was performed on case-triads and unrelated cases 
and controls in HD-NPC, and on case-triads, unrelated cases and parents of 
controls in HD. 
 
Simulated data 
We simulated cohort data under several conditions to model different genotypic 
risk effects involving either child, mother or both child and mother (joint 
fetomaternal effects) (Table 2). Under each model 200 replicate datasets were 
simulated using the R software. Replicates that did not fit the simulated models 
were not included in the analysis. To imitate our childhood leukemia cohort, we 
simulated genotypic data for 200 case-parent triads, 130 unrelated cases and 
325 unrelated control-parent triads for each replicate. For all of our calculations 
we used the same overall number of affected individuals however the methods 
differed in how the case and control data were utilized in each individual test 
(Figure 1). For all of our child-based tests we used the same number of affected 
individuals and unrelated controls (Figure 1): 330 cases (200 case-triads and 
130 unrelated cases) were compared to 325 unrelated controls. However the 
number of cases and population-based controls used for maternal and 
fetomaternal association testing varied depending on the method: CC+CLR 
used the genotypes from 200 case-triads only; HD-NPC used the genotypes of 
330 cases (200 case-triads and 130 unrelated cases) and of 325 unrelated 
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controls; and HD incorporated the genotypic information of the parents (n= 650) 
rather than the unrelated controls themselves (Figure 1).  
 
In HD and HD-NPC, unrelated cases and controls were used by treating their 
parental genotypes as missing and the EM algorithm implemented in the LEM 
software was used to infer missing genotype information (26). Unrelated cases 
and cases belonging to triads were considered to have similar penetrance and 
thus similar genotypic relative risks (GRR). We assumed Hardy-Weinberg 
equilibrium and the absence of population stratification in the form of admixture. 
We evaluated the different approaches in terms of type I error rate and power to 
detect associations by counting the number of replicates found to be 
significantly associated over the total number of replicates that fit the specified 
model.  
 
Simulated scenarios 
We first assessed the behaviour of the three methods in scenarios in which MS 
was assumed across parents. Under MS, HD-NPC and HD were performed by 
forcing six mating-type variables in the log-linear model (9).  
 
A second set of simulations was performed in which we assessed the 
performance of the tests assuming differences in genotype frequencies between 
males and females mating in the population, i.e. assuming varying levels of 
mating asymmetry. MA was evaluated in terms of the degree of departure from 
the expected mate-pair probability under symmetry. We used Ci to denote the 
disequilibrium for the 𝑖th parental mating type. Ci is a multiplicative factor 
between 0 and 2 that describes the over representation (C > 1), under 
representation (C < 1) or symmetry (C = 1) of a mate-pair combination in the 
corresponding 𝑖th mating type. The level of departure from MS is denoted as ΔC, 
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a numerical value ranging from −1 to 1, with C = 1 +  ΔC. The expected parental 
genotype distributions under the assumption of MS and MA are shown in Table 
3. By varying the departure from mating symmetry, ΔC, we introduced varying 
levels of asymmetry into our simulations (Table 2). In this study we assumed a 
model for MA where C1 = C2 and C4 = 1.   Supplementary Figure 1 shows how 
departures from symmetry, as measured by ΔC, translate into differences in 
reciprocal mating types and overall genotype frequencies between males and 
females mating in the population. Under MA, HD-NPC and HD were performed 
by forcing nine mating-type variables in the log-linear model (9) and we tested 
for the presence of asymmetry by comparing the nine mating-type model to the 
six mating-type model with a three degree-of-freedom likelihood-ratio test using 
a cut-off of P<0.05 to declare deviation from symmetry. A less conservative P 
value < 0.10 was also used (data not shown) and yielded similar results. 
 
Childhood acute lymphoblastic leukemia data 
Study subjects. We investigated fetomaternal associations in a pre-B acute 
lymphoblastic leukemia (ALL) cohort. The study population has been previously 
described (27, 28). Briefly, incident cases of childhood pre-B ALL (n=321) were 
diagnosed in the Division of Hematology-Oncology of the Sainte-Justine 
Hospital in Montreal, Canada, between October 1985 and November 2006. Our 
cohort includes 189 boys and 132 girls with a median age of 4.7 years, all 
French-Canadian from the province of Quebec, Canada. Parental DNA was 
available for 203 of the probands. Healthy controls (n=329) consisted of French-
Canadian individuals recruited while using clinical departments other than 
Hematology-Oncology of the Sainte-Justine Hospital.  
 
SNPs, genotyping and quality control checks. We selected 29 SNPs from 12 
candidate cell cycle genes for the analysis (Table 4). Genes were selected 
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based on their function in regulating the G1/S cell cycle checkpoint. Regulatory 
SNPs (found to lie within the proximal promoter region) were chosen based on 
the hypothesis that variation in gene dosage of such critical cell cycle genes due 
to functional regulatory polymorphisms could influence cancer susceptibility by 
altering cell homeostasis (28). For the purpose of this study using a French-
Canadian cohort, we considered European-specific SNPs previously identified 
in (29). DNA was isolated from buccal epithelial cells, peripheral blood or bone 
marrow in remission as previously described (30). SNPs were genotyped using 
the Luminex xMAP/Autoplex Analyser CS1000 system (Perkin Elmer, Waltham, 
MA). Genetic variants were amplified using allele-specific primer extension in 
multiplexed assays and hybridized to Luminex MicroPlex TM –xTAG 
Microsperes as per Koo et al. (31). Primer sequences, amplification conditions, 
and reaction conditions are available upon request. Genotypes were called 
using the Automatic Luminex Genotyping (ALG) software (32). Three negative 
controls and three sample duplicates were used on each 96-well DNA plate. 
The average genotype call rate was 99.8% and rates of discordance were below 
3.3%. In addition, Hardy-Weinberg equilibrium was tested using the 𝑋2 
goodness of fit test and PedCheck (Version 1.1) was used to identify genotype 
incompatibilities using the familial data (33); inconsistent case-parent trios were 
removed from the analyses. Multiple testing corrections were performed on the 
single-step association tests using the Benjamini-Hochberg false discovery rate 
(FDR) method with a type I error rate of 10%; nominal P values are shown. 
 
Results and Discussion 
 
Although there are currently no data to document the frequency of events that 
lead to mating distortions in human populations, it is biologically plausible that 
MA might commonly occur. It is known that assortative mating (selection of a 
mate on the basis of phenotype leading to correlation between phenotypes of 
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mated individuals with respect to a given trait) can lead to genotype frequency 
differences between males and females (34-36). Other mechanisms leading to 
mating asymmetry however are unclear and their evolutionary consequences 
much less understood. If, for a specific marker, MA results in a departure from 
Hardy-Weinberg equilibrium, this genetic marker would be excluded from an 
association study following quality control. However MA could also arise through 
mating selection but with discrimination acting oppositely in each sex, or through 
differential individual mating success for the genotypes of each sex. Both these 
processes could lead to genotype frequency differences between sexes that 
would not lead to detectable deviations from Hardy-Weinberg equilibrium but 
that may incur important biases in fetomaternal association testing. In addition 
to these biological causes, low levels of MA could arise in a study sample simply 
due to the sampling process. Although parents of controls allow direct testing for 
bias due to MA in fetomaternal genotype association testing (9), these samples 
are difficult to collect and a method that can combine case-control and family-
based data and provide a valid analytical framework for fetomaternal 
association testing in the presence of MA is currently not available.  
 
Simulation study 
In this study we used simulations to investigate the ability of three fetomaternal 
genotype association tests: 1) the log-linear, likelihood-based method of 
Weinberg and Umbach (9) using a case-parent/case-control design (HD-NPC), 
2) the conditional logistic regression approach of Cordell et al. (7) combined with 
a case-control test (CC+CLR), and 3) Weinberg and Umbach‘s hybrid design 
using log-linear regression analysis, to distinguish between offspring and 
maternal genetic contributions to disease in the presence of MA. It should be 
noted that since both the log-linear and CLR frameworks are equivalent in terms 
of power and type I error for the detection of maternal genotype effects (7), our 
conclusions regarding the CC+CLR approach would also apply to a case-control 
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combined with the log-linear linear framework of Wilcox et al. (1) and Weinberg 
et al. (3) using case-parent triads. We evaluated type I error rates and power of 
the methods under varying degrees of MA, and genotypic risk models involving 
child, mother or joint effects of both child and mother (Table 2). For clarity 
reasons, we present the results for multiplicative genotype effect models only. 
However similar results were obtained under dominant and recessive models, 
with recessive models yielding expected decreases in power across all 
methods, particularly at low allele frequencies. 
 
As expected, all three methods showed similar low type I error rates, around 5% 
and similar power, above 80% for the detection of child effects (GC11 = 1; GC12 
= 2; GC22 = 3) under MS as well as under MA (data not shown). For a maternal 
main effect (GM11 = 1; GM12 = 2; GM22 = 3), type I error and power under MS 
were also within the acceptable ranges (data not shown). By contrast, under MA 
the CC+CLR method yielded unacceptably high type I error rates for the Mother 
test (Figure 2A). Although we expected that the method developed by Cordell et 
al. would be susceptible to the confounding incurred by MA, we found that CLR 
does not withstand even low levels of asymmetry (ΔC ~0.1) so that even weak 
assumptions concerning population distributions of parental genotypes could 
lead to important bias.  
 
The validity of the Mother tests for HD and HD-NPC were unaffected by MA, 
with type I error rates below the 5% threshold (Figure 2A). Power of the HD 
design was maintained at 100% and was unaffected by MA under the simulation 
conditions considered here, whereas power of HD-NPC considerably dropped, 
averaging around 30% (Figure 2B). When HD-NPC is used under asymmetry, 
genotypes for the parents of controls are inferred based on mating-type 
frequencies estimated from the parents of the cases and based on the 
assumptions that the control offspring genotypes follow Mendelian proportions 
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in relation to their parents (9). Hence, the maternal effect present in the case 
triads is partially captured in the inference of the mating-type frequencies for the 
parents of controls, resulting in a loss of power to detect this maternal effect as 
it becomes confounded with the estimated asymmetry. 
 
The stepwise procedure allows maternal and case effects to be distinguished by 
estimating maternal effects independently of offspring effects and provides a 
valid test for joint fetomaternal associations. Under the null model and MS, the 
stepwise likelihood-ratio testing procedure yielded type I error rates close to 0% 
(data not shown), most likely due to the over-conservative Bonferroni correction 
that was applied. Since the Mother and Child tests are not completely 
independent a permutation test procedure would provide less-conservative type 
I error estimates. When we modelled multiplicative effects of both offspring and 
maternal effects (GC11 = GM11 = 2 and GC12 = GM12 = 3), the power to detect 
fetomaternal associations using the forward stepwise procedure was 
comparable for all three methods and increased with increasing allele 
prevalence for each method, reaching 80% for MAFs > 0.20 (Figure 3A).  
 
We then evaluated type I error rates and power for the stepwise procedure in 
the presence of MA. The performance of both HD and HD-NPC was unaffected 
by MA with type I error rates close to zero even in the presence of high levels of 
asymmetry (Supplementary Figure 2). The type I error rate of the CC+CLR 
approach was close to 5% (Supplementary Figure 2) given that both child and 
maternal effects had to be falsely detected in order for the replicate to be 
counted as a false-positive and the case-control component of the test was 
robust against spurious child associations. Because the CLR maternal test is 
not valid under even low levels of MA, we assessed the power of the other two 
approaches to detect fetomaternal associations for varying levels of MA (Figure 
3B). HD performed significantly better than HD-NPC: sensitivity of the HD 
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design averaged around 100% whereas power of HD-NPC was again 
significantly lower, averaging around 40%.  
 
Based on the above findings, no method seemed to provide a net advantage 
under MS for these simulation conditions; nor did we observe any significant 
loss of power or robustness when the conditional logistic regression or the log-
linear, likelihood-based approaches were used without parents of controls. 
Although power was significantly reduced, the log-linear, likelihood-based 
approach using controls rather than parents had little effect on the specificity of 
the association tests in the presence of MA. However, for the analyses 
performed on MA simulated datasets, we forced the estimation of nine mating-
type parameters. In practice, no a priori assumptions regarding MS could be 
made. To verify the robustness of both methods for the detection of maternal 
(and fetomaternal) genotype effects in the presence of asymmetry, we 
measured type I error rates for the Mother test for scenarios in which either MA 
or MS models are assumed, and for a scenario in which no a priori hypothesis is 
made but rather MS is first evaluated in a three degree-of-freedom likelihood 
ratio test and the appropriate models (MA or MS) are subsequently used for 
association testing. These results show that if one assumes MS and this 
assumption is violated, type I error rates for the maternal test for both HD-NPC 
and HD are significantly inflated (Figure 4).  However, first testing for asymmetry 
and then adjusting the association analyses accordingly provides accurate type 
I error rates for both methods. Similar results were obtained for the forward 
stepwise procedure (data not shown).  
 
The specificity of the HD-NPC test therefore relies on its ability to detect MA and 
then use mating-type models accounting for asymmetry to test for association. 
Given that there are no biological references for the amount of MA that occurs in 
human populations, we evaluated the capacity of the HD and HD-NPC methods 
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to detect various levels of MA (Figure 5). Our simulation results showed that the 
power of HD-NPC to detect asymmetry above ∆C = 0.4 was comparable to that 
of HD. For a risk allele frequency of q = 0.3, HD and HD-NPC reached 80% 
power at ∆C = 0.25 and ∆C = 0.35, respectively. Under low levels (∆C ranging 
from 0 to 0.2) the sensitivity of both methods to detect asymmetry was 
threatened, especially for the HD-NPC approach (Figure 5).  On the other hand, 
the lack of power of HD-NPC and HD to detect low levels of asymmetry is 
compensated by the fact that, without any a priori assumptions regarding mating 
symmetry, both methods maintained low type I error rates, at least under the 
simulation conditions presented here (Figure 4). 
 
Therefore if asymmetry is not strong enough to be detected by the MA test it 
should not be falsely interpreted as a maternally-mediated effect. By contrast if 
a maternal effect is present and HD-NPC is used to test for mating asymmetry 
without parents of controls, type I error rates (of false detection of MA) are high 
(ranging from 0.8 to 0.9 for MAFs of 0.10 to 0.25, respectively) leading to a 
subsequent loss of power to detect maternal effects due to the over-
parameterisation under the MA models (data not shown). Together these results 
show that the log-linear, likelihood-based stepwise procedure using unaffected 
offspring provides a valid framework to evaluate MS without leading to spurious 
maternal associations. And when parents of controls cannot be ascertained but 
an additional set of unrelated controls is available, one can safely use this 
approach to test for fetomaternal associations if willing to accept that certain 
confounded maternally-mediated effects may be missed when parental mating 
is asymmetric.  
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Fetomaternal association study of childhood acute lymphoblastic 
leukemia  
Guided by our simulation results we went on to test for fetomaternal 
associations between 29 SNPs in the proximal promoter regions of 12 cell cycle 
genes (29) and the susceptibility to childhood pre-B ALL. SNP frequencies were 
in agreement with those previously reported in other populations of European 
descent and all distributions were in Hardy-Weinberg equilibrium. Our dataset 
consisted of 118 pre-B ALL patients, 203 ALL case-parent triads, and 329 
unrelated controls. The lack of parents of controls prevents us from excluding 
MA in the source population. Based on the results from our simulation study, we 
used the log-linear framework to perform likelihood-based testing in a stepwise 
fashion. For each SNP, we performed a three degree-of-freedom likelihood-ratio 
test for asymmetry implemented in the LEM software using a slightly less 
stringent P value < 0.10 to reject symmetry in order to reduce false-positives in 
the tests for maternal effects.  Under this threshold, we identified MA at variants 
rs1144944 (P= 0.086) and rs3730485 (P= 0.095) of the MDM2 gene, as well as 
at CDKN2B variant rs2069416 (P= 0.076); we did not detect asymmetry at any 
of the remaining loci tested (P values > 0.10; data not shown). Consequently, 
MA models (nine mating-type parameters) were used to test for association at 
these three SNPs whereas MS models (six mating-type parameters) were used 
for the remaining 26 SNPs (see Figure 6, for the Child and Mother single-step 
test results and Supplementary Table 1 for complete likelihood-ratio chi-square 
test results). Nominally significant genotype associations at the level of the child 
were identified for CDKN2A rs36228834 (Child vs. Null; P= 0.0007), CDKN1B 
rs35756741 (Child vs. Null; P= 0.0235) and CDKN2B rs2069416 (Child vs. Null; 
P= 0.0063); however only CDKN2A rs36228834 and CDKN2B rs2069416 
remained significant after multiple testing corrections (Supplementary Table 1). 
None of the other 26 loci revealed any significant child-mediated genetic 
associations with ALL and no significant maternal genotype effects were 
identified through the Mother vs. Null log-linear test (Figure 6 and 
Supplementary Table 1). 
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Nominally significant SNPs were further analyzed to detect putative joint 
fetomaternal effects. After accounting for the effect of the child‘s genotype, we 
found a significant maternal association at CDKN2A rs36228834 (Child+Mother 
vs. Child; P= 0.0168) only (Supplementary Table 1). The CDKN2A rs36228834 
A allele was overrepresented in patients when compared with controls 
(genotype Fisher‘s exact P= 0.005) and carriers of the A risk allele were 2.5-fold 
more susceptible to ALL (Child vs. Null; TA vs. TT: OR= 2.48; 95%CI(1.45-
4.15); TA/AA vs. TT: OR= 2.56; 95%CI(1.54-4.26)). This risk was further 
increased when the mother‘s genotype was included in the model (Child + 
Mother vs. Null; TA vs. TT: OR= 3.13; 95%CI(1.81-5.40); TA/AA vs. TT: OR= 
3.20; 95%CI(1.85-5.53)) (Table 5). No further maternal association was 
detected for CDKN1B rs35756741 (Child + Mother vs. Child; P= 0.59) or 
CDKN2B rs2069416 (Child + Mother vs. Child; P= 0.33) (Supplementary Table 
1). These results provide evidence of a novel fetomaternal effect at the 
CDKN2A rs36228834 locus that may influence pre-B ALL susceptibility among 
children, and a possible joint effect of both mother and child genotypes without 
main effects at CDKN2B rs36229158. Interestingly, although variant CDKN2B 
rs36229158 presented only a suggestive effect at the level of the child (Child vs. 
Null; P= 0.06), a significant association was found for the mother after we 
accounted for the genotype of the child (Child + Mother vs. Child; P= 0.0217) 
(Supplementary Table 1). Including the mother‘s genotype in the regression 
model significantly increased the risk 2.3-fold for carriers of a C allele (Child + 
Mother vs. Null; CT vs. CC: OR= 2.32; 95%CI(1.23-4.35); CT vs. CC: OR= 2.44; 
95%CI(1.29-4.60)) (Table 5).  
 
Independent replication is required in order to confirm the significance of these 
associations given that some of these variants did not withstand multiple testing 
correction (CDKN1B rs35756741 and CDKN2B rs36229158); and caution is 
warranted in the interpretation of the risk estimates as risk allele frequencies at 
loci CDKN2A rs36228834 and CDKN2B rs36229158 were low (MAFs ≤ 0.05), 
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yielding large confidence intervals, particularly for the rare homozygous 
genotype classes. We also recognize that the interpretation of our real-data 
results relies in part on our simulation results and there are certain limitations to 
our simulation study. These include the restricted number of models used in the 
method evaluations and the important assumptions of absence of population 
substructure and Hardy-Weinberg equilibrium, which necessitate further 
investigation. Our conclusions on the validity of the HD-NPC approach under 
MA should hold for other models. As we noted, the detection of asymmetry and 
maternal effects are partially confounded with HD-NPC and it is difficult to 
imagine a model of asymmetry for which differences in mating type frequencies 
would not be detected by the asymmetry test but would be captured by the 
Mother vs. Null test, thus leading to increased type I error. However, the 
reduction in power of HD-NPC compared to HD will likely be affected by the 
underlying genetic and asymmetry models and should be assessed under a 
wider range of models. Other important genetic effects should also be 
investigated, such as mother-gene child-gene interactions and parent-of-origin 
effects which are not addressed here but can also be involved in early-onset 
disorder risk.  
 
Nonetheless, our results provide evidence that genes that regulate the cell cycle 
could play an important role during fetal development when the rate of cell 
growth and division is high both in child and mother. In silico analysis using the 
MatchTM software (37) revealed that all three variant loci lead to the disruption of 
putative transcription factor binding sites, including the loss of binding sites for 
FOS and MYB at CDKN2A rs36228834. The FOS oncoprotein stimulates 
transcription of genes containing AP-1 regulatory elements and may transform 
cells through alterations in DNA methylation and in histone deacetylation (38). 
Expression of FOS is 100-fold greater in human fetal membranes than in other 
normal human tissues and cells (39). The MYB transcription factor is essential 
for hematopoiesis and controls the proliferation and differentiation of 
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hematopoietic stem and progenitor cells (40). MYB is frequently involved in 
hematopoietic disorders including ALL (41). Although the biological relevance of 
our findings remains to be elucidated, our study suggests that promoter 
variation in the cell cycle inhibitor gene CDKN2A, and possibly CDKN2B, could 
disrupt transcription-factor binding and influence gene expression during 
gestation. Dysregulated cell division caused by aberrant cell cycle inhibitor gene 
expression in both mother and child could disrupt the maternal-fetal interface 
and affect important physiological processes such as the growth of the fetus 
and/or normal haematopoiesis and potentially lead to increased susceptibility to 
ALL. 
 
Conclusions 
 
Given the unique nature of childhood disorders, the investigation of parental 
genetics and maternally-contributed effects is a prerequisite not only for 
understanding disease etiology but also to pave the way toward new 
opportunities in preventive medicine. Although the most powerful approach is 
ideally the most desirable, in practice the best approach might be one that 
combines both valid detection of the possible underlying genetic associations 
involved in early-onset disorders and a feasible design in terms of 
ascertainment and genotyping costs. We have shown that the log-linear, 
likelihood-based framework using a case-triad/case-control design retains the 
ability to control for bias due to MA and can provide valid tests for maternally-
contributed genotype effects even when the assumption of symmetry fails. 
Despite a modest sample size, we successfully used this approach to identify 
putative fetomaternal genotype effects in cell cycle inhibitor genes CDKN2A and 
CDKN2B that are associated with modified risks of childhood pre-B ALL. 
Although these genes have been previously associated with ALL (28), we have 
shown for the first time that their influence on ALL risk might be driven, in part, 
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by the maternal genotype. This study provides the first indication that maternal 
genotype effects can influence the risk of developing pediatric ALL, providing 
useful insights into the genetic mechanisms underlying this early-onset disease. 
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Figures 
 
Figure 1. Cohort data used for simulations 
200 replicate datasets were generated for each model. For all of our 
calculations we used the same overall number of affected individuals and case-
parents however the methods differed in how the case and control data was 
utilized in each individual test (see Materials and Methods). The same number 
of affected individuals (n= 330) and case-parents (n= 400) were used under all 
three methods. For the combined case-control and conditional logistic 
regression analysis (CC+CLR) and the log-linear analysis using unrelated 
controls rather than their parents (HD-NPC), we used the genotypes of 
unrelated controls (n= 325, in blue), whereas for the hybrid design using parents 
of controls in a log-linear framework (HD), we incorporated the genotypic 
information of the parents of these controls rather than the controls themselves 
(n= 650, in red).  
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Figure 2. Type I error rates and power for the maternal association test 
under mating asymmetry 
A) Type I error rates are given for the Mother vs. Null test as a function of 
departure from mating symmetry, as measured by ∆C, under the null model 
where GC11 = GC12 = GC22 = GM11 = GM12 = GM22 = 1 (Table 2, Model 5). Allele 
prevalence is set at q= 0.3. B) Power to detect a maternal effect is shown as a 
function of departure from mating symmetry, as measured by ∆C, for a scenario 
with multiplicative effects of the mother (Table 2, Model 7). Allele prevalence is 
set at q= 0.3. MA models (9 mating-type parameters) were used for log-linear 
regression under the assumption of mating asymmetry. Horizontal reference 
lines indicate type I error rate of α= 0.05 (A) and power= 0.8 (B). HD, hybrid 
design using parents of controls in a log-linear framework; HD-NPC, log-linear 
analysis using unrelated controls rather than their parents; CC+CLR, combined 
case-control and conditional logistic regression analysis.  
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Figure 3. Power of the forward stepwise procedure to detect joint 
fetomaternal associations 
A) Power for the HD, HD-NPC and CC+CLR methods is shown as a function of 
allele prevalence for a scenario with mating symmetry and multiplicative effects 
of both Child and Mother (Table 2, Model 4). B) Power for HD and HD-NPC is 
shown as a function of departure from mating symmetry, as measured by ∆C, 
for a scenario with mating asymmetry and multiplicative effects of both Child 
and Mother (Table 2, Model 8). Allele prevalence is set at q= 0.3. MA models (9 
mating-type parameters) were used for log-linear regression under the 
assumption of mating asymmetry. Horizontal reference lines indicate power= 
0.8. HD, hybrid design using parents of controls in a log-linear framework; HD-
NPC, log-linear analysis using unrelated controls rather than their parents; 
CC+CLR, combined case-control and conditional logistic regression analysis.   
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Figure 4. Type I error rate for the HD and HD-NPC approaches for the 
maternal association test assuming either mating symmetry or asymmetry 
Type I error rates are shown as a function of departure from mating symmetry, 
as measured by ∆C, under the null model where GC11 = GC12 = GC22 = GM11 = 
GM12 = GM22 = 1 (Table 2, Model 5). Allele prevalence is set at q= 0.3. Log-
linear, likelihood-based testing (Mother vs. Null) was performed assuming either 
mating asymmetry estimating nine mating-type parameters in the likelihood-ratio 
tests (Asym), or mating symmetry using only six mating-type parameters in the 
likelihood-ratio tests (Sym), or with no a priori hypothesis, using a 3 degree of 
freedom likelihood-ratio test to first test the assumption of mating symmetry 
(Mating Asymmetry (9df) vs. Mating Symmetry (6df)) and then using either the 
mating asymmetry models when asymmetry was detected or the mating 
symmetry models when it was not (Mixed). Horizontal reference line indicates 
type I error rate of α= 0.05. HD, hybrid design using parents of controls in a log-
linear framework; HD-NPC, log-linear analysis using unrelated controls rather 
than their parents.  
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Figure 5. Power of HD and HD-NPC to detect mating asymmetry 
Power is shown as a function of departure from mating symmetry, as measured 
by ∆C, under the null model where GC11 = GC12 = GC22 = GM11 = GM12 = GM22 = 
1 (Table 2, Model 5). Allele prevalence is set at q= 0.3. Mating asymmetry was 
evaluated in the log-linear framework using a 3 degree of freedom likelihood-
ratio test comparing the 9 mating-type parameter model under MA to a 6 
mating-type parameter model under MS. Horizontal reference line indicates 
power= 0.8. HD, hybrid design using parents of controls in a log-linear 
framework; HD-NPC, log-linear analysis using unrelated controls rather than 
their parents.  
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Figure 6. Log-linear, likelihood-ratio association analysis between 29 regulatory SNPs from 12 cell cycle genes 
and childhood pre-B acute lymphoblastic leukemia (ALL) 
Log-linear regression analysis was performed in LEM using 203 case-triads, 118 unrelated ALL patients and 329 controls. 
Results of the likelihood-ratio chi-square tests (- log P) are shown for the single-step Child (blue) and Mother (red) tests. 
Mating symmetry (i.e. six mating-type parameters) was assumed at all loci but variants rs1144944 and rs3730485 of the 
MDM2 gene, as well as CDKN2B rs2069416 for which MA models (nine mating-type parameters) were used to test for 
association. Horizontal reference line indicates P value of 0.05. Note that for the tri-allelic variant CDKN2B rs2069416 
(A>T,C) individuals were grouped according to their T allele such that **>*T>TT. See Supplementary Table 1 for complete 
likelihood-ratio chi-square test results. 
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Supplementary Figure 1. Relative distribution of reciprocal mating types 
as a function of mating asymmetry 
Genotype frequency differences between mating type pairs are given as a 
function of ∆C, the measure of the departure from mating symmetry. Frequency 
differences are shown for Mother-Father mating type 1 (M11,F12 vs. M12,F11) in 
A) and mating type 2 (M11,F22 vs. M22,F11) in B) for allele frequencies (q) ranging 
from 0.1 to 0.9. 
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Supplementary Figure 2. Type I error rates for fetomaternal association 
testing under mating asymmetry 
Type I error rates are given for the stepwise procedure and are shown as a 
function of departure from mating symmetry, as measured by ∆C, under the null 
model where GC11 = GC12 = GC22 = GM11 = GM12 = GM22 = 1 (Table 2, Model 5). 
Allele prevalence is set at q= 0.3. MA models (9 mating-type parameters) were 
used for log-linear regression under the assumption of mating asymmetry. 
Horizontal reference lines indicate type I error rate of α= 0.05. HD, hybrid design 
using parents of controls in a log-linear framework; HD-NPC, log-linear analysis 
using unrelated controls rather than their parents; CC+CLR, combined case-
control and conditional logistic regression analysis.  
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Tables 
 
Table 1. Forward stepwise likelihood-ratio testing procedure used to dissect child and maternal genotype 
associations 
 
Likelihood-ratio tests were performed in a forward stepwise fashion. The most significant single-step test (Child vs. Null or 
Mother vs. Null) was tested against a joint effects model in a 2 degree of freedom likelihood-ratio test (Child + Mother vs. 
Child or Child + Mother vs. Mother). LR Chi2 indicates likelihood-ratio chi-square test; df, degrees of freedom; GC Child 
genotype relative risk; GM, Mother genotype relative risk.
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Table 2. The eight simulation models used for evaluation of the fetomaternal association tests 
 
(–): indicates a null risk model where the genotype relative risks (GRRs) are GRR11 = GRR12 = GRR22 = 1. GC indicates 
Child genotype relative risk; GM, Mother genotype relative risk; MAF, Minor allele frequency; ΔC, mating-pair 
disequilibrium. MS indicates mating symmetry where ∆C = 0. 
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Table 3. Parental genotype distributions under mating symmetry and 
mating asymmetry 
 
Alleles for a biallelic locus are denoted 1 and 2 and the corresponding 
genotypes 11, 12 or 22. N indicates the number of individuals in the sample; μ
i
 
the 𝑖th mating type probability under the assumption of random mating; Ci the 
mating-pair disequilibrium for the 𝑖th parental couple. C is a multiplicative factor 
between 0 and 2 that describes the over representation (>1), under 
representation (<1) or symmetry (=1) of a mate-pair combination in the 
corresponding 𝑖th mating type.   
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Table 4. Genes and DNA variants genotyped in the pre-B ALL association 
study 
 
269 
 
 
 
2
6
9
 
 
DNA variant positions relative to dbSNP build 130. MAF indicates minor allele 
frequency and was calculated on a control cohort consisting of 329 healthy 
individuals of European descent.
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Table 5. Distribution of CDKN2A rs36228834 and CDKN2B rs36229158 genotypes and associated risk estimates 
for pre-B ALL susceptibility among children 
 
Percentages indicate number of individuals with a given genotype/total number of genotyped individuals. Risk estimation 
was performed using log-linear regression analysis as implemented in the LEM software. Child odd ratios were measured
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using regression models consisting of the child genotype effect only (Child vs. Null) or both child and mother genotypes 
(Child + Mother vs. Null). Mating symmetry (i.e. six mating-type parameters) was assumed at both loci. P values of the 
Wald test provided by LEM are shown for either the 2 degree of freedom (2 child genotype effects) or 1 degree of freedom 
(1 child genotype effect resulting from the collapsed heterozygous/homozygous rare genotypes) tests. OR indicates odds 
ratio; CI, confidence interval. 
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Supplementary Table 1. Log-linear, likelihood-ratio association analysis 
between 29 regulatory SNPs from 12 cell cycle genes and childhood pre-B 
ALL 
Gene, 
    DNA variant 
Model LR Chi2 (df) P  
CCND1       
rs1944129 Child vs. Null 1.2295 (2) 0.5408 
 
Mother vs. Null 2.1512 (2) 0.3411 
    rs36225395 Child vs. Null 0.4281 (2) 0.8073 
 
Mother vs. Null 1.7239 (2) 0.4223 
CDC25a       
rs1903061 Child vs. Null 0.2266 (2) 0.8929 
 
Mother vs. Null 0.2315 (2) 0.8907 
CDKN1A       
rs733590 Child vs. Null 2.5003 (2) 0.2865 
 
Mother vs. Null 2.6508 (2) 0.2657 
    rs762624 Child vs. Null 0.3833 (2) 0.8256 
 
Mother vs. Null 1.9700 (2) 0.3734 
    rs2395655 Child vs. Null 1.8532 (2) 0.3959 
 
Mother vs. Null 1.9417 (2) 0.3788 
CDKN1B       
rs3759217 Child vs. Null 1.8690 (2) 0.3928 
 
Mother vs. Null 0.7517 (2) 0.6867 
    rs35756741 Child vs. Null 7.5044 (2) 0.0235 
 
Mother vs. Null 1.2860 (2) 0.5257 
 
Child + Mother vs. Null 8.5604 (4) 0.0731 
 
Child + Mother vs. Child 1.0560 (2) 0.5898 
    rs36228499 Child vs. Null 0.2166 (2) 0.8973 
 
Mother vs. Null 2.8311 (2) 0.2428 
CDKN2A       
rs36228834 Child vs. Null 14.4130 (2) 0.0007 
 
Mother vs. Null 0.65476 (2) 0.7209 
 
Child + Mother vs. Null 22.5809 (4) 0.0002 
 
Child + Mother vs. Child 8.1678 (2) 0.0168 
CDKN2B       
rs36229158 Child vs. Null 5.6281 (2) 0.0600 
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Mother vs. Null 1.4635 (2) 0.4811 
 
Child + Mother vs. Null 13.2885 (4) 0.0099 
 
Child + Mother vs. Child 7.6604 (2) 0.0217 
    rs2069416
1 
Child vs. Null 10.1261 (2) 0.0063 
 
Mother vs. Null 0.9204 (2) 0.6312 
 
Child + Mother vs. Null 12.3208 (4) 0.0152 
 
Child + Mother vs. Child 2.1947 (2) 0.3338 
    rs2069418 Child vs. Null 0.1654 (2) 0.9206 
 
Mother vs. Null 3.4934 (2) 0.1744 
E2F1       
rs3213141 Child vs. Null 5.3498 (2) 0.0689 
 
Mother vs. Null 3.1276 (2) 0.2093 
HDAC1        
rs1741981 Child vs. Null 4.3556 (2) 0.1133 
 
Mother vs. Null 0.1855 (2) 0.9114 
    rs36212121 Child vs. Null 3.8760 (2) 0.1440 
 
Mother vs. Null 0.0251 (2) 0.9875 
    rs36212119 Child vs. Null 0.0436 (2) 0.9784 
 
Mother vs. Null 1.5479 (2) 0.4612 
MADH3       
rs36221701 Child vs. Null 0.5317 (2) 0.7666 
 
Mother vs. Null 1.0401 (2) 0.5945 
    rs36222034 Child vs. Null 5.0971 (2) 0.0782 
 
Mother vs. Null 5.5164 (2) 0.0634 
    rs11633026 Child vs. Null 0.9712 (2) 0.6153 
 
Mother vs. Null 0.0025 (2) 0.9987 
MDM2        
rs1144944 Child vs. Null 1.9874 (2) 0.3702 
 
Mother vs. Null 0.4247 (2) 0.8087 
    rs3730485 Child vs. Null 0.6397 (2) 0.7263 
 
Mother vs. Null 0.5579 (2) 0.7566 
    rs937282 Child vs. Null 0.0355 (2) 0.9824 
 
Mother vs. Null 1.7830 (2) 0.4100 
    rs2279744 Child vs. Null 2.3131 (2) 0.3146 
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Mother vs. Null 4.2749 (2) 0.1180 
RB1        
rs1573601 Child vs. Null 0.1689 (2) 0.9190 
 
Mother vs. Null 0.2512 (2) 0.8820 
TGFB1        
rs2317130 Child vs. Null 3.3133 (2) 0.1908 
 
Mother vs. Null 1.4944 (2) 0.4737 
    rs4803457 Child vs. Null 1.0157 (2) 0.6018 
 
Mother vs. Null 1.5627 (2) 0.4578 
    rs11466313 Child vs. Null 2.3172 (2) 0.3139 
 
Mother vs. Null 1.4790 (2) 0.4773 
    rs1800469 Child vs. Null 1.8827 (2) 0.3901 
  Mother vs. Null 2.4241 (2) 0.2976 
 
Likelihood-ratio tests were performed in a forward stepwise fashion. The most 
significant single-step test (Child vs. Null or Mother vs. Null) was tested against 
a joint effects model in a 2 degree of freedom likelihood-ratio test (Child + 
Mother vs. Child or Child + Mother vs. Mother). Mating symmetry (i.e. six 
mating-type parameters) was assumed at all loci but variants rs1144944 and 
rs3730485 of the MDM2 gene, as well as CDKN2B rs2069416 for which MA 
models (nine mating-type parameters) were used to test for association. Multiple 
testing corrections were performed on the single-step association tests using 
the Benjamini-Hochberg false discovery rate (FDR) method with a type I error 
rate of 10%; nominal P values are shown, those in bold remain significant after 
FDR adjustment. LR Chi2 indicates likelihood-ratio chi-square test; df, degrees 
of freedom.  
1CDKN2B SNP rs2069416 is tri-allelic A>T,C. For analysis, individuals were 
grouped according to their T allele such that **>*T>TT. 
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CONCLUSIONS 
AND FUTURE PERSPECTIVES 
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SUMMARY AND DISCUSSION OF MAIN FINDINGS 
 
Unravelling the genetic architecture of complex diseases has proven to be a 
daunting task and current analytical approaches geared toward investigating 
high impact gene variations have provided few insights into the genetic 
complexities of polygenic diseases. The relative lack of success of these initial 
efforts emphasizes the need for study designs and methods that account for 
genetic effects other than those mediated by single, inherited genes. In this 
study I attempted to dissect the etiologic intricacies underlying childhood acute 
lymphoblastic leukemia (ALL) and identify genetic factors that shape 
interindividual variability in the susceptibility to this disease. ALL is the most 
common cancer among children and is likely caused by multiple genetic and 
environmental factors. However the identification of established genetic risk 
factors for ALL has been impeded by the complex and heterogenic nature of the 
disease.  
 
To tackle this issue I used three approaches in my doctoral research project, as 
detailed in Chapters Two, Three, and Four. Using a unique study design 
consisting of both case-control and family-trio data, I performed a pathway-
based candidate gene association study of childhood pre-B ALL. I selected 
genes based on their involvement in two core signalling pathways, the G1/S cell 
cycle checkpoint and DNA double-strand break repair (DSBR) pathways, 
following the hypothesis that deregulation of these mechanisms could lead to 
increased genomic instability and mutational burden and disrupt cell 
homeostasis, thereby influencing disease risk. To better depict the genetic 
foundation of childhood ALL I not only investigated the putative effects of 
individual genes on disease risk (Chapter Two) but attempted to further describe 
the combined effects of multiple genes through epistatic interactions or through 
whole pathway effects (Chapter Three). And for the first time, I assessed the 
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role of the mother‘s genes in modulating disease risk in her offspring, either 
directly or through joint effects with the child‘s genotype (Chapter Four). 
Through these studies I successfully identified genetic variants in both the cell 
cycle and DNA repair pathways that are associated with childhood ALL and 
provided evidence for the implication of these biologic mechanisms in 
leukemogenesis. Moreover, I identified genetic variants that act through the 
mother, at least in part, to influence the risk of ALL for the growing fetus; this is 
the first study to demonstrate the role of parental genetic contributions in 
pediatric cancers.  
 
Novel susceptibility loci for childhood ALL that were identified through this study 
include cell cycle control genes CDKN2A, CDKN2B,  and HDAC1 and DNA 
double-strand break repair genes BRCA1, XRCC4 and XRCC5. Individual SNPs 
and/or haplotypes in the promoter regions of these genes were shown to 
significantly modulate ALL risk. These data add to the growing list of genetic 
association studies that have identified susceptibility loci for childhood ALL (see 
Table 4, Chapter One). Yet for the most part the observed associations, 
including some of the ones identified through my studies, have been weak or 
inconsistent or have only been identified in a single study. Additional, larger 
studies are required to confirm the presumed genetic risk factors for ALL 
detected in my doctoral research and to validate their role in disease.  
 
To this effect, we recently participated in a genome-wide association follow-up 
study in which 34 SNPs were replicated in additional case-control series 
(including the QcALL cohort) totaling 2,386 childhood ALL cases and 2,419 
controls1. Among the 34 SNPs interrogated, a single variant rs3731217 mapping 
to chromosomal region 9p21.3, was found to be strongly associated with  
                                                          
1
 (This work has recently been published (Variation in CDKN2A at 9p21.3 influences childhood 
acute lymphoblastic leukemia risk; Sherborne et al. Nat Genet. 2010;42(6):492-4; see Appendix  
IV for full manuscript). 
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childhood ALL within four replication series (1). The 9p21 region encompasses 
the CDKN2A (p16) and CDKN2B (p15) cell cycle inhibitor genes, the CDKN2A 
alternative reading frame transcript which encodes p14/ARF involved in 
activation of the tumor suppressor protein p53, the MTAP gene which encodes 
a phosphorylase that plays an important role in adenine and methionine 
metabolism, as well as the non-coding RNA ANRIL. This region is an important 
susceptibility locus for several diseases with a complex genetic background; 
variants within the region have been associated with coronary artery disease (2-
4), ischaemic stroke (5), aortic aneurysm (6), type II diabetes (7, 8), glioma (9, 
10), and malignant melanoma (11) through large-scale genome-wide 
investigation and candidate gene studies have reported SNPs in this region 
associated with breast (12, 13), ovarian (14), and pancreatic carcinoma (15), as 
well as melanoma (16).  
 
While this GWA study (1) provides unequivocal evidence for a relationship 
between CDKN2A and childhood ALL risk, I am unable to correlate the GWAS 
findings with my candidate gene observations using my samples given that the 
genotype data from Sherborne et al. were not made available to us and the 
CDKN2A variant rs36228834 identified in my study has not been genotyped in 
publicly available datasets such as the HapMap or 1000 Genomes data. My 
data did indicate however that LD between variants CDKN2A rs36228834 and 
CDKN2B rs2069416 in my study is low (D‘= 0.81, R2= 0.02) suggesting that 
they represent independent association signals. And based on data from 
European individuals genotyped in the 1000 Genomes Project, pairwise LD 
between variants CDKN2A rs3731217 and CDKN2B rs2069416 is also 
expected to be low (D‘= 0.32 and R2= 0.01), further suggesting independence of 
the CDKN2A and CDKN2B associations.  
 
 
284 
 
 
 
2
8
4
 
The two CDKN2A SNPs lie 9.3kb apart on chromosome 9 and are not found 
within a region of particularly high LD (Figure 1). The variant reported by the 
GWAS (rs3731217) lies within intron 1 of the CDKN2A/p14/ARF alternative 
reading frame transcript, 9.3kb downstream from our association signal 
(rs36228834) which, although also in intron 1 of CDKN2A/p14/ARF, falls within 
the proximal promoter region of CDKN2A/p16 (Figure 1). Both CDKN2A 
transcripts encode structurally and functionally different proteins. While 
Sherborne et al. found no SNPs in LD with variant rs3731217 in any of the 
coding regions of CDKN2A (including both p16 or p14 isoforms) or any of the 
other genes in the region, nor did they identify any regulatory regions 
surrounding rs3731217 or any effects on gene expression (1), in vitro data from 
my study showed differential DNA-protein binding within the promoter region of 
CDKN2A/p16 and allele-specific promoter activity associated with variant 
rs36228834 (17). It is possible that these associations are independent, and it is 
also possible that they may even be linked to different genes within the 9p21.3 
region (CDKN2A/p16, CDKN2A/p14/ARF, CDKN2B, MTAP, ANRIL). Given that 
we are currently unable to describe LD levels between these two loci, fine-
mapping and additional functional studies are imperative in order to better 
define the causal basis of the 9p21.3 associations with childhood ALL. 
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Figure 1. Details of the linkage disequilibrium region at 9p21.3 
LD statistics (D‘ are shown, color scheme corresponds to r2) from HapMap 
phase II CEU data are shown for a 60kb region (from 21,950,000 to 22,010,000 
on NCBI build 36, dbSNP build 126) on chromosome 9p21.3 containing the 
CDKN2A (isoforms 1 (p16), 3, and 4 (p14)) and CDKN2B (isoforms 1 and 2) 
genes, as well as the non-coding RNA ANRIL (not shown). The darker shading 
indicates strong LD between SNPs. The CDKN2A association signal reported in 
Sherborne et al. (1) (rs3731217) corresponds to SNP 13. Given that variants 
CDKN2A rs36228499 and CDKN2B rs2069416 identified in my study (17) have 
not been genotyped in the HapMap individuals, they are not shown here 
however they would lie between SNPs 8-9 (position 21,964,819) and 36-39  
(position 21,999,754), respectively. 
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Although many forms of human cancers exist, each with their own complexities 
and distinct patterns of genetic aberrations, a restricted number of alterations 
are thought to be shared by most, if not all tumour types (18). Such mutations 
include those that disrupt cell cycle control checkpoints allowing uncontrolled 
proliferation and those that hinder DNA damage response leading to increased 
genomic instability. p53 plays a central role in orchestrating cell cycle arrest 
and/or apoptosis in response to DNA damage and oncogenic signalling (19). 
Though p53 is mutated in over 50% of human cancers, somatic inactivation of 
this gene is infrequent in hematologic malignancies (20) suggesting that other 
mechanisms are likely responsible for disruption of these processes in 
leukemia. One such mechanism is through the inactivation of cell cycle inhibitor 
genes CDKN2A and CDKN2B which occurs frequently in childhood ALL either 
through large chromosomal deletions, promoter methylation or, less frequently, 
through point mutations (21-23). Our study was the first however to provide 
evidence of inherited germline variants in CDKN2A and CDKN2B associated 
with childhood ALL susceptibility (17). These cyclin-dependent kinase inhibitors 
(CDKIs) integrate mitogenic and growth inhibitory signals and coordinate 
passage through the G1/S cell cycle checkpoint. Our studies suggest that 
regulatory variants within the promoter regions of these genes could lead to 
disrupted transcription factor-binding and allele-specific differences in gene 
expression. Though the functional significance of the association results 
requires further in vivo validation, decreases in expression of CDKN2A and 
CDKN2B in hematopoietic cells due to the pSNPs identified in our study could 
lead to decreased cyclin D1-Cdk4/Cdk6 inhibition  and subsequent 
hyperphosphorylation of the RB1 protein facilitating entry into S phase. 
Decreased CDKI levels could thereby provide a proliferative advantage to the 
hematopoietic cells and contribute to leukemogenesis. Reduced CDKN2A and 
CDKN2B expression levels could also contribute to increased genomic 
instability observed in leukemia by limiting the G1/S phase and the time 
allocated for proper DNA repair. 
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However, a recent study showed that the cis-acting transcriptional effects of 
disease-associated SNPs in the 9p21 region, including CDKN2A promoter 
variant rs36228834, strongly influenced the expression of the non-coding RNA 
ANRIL in an allele-specific manner, while associations with CDKN2A and 
CDKN2B expression were weaker and less consistent (24). It may very well be 
that the true 9p21 disease culprit is in fact ANRIL, the effects of which may be 
mediated by post-transcriptional regulation of CDKN2A/2B. From an 
evolutionary point of view, sequence variants acting in cis through ANRIL may 
reflect selection pressure against variants that have direct effects on the 
expression of critical gatekeeper genes such as CDKN2A and CDKN2B. 
Though future studies are warranted to fully describe the involvement of this 
region in the pathogenesis of childhood ALL, my results further corroborate the 
importance of genetic variation at 9p21 in complex disease susceptibility. 
 
Among the other loci identified in my study, only XRCC4 has previously been 
linked to childhood ALL, in a Taiwanese population (25). Reduced expression of 
double-strand break repair genes XRCC4 and XRCC5, variants of which were 
also significantly associated with increased ALL risk in children in my study, 
caused by functional promoter SNPs could lead to decreased capacity of the 
nonhomologous end joining (NHEJ) DNA repair process in which XRCC4 and 
XRCC5 are involved (26) and lead to increased genomic instability and 
potentially leukemia. Sequence variation in the XRCC4 and XRCC5 genes have 
been linked to various other types of cancers (27-35) suggesting that reduced 
double-strand break repair caused by inherited polylmorphisms in these genes 
could serve as a common mechanism for carcinogenesis.  
 
Interestingly, double-strand break repair proteins XRCC4 and XRCC5 also play 
a central role in V(D)J recombination in B lymphocytes (36). Developing 
lymphocytes undergo somatic rearrangements through a series of DNA 
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recombination events (V(D)J recombination) to assemble a diverse repertoire of 
immunoglobins and antigen receptors (37, 38). This process requires 
introduction of double-strand breaks and subsequent repair through NHEJ 
(Figure 2). It is now clear that V(D)J recombination plays a role far beyond the 
generation of antigen receptor diversity and is also essential for precursor 
lymphoctye maturation and differentiation (38). In fact XRCC4-deficient mice 
experience defective lymphogenesis and embryonic lethality due to extensive 
apoptotic cell death; and while additional knockout of p53 allows postnatal 
survival of XRCC4-deficient mice, these mice routinely succumb to pre-B cell 
lymphomas caused by impaired V(D)J recombination (39). Therefore, 
decreased expression levels of NHEJ repair genes XRCC4 and XRCC5 could 
lead to aberrant V(D)J recombination events in B-cell progenitors and produce 
oncogenic chromosomal translocations and the appearance of lymphocytic 
tumours. The t(1;19)/E2A-PBX1 translocation, occurring in ~5% of pediatric B-
cell ALLs, does have some characteristics of translocations mediated by V(D)J 
recombination including site-specific clustering of the breakpoints and the 
presence of additional nucleotides at the fusion junctions (40) (see Figure 2), yet 
the more frequent chromosomal translocations observed in B-cell precursor 
childhood ALL rarely involve V(D)J recombination segments (41). Sequence 
variation in the XRCC4/5 genes could however contribute to aberrant V(D)J 
recombination in B cells and lead to accumulated DSBs and overall genomic 
instability and thus influence ALL susceptibility among children.  
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Figure 2. The V(D)J recombination mechanism 
During development, B and T cells randomly select three types of gene 
segments, one V, one D and one J, which are represented by large arrays in 
mammalian genomes, and randomly fuse them by lymphoid-specific 
recombination events to produce variable coding exons. Shown here is a the 
fusion of D and J elements. The coding regions of the D and J gene segments 
are shown as shaded boxes and are flanked directly by recombinase 
recognition sites (RS; triangles). Initially the RAG complex introduces double-
strand DNA breaks specifically at the RS/coding borders (arrows) of both 
participating gene segments to generate coding ends (CE) on the chromosome 
and signal ends (SE) as extrachromosomal DNA. Ubiquitous DNA repair 
proteins including XRCC5/6 (also known as Ku80/70) and XRCC4, ligate the 
SEs to produce a circular signal join (SJ). These SJs are deleted from the 
genome. CEs are further modified by nucleotide additions and/or deletions 
before ligation to increase the functional diversity of the resulting gene product 
known as the coding join (CJ). 
Figure adapted from Oltz, 2001 (38). 
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This was the first study to identify germline variants in BRCA1 associated with 
childhood ALL. As opposed to the more error-prone branch of the DSBR 
pathway in which XRCC4 and XRCC5 are involved, BRCA1 is involved in 
homologous recombination repair of DNA double-strand breaks (42). There is 
strong evidence for the implication of BRCA1 deficiency in hematologic cancers: 
BRCA1 is downregulated due to promoter hypermethylation in acute and 
chronic forms of myeloid leukemia (43, 44) and deleterious mutations in genes 
encoding proteins within the BRCA1 repair pathway have been shown to 
increase risk for certain leukemias and lymphomas (44). While the mechanisms 
through which promoter sequence variation in BRCA1 might influence ALL risk 
among children remain to be elucidated, it is possible that downregulation of 
BRCA1 expression could lower fidelity of this error-free repair process and 
favour gene rearrangements characteristic of childhood ALL. 
 
Finally, HDAC1 was also identified as a potential susceptibility locus for 
childhood ALL. Histone acetylation/deacetylation is a major factor regulating 
chromatin structure and transcription and also plays an important role in 
controlling cell cycle progression (45). HDAC1 physically interacts with RB1 and 
suppresses transcription of genes required for passage from G1 to S phase 
through histone deacetylation resulting in chromatin condensation and 
transcriptional repression (46). Tight control of HDAC1 expression is therefore 
essential for normal progression through the cell cycle and altered activity could 
confer a growth advantage on hematopoietic cells by allowing expression of S-
phase related genes or conversely by repressing expression of negative 
regulators of the cell cycle, and therefore contribute to leukemogenesis. Studies 
also suggest that HDAC1 is involved in regulating hematopoietic progenitor cell 
differentiation; in fact HDAC1 is overexpressed in acute myeloid leukemia cells 
where it contributes to leukemogenesis by halting myeloid differentiation (47). 
While it remains to be verified experimentally, we could speculate that 
regulatory polymorphisms in the HDAC1 promoter could alter gene expression 
291 
 
 
 
2
9
1
 
levels and contribute to childhood ALL by disrupting normal lymphoid 
differentiation and by facilitating clonal expansion of the undifferentiated 
leukemic blasts. Moreover, widespread changes in gene expression are a 
feature of cancer and subtypes of ALL have been shown to have distinctive 
patterns of global gene expression in microarray analyses (48, 49). Epigenetic 
mechanisms, such as chromatin structural changes, promoter methylation and 
non-coding RNAs, play an important role in deregulating gene expression in 
cancer including leukemogenesis (50). Given the role of HDAC1 in histone 
deacetylation and chromatin remodelling, its altered activity could therefore 
contribute to global epigenetic regulation of gene expression in malignant 
hematopoiesis. 
 
A Candidate Pathway Strategy  
Dysregulation of biological processes that determine a cancer cell‘s fate is 
unlikely to result from the activity of a single gene but rather from multiple genes 
acting jointly in a common regulatory pathway or in parallel in concomitant 
pathways. The integrative pathway-based approach that I adopted in my study 
allowed biological and functional information pertinent to the genes and 
corresponding variants, to be directly incorporated into the association analysis 
(Chapter Three). While prior knowledge on pathway ontologies and in silico 
predictions of function and evolutionary conservation have previously been used 
in this manner (51, 52), this was the first time that a genetic association analysis 
attempted to take advantage of available data from functional assays to directly 
inform risk estimation. In the wake of what is now being called the ―post-
genomics era‖, more and more genomic, proteomic, expression and other high-
throughput data sources are becoming available. To make efficient use of this 
wealth of information in our quest to understanding complex disease processes, 
more comprehensive approaches such as the one used here, represent an 
interesting alternative to conventional methods of analysis. The use of 
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hierarchical models offers a unified approach to modelling the effects of entire 
pathways postulated to be relevant to disease, rather than look at the marginal 
effects of individual polymorphisms, and can act as a bridge between genetic 
epidemiology studies and laboratory data allowing multiple sources of prior 
information to be readily incorporated into the analytical framework. Traditional 
approaches considering one, or even two genes, at a time, neglect potential 
confounding effects and ignore any prior biological and functional knowledge 
that may be available. The hierarchical modeling approach also has the 
advantage of improving risk estimation and provides a means to dealing with the 
issue of multiple comparisons, reducing the likelihood of false positives. 
However given that only a limited number of genes within both pathways were 
interrogated in my study, further characterization of these gene networks, and 
other interconnected pathways such as xenobiotic metabolism and apoptosis, in 
childhood ALL development is required. And even though the biological model 
used in this study obviously represented an incomplete picture of the underlying 
disease process, it still provided insight into the mechanisms that may be driving 
leukemogenesis, suggesting a role for both the cell cycle and DNA double-
strand break repair pathways, and allowed for individual gene variants 
associated with disease to be identified.  
 
While their precise functional role in childhood ALL remains to be verified, my 
study also provided further evidence for the role of cis-acting regulatory variation 
in influencing disease susceptibility, potentially through modulated gene 
expression. Thus, my results suggest that germline variation in genes involved 
in the G1/S checkpoint and in DSBR may contribute to the increased genomic 
instability, the impaired differentiation, and the growth and/or survival advantage 
of hematopoietic cells which leads to leukemia. The novel susceptibility loci 
identified through my doctoral work provide additional insight into the biologic 
mechanisms underlying childhood ALL and perhaps other cancers as well 
(Figure 3). Replication of these genetic associations in independent childhood 
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ALL cohorts through our collaboration with the International Acute 
Lymphoblastic Leukemia Genetics Consortium, will help validate their role as 
childhood ALL susceptibility loci. This is especially important given that this was 
the first report of an association between these variants and childhood ALL and 
given the limited size and modest power of this study (see Appendix II). 
Furthermore, some of these associations, particularly HDAC1, were only weakly 
associated with disease. Further association testing in larger datasets and 
additional in vitro and in vivo functional assays will help identify the true causal 
variants at the identified loci and validate their implication in ALL and its 
particular subgroups.  
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Figure 3. Cellular responses to environmental exposures and childhood 
ALL susceptibility 
Biological processes known to contribute to cancer susceptibility include those 
involved in xenobiotic metabolism, oxidative stress response, DNA repair, cell 
cycle control and apoptosis. Candidate gene association studies have identified 
genes in many of these processes that are associated with ALL risk among 
children; shown in red are the genes identified through my doctoral work. Red 
arrows indicate how variants in these genes can influence their respective 
pathways and contribute to increased genetic instability, increased mutational 
burden and ultimately lead to childhood ALL. 
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Parental Genetics in Early-Onset Disorders 
The early age of onset and evidence for the in utero origins of the disease 
support a role for parentally-mediated effects involved in the development of 
ALL in children. Interestingly, preferential loss of the maternally-derived 9p21 
alleles has previously been demonstrated in leukemic cells further suggesting 
that a germline event involving 9p21 genes may play a role in the onset of 
childhood ALL (53). In Chapter Four, I investigated the potential role the 
mother‘s genes can play in shaping disease susceptibility in her offspring. The 
mother‘s genotype can influence gene expression in the fetus or directly perturb 
the intrauterine environment or even interact with the child‘s genes to modulate 
the overall risk of disease. It is difficult however to distinguish child from 
maternal genotype associations due to simple Mendelian inheritance. A 
susceptibility variant that is acting via the mother and that is therefore more 
prevalent among case-mothers as opposed to control-mothers, will be enriched 
among cases simply due to random transmission of maternal alleles to the 
offspring and can be mistook for an inherited effect within the child (54). In my 
study I attempted to dissect child and maternal genotype associations in 
childhood ALL using a hybrid case-parent trio/case-control design (55).  
 
From a methodological point of view this work was imperative as existing 
methods for the detection of fetomaternal effects are tailored for specific study 
designs (e.g. case-trios only or case-mother/control-mother dyads). It was 
important for us, and potentially for other research groups simultaneously 
ascertaining population- and family-based datasets, to utilize all available 
genotypes in order to maximize analytical power in our study. However the 
adaptability and validity of available analytical methods for dissecting 
fetomaternal genotype associations using such a hybrid design had never been 
tested. And importantly the robustness of these methods, when parents of 
controls are missing and assumptions such as that of mating symmetry are 
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violated, had never been addressed. Mating asymmetry (MA) refers to the non-
random distribution of alleles between males and females mating in the 
population. MA is to fetomaternal association testing what population 
stratification is to case-control association testing, that is an important source for 
confounding. In our study, we used simulations to show that the log-linear, 
likelihood-based framework of Weinberg and Umbach (56) using a case-
triad/case-control design retains the ability to control for bias due to MA and can 
provide valid tests for maternal genetic effects even under MA, while other 
methods perform poorly in the presence of MA with considerable inflation of 
type I error rates. This study will aid in maximizing analytical efficiency to 
account for the underlying genetic complexities of early-onset disorders. 
 
For the first time I showed that maternally-mediated genotype effects acting in 
combination with the child‘s genotype via cell cycle inhibitor genes CDKN2A 
(rs36228834) and CDKN2B (rs36229158) can modulate risk of childhood ALL. 
These studies complement our initial results which showed that inherited 
susceptibility to childhood ALL could be mediated by loss of cell cycle inhibition 
in the hematopoietic cells in the bone marrow of the child. In addition, reduced 
expression of CDKN2A and CDKN2B in the mother might also contribute to 
disease pathogenesis in her offspring. A possible explanation for this could be 
via changes in placental structure and function and disruption of the maternal-
fetal interface. In fact reduced maternal CDKI expression could affect the size of 
the placenta and affect nutrient and hormonal transport to the fetus and perhaps 
provide the link between childhood ALL and high birth weight. At a crucial time 
in development when rapid growth and developmental changes are occurring 
and cell division rates are extremely high, tight regulation of gene expression is 
crucial. Variation in gene dosage of critical cell cycle control genes in both 
mother and child could cause increased proliferative stress on the growing fetus 
and lead to increased genomic instability and potentially contribute to 
leukemogenesis. 
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Though not yet published, I also identified a maternal genotype effect in double-
strand break DNA repair gene XRCC6 (rs132770) and a potential joint 
fetomaternal effect at loci XRCC5 (rs11685387) (see Appendix III for details). 
XRCC5 and XRCC6 form a heterodimer that binds DNA double-strand breaks 
and facilitates repair by the nonhomologous end joining pathway (57). Low 
expression of the XRCC5 and XRCC6 genes leads to genomic instability and 
tumorigenesis (58). If activity of the XRCC5 and XRCC6 genes is inadequate in 
mothers then perturbations in the maternal environment could lead to increased 
mutational burden in the placenta and alter the function of placental proteins in 
key signaling and metabolic pathways and perhaps alter the intrauterine 
environment and contribute to disease susceptibility in the fetus. Furthermore, 
cytoprotective defense mechanisms are considerably less developed in the 
growing fetus therefore variation in genes involved in core processes such as 
maintenance of normal cell division and genomic integrity could have more 
profound consequences during fetal life (59). 
 
The developmental origins of disease hypothesis, also called the Barker 
hypothesis, states that adverse influences early in development, and particularly 
during fetal life, can permanently change the child‘s physiology and metabolism 
in ways that can lead to increased disease risk later on in life (60). Well-
established links between low birth weight and increased risk of coronary heart 
disease, diabetes, hypertension, and stroke in adulthood support the hypothesis 
for the in utero origins of disease (61) and there is also growing evidence that 
the intrauterine environment and enhanced prenatal exposure to estrogens, 
contributes to the predisposition of women to breast cancer in adulthood (62, 
63). Though the mechanisms underlying the developmental origins of childhood 
ALL remain to be fully established, my study further corroborates the importance 
of investigating in utero genetic events to improve our understanding of the 
pathogenesis of childhood ALL. Additional investigation into other parentally-
mediated genetic mechanisms such as maternal-fetal epistasis and parent-of-
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origin effects are also required in order to fully understand genetic susceptibility 
to this early-onset disorder. 
 
Limitations of the Study 
The most obvious limitation of my study is power (see Appendix II for detailed 
power analysis); a total of 321 cases (203 family trios) and 329 controls were 
genotyped. Though these figures are far from those encountered in large-scale 
GWA studies, we have one of the largest childhood ALL trio samples worldwide. 
Availability of parental genotype data allowed us to investigate the role of 
maternal genetic effects in the susceptibility to childhood ALL and to show, for 
the first time, that the mother‘s genotype can influence the risk of leukemia in 
her offspring, further corroborating the importance of parental genetic 
contributions to early-onset disorders such as childhood leukemia. Due to the 
limited power of the study, it is possible that certain associations were missed 
and that effect sizes (odds ratios) were inflated and less precise (i.e. wider 
confidence intervals). Therefore not only may we have missed certain low-risk 
alleles, it is also possible that we have produced false-positive results due to 
over-estimation of the magnitude of the associations. On the other hand, it is 
encouraging to see that associated loci are consistent throughout the study and 
across methods. Still, results should be interpreted with caution and replication 
of the reported associations in larger, independent datasets remains crucial. 
There are also limitations associated with the statistical analysis. Given the 
limited power of the study, it was highly unlikely that we would be able to detect 
gene-gene interactions in my dataset, and subtype analysis was further 
constrained by even smaller sample sizes. Multivariate analysis including 
several SNPs and adjusting for potential confounders could also produce 
unreliable results due to over-parameterization.  
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While it is obviously more appealing to have a large, well-powered study sample 
this isn‘t always feasible. I argue that results from a well-designed small study, if 
interpreted carefully and if not overstated, could yield valuable insight into the 
genetic underpinnings of a disease. Small studies could provide a good setting 
for exploratory analyses, such as our investigation of fetomaternal effects, and 
could be used as the basis to design larger confirmatory studies. 
 
It is also important at this time to discuss the limited power of our study with 
regard to the GWAS replication (Chapter Two, ―Replication analysis confirms 
the association of ARID5B with childhood B-cell acute lymphoblastic leukemia‖, 
p. 167). In this study we successfully replicated five of the fifteen loci 
interrogated (annotating ARID5B) however we did not replicate two other strong 
GWAS signals (particularly IKZF1 which was the strongest signal in one of the 
initial genome-wide studies (64), as well as DDC and CEBPE). The most likely 
culprit for non-replication is insufficient power; we had 80% power at the 5% 
level, to detect a minimum OR of 1.8 with RAFs ≥ 20% and of 2.1 with RAFs ≥ 
10%. Initial risk estimates were already below 1.8 and due to the ―winner‘s 
curse‖ effect, which stipulates that the odds ratio of a disease variant is usually 
overestimated in the study that first describes it (65), it is possible that the true 
effect sizes at these loci may be too low for us to detect in our study sample. 
Lack of replication could also partially reflect between-study heterogeneity in 
terms of phenotypic classification of B-cell ALL patients, population-specific 
differences (though risk allele frequencies in cases did not differ between study 
cohorts) or heterogeneity in exposure to environmental factors (66).  
 
Another interesting possibility is that the causal variant at IKZF1 interacts with 
one or more other functional polymorphisms to influence disease and that these 
interacting loci have different allele frequencies between study populations. 
Greene et al. showed that the power to replicate statistically significant 
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independent main effects of a polymorphism can drop dramatically with a 
change of allele frequency of less than 0.1 at a second interacting 
polymorphism (67). Therefore if the true genetic model is epistatic, attempting to 
replicate a main effect is likely to fail unless allele frequencies of the interacting 
loci are close to identical. Study populations were comparable between studies 
(i.e. of European descent) but were not identical. Cryptic differences in the 
genetic structure of the French-Canadian ―founder‖ population, compared to the 
US and UK populations used in the initial GWAS, could account for the lack of 
replication at these loci. Failure to replicate in our cohort does not necessarily 
invalidate the original findings but further validates the implication of ARID5B in 
childhood ALL susceptibility. And on the other hand, until additional replication 
studies with larger case-control samples are performed, we cannot rule out the 
possibility that the initial GWAS findings were false-positives.  
 
FUTURE PERSPECTIVES 
  
Integrative Genomics 
The challenge in dissecting the genetic architecture of childhood ALL lies in its 
inherent complexity and in this study I have shown that insight into the true 
nature of childhood leukemia can only be gained by combining multiple 
analytical approaches and study designs. However, a complete understanding 
of the signalling pathways involved in leukemogenesis will likely only be 
achieved through systems-level approaches and the integration of diverse data 
types such as genomics, transcriptomics and proteomics data (68). Therefore, 
to completely embrace the complexity of childhood ALL, and of cancer in 
general, a goal should be to develop more comprehensive analytical 
approaches to integrate various different data sources rather than continue to 
use oversimplified one-dimensional methods of analysis (69). Future analyses 
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integrating different sources of ‗omic‘ data for childhood ALL including genomic 
SNP (64, 70, 71) and copy number alteration arrays (72, 73), comparative 
genomic hybridization arrays (74, 75), molecular cytogenetic analyses (76), 
global gene expression profiles (49, 77), genome-wide methylation profiles (78, 
79), and microRNA expression profiles (80), will allow a more comprehensive 
understanding of the mechanisms leading to the pathogenesis of childhood ALL 
and of its various subtypes. What is certain is that as we move forward into the 
post-genomic era, integration of large-scale datasets will be crucial to better 
understand the genetic basis of childhood ALL and the molecular mechanisms 
driving leukemogenesis. 
 
Gene-environment interactions 
The environment plays an important role in modulating interindividual variability 
in disease risk and while my doctoral research focused primarily on the genetic 
basis of childhood ALL, it is likely that an important etiologic component of this 
disease is exposure to environmental factors either acting alone or through 
complex gene-environment interactions involving both mother and child, and 
potentially also the father. For example, the distinct patterns of childhood acute 
lymphoblastic leukemia observed within race, gender, age and socioeconomic 
groups could indicate race- or gender-specific variability in genetic susceptibility, 
or could indicate differential exposure to as yet unidentified environmental 
factors. Or it could be that exposure to particular environmental agents during a 
vulnerable period in development (i.e. fetal life), increases cancer risk in 
genetically predisposed subgroups through gene-environment interactions. 
Given the mounting evidence that genetic variability, particularly in genes whose 
products metabolize carcinogens, repair DNA damage, and control the cell 
cycle, can influence an individual‘s susceptibility (or resistance) to cancer by 
modulating their response to the environment (81), investigation into the role of 
exogenous (e.g. pesticides, radiation) and endogenous factors (e.g. hormones), 
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and of their interaction with genes such as those studied here to influence 
childhood ALL susceptibility is warranted. The integration of environmental 
factors in genetic association studies can be extremely useful for further 
understanding the biological mechanisms involved in disease and gene-
environment studies may help illuminate additional genetic factors involved in 
childhood ALL and help identify modifiable environmental factors for effective 
disease prevention (82). 
  
Candidate Gene Versus Genome-Wide Association Studies 
An important question raised at the beginning of my thesis was whether there 
was still need for candidate gene approaches in the era of genomics. The 
success of the more targeted candidate gene/pathway approaches relies largely 
on the current knowledge of the disease. By choosing functionally relevant 
variants in biologically relevant genes, it may be easier to identify the true 
causal variants through candidate gene studies, however conversely, a more 
agnostic approach may yield novel insight into the mechanisms of disease 
pathogenesis that otherwise may never have been investigated. For example 
the link between autophagy, a biological process that mediates degradation of 
cytoplasmic components in lysosomes and vacuoles, and Crohn‘s Disease was 
made evident through genome-wide association studies (83-85). The ideal 
approach to identifying genetic susceptibility loci might involve a combination of 
both philosophies. Methods for marrying hypothesis-driven approaches with 
whole-genome studies have been proposed, for example use of pathway 
knowledge to inform the analysis of whole-genome data and data mining 
procedures to detect patterns of interaction and novel pathways implicated in 
disease have been suggested (82). Another approach involves creating gene-
centric and functionally relevant genome-wide SNP arrays for GWAS (86). I 
argue however that candidate gene/pathway approaches can be a useful first 
step in exploring potential causal pathways and biologic mechanisms involved in 
the pathogenesis of complex diseases with multifactorial inheritance such as 
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early-onset disorders. Elucidation of the genetic mechanisms through which 
genes act to influence disease risk, e.g. through parentally-mediated genetic 
effects, may better be depicted through focused candidate gene association 
studies. What is certain is that to reach the goal of dissecting the genetic 
architecture of childhood ALL, a combination of many different approaches and 
study designs will be required including both candidate gene/pathway and 
genome-wide association studies. 
 
Common Versus Rare Variants 
The common disease, common variant (CDCV) hypothesis has largely dictated 
how we search for genetic susceptibility loci in complex diseases. In addition to 
the many candidate gene studies that have been published over the years, most 
if not all of the novel genetic susceptibility loci identified through GWAS pertain 
to common genetic variants with minor allele frequencies typically exceeding 
5%, the effect sizes of which are small, explaining but a finite portion of the 
genetic variability associated with human diseases (87-89). This is because 
whole-genome studies rely on a complex disease model in which common DNA 
sequence variants with widespread, but marginal, effects predominate; however 
it may not be that surprising that common variants provide little help in 
predicting complex disease risk. The arguable lack of success of GWAS in 
explaining the heritable component of complex disease susceptibility (90, 91) 
has led to a recent paradigm shift in genetic association testing toward rare 
variants, with presumed strong effects, to explain the missing heritability in 
complex traits (Figure 4). There is strong evidence that rare variants are 
involved in complex disease etiology (92-95) yet the multiple rare variant (MRV) 
paradigm remains unexplored in childhood ALL. With the advent of high-
throughput next-generation sequencing technologies, there is a current push 
towards deep resequencing of entire exomes, and as costs continue to 
decrease whole genomes, in large cohorts to detect the full catalogue of genetic 
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variation (common and rare, sequence and structural) associated with complex 
traits. And it may well be that full appreciation of the importance of rare genetic 
variants in complex disease can only be captured through pathway-based 
analysis strategies, given that the combination of rare sequence variants from 
multiple genes functioning in the same biological pathway is likely to be more 
relevant than the individual effects of single rare sequence variants. Next-
generation sequencing promises to provide an unprecedented view of the 
genetic landscape of complex diseases and of the genetic basis of 
interindividual variability in the susceptibility to childhood ALL (96-98) but in 
order for this genomic data to have a meaningful impact on our understanding of 
the disease, I maintain that an effort must be made to integrate sequencing data 
with all the additional ‗omic‘ information that is being generated. 
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Figure 4. A paradigm shift in genetic association testing – from common 
to rare variants 
The genetic architecture of complex traits likely involves a wide allelic spectrum 
ranging from rare to common genetic variants. The common disease, common 
variant (CDCV) model postulates the existence of genetic variants that are 
common and that confer modest to low effects on disease risk, and has long 
dictated candidate gene and genome-wide association studies (GWAS). The 
multiple rare variant (MRV) model holds that complex traits result from many 
different mutations each of which is individually rare but with very strong 
combined effects, and is at the basis of the emergence of next-generation 
resequencing technologies. These models are not exclusive and it is likely that 
both contribute to interindividual variability in complex disease risk. 
Figure adapted from the Psychiatric GWAS Consortium Steering Committee, 
2009 (99).  
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CONCLUSION 
 
While established genetic risk factors able to predict ALL risk among children 
are still lacking, this study will help point towards new avenues of research and 
provides a strong rationale for further elucidation of the mechanisms through 
which aberrant cell cycle control and double-strand break repair are involved in 
childhood ALL susceptibility. The results of my study also serve to illustrate the 
complexity of childhood cancer and the need for a variety of methods and study 
designs able to capture the underlying genetic intricacies involved in disease 
pathogenesis. Despite the recent shift toward rare SNPs, expected to be more 
functionally relevant than common SNPs in disease susceptibility (88, 95), a 
more realistic disease model is that functional variants involved in ALL have a 
wide spectrum of allele frequencies that range from common to not-so-common 
to rare and that the landscape of genetic variation contributing to ALL 
predisposition includes structural variation, epigenetic changes, and even 
parentally-mediated genetic effects. Yet no matter the architecture, genetic 
susceptibility to ALL can only comprehensively be identified through the use and 
integration of multiple complementary analytical approaches.  
 
Identification of genetic susceptibility factors along with a better understanding 
of the underlying mechanisms that drive leukemogenesis, will help refine risk 
classification and tailored disease management, offering new opportunities for 
personalized medicine. This is important given that, despite improved survival 
rates in childhood cancer, treatment is not optimal and ALL is still the leading 
cause of death among children. Another important point to consider is the late 
effects of therapy. Currently, approximately one in every 400 young adult is a 
childhood cancer survivor (100). Adult survivors of childhood ALL represent a 
new and growing population that did not exist just a few decades ago, a 
population that is at increased risk for chronic health conditions including 
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obesity, hypertension, type II diabetes, depression, as well as secondary 
malignancies due to late-occurring effects of their treatment (101-103). The 
genetic susceptibility loci identified in this study could lead to new therapeutic 
targets for childhood ALL and help reduce the debilitating side effects related to 
the cancer and its treatment. 
 
Ultimately, it is my hope that this study will help shed light on the genetic 
architecture of ALL and thereby contribute to better diagnosis of the patients, to 
more refined treatment protocols, and hopefully lead to overall prevention of the 
disease in children. Though it seems increasingly unlikely that genetic prediction 
will ever be accurate enough for complex multifactorial diseases, the 
identification of established genetic, and eventually environmental, susceptibility 
factors in childhood ALL will certainly be useful in identifying at-risk groups and 
establishing new public health policies to guide lifestyle and health-related 
behavioral changes. This research will provide greater insight into the etiologic 
intricacies of childhood ALL and will bring us one step closer to that ultimate 
goal of decreasing mortality by reducing risk and improving diagnosis and 
treatment. 
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APPENDIX I 
MEASURES OF ASSOCIATION 
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In population-based association studies, an association between a genetic risk 
factor and disease outcome can be measured by directly comparing disease 
frequency differences between individuals with and without the risk factor, or by 
comparing the odds of disease.  
 
Table I. Presentation of data from a cohort study or a case-control study of 
a binary risk factor 
    Risk factor 
Disease   Present Absent Total 
Present   𝑎 𝑏 𝑎 +  𝑏 
Absent   𝑐 𝑑 𝑐 +  𝑑 
Total   𝑎 +  𝑐 𝑏 +  𝑑 𝑛 
 
𝐼 = probability of disease among individuals with the risk factor = 𝑎/(𝑎 +  𝑐). 
𝑈 = probability of disease among individuals without the risk factor = 𝑏/(𝑏 +  𝑑) 
 
𝑃 = probability of carrying the risk factor among cases = 𝑎/(𝑎 +  𝑏). 
𝑄 = probability of carrying the risk factor among controls = 𝑐/(𝑐 +  𝑑) 
 
The relative risk (RR) is the ratio of risks (probability of developing the disease) 
between carriers and non-carriers of the risk factor: 
 𝑅𝑅 =  
𝐼
𝑈
=  
𝑎/(𝑎+𝑐)
𝑏/(𝑏+𝑑)
 . 
And the difference in risk, also known as the attributable risk is simply: 
     𝐼 − 𝑈 =  
𝑎
𝑎  + 𝑐
−  
𝑏
𝑏  + 𝑑
 . 
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Measures of relative risk can only be obtained from cohort designs, in which 
individuals exposed and not exposed to the risk are followed over a period of 
time to identify those that develop the disease. 
 
The incidence refers to the rate at which previously unaffected individuals in a 
given population develop disease, and the prevalence can be defined as the 
proportion of individuals in a population who are affected; each are measures of 
disease frequency. 
 
Because of sampling design, measures of risk cannot be directly measured in a 
case-control design in which individuals are ascertained based on disease 
status. A more useful measure of association is the odds ratio (OR) in which the 
odds of carrying the risk factor among affected individuals is compared to the 
odds of carrying the risk factor among unaffected individuals.  
Odds of carrying the risk factor among cases:  𝑃/(1 − 𝑃) =  
𝑎/(𝑎+𝑏)
(1−(𝑎/(𝑎+𝑏))
  
Odds of carrying the risk factor among controls: 𝑄/(1 − 𝑄) =  
𝑐/(𝑐  +𝑑)
(1−(𝑐/(𝑐+𝑑))
 
 
𝑂𝑅 =
 𝑃/(1 − 𝑃)
𝑄/(1 − 𝑄)
=  
𝑎/(𝑎 + 𝑏)
𝑏/(𝑎 + 𝑏)
𝑐/(𝑐 + 𝑑)
𝑑/(𝑐 + 𝑑)
=  
𝑎𝑑
𝑏𝑐
 
The variance of the OR can be estimated by: 
𝑣𝑎𝑟(ln𝑂𝑅) =  
1
𝑎
+
1
𝑏
+
1
𝑐
+
1
𝑑
 
 
And a 95% confidence interval (95%CI) by: 
𝑒𝑥𝑝 ln𝑂𝑅 ± 1.96 𝑣𝑎𝑟(ln𝑂𝑅)  
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The OR of exposure in a case-control study is identical to the OR of disease in a 
cohort study and for a rare disease, the OR approximates the relative risk (1). 
 
The OR is a measure of effect size, describing the strength of association 
between a risk factor and the disease. An OR = 1 if both the risk factor and 
disease outcome are independent, if OR>1 there is evidence of a positive effect 
of the risk factor on increased disease risk while OR<1 suggests a protective 
effect. The calculation for the OR can be modified to include multiple levels of 
risk exposure or linear measures of exposure and to accommodate the 
sampling procedure (e.g. pair-matched case-control study) (2). 
 
Besides the 2 x 2 contingency table, another way of generating an OR beyond 
two binary variables is by using logistic regression (3). The effect of a risk factor, 
say a SNP, on disease outcome can be measured through logistic regression as 
follows: 
ln  
𝑝
1 − 𝑝
 =  𝛽0 + 𝛽1𝑋1 
where 𝑝 is the probability of disease occurring, 𝑝/(1 –  𝑝) the odds of that event 
occurring, 𝑋1 is the risk factor (e.g. SNP alleles coded 0 or 1) and the coefficient 
of 𝛽1 is the effect of the SNP on disease risk.   
 
The OR is obtained through the following transformation: 
                                           ln  
𝑝
1−𝑝
 =  𝛽0 + 𝛽1𝑋1 → 𝑂𝑅𝑋1 = exp(𝛽1) 
Using the data in Table I a test of the null hypothesis that the risk factor is not 
associated with disease, 𝐻0:𝑂𝑅 = 1, is given by the chi-square test: 
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𝑋2 =  
 𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑 − 𝐸𝑥𝑝𝑒𝑐𝑡𝑒𝑑 2
𝐸𝑥𝑝𝑒𝑐𝑡𝑒𝑑
  
𝑋2 =  
 𝑎 − 𝐸(𝑎) 2
𝐸(𝑎)
 +   
 𝑏 − 𝐸(𝑏) 2
𝐸(𝑏)
+   
 𝑐 − 𝐸(𝑐) 2
𝐸(𝑐)
+  
 𝑑 − 𝐸(𝑑) 2
𝐸(𝑑)
 
Under the null hypothesis, 𝑋2 has asymptotically (in large samples) a chi-square 
distribution with 1 degree of freedom (df). 
 
For small sample sizes a more appropriate test for significance is the Fisher‘s 
exact test: 
𝑃 =  
 𝑎 + 𝑏 !  𝑐 + 𝑑 !  𝑎 + 𝑐 !  𝑏 + 𝑑 !
𝑎! 𝑏! 𝑐!𝑑!𝑛!
 
 
In family-based association designs consisting of case-trios (proband and both 
parents), the simplest association test is the transmission disequilibrium test 
(TDT) which compares observed allele distributions to those expected under 
Mendelian transmissions (4). Given that homozygous parents are uninformative, 
only heterozygote parents are used in the TDT. An advantage of family-based 
designs is that over-transmission of an allele to affected offspring is evidence of 
both linkage and association of the marker allele with a disease susceptibility 
locus.  
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Table II. Presentation of data from a family-based case-trio study of a 
binary risk factor 
    Transmitted allele 
Non-transmitted 
allele 
  A a Total 
A   𝑎 𝑏 𝑎 +  𝑏 
a   𝑐 𝑑 𝑐 +  𝑑 
Total   𝑎 +  𝑐 𝑏 +  𝑑 𝑛 
 
The appropriate matched analysis for the data presented in Table 1-2 is 
achieved using McNemar‘s chi-square test to see whether or not the a allele is 
transmitted more often than expected to affected offspring: 
𝑇𝐷𝑇 =  
(𝑏 − 𝑐)2
(𝑏 + 𝑐)
 
Under the null hypothesis of no linkage and no association, the TDT has 
asymptotically a chi-square distribution with 1 degree of freedom (df). Both 
linkage and association between the disease locus and the marker have to be 
present for the TDT to reject the null hypothesis. 
 
The OR for the TDT can be estimated as, 𝑂𝑅 = 𝑏/𝑐, with 𝑣𝑎𝑟(ln𝑂𝑅) = 
1
𝑏
+
1
𝑐
. 
 
An extension of the TDT is the family-based association test (FBAT) which 
allows testing with trios with missing parents, haplotypes or markers with 
multiple alleles, different genetic models, different sampling designs, different 
disease phenotypes all in the same framework (5, 6). 
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Let 𝑋 denote a variable that translates an offspring‘s genotype to a numeric 
value (for example X can count the number of a alleles, say 0 for AA, 1 for Aa 
and 2 for aa). Let 𝑃 denote the genotype of the parents, and 𝑇 is the coded 
offspring trait (say 0 for unaffected, 1 for affected). The covariance statistic used 
in the FBAT test is: 
𝑈 =  𝑇 ∗ (𝑋 − 𝐸(𝑋|𝑃)) 
where 𝑈 is the covariance, 𝐸(𝑋|𝑃) is the expected value of X computed under 
the null hypothesis, and summation is over all offspring in the sample. Mendel‘s 
laws of transmission underlie the calculation of 𝐸(𝑋|𝑃). 
 
The FBAT statistic is defined by dividing 𝑈2 by its variance which is also 
calculated under the null hypothesis by conditioning on parental genotypes (see 
(7) for details): 
𝑍 = 𝑈/ 𝑣𝑎𝑟(𝑈), or equivalently, 𝑋𝐹𝐵𝐴𝑇
2 =  𝑈2/𝑣𝑎𝑟(𝑈) 
A positive 𝑍 score indicates over-transmission of the allele to affected offspring 
providing evidence of linkage and association with disease whereas a negative 
𝑍 score indicates preferential under-transmission of the allele suggesting a 
protective effect.  
 
For large samples, 𝑍 is approximately distributed N(0,1) and 𝑋𝐹𝐵𝐴𝑇
2  has 
asymptotically a chi-square distribution with 1 df. The FBAT statistic is exactly 
the same as the TDT statistic: 
𝑋𝐹𝐵𝐴𝑇
2 =  𝑋𝑇𝐷𝑇
2   
When both parents are genotyped, only affected offspring are included in the 
model, and an additive mode of inheritance is assumed, that is 𝑋 counts the 
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number of a alleles. Changing how 𝑇 is defined allows us to include unaffected 
offspring or fit alternative or multiple traits, while changing how 𝑋 is defined 
allows us to test alternative genetic models or incorporate multiple alleles (e.g. 
haplotypes) (5). 
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POWER OF THE ASSOCIATION STUDY 
 
Table I. Power calculations for main effects using a case-control design 
D' OR PM   Recessive Dominant Multiplicative 
      PD:PM 1:1.5 1:1 1.5:1 1:1.5 1:1 1.5:1 1:1.5 1:1 1.5:1 
0.8 1.25 0.05   0.0500 0.0502 0.0504 0.0765 0.1071 0.1003 0.0787 0.1146 0.1106 
    0.1   0.0503 0.0513 0.0526 0.0975 0.1453 0.1229 0.1062 0.1727 0.1569 
    0.2   0.0518 0.0592 0.0654 0.1194 0.1776 0.1195 0.1479 0.2644 0.2070 
    0.3   0.0554 0.0767 0.0852 0.1251 0.1719 0.0922 0.1776 0.3235 0.2083 
    0.4   0.0609 0.1032 0.0984 0.1196 0.1475 0.0672 0.1939 0.3534 0.1731 
                          
  1.5 0.05   0.0501 0.0507 0.0515 0.1503 0.2593 0.2315 0.1604 0.2904 0.2737 
    0.1   0.0511 0.0552 0.0623 0.2267 0.3835 0.3012 0.2641 0.4803 0.4252 
    0.2   0.0572 0.0861 0.1094 0.2978 0.4649 0.2750 0.4077 0.6987 0.5524 
    0.3   0.0712 0.1540 0.1806 0.3087 0.4344 0.1800 0.4948 0.7910 0.5391 
    0.4   0.0925 0.2526 0.2194 0.2832 0.3534 0.1007 0.5348 0.8233 0.4305 
                          
  2 0.05   0.0505 0.0527 0.0558 0.3976 0.6578 0.5849 0.4374 0.7305 0.6926 
    0.1   0.0542 0.0704 0.0898 0.5940 0.8335 0.6956 0.6950 0.9328 0.8840 
    0.2   0.0783 0.1902 0.2693 0.7119 0.8868 0.6043 0.8855 0.9925 0.9494 
    0.3   0.1327 0.4254 0.4723 0.7071 0.8385 0.3750 0.9399 0.9978 0.9293 
    0.4   0.2131 0.6679 0.5339 0.6418 0.7186 0.1731 0.9538 0.9985 0.8233 
                          
1 1.25 0.05   0.0501 0.0503 0.0506 0.0911 0.1385 0.1279 0.0946 0.1501 0.1438 
    0.1   0.0541 0.0520 0.0541 0.1241 0.1983 0.1636 0.1377 0.2402 0.2162 
    0.2   0.0528 0.0643 0.0741 0.1590 0.2492 0.1591 0.2034 0.3786 0.2939 
    0.3   0.0584 0.0919 0.1053 0.1683 0.2413 0.1163 0.2501 0.4639 0.2970 
    0.4   0.0671 0.1340 0.1263 0.1598 0.2038 0.0771 0.2759 0.5063 0.2438 
                          
  1.5 0.05   0.0502 0.0511 0.0523 0.2047 0.3648 0.3250 0.2200 0.4080 0.3849 
    0.1   0.0517 0.0581 0.0659 0.3209 0.5361 0.4271 0.3751 0.6522 0.5878 
    0.2   0.0612 0.1065 0.1432 0.4261 0.6404 0.3938 0.5717 0.8659 0.7357 
    0.3   0.0832 0.2135 0.2547 0.4434 0.6076 0.2538 0.6778 0.9306 0.7255 
    0.4   0.1169 0.3642 0.3147 0.4088 0.5063 0.1300 0.7237 0.9497 0.6052 
                          
  2 0.05   0.0508 0.0543 0.0590 0.5480 0.8204 0.7544 0.5961 0.8777 0.8489 
    0.1   0.0565 0.0818 0.1121 0.7702 0.9474 0.8578 0.8573 0.9879 0.9708 
    0.2   0.0943 0.2685 0.3856 0.7862 0.9744 0.7862 0.9739 0.9997 0.9933 
    0.3   0.1801 0.5966 0.6523 0.5329 0.9555 0.5329 0.9918 1.0000 0.9892 
    0.4   0.3052 0.8477 0.7228 0.2438 0.8862 0.2438 0.9951 1.0000 0.9497 
Power calculations were performed using the genetic power calculator of Purcell 
& Sham (1). When the measured locus M occurs with frequency PM then the 
ratio of frequencies between M and the disease locus D is given by PD : PM. The 
measure of linkage disequilibrium between M and P was set at D‘= 0.8 or 1. PM 
was allowed to vary from 5% to 40%. PD varied from 1.5-times lower to 1.5-
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times higher than the marker allele frequency. A type I error rate of 0.05 (two-
sided) was used for a sample size of N=321 and an unmatched case-control 
ratio of 1:1, assuming an overall disease prevalence rate of 0.0001. 
xxxv 
 
 
 
x
x
x
v
 
Table II. Power calculations for main effects in the family-based study 
design 
MAF OR 
Power 
Recessive Dominant Multiplicative 
0.05 1 0.05 0.05 0.05 
  1.25 0.05076 0.1031 0.1108 
  1.5 0.05172 0.2441 0.2744 
  1.75 0.05287 0.4374 0.4957 
  2 0.05426 0.6334 0.7072 
  2.25 0.05587 0.791 0.8591 
  2.5 0.05772 0.8954 0.9439 
  2.75 0.05983 0.9538 0.9815 
  3 0.06218 0.9818 0.9949 
          
0.1 1 0.05 0.05 0.05 
  1.25 0.05241 0.1398 0.1673 
  1.5 0.05705 0.3665 0.4615 
  1.75 0.06393 0.6277 0.759 
  2 0.07304 0.8244 0.9265 
  2.25 0.08437 0.932 0.9845 
  2.5 0.09789 0.9779 0.9977 
  2.75 0.1136 0.9938 0.9998 
  3 0.1314 0.9985 1 
          
0.15 1 0.05 0.05 0.05 
  1.25 0.05567 0.1614 0.2162 
  1.5 0.06895 0.4288 0.5945 
  1.75 0.08975 0.7025 0.8788 
  2 0.118 0.8781 0.9788 
  2.25 0.1533 0.9591 0.9977 
  2.5 0.1955 0.9882 0.9998 
  2.75 0.2438 0.997 1 
  3 0.2974 0.9993 1 
          
0.2 1 0.05 0.05 0.05 
  1.25 0.06109 0.1711 0.2573 
  1.5 0.08955 0.4509 0.6842 
  1.75 0.135 0.722 0.9326 
  2 0.1967 0.8874 0.9924 
  2.25 0.2724 0.9615 0.9995 
  2.5 0.3588 0.9884 1 
  2.75 0.4515 0.9968 1 
  3 0.5455 0.9992 1 
          
0.25 1 0.05 0.05 0.05 
  1.25 0.06898 0.1716 0.2906 
  1.5 0.1201 0.4462 0.7435 
  1.75 0.202 0.7097 0.9578 
  2 0.3098 0.874 0.9965 
  2.25 0.4339 0.9521 0.9998 
  2.5 0.562 0.9834 1 
  2.75 0.6815 0.9945 1 
  3 0.783 0.9983 1 
xxxvi 
 
 
 
x
x
x
v
i 
          
0.3 1 0.05 0.05 0.05 
  1.25 0.07946 0.1656 0.3163 
  1.5 0.161 0.423 0.7818 
  1.75 0.2891 0.6748 0.9702 
  2 0.4472 0.8422 0.998 
  2.25 0.6094 0.9306 0.9999 
  2.5 0.751 0.9712 1 
  2.75 0.8575 0.9884 1 
  3 0.9269 0.9954 1 
          
0.35 1 0.05 0.05 0.05 
  1.25 0.09242 0.155 0.335 
  1.5 0.2112 0.3869 0.8054 
  1.75 0.3903 0.6219 0.9763 
  2 0.5897 0.7915 0.9986 
  2.25 0.7629 0.8926 1 
  2.5 0.8832 0.9466 1 
  2.75 0.9511 0.9739 1 
  3 0.9827 0.9872 1 
          
0.4 1 0.05 0.05 0.05 
  1.25 0.1075 0.1417 0.347 
  1.5 0.2685 0.3429 0.818 
  1.75 0.4964 0.5547 0.9789 
  2 0.7172 0.7211 0.9988 
  2.25 0.8725 0.8329 1 
  2.5 0.9541 0.9019 1 
  2.75 0.9869 0.9427 1 
  3 0.997 0.9663 1 
          
0.45 1 0.05 0.05 0.05 
  1.25 0.1242 0.1271 0.3527 
  1.5 0.3297 0.2948 0.8219 
  1.75 0.5972 0.4777 0.9792 
  2 0.8168 0.6328 0.9987 
  2.25 0.9379 0.7487 1 
  2.5 0.9844 0.8295 1 
  2.75 0.9971 0.8842 1 
  3 0.9996 0.9207 1 
          
0.5 1 0.05 0.05 0.05 
  1.25 0.1418 0.1123 0.3524 
  1.5 0.3908 0.2465 0.818 
  1.75 0.6848 0.3965 0.9773 
  2 0.886 0.5319 0.9985 
  2.25 0.9716 0.642 0.9999 
  2.5 0.9951 0.727 1 
  2.75 0.9994 0.7909 1 
  3 1 0.8385 1 
Power calculations for the family-based study design were performed in PBAT 
(Version 3.5) (2). Recessive, dominant and multiplicative inheritance models 
were tested for minor allele frequencies (MAFs) varying from 0.05 to 0.5 and 
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main effect sizes (ORs) varying from 1.0 to 3.0. A type I error rate of 0.05 (two-
sided) was used for a sample size consisting of 203 complete trios (father, 
mother and one affected child) and an overall disease prevalence rate of 
0.0001.  
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Table III. Power calculations for gene-gene interaction effects in the case-
control study design 
    Gene B 
    Dominant Recessive Multiplicative 
Gene A OR
a
 (MAF=0.4;OR=1.0) (MAF=0.3;OR=1.5) (MAF=0.3;OR=3.0) 
Dominant 1 0.05 0.05 0.05 
(MAF=0.3;OR=1.5) 1.25 0.1008 0.072 0.1351 
  1.5 0.2165 0.1253 0.3154 
  1.75 0.3555 0.1973 0.5003 
  2 0.489 0.2788 0.6452 
  2.25 0.6025 0.3626 0.7458 
  2.5 0.6927 0.4438 0.8125 
  2.75 0.7619 0.5192 0.8563 
  3 0.814 0.5871 0.8853 
          
Recessive 1 0.05 0.05 0.05 
(MAF=0.2;OR=1.0) 1.25 0.0584 0.0536 0.065 
  1.5 0.0786 0.0629 0.1031 
  1.75 0.1059 0.0762 0.1573 
  2 0.1377 0.0924 0.2219 
  2.25 0.172 0.111 0.2921 
  2.5 0.2075 0.1312 0.3641 
  2.75 0.2434 0.1528 0.4345 
  3 0.2789 0.1753 0.5012 
          
Multiplicative 1 0.05 0.05 0.05 
(MAF=0.1;OR=1.5) 1.25 0.0945 0.0689 0.1283 
  1.5 0.2007 0.1176 0.3155 
  1.75 0.3358 0.1872 0.5286 
  2 0.4727 0.2702 0.7027 
  2.25 0.5944 0.3594 0.8201 
  2.5 0.6941 0.4487 0.8913 
  2.75 0.7717 0.5336 0.9325 
  3 0.8302 0.6109 0.9559 
Power calculations were performed for gene-gene interaction effects in Quanto 
(Version 1.1) (3). Different combinations of recessive, dominant and 
multiplicative (log-additive) inheritance models were tested for minor allele 
frequencies (MAFs) varying from 0.1 to 0.5 and main effect sizes (ORs) varying 
from 1.0 to 3.0. A type I error rate of 0.05 (two-sided) was used for a sample 
size of N=321 and an unmatched case-control ratio of 1:1, assuming an overall 
disease prevalence rate of 0.0001. 
a OR, interaction odds ratio. 
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POPULATION-BASED CASE-CONTROL ASSOCIATION STUDY 
 
Statistical analyses were done using STATA/IC Version 10.1 (StataCorp, 
College Station, TX). Pearson‘s 𝑋2  test or Fisher‘s exact test, as appropriate, 
was used to compare allele/genotype/haplotype carriership in patients and 
controls. Crude odds ratios (ORs) were measured using logistic regression or 
conventional 2x2 contingency table point estimation and are given with 95% 
confidence intervals (CIs). Haplotype reconstruction was performed using the 
FAMHAP Software, using parental data when available (4). Haplotype-specific 
ORs were estimated using the most common haplotype as reference and a 
likelihood ratio test implemented in FAMHAP was used to test for global 
haplotype association with disease status (5).  
 
I assessed gender-specific associations through stratified analysis comparing 
male cases to male controls or female cases to female controls and the Mantel-
Haenszel (MH) chi-square test of homogeneity was used to test for significant 
risk differences between males and females. I also tested for age-specific 
effects. The Shapiro-Francia test for normality was applied to the data and 
showed strong evidence against the assumption of normality for age at 
diagnosis. The nonparametric Kruskal-Wallis test was therefore used to 
compare the median age at diagnosis across genotype groups followed by 
Cuzick‘s nonparametric test for trend to assess gene-dosage effects. No 
significant effects of age at diagnosis were found for any of the variants tested 
therefore these results are not shown. 
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Figure I. Allelic associations of cell cycle checkpoint gene variants with 
childhood ALL 
Results are presented as –log(P value) of the chi-square test for association for 
each variant. The horizontal reference line represents a nominal P value of 0.05. 
Note that for the tri-allelic variant CDKN2B −593A>T,C (rs2069416) only results 
for the T vs. A allele are shown. 
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Table IV. Allele frequencies of promoter SNPs in G1/S cell cycle 
checkpoint genes among B-cell ALL cases and controls from the Quebec 
childhood ALL cohort and their effect on ALL risk 
Gene and SNP Allele 
No. (%) 
OR (95% CI) P ALL 
patients 
Controls 
CCND1  
     
rs1944129 T 318 (51.1) 330 (51.2) 
1.00 (.80-1.26) .97 
  C 304 (48.9) 314 (48.8) 
  
     
rs36225395* - 333 (53.5) 356 (54.8) 
1.05 (.84-1.32) .66 
  INS C 289 (46.5) 294 (45.2) 
CDC25A  
     
rs1903061 G 553 (91.3) 585 (89.7) 
0.84 (.56-1.24) .36 
  T 53 (8.7) 67 (10.3) 
CDKN1A  
     
rs733590 T 370 (61.5) 406 (63.8) 
1.11 (.87-1.40) .39 
  C 232 (38.5) 230 (36.2) 
  
     
rs762624 T 433 (73.6) 459 (72.9) 
0.96 (.74-1.25) .76 
  G 155 (26.4) 171 (27.1) 
  
     
rs2395655 T 343 (57.6) 380 (60.3) 
1.12 (.89-1.42) .32 
  C 253 (42.4) 250 (39.7) 
CDKN1B 
     
rs3759217 C 534 (89.3) 557 (88.4) 
0.91 (.63-1.33) .62 
  T 64 (10.7) 73 (11.6) 
  
     
rs35756741 G 550 (90.2) 581 (91.4) 
1.15 (.77-1.73) .47 
  A 60 (9.8) 55 (8.6) 
  
     
rs36228499 G 345 (57.9) 361 (56.6) 
0.95 (.75-1.20) .64 
  T 251 (42.1) 277 (43.4) 
CDKN2A  
     
 rs36228834 T 571 (93.0) 615 (96.7) 
2.21 (1.26-3.96) .003† 
  A 43 (7.0) 21 (3.3) 
CDKN2B  
     
rs36229158 C 578 (95.4) 620 (97.2) 
1.67 (.88-3.24) .10† 
  T 28 (4.6) 18 (2.8) 
  
     
rs2069416 A 393 (65.7) 376 (59.9) 1 (referent) ― 
  T 188 (31.4) 235 (37.4) 0.77 (.60-.98) .028 
  C 17 (2.8) 17 (2.7) 0.96 (.45-2.03) 1.0† 
  
     
rs2069418 G 345 (57.7) 362 (57.3) 
0.98 (.78-1.24) .88 
  C 253 (42.3) 270 (42.7) 
E2F1 
     
rs3213141 C 463 (77.4) 480 (75.1) 
0.92 (.70-1.21) .54 
  T 135 (22.6) 152 (24.1) 
HDAC1  
     
rs1741981 T 435 (71.8) 434 (67.0) 
0.80 (.62-1.02) .07 
  C 171 (28.2) 214 (33.0) 
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 rs36212119 T 571 (91.2) 603 (91.6) 
1.06 (.70-1.59) .78 
  C 55 (8.9) 55 (8.4) 
MDM2  
     
rs1144944 A 311 (49.4) 334 (50.8) 
1.06 (.84-1.32) .62 
  G 319 (50.6) 324 (49.2) 
  
     
rs3730485 AAAAAGC(40bp) 364 (58.9) 389 (59.5) 
1.02 (.81-1.29) .83 
  DEL 40bp 254 (41.1) 265 (40.5) 
  
     
rs937282 C 320 (51.1) 339 (51.7) 
1.02 (.82-1.28) .84 
  G 306 (48.9) 317 (48.3) 
  
     
 rs2279744 T 421 (67.3) 412 (63.4) 
0.84 (.66-1.07) .15 
  G 205 (32.7) 238 (36.6) 
SMAD3  
     
 rs36221701 T 554 (88.8) 574 (87.2) 
0.86 (.61-1.23) .39 
  C 70 (11.2) 84 (12.8) 
RB1  
     
 rs1573601 C 462 (76.7) 478 (75.2) 
0.92 (.70-1.20) .51 
  A 140 (23.3) 158 (24.8) 
TGFB1  
     
 rs2317130 A 411 (65.9) 439 (68.6) 
1.13 (.89-1.44) .30 
  G 213 (34.1) 201 (31.4) 
  
     
rs4803457 G 360 (58.8) 388 (60.6) 
1.08 (.85-1.36) .52 
  A 252 (41.2) 252 (39.4) 
  
     
rs11466313 AGG 413 (67.0) 446 (69.0) 
1.10 (.87-1.39) .45 
  DEL AGG 203 (33.0) 200 (31.0) 
  
     
rs1800469 G 412 (66.2) 444 (68.7) 
1.12 (.88-1.43) .34 
  A 210 (33.8) 202 (31.3) 
Percentages indicate number of individuals with a given allele/total number of 
genotyped alleles. The most common allele was used as reference. Association 
was tested for using a chi-square or Fisher‘s exact test, as appropriate. 
Nominally significant results are shown in bold. OR indicates odds ratio; CI, 
confidence interval; –, not applicable; bp, base pairs.  
*Variant CCND1 -1537INS C (rs36225395) significantly deviated from Hardy-
Weinberg equilibrium among controls (P<0.01). 
†P value indicates result of two-sided Fisher‘s exact test.  
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Table V. Distribution of G1/S cell cycle genotypes among B-cell ALL cases 
and controls from the Quebec childhood ALL cohort and their effect on 
ALL risk, as estimated by logistic regression 
Gene and SNP Genotype 
No. (%) 
OR (95% CI) P ALL 
patients 
Controls 
CCND1  
     
rs1944129 TT 78 (25.1) 74 (23.0) 1 (referent) ― 
  TC 162 (52.1) 182 (56.5) 0.84 (.58-1.24) .39 
  CC 71 (22.8) 66 (20.5) 1.02 (.64-1.62) .93 
  
     
rs36225395* -/- 85 (27.3) 85 (26.2) 1 (referent) ― 
  -/C 163 (52.4) 186 (57.2) 0.88 (.61-1.26) .48 
  CC 63 (20.3) 54 (16.6) 1.17 (.73-1.87) .52 
CDC25A  
     
rs1903061 GG 253 (83.5) 262 (80.4) 1 (referent) ― 
  GT 47 (15.5) 61 (18.7) 0.80 (.52-1.21) .29 
  TT 3 (1.0) 3 (0.9) 1.04 (.21-5.18) .97 
CDKN1A  
     
rs733590 TT 108 (35.9) 126 (39.6) 1 (referent) ― 
  TC 154 (51.2) 154 (48.4) 1.17 (.83-1.64) .89 
  CC 39 (12.9) 38 (11.9) 1.20 (.72-2.00) .68 
  
     
rs762624 TT 160 (54.4) 168 (53.3) 1 (referent) ― 
  TG 113 (38.4) 123 (39.0) 0.96 (.69-1.35) .83 
  GG 21 (7.1) 24 (7.6) 0.92 (.49-1.71) .79 
  
     
rs2395655‡ TT 94 (31.5) 112 (35.6) 1 (referent) ― 
  TC 155 (52.0) 156 (49.5) 1.18 (.83-1.68) .35 
  CC 49 (16.5) 47 (14.9) 1.24 (.76-2.02) .38 
CDKN1B  
     
rs3759217 CC 238 (79.6) 243 (77.1) 1 (referent) ― 
  CT 58 (19.4) 71 (22.5) 0.83 (.56-1.23) .36 
  TT 3 (1.0) 1 (0.3) 3.06 (.32-29.65) .37† 
  
     
rs35756741 GG 245 (80.3) 267 (84.0) 1 (referent) ― 
  GA 60 (19.7) 47 (14.8) 1.39 (.91-2.11) .12 
  AA 0 (0.0) 4 (1.2) ― ― 
  
     
rs36228499 GG 93 (31.2) 99 (31.0) 1 (referent) ― 
  GT 159 (53.4) 163 (51.1) 1.04 (.73-1.48) .84 
  TT 46 (15.4) 57 (17.9) 0.86 (.53-1.39) .54 
      
CDKN2A  
     
 rs36228834 TT 266 (86.6) 298 (93.7) 1 (referent) ― 
  TA 39 (12.7) 19 (6.0) 2.30 (1.30-4.08) .004 
  AA 2 (0.7) 1 (0.3) 2.24 (.20-24.85) .60† 
CDKN2B  
     
rs36229158 CC 277 (91.4) 302 (94.7) 1 (referent) ― 
  CT 24 (7.9) 16 (5.0) 1.64 (.85-3.14) .14 
  TT 2 (0.7) 1 (0.3) 2.18 (.20-24.18) .61† 
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rs2069416 AA 129 (43.1) 107 (34.1) 1 (referent) ― 
  AT 124 (41.5) 150 (47.8) 0.69 (.48-.97) .03 
  AC 11 (3.7) 12 (3.8) 0.60 (.35-1.03) .07† 
  TT 29 (9.7) 40 (12.7) 0.76 (.32-1.79) .53 
  TC 6 (2.0) 5 (1.6) 0.99 (.30-3.35) .99† 
  CC 0 0 ― ― 
  
     
rs2069418 GG 102 (34.1) 97 (30.7) 1 (referent) ― 
  GC 141 (47.2) 168 (53.2) 0.80 (.56-1.14) .22 
  CC 56 (18.7) 51 (16.1) 1.04 (.65-1.67) .86 
E2F1  
     
rs3213141 CC 172 (57.5) 180 (57.0) 1 (referent) ― 
  CT 119 (29.8) 120 (38.0) 1.04 (.75-1.44) .82 
  TT 8 (2.7) 16 (5.1) 0.52 (.22-1.25) .15† 
HDAC1  
     
rs1741981 TT 151 (49.8) 143 (44.1) 1 (referent) ― 
  TC 133 (43.9) 148 (45.7) 0.85 (.61-1.18) .33 
  CC 19 (6.3) 33 (10.2) 0.54 (.30-1.00) .05 
  
     
 rs36212119 TT 261 (83.4) 277 (84.2) 1 (referent) ― 
  TC 49 (15.6) 49 (14.9) 1.06 (.69-1.63) .79 
  CC 3 (1.0) 3 (0.9) 1.06 (.21-5.30) .94† 
MDM2  
     
rs1144944 AA 73 (23.2) 82 (24.9) 1 (referent) ― 
  AG 165 (52.4) 170 (51.7) 1.09 (.74-1.60) .66 
  GG 77 (24.4) 77 (23.4) 1.12 (.72-1.76) .61 
  
     
rs3730485 AAAAAGC(40bp) 104 (33.6) 119 (36.4) 1 (referent) ― 
  AAAAAGC(40bp)/- 156 (50.5) 151 (46.2) 1.18 (.84-1.67) .34 
  -/- 49 (15.9) 57 (17.4) 0.98 (.62-1.56) .94 
  
     
rs937282 CC 78 (24.9) 84 (25.6) 1 (referent) ― 
  CG 164 (52.4) 171 (52.1) 1.03 (.71-1.50) .87 
  GG 71 (22.7) 73 (22.3) 1.05 (.67-1.64) .84 
  
     
 rs2279744 TT 141 (45.1) 125 (38.5) 1 (referent) ― 
  TG 139 (44.4) 162 (49.8) 0.76 (.55-1.06) .11 
  GG 33 (10.5) 38 (11.7) 0.77 (.45-1.30) .33 
SMAD3  
     
 rs36221701 TT 246 (78.8) 254 (77.2) 1 (referent) ― 
  TC 62 (19.9) 66 (20.1) 0.97 (.66-1.43) .88 
  CC 4 (1.3) 9 (2.7) 0.46 (.14-1.51) .20† 
      
RB1 
     
 rs1573601 CC 175 (58.1) 176 (55.3) 1 (referent) ― 
  CA 112 (37.2) 126 (39.6) 0.89 (.64-1.24) .51 
  AA 14 (4.7) 16 (5.0) 0.88 (.42-1.86) .74† 
TGFB1  
     
 rs2317130 AA 138 (44.2) 144 (50.0) 1 (referent) ― 
  AG 135 (43.3) 151 (47.2) 0.93 (.67-1.30) .68 
  GG 39 (12.5) 25 (7.8) 1.63 (.94-2.83) .09 
  
     
rs4803457 GG 105 (34.3) 113 (35.3) 1 (referent) ― 
  GA 150 (49.0) 162 (50.6) 1.00 (.70-1.41) .98 
  AA 51 (16.7) 45 (14.1) 1.22 (.75-1.97) .42 
      
rs11466313 AGG/AGG 140 (45.4) 149 (46.1) 1 (referent) ― 
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  AGG/- 133 (43.2) 148 (45.8) 0.96 (.69-1.33) .79 
  -/- 35 (11.4) 26 (8.1) 1.43 (.82-2.50) .21 
  
     
rs1800469 GG 138 (44.4) 147 (45.5) 1 (referent) ― 
  GA 136 (43.7) 150 (46.4) .97 (.70-1.34) .84 
  AA 37 (11.9) 26 (8.1) 1.52 (.87-2.63) .14 
Percentages indicate number of individuals with a given genotype/total number 
of genotyped individuals. The homozygous genotype of the most common allele 
was used as reference. Association was tested for using a chi-square or 
Fisher‘s exact test, as appropriate. Nominally significant results are shown in 
bold. OR indicates odds ratio; CI, confidence interval; –, not applicable; bp, base 
pairs. 
*Variant CCND1 -1537INS C (rs36225395) significantly deviated from Hardy-
Weinberg equilibrium among controls (P<0.01). 
†P value indicates result of two-sided Fisher‘s exact test.  
‡ Significant risk differences between males and females for variant CDKN1A 
rs2395655 CC vs. TT; Males: OR(95%CI)= 0.77(.41-1.45), Females: 
OR(95%CI)= 2.36(1.09-5.08), Mantel-Haenszel P= 0.03. 
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Table VI. Distribution of G1/S cell cycle haplotypes among B-cell ALL cases and controls from the Quebec 
childhood ALL cohort and their effect on ALL risk 
Gene and 
    Haplotype 
DNA variant 
No. (%) 
OR (95% CI) P 
Global 
𝑿𝟐(df) 
Global 
P ALL 
patients 
Controls 
CCND1 rs1944129 rs36225395 
        
CCND1*1 T DEL C 
  
319 (51.1) 337 (51.5) 1 (referent) ― 
1.57 (3) .67 
CCND1*2 C C 
  
287 (46.0) 297 (45.4) 1.02 (.81-1.28) .86 
CCND1*3 C DEL C 
  
16 (2.6) 20 (3.1) 0.85 (.40-1.75) .73† 
CCND1*4 T C 
  
2 (0.3) 0 (0.0) ― ― 
CDKN1A rs733590 rs762624 rs2395655 
       
CDKN1A*1 T T T 
 
346 (56.1) 370 (58.2) 1 (referent) ― 
7.54 (7) .37 
CDKN1A*2 C G C 
 
126 (20.5) 140 (22.0) 0.96 (.72-1.29) .79 
CDKN1A*3 C T C 
 
106 (17.2) 86 (13.5) 1.32 (.95-1.84) .09 
CDKN1A*4 T G C 
 
29 (4.7) 29 (4.6) 1.07 (.60-1.89) .89† 
CDKN1A* ― ― ― 
 
9 (1.5) 11 (1.7) 0.87 (.32-2.35) .82† 
CDKN1B rs3759217 rs35756741 rs36228499 
       
CDKN1B*1 C G T 
 
266 (42.8) 277 (43.4) 1 (referent) ― 
4.01 (5) .55 
CDKN1B*2 C G G 
 
231 (37.1) 233 (36.5) 1.03 (.80-1.33) .80 
CDKN1B*3 T G G 
 
62 (10.0) 73 (11.4) 0.88 (.59-1.31) .52 
CDKN1B*4 C A G 
 
60 (9.6) 55 (8.6) 1.14 (.74-1.74) .53 
CDKN1B*5 ― ― ― 
 
3 (0.5) 0 (0.0) ― ― 
CDKN2B rs36229158 rs2069416 rs2069418 
       
CDKN2B*1 C A C 
 
267 (43.1) 276 (43.3) 1 (referent) ― 
20.88 (7) .004 
CDKN2B*2 C T G 
 
192 (31.0) 236 (37.0) 0.84 (.65-1.09) .19 
CDKN2B*3 C A G 
 
116 (18.7) 91 (14.3) 1.32 (.94-1.84) .09 
CDKN2B*4 T A G 
 
29 (4.7) 18 (2.8) 1.67 (.87-3.26) .13† 
CDKN2B* ― ― ― 
 
16 (2.6) 17 (2.7) 0.97 (.45-2.09) 1.0† 
HDAC1 rs1741981 rs36212119 
        
HDAC1*1 T T 
  
406 (63.8) 390 (59.3) 1 (referent) ― 
5.25 (3) 0.15 
HDAC1*2 C T 
  
172 (27.0) 213 (32.4) 0.76 (.60-1.00) .04 
HDAC1*3 T C 
  
58 (9.2) 54 (8.2) 1.03 (.68-1.56) .88 
HDAC1*4 C C 
  
0 (0.0) 1 (0.1) ― ― 
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MDM2 rs1144944 rs3730485 rs937282 rs2279744 
      
MDM2*1 G DEL 40bp G T 254 (39.8) 261 (39.7) 1 (referent) ― 
16.68 
(14) 
.27 
MDM2*2 A AAAAAGC(40bp) C G 196 (30.7) 238 (36.2) 0.85 (.65-1.10) .20 
MDM2*3 A AAAAAGC(40bp) C T 112 (17.6) 92 (14.0) 1.25 (.89-1.76) .18 
MDM2*4 G AAAAAGC(40bp) G T 52 (8.5) 54 (8.2) 0.99 (.64-1.54) .96 
MDM2* ― ― ― ― 24 (3.8) 13 (2.0) 1.90 (.90-4.15) .09† 
TGFB1 rs2317130 rs4803457 rs11466313 rs1800469 
      
TGFB1*1 A G AGG G 362 (56.9) 387 (59.9) 1 (referent) ― 
10.77 
(12) 
.55 
TGFB1*2 G A DEL AGG A 205 (32.2) 196 (30.3) 1.12 (.87-1.44) .37 
TGFB1*3 A A AGG G 49 (7.7) 52 (8.1) 1.01 (.65-1.56) .97 
TGFB1* ― ― ― ― 20 (3.1) 11 (1.7) 1.94 (.87-4.55) .10† 
Haplotype reconstruction was performed using the FAMHAP Software, using parental data when available. Percentages 
indicate number of chromosomes with given haplotype/total number of chromosomes for each gene. Haplotypes with 
relative frequencies <5% are grouped and are represented as * combinations of the respective DNA variants. The risk of 
ALL was evaluated for each haplotype compared with the most common haplotype which was chosen as reference. 
Association was tested for using a chi-square or Fisher‘s exact test, as appropriate. A likelihood ratio test was performed 
in FAMHAP to compare global haplotype differences between cases and controls and is reported here as a Global chi-
square (𝑋2) test with number of haplotype parameters different from zero−1 degrees of freedom. Nominally significant 
results are shown in bold. OR indicates odds ratio; CI, confidence interval; –, not applicable; bp, base pairs. 
†P value indicates result of two-sided Fisher‘s exact test.  
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Figure II. Allelic associations of DNA double-strand break repair gene 
variants with childhood ALL 
Results are presented as –log(P value) of the chi-square test for association for 
each variant. The horizontal reference line represents a nominal P value of 0.05.  
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Table VII. Allele frequencies of promoter SNPs in DNA double-strand break 
repair genes among B-cell ALL cases and controls from the Quebec 
childhood ALL cohort and their effect on ALL risk 
Gene and SNP Allele 
No. (%) 
OR (95% CI) P ALL 
patients 
Controls 
ATM 
     
rs4987876 G 516 (89.3) 573 (90.4) 
1.13 (.76-1.67) .52 
  T 62 (10.7) 61 (9.6) 
  
     
rs228589 T 359 (63.7) 368 (58.2) 
0.80 (.63-1.01) .06 
  A 205 (36.3) 264 (41.8) 
BRCA1  
     
rs4793204 T 404 (66.2) 434 (67.6) 
1.06 (.83-1.36) .61 
  C 206 (33.8) 208 (32.4) 
  
     
rs799906 A 394 (65.0) 433 (66.6) 
1.07 (.84-1.35) .55 
  G 212 (35.0) 217 (33.4) 
  
     
rs8176071 - 405 (66.2) 443 (67.7) 
1.07 (.85-1.37) .55 
  INS ACA 207 (33.8) 211 (32.3) 
  
     
rs3092986 A 575 (94.6) 590 (91.0) 
0.58 (.36-.99) .017† 
  G 33 (5.4) 58 (9.0) 
BRCA2  
     
rs206114 C 357 (56.7) 386 (58.7) 
1.09 (.86-1.36) .47 
  A 273 (43.3) 272 (41.3) 
  
     
rs3072036 GTCTAA 367 (58.6) 395 (60.4) 
1.08 (.86-1.35) .52 
  
DEL 
GTCTAA 
259 (41.4) 259 (39.6) 
  
     
rs206115 A 328 (55.0) 377 (59.1) 
1.18 (.94-1.49) .15 
  G 268 (45.0) 261 (40.9) 
  
     
 rs206116 C 332 (57.4) 378 (59.8) 
1.10 (.87-1.40) .40 
  T 246 (42.6) 254 (40.2) 
  
     
rs206117 C 351 (57.7) 387 (60.3) 
1.11 (.88-1.40) .36 
  T 257 (42.3) 255 (39.7) 
  
     
rs3092989 G 529 (83.4) 523 (79.5) 
0.77 (.57-1.03) .07 
  A 105 (16.6) 135 (20.5) 
RAD51  
     
rs2619679 A 313 (50.0) 330 (50.9) 
1.04 (.83-1.30) .74 
  T 313 (50.0) 318 (49.1) 
XRCC4  
     
rs3763063 T 336 (56.6) 324 (50.5) 
0.78 (.62-.98) .03 
  C 258 (43.4) 318 (49.5) 
  
     
  
     
rs1993947 C 517 (88.8) 581 (91.6) 
1.38 (.94-2.06) .10 
  G 65 (11.2) 53 (8.4) 
l 
 
 
 
l 
      
XRCC5  
     
rs828907 G 355 (56.5) 347 (52.9) 
.86 (.69-1.08) .19 
  T 273 (43.5) 309 (47.1) 
  
     
rs11685387 C 419 (67.1) 488 (74.4) 
1.42 (1.11-1.82) .004 
  T 205 (32.9) 168 (25.6) 
XRCC6  
     
rs28384701* C 575 (93.3) 615 (95.5) 
1.51 (.90-2.56) .11† 
  T 41 (6.7) 29 (4.5) 
  
     
rs2267437 C 349 (56.6) 393 (61.4) 
1.22 (.97-1.52) .09 
  G 267 (43.4) 247 (38.6) 
  
     
rs132770 G 498 (79.0) 490 (74.9) 
0.79 (.60-1.04) .08 
  A 132 (21.0) 164 (25.1) 
Percentages indicate number of individuals with a given allele/total number of 
genotyped individuals. The most common allele was used as reference. 
Association was tested for using a chi-square or Fisher‘s exact test, as 
appropriate. Nominally significant results are shown in bold. OR indicates odds 
ratio; CI, confidence interval; –, not applicable.  
*Variant XRCC6 -1469C>T (rs28384701) significantly deviated from Hardy-
Weinberg equilibrium among controls (P<0.01). 
†P value indicates result of two-sided Fisher‘s exact test.  
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Table VIII. Distribution of DNA double-strand break repair genotypes 
among B-cell ALL cases and controls from the Quebec childhood ALL 
cohort and their effect on ALL risk, as estimated by logistic regression 
Gene and SNP Genotype 
No. (%) 
OR (95% CI) P ALL 
patients 
Controls 
ATM  
     
rs4987876 GG 231 (79.9) 261 (82.3) 1 (referent) ― 
  GT 54 (18.7) 51 (16.1) 1.20 (.78-1.82) .29 
  TT 4 (1.4) 5 (1.6) 0.90 (.24-3.41) 1† 
  
     
rs228589 TT 111 (39.4) 111 (35.1) 1 (referent) ― 
  TA 137 (48.6) 146 (46.2) 0.94 (.66-1.33) .68 
  AA 34 (12.0) 59 (18.7) 0.58 (.35-.95) .03 
BRCA1  
     
rs4793204 TT 130 (42.6) 149 (46.4) 1 (referent) ― 
  TC 144 (47.2) 136 (42.4) 1.21 (.87-1.69) .25 
  CC 31 (10.2) 36 (11.2) 0.99 (.58-1.68) .96 
  
     
rs799906 AA 124 (40.9) 145 (44.6) 1 (referent) ― 
  AG 146 (48.2) 143 (44.0) 1.19 (.86-1.66) .30 
  GG 33 (10.9) 37 (11.4) 1.04 (.61-1.77) .88 
  
     
rs8176071 -/- 130 (42.5) 151 (46.2) 1 (referent) ― 
  -/ACA 145 (47.4) 141 (43.1) 1.19 (.86-1.66) .29 
  ACA/ACA 31 (10.1) 35 (10.7) 1.03 (.60-1.76) .92 
  
     
rs3092986 AA 272 (89.5) 268 (82.7) 1 (referent) ― 
  AG 31 (10.2) 54 (16.7) 0.56 (.35-.91) .018 
  GG 1 (0.3) 2 (0.6) 0.49 (.04-5.47) .62† 
BRCA2  
     
rs206114 CC 112 (35.5) 116 (35.3) 1 (referent) ― 
  CA 133 (42.2) 154 (46.8) 0.89 (.63-1.27) .53 
  AA 70 (22.2) 59 (17.9) 1.23 (.80-1.89) .35 
  
     
rs36221753 GTCTAA/GTCTAA 115 (36.7) 117 (35.8) 1 (referent) ― 
  GTCTAA/- 137 (43.8) 161 (49.2) .86 (.61-1.22) .41 
  -/- 61 (19.5) 49 (15.0) 1.27 (.80-2.00) .31 
  
     
rs206115 AA 97 (32.5) 110 (34.5) 1 (referent) ― 
  AG 134 (45.0) 157 (49.2) .97 (.68-1.38) .86 
  GG 67 (22.5) 52 (16.3) 1.46 (.93-2.30) .10 
  
     
 rs206116 CC 105 (36.3) 111 (35.1) 1 (referent) ― 
  CT 122 (42.2) 156 (49.4) 0.83 (.58-1.18) .30 
  TT 62 (21.5) 49 (15.5) 1.34 (.84-2.12) .21 
  
     
      
      
rs206117 CC 108 (35.5) 115 (35.8) 1 (referent) ― 
  CT 135 (44.4) 157 (48.9) 0.91 (.64-1.30) .62 
  TT 61 (20.1) 49 (15.3) 1.32 (.84-2.10) .23 
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rs3092989 GG 220 (69.4) 205 (62.3) 1 (referent) ― 
  GA 89 (28.1) 113 (34.3) 0.73 (.52-1.03) .07 
  AA 8 (2.5) 11 (3.3) 0.68 (.27-1.72) .49† 
RAD51  
     
rs2619679 AA 76 (24.3) 81 (25.0) 1 (referent) ― 
  AT 161 (51.4) 168 (51.9) 1.02 (.70-1.49) .91 
  TT 76 (24.3) 75 (23.1) 1.08 (.69-1.69) .74 
XRCC4  
     
rs3763063 TT 98 (33.0) 79 (24.6) 1 (referent) ― 
  TC 140 (47.1) 166 (51.7) 0.68 (.47-.98) .042 
  CC 59 (19.9) 76 (23.7) 0.63 (.40-.98) .042 
  
     
rs1993947 CC 229 (78.7) 266 (83.9) 1 (referent) ― 
  CG 59 (20.3) 49 (15.5) 1.40 (.92-2.12) .12 
  GG 3 (1.0) 2 (0.6) 1.74 (.29-10.52) .67† 
XRCC5  
     
rs828907‡ GG 101 (32.2) 88 (26.8) 1 (referent) ― 
  GT 153 (48.7) 171 (52.1) 0.78 (.54-1.12) .17 
  TT 60 (19.1) 69 (21.1) 0.76 (.48-1.19) .22 
  
     
rs11685387 CC 140 (44.9) 178 (54.3) 1 (referent) ― 
  CT 139 (44.5) 132 (40.2) 1.34 (.97-1.85) .08 
  TT 33 (10.6) 18 (5.5) 2.33 (1.26-4.31) .007† 
XRCC6  
     
rs28384701* CC 267 (86.7) 297 (92.2) 1 (referent) ― 
  CT 41 (13.3) 21 (6.5) 2.17 (1.25-3.77) .007† 
  TT 0 (0.0) 4 (1.2) ― ― 
  
     
rs2267437 CC 97 (31.5) 115 (35.9) 1 (referent) ― 
  CG 155 (50.3) 163 (50.9) 1.13 (.80-1.60) .50 
  GG 56 (18.2) 42 (13.1) 1.58 (.98-2.56) .06 
  
     
rs132770 GG 197 (62.5) 189 (57.8) 1 (referent) ― 
  GA 104 (33.0) 112 (34.2) 0.89 (.64-1.24) .50 
  AA 14 (4.5) 26 (8.0) 0.52 (.26-1.02) .07† 
Percentages indicate number of individuals with a given genotype/total number 
of genotyped individuals. The homozygous genotype of the most common allele 
was used as reference. Association was tested for using a chi-square or 
Fisher‘s exact test, as appropriate. Nominally significant results are shown in 
bold. 
OR indicates odds ratio; CI, confidence interval; –, not applicable. 
*Variant XRCC6 -1469C>T (rs28384701) significantly deviated from Hardy-
Weinberg equilibrium among controls (P<0.01). 
†P value indicates result of two-sided Fisher‘s exact test.  
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‡ Significant risk differences between males and females for variant XRCC5 
rs828907 TT vs. GG; Males: OR(95%CI)= 0.44(.24-.81), Females: OR(95%CI)= 
1.56(.79-3.10), Mantel-Haenszel P= 0.007. 
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Table IX. Distribution of DNA double-strand break repair haplotypes among B-cell ALL cases and controls from the 
Quebec childhood ALL cohort and their effect on ALL risk 
Gene and 
Haplotype 
DNA variant 
No. (%) 
OR (95% CI) P 
Global 
X
2
 (df) 
Global 
P ALL 
patients 
Controls 
ATM rs4987876 rs228589 
          
ATM*1 G T 
    
348 (55.8) 321 (50.0) 1 (referent) ― 
2.41 
(3) 
.49 
ATM*2 G A 
    
212 (34.0) 260 (40.5) 0.75 (.59-.96) .018 
ATM*3 T T 
    
62 (9.9) 57 (8.9) 1.00 (.67-1.51) .99 
ATM*4 T A 
    
2 (0.3) 4 (0.6) 0.46 (.04-3.25) .44† 
BRCA1 rs4793204 rs799906 rs8176071 rs3092986 
        
BRCA1*1 T A DEL ACA A 
  
377 (60.4) 377 (57.6) 1 (referent) ― 
9.77 
(7) 
.20 
BRCA1*2 C G ACA A 
  
209 (33.5) 211 (32.3) 0.99 (.77-1.27) .94 
BRCA1*3 T A DEL ACA G 
  
32 (5.1) 58 (8.9) 0.55 (.34-.89) .01† 
BRCA1* ― ― ― ― 
  
6 (1.0) 8 (1.2) 0.75 (.21-2.49) .79† 
BRCA2 rs206114 rs36221753 rs206115 rs206116 rs206117 rs3092989 
      
BRCA2*1 A GTCTAA G C C G 261 (41.2) 263 (40.0) 1 (referent) ― 
41.23 
(22) 
.008 
BRCA2*2 C 
DEL 
GTCTAA 
A T T G 246 (38.8) 245 (37.2) 1.01 (.78-1.30) .93 
BRCA2*3 C GTCTAA A C C A 89 (14.0) 125 (19.0) 0.72 (.51-1.00) .04 
BRCA2* ― ― ― ― ― ― 38 (6.0) 25 (3.8) 1.53 (.87-2.73) .14† 
XRCC4 rs6452505 rs1993947 
          
XRCC4*1 C C 
    
261 (41.5) 320 (49.7) 1 (referent) ― 
5.58 
(3) 
.13 
XRCC4*2 T C 
    
293 (46.7) 271 (42.1) 1.33 (1.04-1.68) .02 
  
XRCC4*3 T G 
    
73 (11.6) 53 (8.2) 1.69 (1.12-2.55) .008 
XRCC4*4 ― ― 
    
1 (0.2) 0 (0.0) ― ― 
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XRCC5 rs828907 rs11685387 
          
XRCC5*1 T C 
    
280 (43.9) 309 (47.1) 1 (referent) ― 
9.36 
(2) 
.009 XRCC5*2 G C 
    
146 (22.9) 179 (27.3) 0.90 (.68-1.19) .45 
XRCC5*3 G T 
    
212 (33.2) 168 (25.6) 1.39 (1.06-1.82) .01 
XRCC6 rs28384701 rs2267437 rs132770 
         
XRCC6*1 C G G 
   
266 (41.8) 253 (38.7) 1 (referent) ― 
17.07 
(8) 
.03 
XRCC6*2 C C G 
   
224 (35.2) 231 (35.3) 0.92 (.71-1.20) .53 
XRCC6*3 C C A 
   
90 (14.2) 137 (20.9) 0.62 (.45-.87) .003 
XRCC6*4 T C A 
   
42 (6.6) 27 (4.1) 1.48 (.86-2.57) .16† 
XRCC6* ― ― ― 
   
14 (2.2) 6 (0.9) 2.22 (.78-7.15) .11† 
Haplotype reconstruction was performed using the FAMHAP Software, using parental data when available. Percentages 
indicate number of chromosomes with given haplotype/total number of chromosomes for each gene. Haplotypes with relative 
frequencies <5% are grouped and are represented as * combinations of the respective DNA variants. The risk of ALL was 
evaluated for each haplotype compared with the most common haplotype which was chosen as reference. Association was 
tested for using a chi-square or Fisher‘s exact test, as appropriate. A likelihood ratio test was performed in FAMHAP to compare 
global haplotype differences between cases and controls and is reported here as a Global chi-square (𝑋2) test with number of 
haplotype parameters different from zero−1 degrees of freedom. Nominally significant results are shown in bold. OR indicates 
odds ratio; CI, confidence interval; –, not applicable; bp, base pairs. 
†P value indicates result of two-sided Fisher‘s exact test.  
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FAMILY-BASED ASSOCIATION STUDY 
 
Transmission disequilibrium from parents to children of individual SNPs and 
corresponding haplotypes was assessed with the FBAT (family-based 
association test) software (6, 7). A multiallelic test was also carried out in FBAT 
to obtain the global haplotype association significance in the family-based 
setting. 
 
Please note that multiple testing corrections were not performed on the data 
presented here and only nominal P values are shown. 
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Table X. Family-based association analysis of promoter SNPs in G1/S cell 
cycle checkpoint genes 
Gene and 
SNP 
DNA variant MAF 
No. 
of families* 
S–E(S)† Var(S)‡ Z P 
CCND1  
       
rs1944129 T>C .49 123 -6.00 40.00 -0.95 .34 
rs36225395 INS C .47 120 -2.50 37.75 0.41 .68 
CDC25A  
       
rs1903061 G>T .08 41 1.50 10.75 0.46 .65 
CDKN1A  
       
rs733590 T>C .39 114 1.50 38.75 0.24 .81 
rs762624 T>G .28 101 0.00 32.50 0.00 1 
rs2395655 T>C .44 111 5.00 38.00 0.81 .42 
CDKN1B 
       
rs3759217 C>T .12 67 -5.50 19.25 -1.25 .21 
rs35756741 G>A .10 58 3.00 15.00 0.78 .44 
rs36228499 G>T .42 102 -5.00 35.50 -0.84 .40 
CDKN2A  
       
 s36228834 T>A .06 33 11.00 8.50 3.77 .0002 
CDKN2B  
       
rs36229158 C>T .04 23 7.00 6.00 2.86 .004 
rs2069416 A>T,C .35/.03 117/15 17.50 37.75/4.00 -2.85/-0.5 .004/.62 
rs2069418 G>C .42 124 5.00 41.50 0.78 .44 
E2F1 
       
rs3213141 C>T .24 100 -0.50 30.25 -0.09 .93 
HDAC1  
       
rs1741981 T>C .29 100 -7.50 32.25 -1.32 .19 
rs36212119 T>C .09 30 2.50 7.75 0.98 .37 
MDM2  
       
rs1144944 A>G .50 125 1.50 43.75 0.23 .82 
rs3730485 
DEL 
AAAAAGC(40bp) 
.41 125 -9.50 41.25 -1.48 .14 
rs937282 C>G .48 121 -5.50 42.25 -0.85 .40 
 rs2279744 T>G .34 126 -2.00 41.00 -0.31 .75 
SMAD3  
       
rs36221701 T>C .11 47 -2.50 13.75 -0.67 .50 
RB1  
       
 rs1573601 C>A .23 94 -2.00 29.00 -0.37 .71 
TGFB1  
       
 rs2317130 A>G .33 113 5.00 36.50 0.83 .41 
rs4803457 G>A .40 118 9.00 39.00 1.44 .15 
rs11466313 DEL AGG .32 112 6.50 35.25 1.10 .27 
rs1800469 G>A .33 119 2.00 38.00 0.32 .75 
 
FBAT analyses were performed under the additive model. Only the results for 
the minor alleles are shown. A positive Z value indicates overtransmission of a 
given allele to affected offspring; a negative Z value indicates 
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undertransmission. Nominally significant results are shown in bold. MAF 
indicates minor (i.e., variant) allele frequency. 
*Number of informative families (i.e., families with at least one heterozygote 
parent). 
†Test statistic (S) from FBAT for the observed number of transmitted alleles –  
the expected value of S (E(S)) under Mendelian transmission and the null 
hypothesis (i.e., no linkage or association). 
‡Variance of the test statistic S. 
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Table XI. Family-based association analysis of promoter haplotypes in 
G1/S cell cycle checkpoint genes 
Gene and 
Haplotype 
Alleles Freq. 
No. of 
families* 
S–E(S)† Var(S)‡ Z P 
Global 
𝑿𝟐 (df) 
Global 
P 
CCND1  
         
CCND1*1 T(-) .49 102 5.00 39.00 0.80 .42 
2.38 
(3) 
.50 
CCND1*2 CC .47 102 -2.50 36.75 -0.41 .68 
CCND1*3 C(-) .03 14 -2.00 3.50 -1.07 .29 
CCND1*4 TC .001 0 ― ― ― ― 
CDKN1A  
         
CDKN1A*1 TTT .59 88 -7.00 37.38 -1.15 .25 
5.09 
(4) 
.28 
CDKN1A*2 CGC .20 78 -4.90 27.81 -0.94 .35 
CDKN1A*3 CTC .15 71 7.90 21.38 1.72 .09 
CDKN1A*4 TGC .04 31 3.40 9.18 1.13 .26 
CDKN1B 
         
CDKN1B*1 CGT .43 93 -3.47 33.76 -0.60 .55 
3.90 
(4) 
.42 
CDKN1B*2 CGG .39 102 6.97 32.21 1.23 .22 
CDKN1B*3 TGG .10 55 -5.97 15.71 -1.51 .13 
CDKN1B*4 CAG .08 49 2.50 12.25 0.71 .48 
CDKN2B  
         
CDKN2B*1 CAC .42 109 5.91 40.49 0.93 .35 
14.32 
(6) 
.03 
CDKN2B*2 CTG .35 106 -16.51 41.21 -2.57 .01 
CDKN2B*3 CAG .18 77 3.59 21.13 0.78 .43 
CDKN2B*4 TAG .03 22 6.42 6.18 2.59 .01 
HDAC1  
         
HDAC1*1 TT .65 90 4.34 27.68 0.82 .41 
3.93 
(3) 
.27 
HDAC1*2 CT .28 81 -5.84 25.69 -1.15 .25 
HDAC1*3 TC .07 26 2.66 5.77 1.11 .27 
HDAC1*4 CC .002 0 ― ― ― ― 
MDM2  
         
MDM2*1 G(-)GT .40 93 -5.50 34.68 -0.94 .35 
8.15 
(4) 
.09 
MDM2*2 A(40bp)CG .32 96 1.09 35.91 0.18 .86 
MDM2*3 A(40bp)CT .16 77 2.92 20.97 0.64 .52 
MDM2*4 G(40bp)GT .07 39 5.58 9.73 1.79 .07 
TGFB1  
         
TGFB1*1 AG(AGG)G .63 107 -6.01 41.45 -0.93 .35 
5.93 
(3) 
.12 TGFB1*2 GA(-)A .27 93 6.99 33.42 1.21 .23 
TGFB1*3 AA(AGG)G .07 39 2.50 9.63 0.81 .42 
Haplotype-specific FBAT analyses were performed under the additive model. A 
multiallelic chi-square test (𝑋2) was also carried out in FBAT to obtain the global 
haplotype association significance in the family-based setting. A positive Z value 
indicates overtransmission of a given haplotype to affected offspring; a negative 
Z value indicates undertransmission. Nominally significant results are shown in 
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bold. Freq. indicates haplotype frequency; df indicates degrees of freedom; —, 
not applicable due to lack of informative families (i.e., < 10). 
*Number of informative families (i.e., families with at least 1 heterozygote 
parent). 
†Test statistic (S) from FBAT for the observed number of transmitted haplotypes 
–  expected value of S (E(S)) under Mendelian transmission and the null 
hypothesis (i.e., no linkage or association). 
‡Variance of the test statistic S. 
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Table XII. Family-based association analysis of promoter SNPs in DNA 
double-strand break repair genes 
Gene and 
SNP 
DNA variant MAF 
No. of 
families* 
S–E(S)† Var(S)‡ Z P 
ATM 
       
rs4987876 G>T .10 48 0.50 13.75 0.14 .89 
rs228589 T>A .38 99 4.00 32.00 0.71 .48 
BRCA1  
       
rs4793204 T>C .34 114 -5.00 37.00 -0.82 .41 
rs799906 A>G .35 118 -6.50 37.75 -1.06 .29 
rs8176071 INS ACA .35 119 -6.0 38.50 -0.97 .33 
rs3092986 A>G .05 27 -1.50 6.75 -0.58 .56 
BRCA2  
       
rs206114 C>A .42 126 1.50 40.75 0.24 .81 
rs3072036 DEL GTCTAA .41 114 4.50 38.75 0.72 .47 
rs206115 A>G .44 111 6.00 38.00 0.97 .33 
 rs206116 C>T .42 103 3.00 35.50 0.50 .61 
rs206117 C>T .42 112 7.00 38.00 1.14 .26 
rs3092989 G>A .18 90 -9.00 27.50 -1.72 .09 
RAD51  
       
rs2619679 A>T .50 120 -1.00 40.00 -0.16 .87 
XRCC4  
       
rs3763063 T>C .44 127 -5.5 42.75 -0.84 .40 
rs1993947 C>G .11 47 3.0 13.50 0.82 .41 
XRCC5  
       
rs828907 G>T .44 137 0.0 47.00 0.00 1 
rs11685387 C>T .31 107 8.0 36.50 1.32 .19 
XRCC6  
       
rs28384701 C>T .06 39 3.5 10.25 1.09 .27 
rs2267437 C>G .43 117 1.0 38.50 0.16 .87 
rs132770 G>A .21 106 -0.5 30.25 -0.90 .93 
FBAT analyses were performed under the additive model. Only the results for 
the minor alleles are shown. A positive Z value indicates overtransmission of a 
given allele to affected offspring; a negative Z value indicates 
undertransmission. Nominally significant results are shown in bold. MAF 
indicates minor (i.e., variant) allele frequency. 
*Number of informative families (i.e., families with at least one heterozygote 
parent). 
†Test statistic (S) from FBAT for the observed number of transmitted alleles –  
the expected value of S (E(S)) under Mendelian transmission and the null 
hypothesis (i.e., no linkage or association). 
‡Variance of the test statistic S. 
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Table XIII. Family-based association analysis of promoter haplotypes in 
DNA double-strand break repair genes 
Gene and 
Haplotype 
Alleles MAF 
No. of 
families* 
S–E(S)† Var(S)‡ Z P 
Global 
𝑿𝟐 (df) 
Global 
P 
ATM 
         
ATM*1 GT .55 105 -3.46 34.71 -0.59 .56 
1.53 
(3) 
.67 
ATM*2 GA .36 96 3.46 33.73 0.60 .55 
ATM*3 TT .08 43 -0.55 13.23 -0.15 .88 
ATM*4 TA .002 0 
    
BRCA1 
         
BRCA1*1 TA(-)A .63 107 8.00 35 1.35 .18 
4.36 
(3) 
.22 BRCA1*2 CG(ACA)A .32 95 -5.50 34.25 -0.94 .35 
BRCA1*3 TA(-)G .04 25 -0.50 6.25 -0.20 .84 
BRCA2 
         
BRCA2*1 A(GTCTAA)GCCG .40 90 8.48 38.23 1.37 .17 
12.08 
(3) 
0.007 BRCA2*2 C(-)ATTG .38 81 6.00 33.50 1.04 .30 
BRCA2*3 C(GTCTAA)ACCA .16 65 -7.49 22.75 -1.57 .12 
XRCC4 
         
XRCC4*1 CC .45 120 -5.08 41.89 -0.79 .43 
1.51 
(3) 
.68 XRCC4*2 TC .46 121 1.08 41.26 0.17 .87 
XRCC4*3 TG .09 44 3.92 11.89 1.14 .26 
XRCC5 
         
XRCC5*1 TC .43 117 0.50 47.75 0.07 .94 
3.95 
(2) 
.14 XRCC5*2 GC .27 108 -9.50 33.75 -1.64 .10 
XRCC5*3 GT .30 87 9.00 33.50 1.56 .12 
XRCC6 
         
XRCC6*1 CGG .42 114 2.41 38.14 0.39 .70 
3.24 
(4) 
.52 
XRCC6*2 CCG .39 121 -0.41 40.43 -0.07 .95 
XRCC6*3 CCA .14 75 -5.52 20.69 -1.21 .23 
XRCC6*4 TCA .04 38 3.93 8.87 1.32 .19 
Haplotype-specific FBAT analyses were performed under the additive model. A 
multiallelic chi-square test (𝑋2) was also carried out in FBAT to obtain the global 
haplotype association significance in the family-based setting. A positive Z value 
indicates overtransmission of a given haplotype to affected offspring; a negative 
Z value indicates undertransmission. Nominally significant results are shown in 
bold. Freq. indicates haplotype frequency; df indicates degrees of freedom; —, 
not applicable due to lack of informative families (i.e., < 10). 
*Number of informative families (i.e., families with at least 1 heterozygote 
parent). 
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†Test statistic (S) from FBAT for the observed number of transmitted haplotypes 
–  expected value of S (E(S)) under Mendelian transmission and the null 
hypothesis (i.e., no linkage or association). 
‡Variance of the test statistic S. 
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APPENDIX III 
RESULTS OF THE FETOMATERNAL 
ASSOCIATION TESTS FOR THE DNA 
DOUBLE-STRAND BREAK REPAIR GENES 
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Figure I. Log-linear, likelihood-ratio association analysis between 20 
regulatory SNPs from 7 DNA double-strand break repair genes and 
childhood pre-B acute lymphoblastic leukemia 
Log-linear regression analysis was performed in LEM (1-2) using 203 case-
triads, 118 unrelated ALL patients and 329 controls. Results of the likelihood-
ratio chi-square tests (- log P) are shown for the single-step Child and Mother 
tests. A three degree-of-freedom likelihood-ratio test for mating asymmetry (MA) 
was performed using a P value < 0.10 to reject symmetry. Under this threshold, 
mating symmetry (i.e. six mating-type parameters) was assumed at all loci but 
variants rs36221753 and rs206116 of the BRCA2 gene for which MA models 
(nine mating-type parameters) were used to test for association. Horizontal 
reference line indicates P value of 0.05.  
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Table I. Log-linear, likelihood-ratio association analysis between 20 
regulatory SNPs from 7 double-strand break repair genes and childhood 
pre-B ALL 
Gene, 
    DNA variant 
Model LR Chi2 (df) P 
ATM 
   
rs4987876 Child vs. Null 0.5477 (2) 0.7604 
 
Mother vs. Null 0.0126 (2) 0.9937 
    
rs228589 Child vs. Null 3.1310 (2) 0.2090 
 
Mother vs. Null 4.6616 (2) 0.0972 
BRCA1 
   
rs4793204 Child vs. Null 0.1228 (2) 0.9405 
 
Mother vs. Null 3.7985 (2) 0.1497 
    
rs799906 Child vs. Null 0.0573 (2) 0.9717 
 
Mother vs. Null 3.4793 (2) 0.1756 
    
rs8176071 Child vs. Null 0.0826 (2) 0.9595 
 
Mother vs. Null 3.9198 (2) 0.1409 
    
rs3092986 Child vs. Null 3.0368 (2) 0.2191 
 
Mother vs. Null 4.1961 (2) 0.1227 
BRCA2 
   
rs206114 Child vs. Null 2.1435 (2) 0.3424 
 
Mother vs. Null 3.7607 (2) 0.1525 
    
rs36221753 Child vs. Null 3.5219 (2) 0.1719 
 
Mother vs. Null 0.5142 (2) 0.7733 
    
rs206115 Child vs. Null 3.7406 (2) 0.1541 
 
Mother vs. Null 4.6467 (2) 0.0979 
    
rs206116 Child vs. Null 5.4814 (2) 0.0645 
 
Mother vs. Null 0.6138 (2) 0.7357 
    
    
rs206117 Child vs. Null 4.0435 (2) 0.1324 
 
Mother vs. Null 2.0003 (2) 0.3678 
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rs3092989
 
Child vs. Null 4.4101 (2) 0.1102 
 
Mother vs. Null 5.2825 (2) 0.0713 
RAD51 
   
rs2619679 Child vs. Null 0.0930 (2) 0.9546 
 
Mother vs. Null 0.2173 (2) 0.8970 
XRCC4 
   
rs3763063 Child vs. Null 5.6530 (2) 0.0592 
 
Mother vs. Null 2.1153 (2) 0.3473 
    
rs1993947 Child vs. Null 3.3329 (2) 0.1889 
 
Mother vs. Null 3.1122 (2) 0.2110 
XRCC5 
   
rs828907 Child vs. Null 1.0927 (2) 0.5791 
 
Mother vs. Null 3.0183 (2) 0.2211 
    
rs11685387 Child vs. Null 7.7518 (2) 0.0207 
 
Mother vs. Null 9.0817 (2) 0.0107 
 Child + Mother vs. Null 
13.8334 (4) 0.0078 
 Child + Mother vs. Mother 
4.7517 (2) 0.0929 
 Child + Mother vs. Child 
6.0815 (2) 0.0478 
XRCC6 
   
rs28384701 Child vs. Null 12.0886 (2) 0.0024 
 
Mother vs. Null 4.0077 (2) 0.1348 
 Child + Mother vs. Null 
13.2668 (4) 0.0100 
 Child + Mother vs. Child 
1.1782 (2) 0.5548 
    
rs2267437 Child vs. Null 1.9515 (2) 0.3769 
 
Mother vs. Null 2.8099 (2) 0.2454 
    
rs132770 Child vs. Null 1.4259 (2) 0.4902 
 
Mother vs. Null 7.8070 (2) 0.0202 
 Child + Mother vs. Null 
7.8453 (4) 0.0974 
 Child + Mother vs. Mother 
0.0383 (2) 0.9810 
Likelihood-ratio tests were performed in a forward stepwise fashion. The most 
significant single-step test (Child vs. Null or Mother vs. Null) was tested against 
a joint effects model in a 2 degree of freedom likelihood-ratio test (Child + 
Mother vs. Child or Child + Mother vs. Mother). A three degree-of-freedom 
likelihood-ratio test for mating asymmetry (MA) was performed using a P value < 
0.10 to reject symmetry. Under this threshold, mating symmetry (i.e. six mating-
type parameters) was assumed at all loci but variants rs36221753 and rs206116 
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of the BRCA2 gene for which MA models (nine mating-type parameters) were 
used to test for association. Nominally significant P values are shown in bold 
remain. LR Chi2 indicates likelihood-ratio chi-square test; df, degrees of 
freedom.  
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